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The first successful open surgical repair of an abdominal aortic aneurysm was in 1951 
by Dubost and represented a tremendous milestone in the care of this challenging 
disease. The introduction of endovascular repair in 1991 by Parodi furthered the care of 
these patients by allowing for lower morbidity and mortality rates and also, enabling 
surgeons to extend surgical treatment to patients traditionally deemed too high of a 
surgical risk. This new book on Aortic Disease covers many interesting and vital topics 
necessary for both the practicing surgeon as well as a student of vascular disease. The 
book starts with background information on the evolution of aortic management 
from traditional open surgical repair to modern endovascular therapies. There is also 
a chapter covering the data supporting current treatment modalities and how these 
data have supported modern management. Also, the use of endovascular means for 
care of the challenging situation of ruptured aneurysms is discussed. In addition to 
management of abdominal aneurysm, there is a chapter on treatment of aneurysms 
of the ascending aorta. Along with surgical treatment, one must also understand 
the molecular basis for how blood vessels remodel and thus, the role of cathepsins in 
aortic disease is elucidated. Lastly, chapters discussing the perioperative management 
of radiation exposure and ultrasound-guided nerve blocks as well as the need for 
high-quality postoperative nutrition will lend well to a full understanding of how to 
management patients from presentation to hospital discharge. We hope you enjoy this 
book, its variety of topics, and gain a fuller knowledge of Aneurysmal Disease of the 
Thoracic and Abdominal Aorta.
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The first successful open surgical repair of an abdominal aortic aneurysm was in 1951 
by Dubost and represented a tremendous milestone in the care of this challenging 
disease. The introduction of endovascular repair in 1991 by Parodi furthered the care 
of these patients by allowing for lower morbidity and mortality rates and also, 
enabling surgeons to extend surgical treatment to patients traditionally deemed too 
high of a surgical risk. This new book on Aortic Disease covers many interesting and 
vital topics necessary for both the practicing surgeon as well as a student of vascular 
disease. The book starts with background information on the evolution of aortic 
management from traditional open surgical repair to modern endovascular therapies. 
There is also a chapter covering the data supporting current treatment modalities and 
how these data have supported modern management. Also, the use of endovascular 
means for care of the challenging situation of ruptured aneurysms is discussed. In 
addition to management of abdominal aneurysm, there is a chapter on treatment of 
aneurysms of the ascending aorta. Along with surgical treatment, one must also 
understand the molecular basis for how blood vessels remodel and thus, the role of 
cathepsins in aortic disease is elucidated. Lastly, chapters discussing the perioperative 
management of radiation exposure and ultrasound-guided nerve blocks as well as the 
need for high-quality postoperative nutrition will lend well to a full understanding of 
how to management patients from presentation to hospital discharge. We hope you 
enjoy this book, its variety of topics, and gain a fuller knowledge of Aneurysmal 
Disease of the Thoracic and Abdominal Aorta.  
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Part 1 
Evolution of Care for Aortic Disease 
 1 
The Evidence for Management of  
Abdominal Aortic Aneurysms: Lessons  
Learned from Randomised Controlled Trials 
Reza Mofidi1 and Stuart A. Suttie2 
1James Cook University Hospital, Middlesbrough 
2University of Dundee, Dundee, 
United Kingdom 
1. Introduction 
Abdominal aortic aneurysm (AAA) is a common life threatening condition in the western 
world. In England and Wales alone, over 2500 patients present to hospital with rupture of 
AAA annually, of whom over two thirds die of their condition1. The best treatment for AAA 
is elective repair of pre-symptomatic abdominal aortic aneurysms. Such a therapeutic 
strategy depends on effective identification of patients with AAA and the subgroup of 
patients in whom there is a real risk of aneurysm rupture. As the vast majority of patients 
with AAAs are asymptomatic, timely identification of AAA may be achieved through 
targeted screening of the at risk populations. Over the last two decades longitudinal studies 
of patients with smaller AAAs have provided insights into the timing of AAA repair and the 
need for and frequency of ultrasound surveillance if an expectant management strategy is 
followed. This chapter discusses the available evidence for screening for AAA as well as all 
the other measures which have helped to optimise therapeutic strategies in the management 
of patients with AAA throughout the patients’ journey from the initial diagnosis to the 
eventual repair of AAA.  
2. Targeted screening for AAA 
In the past 40 years with the advent and generalised use of abdominal ultrasonography 
there has been an accurate, cheap and non invasive tool for the diagnosis of abdominal 
aortic aneurysms. Abdominal ultrasonography has been found to be an accurate and 
reproducible modality in measuring the dimensions of AAA. This has led to the concept of 
its use for screening of at risk populations. In the last 20 years there have been four 
population based randomised controlled trials which have assessed the value of targeted 
screening in reducing mortality from abdominal aortic aneurysms in the unselected elderly 
male population2-5. These trials which have been undertaken in Chichester (England)2, 
England (MASS trial) 3, Viborg County (Denmark) 4 and the city of Perth and suburbs 
(Western Australia)5 have together recruited over 120,000 subjects. All of these studies have 
reported on long term (over 10 years) follow up. Using the predefined criteria set by the US 
Preventative Screening Task Force USPSTF 6 the MASS trial has been classified as good with 
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the other three trials classified as fair i.e. not meeting all the criteria but judged to have no 
fatal flaws7.  
The Chichester trial was the first to assess the value of screening for AAA in the at risk 
population. It was also unique as it included women as well as men. It identified all men 
and women aged between 65 and 80 years of age from 9 general practices in the catchment 
area of St Richard’s hospital in Chichester between 1988 and 19912,8,9. The subjects were 
randomised to undergo a single screening ultrasound (US) or a control group who were 
followed up. AAA rupture rates, aneurysm related mortality, and overall mortality was 
compared between the two groups. Upon identification of AAA the therapeutic strategy for 
AAAs with maximum diameters between 30-44mm was once yearly surveillance US, AAAs 
between 44 and 59mm underwent 3 monthly ultrasound scans, whilst aneurysms greater 
than 60mm in diameter were considered for repair2.8.9. Overall 6040 men were randomised, 
the authors reported a significant reduction in aneurysm related mortality which has been 
maintained over 15 years. However, to date this study has demonstrated no difference in the 
all cause mortality between the two groups. The Chichester trial has been criticized for its 
relative small size, a relatively high aneurysm diameter threshold for repair and including 
75-80 year old patients in whom the benefits of screening are marginal. In addition 27-
percent of subjects who were invited for screening refused to participate thereby diluting 
the benefits of screening. Despite these criticisms the Chichester study remains a land mark 
as it demonstrated the feasibility of US screening for AAA and its potential value and 
remains a blue print for other aneurysm screening studies. This study identified a low but 
none the less troubling rate of AAA rupture in patients who had a non aneurysmal aorta on 
the first screening study2. A population based screening study in Gloucester demonstrated 
that 2.2-percent of men aged 65-73 years have a maximal aortic diameter of 2.5 to 2.9 mm 
and suggested that this group of patients should undergo repeat US scanning at 5 yearly 
intervals10. 
The second RCT to study the value of population based screening for AAA was carried out 
in Viborg County of Denmark. In 1994 all men aged between 65 and 74 were randomised to 
either undergo a single screening US or the control group. In all 12639 patients were 
randomised4,11,12. This study reported a 66-percent reduction in the aneurysm related 
mortality which has been maintained over 14-years. In addition they reported a 2-percent 
reduction in overall mortality after long term follow-up which did not reach significance4.  
The Western Australia population based screening was a study of similar design. It 
randomised 41000 men between the ages of 65 and 85 years to a single US screening and a 
control groups. They reported no difference in aneurysm outcomes in the full study 
population but when the analysis was restricted to 65-74 year old men they reported a 
significant reduction in aneurysm related mortality after 5 years of follow-up5. Long term 
follow-up results of this study have not been published as a separate publication to date, 
however in a reply to a correspondence by Lederle, Norman and Lindholt did report a 
surprisingly high, 3-percent reduction in overall mortality in the restricted (65-74 year old) 
patient population after 10 years of follow-up from the Western Australia trial which was 
statistically significant13.  
The MASS trial which was a population based screening RCT for men aged between 65 and 
74 years of age included 4 screening centres in the United Kingdom. This study randomised 
67770 patients again to single screening ultrasound or a control group and was designed to 
study cost effectiveness of screening in addition to reductions aneurysm related and overall 
mortality3,14,15. This study reported a 48-percent relative risk reduction in aneurysm related 
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mortality as a result of screening. This benefit was present at 4 years 14 and was maintained 
at 10 years (Figure-1)3. There was a reduced AAA rupture rate in the patients who were 
invited for screening. Most of these ruptures occurred in patients who were excluded from 
the potential benefits of screening, such as patients who refused or did not attend screening, 
patients who were lost to follow-up and those who either refused or deemed not fit for 
surgery3. The MASS trial also reported a small rate of AAA rupture in patients who did not 
have an AAA on the screening scan, this rate was reported as 3 per 10,000 person years after 
10 years of follow up3. 
 
 
Fig. 1. Cumulative deaths related to abdominal aortic aneurysm, by time since 
randomisation (MASS Trial) 3. From: Thompson SG, Ashton HA, Gao L, Scott RA and 
Multicentre Aneurysm Screening Study Group, Screening men for abdominal aortic 
aneurysm: 10 year mortality and cost effectiveness results from the randomised Multicentre 
Aneurysm Screening Study, BMJ 2009; 338: b2307. 
In addition to the above RCTs a number of systematic reviews and meta-analyses have 
attempted to assess the value of population based screening in the medium and long term. 
Cosford and Leng in a Cochrane systematic review reported that there was significant 
evidence of reduction in aneurysm related mortality from AAA in men aged 65 to 80 years 
who undergo population based ultrasound screening, but no significant reduction in all 
cause mortality16. This review was based on the 3-5 year follow up data from the above 
RCTs. Subsequent to this Norman and Lindholt published a meta-analysis which showed 
that population based AAA screening after 7-15 years of follow up resulted in a reduction of 
both AAA and all cause mortality17. Their findings were contested as the reported 3-percent 
all cause mortality reduction was larger than what was expected by an approximately 50-
percent reduction in aneurysm related mortality, bearing in mind that the mortality from 
AAA in the patient population is reported to be between 1.1 to 3-percent18.  
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Takagi et al. conducted a further meta-analysis of US screening in the male population over 
the age of 65years using long term 10 to 15 year follow up data from the RCTs. They 
reported an absolute risk reduction in aneurysm related mortality of 4 per 1000 subjects 
screened (Figure-2). They also revealed a strong trend towards a significant reduction in all 
cause mortality7. The latter finding was surprising for the reasons mentioned already. The 
authors hypothesized that screening may coincide with the asymptomatic at risk population 
for cardiovascular disease coming in contact with health care professionals and becoming 
aware of smoking risk, their blood pressure etc.  The resultant reduction in cardiovascular 
risk factors may be in part responsible for additional reduction in all cause mortality. Such a 
hypothesis opens the door to the possibility of risk factor alteration and institution of 
secondary prevention measures such as commencement of anti-platelet agents and statin 
therapy during screening programmes thereby increasing the value of the screening7.  
 
 
Fig. 2. Forrest Plot of illustrating the reduction in aneurysm related mortality (A) and the 
trend towards a reduction in overall mortality (B) as a result of population based screening 
of men between the ages of 65 and 80 years after 10 years of follow up7. 
From: Takagi H, Goto SN, Matsui M, Manabe H, Umemoto T. A further meta-analysis of 
population-based screening for abdominal aortic aneurysm. J Vasc Surg. 2010; 52(4):1103-8. 
Cost effectiveness of a population based screening programme is calculated by measuring the 
costs of ultrasound screening as well as the extra procedures and surveillance that is required 
for the screen identified AAA and subtracting them from the costs of treating ruptured AAA. 
It is expressed in cost per life year gained. As the survival advantage in terms of life year 
gained continues to increase with time, the cost effectiveness of screening continues to 
improve. A comprehensive analysis of costs of screening was performed by the MASS trial 
participants. They calculated the cost per life year gained to be £41,000 after 4 years14, £14,000 
after 7 years 15and £7600 after 10 years3. Using the estimated life span of men aged 65 years the 
cost per life year gained is estimated to be in the region of £2300, which is well below the 
guideline figure of £25,000 which is considered acceptable for the adaptation of new medical 
technologies and interventions in the National Health Service of the United Kingdom19. 
Lindholt et al. also performed a comprehensive cost analysis of population based AAA 
screening using data obtained from the Viborg trial. They reported cost per Quality 
The Evidence for Management of Abdominal Aortic  
Aneurysms: Lessons Learned from Randomised Controlled Trials 7 
Adjusted Life Year (QALY) gained as a result of screening to be €179 albeit with relatively 
wide 95% confidence intervals (€-4083 to €4682) 4. Both of these values for costs of screening 
are much lower than the cost analysis carried out by the USPSTF using primarily economic 
modelling in 2003 and suggest that population based AAA screening in men is more cost 
effective than the initial assessments suggested20. 
The role of screening for AAA in women remains controversial. To date there is no evidence 
that screening for AAA in an unselected population of women is associated with a reduction 
even in aneurysm-related mortality. Scott and colleagues conducted the only RCT 
(Chichester trial) which studied the value of screening in women over the age of 65 in an 
unselected population (n=9342) 21. They reported the prevalence of AAA in women to be 1·3 
percent, with other authors reporting a similar rate of 0·7–1·3 percent in unselected 
populations22-24. Scott et al. did not demonstrate a difference in rupture rates between the 
women randomized to screening and control populations of women at 5- and 10-year 
follow-up21. They concluded that screening for women was neither clinically indicated nor 
economically viable21. This study was limited by high rate of non attendance of women for 
AAA screening which ranged between 27 and 42-percent depending on patients age. They 
screened an unselected population of women without consideration of risk factors for 
aneurysm disease and fitness for repair; consequently a large proportion of women who 
were found to have an AAA did not undergo aneurysm repair25. The UK Small Aneurysm 
Trial revealed that female sex was an independent risk factor for AAA rupture; the rupture 
rate in women was three times higher than that in men, despite a smaller initial AP 
diameter. Furthermore, mean AP diameter preceding rupture was significantly lower in 
women than men26. A number of other authors have reported a higher growth and rupture 
rate of AAA in women 27-33. A Finnish community-based follow-up study reported that the 
aortic diameter was less than 5·5 cm in 24 per cent of women with a ruptured AAA, 
compared with only 5 per cent of men21. In light of these findings the 6 cm cut off value for 
repair of AAA in Chichester trial may have been too large to prevent aneurysm rupture in a 
proportion of screened women thereby reducing the value of screening in women.  
For screening to be effective in reducing aneurysm-related mortality in women, it will need 
to be limited to high-risk women who are fit to undergo aneurysm repair22. There is 
increasing evidence that women with atherosclerotic disease are at significantly higher risk 
of developing AAA. Derubertis and colleagues22 reported that the prevalence of AAA in 
women with multiple (more than three) atherosclerotic risk factors was 6·4 per cent. When 
these findings are considered in conjunction with the increased growth rates of AAA26 and 
higher aneurysm rupture rate in women, screening in women with multiple risk factors for 
AAA may become clinically and economically viable34-36. 
3. Optimum therapeutic strategy for small AAAs 
Abdominal aortic aneurysms are treated in order to prevent rupture and the associated 
mortality. Aneurysm treatment has its own associated morbidity and mortality. Open 
surgical repair is an invasive procedure which is tolerated poorly by the subgroup of 
patients with multiple medical co-morbidities. Even endovascular repair cannot be 
accomplished without an obligatory complication rate as a result of the initial deployment 
of the stent graft, in addition to which a proportion of patients require secondary 
procedures necessary to address complications such as endoleaks, device migration and 
stent thrombosis requiring long term close surveillance37. A small proportion of patients 
 
Aneurysmal Disease of the Thoracic and Abdominal Aorta 6 
Takagi et al. conducted a further meta-analysis of US screening in the male population over 
the age of 65years using long term 10 to 15 year follow up data from the RCTs. They 
reported an absolute risk reduction in aneurysm related mortality of 4 per 1000 subjects 
screened (Figure-2). They also revealed a strong trend towards a significant reduction in all 
cause mortality7. The latter finding was surprising for the reasons mentioned already. The 
authors hypothesized that screening may coincide with the asymptomatic at risk population 
for cardiovascular disease coming in contact with health care professionals and becoming 
aware of smoking risk, their blood pressure etc.  The resultant reduction in cardiovascular 
risk factors may be in part responsible for additional reduction in all cause mortality. Such a 
hypothesis opens the door to the possibility of risk factor alteration and institution of 
secondary prevention measures such as commencement of anti-platelet agents and statin 
therapy during screening programmes thereby increasing the value of the screening7.  
 
 
Fig. 2. Forrest Plot of illustrating the reduction in aneurysm related mortality (A) and the 
trend towards a reduction in overall mortality (B) as a result of population based screening 
of men between the ages of 65 and 80 years after 10 years of follow up7. 
From: Takagi H, Goto SN, Matsui M, Manabe H, Umemoto T. A further meta-analysis of 
population-based screening for abdominal aortic aneurysm. J Vasc Surg. 2010; 52(4):1103-8. 
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Adjusted Life Year (QALY) gained as a result of screening to be €179 albeit with relatively 
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accomplished without an obligatory complication rate as a result of the initial deployment 
of the stent graft, in addition to which a proportion of patients require secondary 
procedures necessary to address complications such as endoleaks, device migration and 
stent thrombosis requiring long term close surveillance37. A small proportion of patients 
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who have undergone endovascular repair (EVAR) succumb to rupture. Therefore the 
natural history of the AAA needs to be balanced against the risk associated with treatment.  
Aneurysm diameter is one variable which has been consistently associated with the risk of 
rupture and has therefore been used to stratify patients into risk categories which decides 
whether US based surveillance or intervention is required to repair the aneurysm. In 
patients who are entered into surveillance programmes the maximum diameter of the 
aneurysm is used to decide on the frequency of scanning. In case of aneurysms greater than 
5.5 cm there is consensus that risk of rupture mandates repair if the patient is fit to undergo 
the procedure. In the case of aneurysms less than 4.0 cm in diameter, most clinicians agree 
on a watchful waiting approach. The evidence for the optimum therapeutic strategy in the 
mid-sized aortic aneurysms (maximum diameter between 4.0 to 5.5 cm in diameter) has 
been strengthened by a number of randomised controlled trials in the last 20 years which 
have consolidated the modern management of AAA26,38-41.  
The UK small aneurysm trial (UKSAT) was a multicentre RCT which randomised 1090 
patients, who were diagnosed as having an AAA with maximum AP diameter of 4.0 to 
5.5cm and were deemed fit to undergo an open repair of AAA to either immediate open 
repair or 3 monthly ultrasound surveillance. They reported the rupture rate of these AAA in 
the surveillance group to be in the 1-percent per year. They did not find any significant 
difference in aneurysm related or all cause mortality between the two groups after a follow 
up period of 7 years (Figure-3)26. During the follow up period over two thirds of patients 
who were randomised to surveillance had undergone repair of their aneurysms based on 
clinical grounds. 26 Long term follow up data from the small aneurysm trial has confirmed 
the initial findings of the UKSAT38.  
 
 
Fig. 3. Kaplan-Meier survival curves comparing survival of patients with small abdominal 
aortic aneurysms randomised to ultrasound surveillance and early surgery from UK small 
aneurysm trial26. From: United Kingdom Small Aneurysm Trial Participants. Long-term 
outcomes of immediate repair compared with surveillance of small abdominal aortic 
aneurysms. Lancet 1998;352: 1649-55. 
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A number of years after the publication of the UKSAT, the Veterans Affairs Cooperative 
Study group published the Aneurysm Detection and Management ADAM study39. This 
study involved screening of 126,196 veterans aged between 50 and 79 years of age for AAA 
with a single abdominal US. Those with AAA measuring 4.0 to 5.4 cm in diameter were 
offered entry to the trial. In all, 1136 subjects were randomly assigned to undergo early 
elective repair or ultrasound surveillance. Annualized rupture rate in the surveillance arm 
of the study was 0.6-percent, with no difference in aneurysm related and overall mortality 
between the two arms of the study 39. In this study as in UKSAT the majority of patients in 
the surveillance arm of the study had undergone elective repair after 8 years of follow up 
based on clinical grounds (symptomatic aneurysm, growth to greater than 5.5cm in 
diameter or rapid expansion by greater than 1 cm per year) 39. Completion of these two 
landmark trials which utilised open elective repair coincided with the advent and 
generalised use of endovascular repair as a primary  modality treatment of AAA. This 
resulted in some authors questioning the validity of these landmark trials in the era of 
endovascular repair and suggested that as endovascular repair can be performed with 
significantly lower peri-procedural morbidity and mortality a policy of surveillance for 
smaller AAAs should be examined against endovascular repair. 
To date two randomised controlled trials (PIVOTAL40 and CAESAR41) have been conducted 
to compare early endovascular repair of small AAAs with ultrasound surveillance. The 
prerequisite for both studies was that the patients which were randomised had AAAs which 
were anatomically suitable for endovascular repair.   
The PIVOTAL trial which was published in 2010, randomised 728 patients with AAAs 
measuring 40 to 50 mm in diameter to ultrasound based surveillance or early 
endovascular repair40. The mean duration of follow up was 20 months (+/-12 months) 
they found no difference in all cause or aneurysm related mortality between the two 
groups 40. At the end of the relatively short follow up duration almost one third of 
patients who were in the surveillance group had undergone an aneurysm repair based on 
clinical grounds40. The other study of a similar design was the CAESAR trial which 
randomised 360 patients with AAAs measuring between 40 and 54 mm to early 
endovascular repair or a watchful waiting strategy. 41 After 54 months of follow up there 
was no significant difference in rupture rates, aneurysm related and overall mortality 
between the two groups (Figure-4). This study revealed that the probability of the patients 
in the surveillance arm of the study requiring delayed repair based on clinical grounds 
during the duration of follow up was 60-percent41. In addition they reported that 16.4-
percent of aneurysms which upon entry into the trial were suitable for endovascular 
repair will be no longer suitable for EVAR after 36 months41.  
A constant finding in these trials has been that a significant proportion of AAAs under 
ultrasonographic surveillance come to require repair within the duration of the study26,39. 
This, taken together with the low but present annual risk of rupture has lead to differing 
interpretations of the results of these trials with some authors still advocating in favour of 
early repair of small AAA using the justification that a policy of early EVAR is as safe as a 
policy of US Surveillance42. To date there is no objective data to recommend either open or 
endovascular repair of smaller AAAs over a policy of watchful waiting and US surveillance. 
A policy of early EVAR is associated with a risk of early and delayed complications and a 
need for secondary procedures, thus mandating the need for close surveillance in patients 
who undergo early EVAR. It is therefore unlikely that there will be an economic justification 
for early endovascular repair.   
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prerequisite for both studies was that the patients which were randomised had AAAs which 
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The PIVOTAL trial which was published in 2010, randomised 728 patients with AAAs 
measuring 40 to 50 mm in diameter to ultrasound based surveillance or early 
endovascular repair40. The mean duration of follow up was 20 months (+/-12 months) 
they found no difference in all cause or aneurysm related mortality between the two 
groups 40. At the end of the relatively short follow up duration almost one third of 
patients who were in the surveillance group had undergone an aneurysm repair based on 
clinical grounds40. The other study of a similar design was the CAESAR trial which 
randomised 360 patients with AAAs measuring between 40 and 54 mm to early 
endovascular repair or a watchful waiting strategy. 41 After 54 months of follow up there 
was no significant difference in rupture rates, aneurysm related and overall mortality 
between the two groups (Figure-4). This study revealed that the probability of the patients 
in the surveillance arm of the study requiring delayed repair based on clinical grounds 
during the duration of follow up was 60-percent41. In addition they reported that 16.4-
percent of aneurysms which upon entry into the trial were suitable for endovascular 
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Fig. 4. Kaplan–Meier estimates of survival at 54 months from time of randomisation in 
EVAR versus Surveillance groups. P = 0.6. Numbers at risk are shown. CAESAR trial41. 
From:Cao P; DeRango P, Verzini F, Parlani G et al. Comparison of surveillance vs Aortic 
Endografting for Small Aneurysm Repair (CAESAR) trial: results of a randomised 
controlled trial. Eur J Vasc Endovasc Surg. 2011; 41(1): 13-25. 
4. Open versus endovascular repair of AAA 
Ever since its inception, EVAR has offered the promise of reducing the perioperative 
morbidity and mortality which has been associated with open elective repair. By the end of 
last century, data from EVAR registries such as RETA 43and EUROSTAR 44 suggested that 
endovascular repair, although safe was associated with an immediate complication rate in 
addition to events such as endoleak and device migration which mandate lifelong 
surveillance and in a group of patients re-intervention. As with any new or emerging 
technology or intervention the case for primacy of EVAR over open repair in terms of 
perioperative mortality rate, post operative complications and cost effectiveness needs to be 
made using good quality evidence. A number of trials with a similar design have been 
commissioned in order to compare the outcomes following EVAR and open repair of AAA 
in patients who are anatomically suitable to undergo endovascular repair and fit to undergo 
open repair. These include the Dutch Randomised Endovascular Aneurysm Management 
(DREAM) 45,46trial, EVAR-1 Trial (United Kingdom) 47, ACE trial (France) 48 and Open 
Versus Endovascular Repair (OVER) of abdominal aortic aneurysms trial (United States) 49. 
The DREAM trial which was the first to report its results enrolled 351 patients between 
November 2000 and December 2003 from 24 centres in the Netherlands and 4 centres in 
Belgium. This study focused on short term combined mortality and morbidity outcomes45. It 
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reported a significantly lower operative mortality and severe complication rates in the 
EVAR group compared to the patients who had been randomised to open repair. At 2 years 
follow up aneurysm related mortality following EVAR was still significantly lower than 
open repair (2.1% versus 5.7%) however after 2 years of follow up there was no significant 
difference in the overall survival rates or freedom from moderate to severe complications 
between the two groups. The conclusions drawn from this trial was that there was a 
significant reduction in early morbidity and mortality following EVAR compared to open 
aneurysm repair but this difference is not sustained past 2 years45,46. 
EVAR-1 trial was a multicentre RCT which was conducted in 37 hospitals in the UK. It 
randomised 1252 patients with large AAA to either open or endovascular repair. Unlike the 
DREAM trial, EVAR-1 was designed to perform a comparison of long term survival, graft 
durability, quality of life and hospital costs associated with open repair and EVAR in 
addition to comparing short term mortality and morbidity between the two groups47.  They 
reported a significantly lower in perioperative morbidity and mortality following EVAR. 
Four years after randomisation, all cause mortality was similar between the two groups, 
although there was a persistent reduction in aneurysm related mortality in the EVAR 
group,(Figure-5)47. After 12 months there was no difference in quality of life scores between 
the two groups with a greater number of complications and re-interventions at 4 years in the 




Fig. 5. EVAR-1 Kaplan-Meier survival curves comparing aneurysm related and overall 
mortality between patients who have been randomised to open elective and endovascular 
(EVAR) repair of AAA (EVAR-1 trial)47. From: EVAR trial participants. Endovascular 
aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 
1): randomised controlled trial. Lancet 2005; 365(9478): 2179-86. 
The OVER trial is a RCT which included 42 Veterans Affairs medical centres in the United 
States. It randomised 881 patients who had AAA with a greater than 50 mm in maximal 
diameter, an iliac aneurysm greater than 30mm in diameter or rapid sac expansion, to 
elective open repair or EVAR. The preliminary results from this study indicated that the 
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reported a significantly lower operative mortality and severe complication rates in the 
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open repair (2.1% versus 5.7%) however after 2 years of follow up there was no significant 
difference in the overall survival rates or freedom from moderate to severe complications 
between the two groups. The conclusions drawn from this trial was that there was a 
significant reduction in early morbidity and mortality following EVAR compared to open 
aneurysm repair but this difference is not sustained past 2 years45,46. 
EVAR-1 trial was a multicentre RCT which was conducted in 37 hospitals in the UK. It 
randomised 1252 patients with large AAA to either open or endovascular repair. Unlike the 
DREAM trial, EVAR-1 was designed to perform a comparison of long term survival, graft 
durability, quality of life and hospital costs associated with open repair and EVAR in 
addition to comparing short term mortality and morbidity between the two groups47.  They 
reported a significantly lower in perioperative morbidity and mortality following EVAR. 
Four years after randomisation, all cause mortality was similar between the two groups, 
although there was a persistent reduction in aneurysm related mortality in the EVAR 
group,(Figure-5)47. After 12 months there was no difference in quality of life scores between 
the two groups with a greater number of complications and re-interventions at 4 years in the 
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1): randomised controlled trial. Lancet 2005; 365(9478): 2179-86. 
The OVER trial is a RCT which included 42 Veterans Affairs medical centres in the United 
States. It randomised 881 patients who had AAA with a greater than 50 mm in maximal 
diameter, an iliac aneurysm greater than 30mm in diameter or rapid sac expansion, to 
elective open repair or EVAR. The preliminary results from this study indicated that the 
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EVAR group had significantly lower 30-day mortality as well as all cause mortality49. After a 
mean follow up of 1.8 years the complication rate was not significantly different between the 
two groups nor was the secondary reintervention rate. As in the DREAM trial, the 
reintervention following EVAR was mainly due to a device related complications whereas 
the commonest reason for reintervention following open repair was for incisional hernia46,49. 
Early results from the ACE trial suggest similar early mortality benefit following 
endovascular repair which is lost after medium term follow up48. 
Some subgroups of patients such as those who have significant co-morbidities such as 
cardiovascular or respiratory disease, octogenarians and women with AAA, require an 
individualised approach and revised criteria for the management of AAA. From its 
inception EVAR has provided the promise of repairing AAA in patients in whom open 
repair poses a high risk. Therefore armed with the knowledge that smaller AAAs are best 
managed by a policy of watchful waiting, EVAR appeared to be an ideal modality for the 
management of patients with larger AAAs which are anatomically suitable for endovascular 
repair, have a reasonable predicted longevity but are unfit to undergo open repair. The 
EVAR-2 trial was designed to answer this question. EVAR-2 trial was a randomised 
controlled trial of 338 patients who had an AAA with a maximum diameter of greater than 
5.5cm and their aneurysm morphology was anatomically suitable for EVAR, but were 
medically unsuitable to undergo open repair. Primary endpoint was all-cause mortality, 
with secondary endpoints of aneurysm-related mortality, health-related quality of life, 
postoperative complications, and hospital costs50. 
The 30-day operative mortality in the EVAR group was 9.0-percent and the no intervention 
group had an annual rupture rate of 9·0-percent per year. Aneurysm related mortality in the 
patient population was 13-percent and all cause mortality after 4 years of follow up was 64-
percent 50.  
 
 
Fig. 6. Kaplan-Meier curves comparing aneurysm related and overall mortality between 
patients who have been randomised to EVAR and no intervention group (EVAR-2 trial)50. 
From: EVAR trial participants. Endovascular aneurysm repair and outcome in patients unfit 
for open repair of abdominal aortic aneurysm (EVAR trial 2): randomised controlled trial. 
Lancet 2005; 365(9478): 2187–92. 
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There was no significant difference in all-cause mortality between the EVAR group and the 
no intervention group (hazard ratio 1·21, 95% CI 0·87–1·69). There was no difference in 
aneurysm-related mortality (Figure-6) 50. A policy of early endovascular repair was 
significantly more expensive than expectant management and was associated with a higher 
complication and reintervention rate. There was no difference in quality of life scores 
between the two arms of the study50. Therefore the conclusion drawn by the authors was 
that this population of patients are best served by conservative treatment. Clearly the design 
of such a study provides one difficulty and that is the definition of not fit for open AAA 
repair is subject to clinical opinion and may be related to factors that do not affect patient’s 
longevity. The other group of patients are those with one organ morbidity such as 
respiratory disease or border line medical fitness, who have a large AAA and favourable 
anatomy for endovascular repair. Therefore clinical judgement is exercised in the 
application of results of EVAR-2 trial.  
5. Medical treatment of patients with AAA 
In addition to risk of growth and rupture, patients with AAA are at risk from other 
cardiovascular events by the virtue of their age, medical co-morbidities and male 
preponderance of AAA. Medical management of patients with known AAA follows two 
parallel but different aims, reducing cardiovascular event rates perioperatively and during 
follow up in addition to aneurysm specific therapy which is aimed at slowing aneurysm 
growth and reducing the risk of rupture51-53. 
Hyperlipidaemia, a known modifiable risk factor in the development of cardio-vascular 
disease, can be treated with the use of drugs such as the statins (3-hydroxyl-3-
methylglutaryl coenzyme A reductase inhibitors). Patients with AAA are known to be at 
high risk of cardio-vascular disease as well as increased risk of cardio-vascular 
complications following AAA repair 54. Statin therapy has been associated with improved 
survival due to decreased risk of cardio-vascular complications, in both open and 
endovascular repair 54-58.  Although the primary mechanism of statins is in reducing low 
density lipoproteins and total cholesterol levels along with increasing levels of high density 
lipoproteins, other protective non lipid mechanism may be at work. These so called 
pleiotropic effects describe a diversity of cellular events which have an effect on several 
components of the arterial wall, including: endothelial cells; smooth muscle cells; platelet 
function, monocytes and macrophages, which together help to modify the inflammatory 
process in the vessel wall. Statins have been shown to be beneficial in the secondary 
prevention of coronary heart disease even in those patients with normal lipid profiles59-60. 
Matrix Metallo Proteinase-9 (MMP-9) expression is closely linked to aneurysm formation in 
animal models. In vitro experiments have shown that addition of Cerivstatins to human 
organ cultures from AAA reduces tissue levels of both total and active MMP-9 in a 
concentration dependent manner. Evans et al reported significantly reduced MMP-9 levels 
in excised tissue obtained from the aneurysm sac at the time of the aneurysm repair in 
patients who had been started on statins 3-weeks preoperatively compared with controls59. 
Schouten et al monitored 150 patients with small AAAs for 12 months and reported a 
reduction in the aneurysm expansion rate in patients receiving statin therapy60. In an 
observational study of 130 patients under surveillance, Sukhija reported no aneurysm 
expansion in 75 patients who were on statin therapy over a 2 year follow up period61. 
Schlosser et al in an analysis of the results of a large observational cohort study which 
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EVAR group had significantly lower 30-day mortality as well as all cause mortality49. After a 
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group had an annual rupture rate of 9·0-percent per year. Aneurysm related mortality in the 
patient population was 13-percent and all cause mortality after 4 years of follow up was 64-
percent 50.  
 
 
Fig. 6. Kaplan-Meier curves comparing aneurysm related and overall mortality between 
patients who have been randomised to EVAR and no intervention group (EVAR-2 trial)50. 
From: EVAR trial participants. Endovascular aneurysm repair and outcome in patients unfit 
for open repair of abdominal aortic aneurysm (EVAR trial 2): randomised controlled trial. 
Lancet 2005; 365(9478): 2187–92. 
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There was no significant difference in all-cause mortality between the EVAR group and the 
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between the two arms of the study50. Therefore the conclusion drawn by the authors was 
that this population of patients are best served by conservative treatment. Clearly the design 
of such a study provides one difficulty and that is the definition of not fit for open AAA 
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application of results of EVAR-2 trial.  
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prevention of coronary heart disease even in those patients with normal lipid profiles59-60. 
Matrix Metallo Proteinase-9 (MMP-9) expression is closely linked to aneurysm formation in 
animal models. In vitro experiments have shown that addition of Cerivstatins to human 
organ cultures from AAA reduces tissue levels of both total and active MMP-9 in a 
concentration dependent manner. Evans et al reported significantly reduced MMP-9 levels 
in excised tissue obtained from the aneurysm sac at the time of the aneurysm repair in 
patients who had been started on statins 3-weeks preoperatively compared with controls59. 
Schouten et al monitored 150 patients with small AAAs for 12 months and reported a 
reduction in the aneurysm expansion rate in patients receiving statin therapy60. In an 
observational study of 130 patients under surveillance, Sukhija reported no aneurysm 
expansion in 75 patients who were on statin therapy over a 2 year follow up period61. 
Schlosser et al in an analysis of the results of a large observational cohort study which 
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involved 5057 patients with vascular disease (Second Manifestation of ARTerial disease 
(SMART) study) and included 230 patients with small AAA revealed an independent 
association between statin therapy and reduced aneurysm growth rate. This reduced growth 
and rupture rates were independent of serum lipid values62,63.  
Over the years there has been some interest in β-blockers, both to slow the growth rate of 
AAA and to reduce perioperative morbidity form cardiovascular events. The benefit was 
postulated partly due to their haemodynamic properties and partly due to the effect of β-
blockers on matrix proteins. In a trial reported by Lindholt and colleagues the use of 
Propranolol did not reduce the rate of expansion of AAA, admittedly in the treatment arm 
of the study the compliance was poor with only 22-percent continuing on Propranolol by 2-
years64. Another trial which was carried out in Canada came to a similar conclusion owing 
to poor patient compliance in the treatment arm of the study65.   
In the last 15 years there has been significant interest in using peri-operative β-blockade as a 
means of increasing myocardial oxygen delivery thereby reducing the risk of perioperative 
myocardial infarction and death.  Mangano et al randomised 200 patients who were 
undergoing major elective non-cardiac surgery to either receive Atenolol or placebo. This 
was started before the induction of anaesthesia. Patients with evidence of congestive cardiac 
failure, systolic blood pressure of less than 100mmHg orpulse rate of less than 55 beats 
/minute, 3rd degree heart block or broncho-spasm were excluded. This treatment was 
continued for 6 months postoperatively. They reported a significant reduction in 
cardiovascular event rate and death from cardiac causes66. 
Poldermans and colleagues performed a similar study in patients undergoing elective 
aneurysm or infrainguinal arterial reconstruction. They screened 1351 patients for cardiac 
disease using Dobutamine stress testing, 173 patients had a positive test of whom 59 were 
randomised to receive Bisoprolol and 53 placebo67.  They also reported a significant 
reduction in non fatal cardiac events as well as cardiac death. In these patients β-blockade 
was started at least a week in advance of the operation and they were screened for 
bradycardia and hypotension preoperatively67.  
POISE was a large international randomised controlled trial of the use of extended release 
Metoprolol in patients undergoing non-cardiac surgery, the study randomised 8351 patients 
to either receive Metoprolol or placebo which was started 2-4 hrs before surgery and 
continued for 30 days. They reported a significantly reduced risk of myocardial infarction in 
the Metoprolol group but at the expense of higher mortality and stroke rate in the treatment 
arm of the study68. Similarly, Yang et al randomised such patients undergoing major 
vascular surgery, not already β-blocked, to dose adjusted Metoprolol or placebo 2 hours 
prior to surgery and until discharge or maximum of 5 post-operative days, and found no 
protective effects of β-blockade in terms of 30 day myocardial infarction and death rates69. β-
blockade did result in significantly more episodes of bradycardia and hypotension. In light 
of these findings the American Heart Association guidelines regarding perioperative β-
blocker therapy in patients undergoing non cardiac surgery have been altered to be more 
cautious and circumspective (Table-)70. 
In a large observational study, Hackham et al have shown that the use of Angiotensin 
Converting Enzyme Inhibitor (ACEI) therapy taken 3-12 months prior to data analysis 
significantly reduced the risk of rupture from AAA, independently of blood pressure71. This 
data was obtained from a large administrative database of 3379 patients with ruptured and 
11947 with non ruptured AAA. Other anti-hypertensive medications had no such effect 71. 
Interestingly, patients who had stopped ACEI therapy prior to admission were more likely 
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to present with ruptured AAA 71. The effect of ACEI on expansion of AAA is still equivocal, 
with some studies demonstrating no protective effect of ACEI therapy 72-73. Thompson et al 
in a recent observational study of 1269 patients with small AAA who were followed up for a 
mean of 3.4 years, reported a significant reduction in aneurysm growth rate as a result of 
ACE inhibitor therapy72. The follow up data from UK small aneurysm trial does not support 
the above finding74. 
Infection with Chlamydiae pneumonia has been postulated as a risk factor for AAA 
expansion, as the organism has been isolated from atherosclerotic plaque and the walls of 
AAA 75,76. Three small trials have aimed to elucidate the effect of the antibiotics Doxycycline 
and Roxithromycin in AAA growth, two of which have shown reduced aortic expansion 
associated with treatment 77,78, whilst another one by Baxter and colleagues showed no effect 
of doxycycline on aortic diameter 79. These three trials were limited by their small numbers. 
In addition administration of Doxycycline has been shown to suppress MMP-9 in both 
human and animal studies 79-81, suggesting that the reduction in aneurysm expansion rate 
with administration Doxycycline may be mediated through a mechanism which is 
independent from treatment of Chlamydiae pneumoniae infection. 
To date there is no conclusive evidence that any medical therapy is associated with a 
reduction in aneurysm growth or risk of rupture. However diagnosis of AAA provides a 
forum for instituting appropriate secondary prevention therapies, which will reduce 
morbidity and mortality in the peri-operative period as well reduce long term cardio-
vascular risk. There is some evidence that instituting some of these treatments such as statin 
therapy, ACE inhibitors may well have an effect on aneurysm growth and rupture rates.  
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1. Introduction 
The history and evolution of aortic aneurysm repair demonstrates an important paradigm 
within surgery, namely the importance of surgical pioneers and innovators who have 
strived to achieve technical excellence and improve patient care. It also highlights the wider 
evolution of surgery from traditional open operative techniques to the modern minimally 
invasive procedures. The following chapter discusses the surgical innovators and the 
techniques they have described that have enabled the repair of both thoracic aortic 
aneurysms (TAA) and abdominal aortic aneurysms (AAA).  
Aortic aneurysms represent a significant health risk particularly for the elderly population. 
AAA is the 14th-leading cause of death for the 60- to 85-year–old age group in the United 
States (10.8 deaths per 100,000 population). TAA by contrast is less frequent with an 
incidence of 10.4 per 100,000. Both AAA and TAA are known to increase in prevalence with 
advancing age and have an increased prevalence in males. The risk of aneurysm rupture 
increases with increasing aneurysm diameter over 5.5-6.0 cm and is the primary indication 
for the repair of both TAA and AAA. Therefore surgery to repair both AAA and TAA is 
either pre-emptive to prevent rupture or emergent to repair a rupture. Repair of TAA and 
AAA by either open or minimally invasive techniques significantly reduces the risk of 
rupture and improves patient mortality. The establishment of these techniques has required 
the development of procedures from embryonic thoughts in the minds of the surgeons of 
antiquity through to the utilisation of ever increasing modern technologies.  
2. History of aortic aneurysm repair 
The Ebers Papyrus of approximately 2000BC describes arterial aneurysms among diseases 
afflicting the Egyptians albeit the site of the aneurysms is not mentioned. Yet given Egyptian 
embalmers reluctance to open body cavities it is likely that the aneurysms were evident 
upon the external surface of the body. There is no convincing evidence to suggest that the 
ancient Egyptians attempted aneurysm repair, although it was advised “to treat it with a 
knife and burn it with a fire so that it bleeds not too much” (Thompson, 1998). Unlike 
atherosclerosis, no aneurysms have been  found in Egyptian mummies. 
The most important surgeon with respect to aortic aneurysm surgery in antiquity is the third 
century Greek surgeon, Antyllus, who should rightly be regarded as the ‘Father of Aneurysm 
Surgery’ if not vascular surgery as a whole. Indeed he has been described as a ‘comet on the 
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surgical horizon’ for his pioneering work on aneurysm repair (Major, 1954). This innovative 
surgeon attempted surgical repair of abdominal aortic aneurysm which has led to the term the 
Antyllus method; ligation of the artery above and below an aneurysm, followed by incision 
into and emptying of the sac. Antyllus was also the first to recognize two forms of aneurysm. 
The developmental type caused by dilation, which pertains to this chapter, and those which 
follow arterial trauma. He also created a taxonomy related to an aneurysm's potential for 
rupture. Much of Antyllus’s remarkable pioneering work and his surgical methods of 
aneurysmal repair would have been lost to history were it not for the writings of the Greek 
medical writer and physician Oribasius. It is clear that Antyllus also developed specific 
instructions for a number of operations including hydrocele repair and cataract surgery. He 
also listed the indications and contraindications for surgery and described the complications 
that could arise from the operations. In large part, Antyllus’s operation for aneurysm remained 
the standard procedure until the 19th century thereby illustrating his surgical genius. 
Antyllus's contribution toward the development of modern vascular surgery cannot be 
overstated. Indeed he should be held in the same regard as the dominant figure of Greek 
medicine, Galen who also described traumatic aneurysms and noted that rupture could be 
forestalled in some circumstances by external compression. Galen, the physician to the 
Roman gladiators, would have treated traumatic aneurysms following venesection in the 
cubital fossa- lesions which were easier to observe than AAA and TAA. Taken together, the 
work of Antyllus and Galen established the foundations for future surgeons to develop the 
techniques required for successful aortic aneurysm surgery and repair. 
In the fifth century AD the Byzantine physician Aëtius of Amida described a now well-
established principle of operative treatment of aneurysms in which proximal arterial control 
is followed by ligature from within the aneurysm of the orifices of inflow and outflow 
vessels, thus building upon Antyllus’s method. In addition he described the clinical signs of 
aneurysms mentioning that they can occur in any part of the body including the head.  
Unfortunately, there again followed a long hiatus in the history of aortic aneurysm repair. 
The next significant contribution was in 1452 by the French physician Jean Francois Fernel 
who observed that aneurysms could occur in the chest, adjacent to the spleen and within 
the mesentery of the bowel. It is not clear whether Fernel was referring to thoracic 
aneurysms at this stage. Andreas Vesalius offered the first clinical description of an 
aneurysm of the abdominal aorta, while his 16th century contemporary Ambroise Pare 
stated that arterial wall degeneration can be caused by syphilis, that aneurysms may 
thrombose and that injudicious incision of an inflamed pulsatile mass may cause 
exsanguinating haemorrhage.  
The English physicians and brothers William and John Hunter portrayed a unique 
experimental and clinical genius rarely present in late 18th century medicine. They made 
significant advances in both the physiology and surgical repair of blood vessels and 
pioneered the treatment of peripheral aneurysms. Indeed their important contributions to 
vascular surgery have prevailed until today while their studies of aneurysm formation, 
pathology and treatment laid the foundation for modern aneurysm repair. John Hunter 
developed a successful operation for popliteal aneurysm based on his meticulous laboratory 
investigations on collateral blood flow which led to a more logical approach to these lesions 
with improved proximal arterial occlusion by ligature.  
One of John Hunter’s pupils, the English surgeon and anatomist Astley Cooper, applied 
Hunterian principles for ligation of aneurysms of common carotid and internal and external 
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iliac artery aneurysms. In 1817 he was the first surgeon to ligate the abdominal aorta 
proximal to a leaking left iliac artery aneurysm. 
The early 20th century saw an explosion in numerous novel attempts to repair and halt the 
inexorable growth of aneurysms in the decades before the development of modern vascular 
surgical techniques. Yet, despite extensive research and application of experimental 
techniques AAA repair remained unsuccessful until 1923 when the American surgeon 
Rudolph Matas renovated the approach of Antyllus and Aëtius of Amida and carried out 
endoaneurysmal ligature of peripheral aneurysms. The approach spared collaterals around 
the aneurysmal sac. Matas also first proposed the concept of endoaneurysmorrhaphy and 
performed the first successful aortic ligation on a human. The Canadian physician William 
Osler called him the ‘Father of Vascular Surgery’ but perhaps this would be better reserved 
for Antyllus. Other novel techniques for AAA repair included arterial walls that were 
scarified with talc, wrapped in polythene or cellophane or filled with meters of wire to 
which a galvanic current could be applied. Notably Albert Einstein was operated upon by 
Rudolf Nissen in 1949 using the polythene/cellophane technique, and survived six years 
after the operation when the aneurysm ruptured. 
The 1950’s was the decade which heralded the modern era of aortic aneurysm surgery. In 
1951, Lam and Aram reported the first successful repair of a thoracic aortic aneurysm while 
in the same year the first successful AAA resection with allograft reconstruction was 
reported by Charles Dubost in Paris (Dubost C et al, 1951). In 1953 Bahnson reported a series 
of saccular aneurysms repaired using a technique of lateral resection with primary suture 
(Bahnson, 1953). The development of treatment modalities for thoracic aneurysms followed 
successful treatment of AAA almost akin to a domino effect. Most of the initial successful 
repairs involved the use of preserved aortic allografts, thus triggering the establishment of 
numerous aortic allograft banks. Simultaneously, Gross and colleagues successfully used 
allografts to treat complex thoracic aortic coarctations, including those with aneurysmal 
involvement (Gross et al, 1948). Ascending aortic replacement required the development of 
cardiopulmonary bypass and was first performed in 1956 by the American surgeons Cooley 
and DeBakey (Cooley & DeBakey, 1957). They successfully replaced the ascending aorta 
with an aortic allograft. Successful replacement of the aortic arch with its inherent risk of 
cerebral ischaemia was understandably more challenging and was not reported until 1957 
again by DeBakey et al (DeBakey et al, 1957). Although the use of aortic allografts as aortic 
replacement was widely accepted in the early 1950s, the search for synthetic substitutes was 
well underway prompted by the inevitable aneurysmal degeneration of such allografts. The 
synthetic material Dacron was introduced by DeBakey and by 1955, Deterling and Bhonslay 
believed that Dacron was the best material for aortic substitution (Deterling & Bhonslay, 
1955), a conclusion which pertains to the present time. 
Finally, in 1966, Oscar Creech, a pupil of Rudolf Matas, emphasized the virtues of intra-
saccular graft interposition now universally used for open aortic aneurysmal repair. 
Following in the footsteps of the ancient pioneering surgeons, later surgeons have 
developed the techniques of both open and minimally invasive aortic aneurysm repair.  
3. Open repair of abdominal aortic aneurysm 
3.1 Open AAA repair 
The advances dating from Antyllus through to Oscar Creech led to the development of a 
standard operative procedure to repair AAA. More recently, non-invasive screening 
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programs and a dramatic rise in the elderly population have led to an increased incidence of 
asymptomatic AAA. Despite adopting an aggressive surgical posture toward elective repair 
of AAA the incidence of ruptured AAA has continued to increase. Annually 35 000 to 40 000 
aneurysms are repaired in the United States. AAAs are conventionally defined as a ≥50% 
increase in aortic diameter compared with the normal proximal aorta. Indications for 
surgical replacement of aneurysms are determined by weighing the risk of rupture against 
the surgical morbidity and mortality rates. Repair is generally indicated when the diameter 
of the aneurysm exceeds 5.5 cm (Lederle et al 2002), the annual expansion rate exceeds 1 cm 
per year or when the aortic aneurysm becomes symptomatic.  
Comprehensive radiological imaging forms the basis of planning open AAA repair. Figure 1 
shows the typical appearance of an AAA on transverse computed tomography (CT).  
 
 
Fig. 1. Typical appearance of a fusiform AAA as seen on transverse CT. The aneurysm 
contains thrombus with radio-contrast seen within the lumen. 
CT defines the aneurysm in terms of morphology, either fusiform or saccular, but more 
importantly defines the anatomy of the aneurysm neck. Ninety five per cent of AAA are 
infra-renal, ie. the neck of the aneurysm originates below the origin of the renal arteries and 
thus aneurysm replacement is associated with fewer post-operative complications when 
compared to supra-renal AAA replacement when the aneurysm neck originates above the 
renal arteries (see below). Aneurysms that involve the descending thoracic and abdominal 
components of the aorta can be described by the Crawford classification (Table 1). This 
classification is of practical use when considering intervention, for example, in choosing the 
extent of the incision and planning implantation. For instance a laparotomy will often 
suffice for repair of a type IV aneurysm whilst a thoraco-laparotomy is required for a type II 
aneurysm.  
Open aneurysm repair using homografts and subsequently Dacron has successfully been 
employed to prevent rupture since the 1950s. Since Matas’s original description of the 
surgical repair of AAA the operation has evolved to be applied in both the elective and 
emergency setting. The open surgical approach in the modern era is performed either via a 
trans-peritoneal or retroperitoneal exposure to obtain proximal and distal aortic control 
using vascular clamps (Figure 2). 
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Type Proximal Extent Distal Extent 
I Left subclavian artery Visceral Aorta (usually suprarenal) 
II Left subclavian artery Infrarenal aorta 
III Mid-thoracic aorta Infrarenal aorta 
IV Diaphragm Infrarenal aorta 
V Mid-thoracic aorta Visceral aorta (usually suprarenal) 
Table 1. Crawford classification of thoraco-abdominal aneurysms. 
 
 
Fig. 2. An infrarenal AAA during surgical repair. A typical infra-renal AAA is seen with 
placement of a clamp to establish proximal aortic control. The iliac vessels have been 
controlled with vascular sloops to be clamped to achieve distal aortic control.  
Intravenous heparin is administered, the aneurysm sac opened and back-bleeding branch 
arteries (lumbar and inferior mesenteric) are ligated. A prosthetic graft, usually made of 
Dacron, is sutured to the proximal aorta and the aorta proximal to the bifurcation (Figure 3). 
 
 
Fig. 3. An orthotopic Dacron graft has been sutured to replace the AAA. 
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Demonstrates the satisfactory position of a Dacron graft sutured into the original site of the 
AAA. 
If the AAA is aorto-iliac ie. the iliac arteries are also aneurysmal a bifurcated graft or ‘Y-
graft’ is used and sutured to the iliac segments usually at the iliac bifurcation. Flow is 
restored to the lower extremities and the aneurysm sac closed over the synthetic graft. 
Although effective and durable in treating AAA and preventing rupture the operation has 
been associated with mortality rates of >4% since the 1980s although in large volume 
units, rates of 1-2% are now reported. This has provided the impetus for the development 
of minimally invasive or endovascular techniques. However, traditional open aneurysm 
repair may still be considered superior to endovascular repair (EVAR) because it provides 
secure fixation at all anastomotic sites, ligation of all lumbar branches and other aortic 
branches with virtual elimination of the possibility of endoleaks associated with EVAR 
(see below). In addition, open AAA repair offers complete treatment of aneurysmal 
disease with obliteration of the aneurysmal sac and debridement of its clot and 
atheromatous debris and most importantly is of proven durability. Of all the technical 
advantages of open repair, secure fixation at all anastomoses is probably the most 
important. Many authors submit that suture fixation with continuous polypropylene is 
superior to metallic barbs, hooks, and struts that are part of the current generation of 
EVAR devices (Clagett, 2008). Also it remains to be determined whether endostaplers, 
used during EVAR to provide aortic fixation, will adequately penetrate the diseased 
aneurysmal aortic wall. Hence, open repair still has a prominent role in the surgical 
treatment of aortic aneurysmal disease.  
3.2 Complex open AAA repairs 
Five per cent of AAAs are supra-renal where the aneurysm neck originates at any point 
above the origin of the renal arteries. Most infra-renal AAAs can be repaired safely under 
infra-renal aortic cross-clamping using the technique detailed above (Figure 2). However, 
juxtarenal (ie. an infrarenal neck inadequate for clamp placement) and suprarenal AAA’s 
necessitate control of the aorta using suprarenal, inter-visceral, or supra-celiac aortic clamps. 
The procedure for repair remains essentially the same with suturing of a Dacron graft to the 
proximal and distal aorta following exclusion of the aneurysm but may necessitate 
mesenteric and/or renal arterial implantation into the graft. Anecdotal evidence suggests 
that inappropriate infra-renal clamping may cause renal embolization and a higher 
incidence of para-anastomotic pseudoaneurysms. Supra-renal clamping induces the risk of 
renal and gastrointestinal complications. Clamping between the renal arteries and the 
superior mesenteric artery (SMA) is associated with a disturbingly high rate of 
complications and should be avoided (Crawford et al, 1986). However, supra-celiac 
clamping avoids the need for retraction and manipulation of large aneurysms and may 
reduce the risk of embolization during dissection. In a study by Green and colleagues, 
patients whose aortas were clamped immediately above the renal arteries had higher peri-
operative mortality rates and a higher incidence of renal failure requiring dialysis than did 
patients whose aortas were clamped at the supra-celiac or infra-renal level (Green et al, 
1989). However, some researchers have noted no differences in mortality rates with regard 
to the site of aortic clamping and comparable or even favourable cardiac morbidity rates 
with more proximal clamping (El-Sabrout & Reul, 2001.). Direct comparison of early 
mortality after supra-renal and supra-celiac clamping with infra-renal clamping appeared to 
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reveal a strikingly higher mortality rate after supra-renal and supra-celiac clamping. 
However, in-depth analysis reveals that most patients in the supra-renal and supra-coelic 
group had considerably more risk factors and underwent more extensive procedures than 
did those in the infra-renal group (Green et al, 1989). Myocardial infarction or congestive 
heart failure in the early post-operative period developed more often after supra-renal and 
supra-coelic clamping than after infra-renal clamping and was associated with a higher 
patient mortality. In a study by Sasaki et al, post-operative renal dysfunction developed in 
50% of patients after bilateral supra-renal clamping, in comparison with only 8.4% after 
infra-renal clamping (Sasaki et al, 2000). Other authors have reported that the rates of 
transient postoperative renal dysfunction after elective supra-renal and supra-coeliac 
clamping was 12.6% as opposed to 3.35% after infra-renal clamping (Barratt et al, 2000). 
Importantly, chronic renal failure is a rare complication of openAAA repair. 
3.3 Complications of open AAA repairs 
Complications which may follow open AAA repair include not only cardiac and respiratory 
dysfunction but also visceral ischaemia/ischaemic colitis, trash foot, aorto-enteric fistula, 
sexual dysfunction, persistent chronic peri-aortitis and acute renal failure. 
In 1974 Willard et al reported in a series of 6100 patients an incidence of visceral ischaemia 
and/or infarction of 1.5% (Willard et al, 1974). Such early studies advocated the re-
implantation of the inferior mesenteric artery (IMA). The incidence of this complication has 
changed little over the decades but selective IMA re-implantation is now preferred if there is 
evidence or suspicion of colonic ischaemia.  
Acute lower limb ischaemia following aortic surgery is commonly termed 'trash foot', an 
unwelcome complication that is associated with a high morbidity and mortality. 
 
 
Fig. 4. The typical appearance of a trash foot following open AAA repair. The aetiology 
remains uncertain. Embolectomy may be required to restore limb perfusion. 
The exact cause of the ischaemia remains uncertain, but it has been attributed to either 
athero-emboli from native arteries, thrombo-emboli from the prosthetic graft or thrombosis 
of small vessels in the distal arterial tree. It’s reported incidence is 1.4% for open AAA 
repairs and may result in early or delayed amputation of digits or limb (Kuhan et al, 1997). 
The 30-day mortality can be as high as 25%. Attempts to reduce the incidence involve early 
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mobilization and clamping of the iliac arteries, and irrigation of the aortic anastomosis and 
graft with heparin saline solution (Kuhan et al, 1997).  
Aorto-enteric fistulas (AEF) are abnormal communications between the aorta and the intestine. 
It may occur after previous aortic aneurysm surgery with the duodenum as the most frequent 
site of fistulation (Saers et al, 2005). Presentation of AEFs is usually with massive 
gastrointestinal haemorrhage with or without associated aortic or graft sepsis. AEFs are 
difficult to diagnose with a high an index of suspicion needed in patients with previous aortic 
aneurysm surgery. If not treated promptly, AEFs are fatal (Voorhoeve et al 1996; Song Y et al 
2008). Surgery offers the only definitive treatment. The favoured technique involves aortic 
debridement, repair of the intestinal defect and in situ aortic replacement which remains a high 
risk procedure with an operative mortality of 30-40%. Extra-anatomic bypass is performed in 
patients with extensive local sepsis and is associated with an even higher mortality (Song Y et 
al, 2008). Endovascular techniques can achieve rapid control of bleeding associated with AEFs 
and avoid intervention in a hostile abdomen, while eliminating the complications associated 
with open surgery. However, placing new prosthetic material in an infected field may be 
hazardous. A recent review found that 44% of such patients developed recurrent graft 
infection; this complication was more likely in patients who had evidence of sepsis pre-
operatively and resulted in a higher 30-day and overall mortality; importantly life-long 
antibiotic therapy did not reduce recurrent sepsis (Antiniou et al, 2009). Hence AEFs require 
multi-modal and multi-disciplinary management to optimise patient outcome. 
Surgical treatment of AAA’s is appreciated to adversely affect sexual function, with the 
incumbent negative impacts upon the quality of life. The reported level of sexual 
dysfunction after open AAA repair is 30% (Jimenez et al, 2004). Moreover, the incidence 
rises during the first post-operative year. Of course, patients with aortic aneurysms have 
atherosclerosis in other regions of the vascular tree and often have pre-existing sexual 
dysfunction. After AAA repair patients undergoing open repair report a greater magnitude 
of sexual dysfunction when compared to those undergoing EVAR (Prissen et al, 2004). 
Importantly EVAR and open elective AAA repair both have an impact on sexual function in 
the early postoperative period but EVAR appears to offer improved sexual function over the 
longer term (Jimenez et al, 2004).  
As with any prosthetic material, Dacron, can become infected and result in an inflamed 
aorta/graft termed chronic peri-aortitis. This process can result in peri-aortic fibrosis and/or 
ureteral obstruction. Diagnosis involves clinical and radiological findings allied to blood 
inflammatory markers while treatment involves surgical intervention. However fibrosis 
and/or ureteral obstruction may recur (van Bommel et al, 2008).  
The incidence of acute renal failure following complex AAA repair is discussed in detail 
above. Recent studies report the incidence of acute renal failure as approximately 10% (Kim 
GS et al, 2011). Despite this incidence the number of patients requiring dialysis after AAA 
repair remains low. However the reduction in relative incidence of acute renal failure after 
AAA repair using EVAR is a definite advantage of the minimally invasive approach. In a 
large cohort study by Wald et al the incidence of acute renal failure was reported as 6.7% 
(Wald et al, 2006). However EVAR was associated with lower odds of acute renal failure 
and acute renal failure requiring dialysis.  
A recent study has shown that patient mortality after open AAA repair is most closely 
correlated with surgeon rather than institutional case volume (McPhee et al, 2011). 
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4. Open descending thoracic aortic aneurysm repair 
4.1 Introduction to open TAA repair 
Diseases of the thoracic aorta remain among the most lethal of conditions and the most 
difficult to treat. Not surprisingly, the surgical techniques required to achieve successful 
TAA repair took longer to develop than those applied to open AAA repair but have evolved 
significantly during the past 20 years.  
The procedure and outcome of ascending TAA repair are discussed within another chapter 
of the book and will not be considered here. The outcome from open repair of the 
descending TAA has steadily improved (Svennson et al, 1993). Many factors are responsible 
including advancements in anaesthesia, improved operative techniques, and advances in 
critical care. Although open surgical repair of this type of aneurysm once entailed great 
operative risk, experienced surgical centres now report acceptable surgical mortality and 
morbidity rates despite the inherent complexity of the repair.  
4.2 Surgical technique of open descending TAA repair 
Pre-operative assessment forms a key part of patient selection. Identification of pre-existing 
cardiovascular, pulmonary or renal risk factors enables development of a customised 
approach to open descending TAA repair. For example, the use of diaphragm-sparing 
techniques may be particularly helpful in patients with poor pulmonary reserve (Engle et al, 
1999). The procedure is performed under general anaesthesia with the patient positioned in 
the right lateral decubitus position. A cerebrospinal fluid (CSF) catheter is placed in the third 
or fourth lumbar space to allow CSF drainage and pressure monitoring. The benefits of 
general hypothermia are well-established and for open descending TAA repair many 
centres routinely reduce the core body temperature to 32-34°C during surgery. Organ 
ischaemia remains a major source of morbidity. Moderate systemic heparinisation, 
permissive hypothermia and sequential aortic clamping are used routinely. The kidneys 
may be intermittently perfused with cold (4°C) crystalloid to maximise renal hypothermia 
which affords better protection against acute renal dysfunction. To reduce the risk of peri-
operative coagulopathy and bacterial translocation after the aorta is opened adjacent to the 
visceral branches, separate balloon perfusion catheters may be used to selectively perfuse 
the coeliac axis and superior mesenteric artery by connection to a left heart bypass (LHB) 
circuit. Oxygenated blood flows to the abdominal viscera while the intercostal and visceral 
branches are reattached to the graft substantially reducing mesenteric ischaemic time. After 
repair of the aneurysm the operative field is rewarmed with warm saline to reverse cooling. 
A modified thoraco-abdominal incision is utilised for open descending TAA repair. The 
incision begins in the abdomen 3 cm below the costal margin and continuing over the sixth 
rib before curving cephalad just posterior to the tip of the scapula. Following division of the 
relevant muscular layers the lung is deflated, and the sixth rib is usually excised. The 
incision is completed by dividing the costal cartilage. The diaphragm is partially incised 
circumferentially to improve exposure and to avoid traction injury to the phrenic nerve. The 
pericardium is opened posterior to the phrenic nerve, and the patient given intravenous 
heparin to reduce the risk of thrombotic complications and to preserve perfusion of the 
intercostal and lumbar arteries which reduces the risk of spinal cord ischaemia. The left 
atrium is cannulated through the left pulmonary vein or the left atrial appendage. A pump 
with an inline heat exchanger is attached to the cannula, and the arterial inflow established 
through the left femoral artery or the descending thoracic aorta. Distal aortic perfusion is 
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mobilization and clamping of the iliac arteries, and irrigation of the aortic anastomosis and 
graft with heparin saline solution (Kuhan et al, 1997).  
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risk procedure with an operative mortality of 30-40%. Extra-anatomic bypass is performed in 
patients with extensive local sepsis and is associated with an even higher mortality (Song Y et 
al, 2008). Endovascular techniques can achieve rapid control of bleeding associated with AEFs 
and avoid intervention in a hostile abdomen, while eliminating the complications associated 
with open surgery. However, placing new prosthetic material in an infected field may be 
hazardous. A recent review found that 44% of such patients developed recurrent graft 
infection; this complication was more likely in patients who had evidence of sepsis pre-
operatively and resulted in a higher 30-day and overall mortality; importantly life-long 
antibiotic therapy did not reduce recurrent sepsis (Antiniou et al, 2009). Hence AEFs require 
multi-modal and multi-disciplinary management to optimise patient outcome. 
Surgical treatment of AAA’s is appreciated to adversely affect sexual function, with the 
incumbent negative impacts upon the quality of life. The reported level of sexual 
dysfunction after open AAA repair is 30% (Jimenez et al, 2004). Moreover, the incidence 
rises during the first post-operative year. Of course, patients with aortic aneurysms have 
atherosclerosis in other regions of the vascular tree and often have pre-existing sexual 
dysfunction. After AAA repair patients undergoing open repair report a greater magnitude 
of sexual dysfunction when compared to those undergoing EVAR (Prissen et al, 2004). 
Importantly EVAR and open elective AAA repair both have an impact on sexual function in 
the early postoperative period but EVAR appears to offer improved sexual function over the 
longer term (Jimenez et al, 2004).  
As with any prosthetic material, Dacron, can become infected and result in an inflamed 
aorta/graft termed chronic peri-aortitis. This process can result in peri-aortic fibrosis and/or 
ureteral obstruction. Diagnosis involves clinical and radiological findings allied to blood 
inflammatory markers while treatment involves surgical intervention. However fibrosis 
and/or ureteral obstruction may recur (van Bommel et al, 2008).  
The incidence of acute renal failure following complex AAA repair is discussed in detail 
above. Recent studies report the incidence of acute renal failure as approximately 10% (Kim 
GS et al, 2011). Despite this incidence the number of patients requiring dialysis after AAA 
repair remains low. However the reduction in relative incidence of acute renal failure after 
AAA repair using EVAR is a definite advantage of the minimally invasive approach. In a 
large cohort study by Wald et al the incidence of acute renal failure was reported as 6.7% 
(Wald et al, 2006). However EVAR was associated with lower odds of acute renal failure 
and acute renal failure requiring dialysis.  
A recent study has shown that patient mortality after open AAA repair is most closely 
correlated with surgeon rather than institutional case volume (McPhee et al, 2011). 
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4. Open descending thoracic aortic aneurysm repair 
4.1 Introduction to open TAA repair 
Diseases of the thoracic aorta remain among the most lethal of conditions and the most 
difficult to treat. Not surprisingly, the surgical techniques required to achieve successful 
TAA repair took longer to develop than those applied to open AAA repair but have evolved 
significantly during the past 20 years.  
The procedure and outcome of ascending TAA repair are discussed within another chapter 
of the book and will not be considered here. The outcome from open repair of the 
descending TAA has steadily improved (Svennson et al, 1993). Many factors are responsible 
including advancements in anaesthesia, improved operative techniques, and advances in 
critical care. Although open surgical repair of this type of aneurysm once entailed great 
operative risk, experienced surgical centres now report acceptable surgical mortality and 
morbidity rates despite the inherent complexity of the repair.  
4.2 Surgical technique of open descending TAA repair 
Pre-operative assessment forms a key part of patient selection. Identification of pre-existing 
cardiovascular, pulmonary or renal risk factors enables development of a customised 
approach to open descending TAA repair. For example, the use of diaphragm-sparing 
techniques may be particularly helpful in patients with poor pulmonary reserve (Engle et al, 
1999). The procedure is performed under general anaesthesia with the patient positioned in 
the right lateral decubitus position. A cerebrospinal fluid (CSF) catheter is placed in the third 
or fourth lumbar space to allow CSF drainage and pressure monitoring. The benefits of 
general hypothermia are well-established and for open descending TAA repair many 
centres routinely reduce the core body temperature to 32-34°C during surgery. Organ 
ischaemia remains a major source of morbidity. Moderate systemic heparinisation, 
permissive hypothermia and sequential aortic clamping are used routinely. The kidneys 
may be intermittently perfused with cold (4°C) crystalloid to maximise renal hypothermia 
which affords better protection against acute renal dysfunction. To reduce the risk of peri-
operative coagulopathy and bacterial translocation after the aorta is opened adjacent to the 
visceral branches, separate balloon perfusion catheters may be used to selectively perfuse 
the coeliac axis and superior mesenteric artery by connection to a left heart bypass (LHB) 
circuit. Oxygenated blood flows to the abdominal viscera while the intercostal and visceral 
branches are reattached to the graft substantially reducing mesenteric ischaemic time. After 
repair of the aneurysm the operative field is rewarmed with warm saline to reverse cooling. 
A modified thoraco-abdominal incision is utilised for open descending TAA repair. The 
incision begins in the abdomen 3 cm below the costal margin and continuing over the sixth 
rib before curving cephalad just posterior to the tip of the scapula. Following division of the 
relevant muscular layers the lung is deflated, and the sixth rib is usually excised. The 
incision is completed by dividing the costal cartilage. The diaphragm is partially incised 
circumferentially to improve exposure and to avoid traction injury to the phrenic nerve. The 
pericardium is opened posterior to the phrenic nerve, and the patient given intravenous 
heparin to reduce the risk of thrombotic complications and to preserve perfusion of the 
intercostal and lumbar arteries which reduces the risk of spinal cord ischaemia. The left 
atrium is cannulated through the left pulmonary vein or the left atrial appendage. A pump 
with an inline heat exchanger is attached to the cannula, and the arterial inflow established 
through the left femoral artery or the descending thoracic aorta. Distal aortic perfusion is 
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commenced when the cross-clamp is applied. By maintaining distal aortic perfusion during 
aortic reconstruction, LHB reduces spinal and visceral ischaemic time and prevents many of 
the complications seen after open AAA repair. Aortic control is established using the 
familiar proximal and distal paradigm using appropriate vascular clamps. It is vital at this 
stage to allow the important lower intercostal arteries to be perfused from below during of 
arterial construction of the proximal anastomosis and decrease the spinal cord ischemic time. 
This period requires carefully maintenance of normal proximal aortic pressure.  
Vascular clamps are placed on the aortic arch between the left common carotid and left 
subclavian arteries. A vascular clamp is also applied to the left subclavian artery. The aorta 
is opened longitudinally and divided circumferentially a few centimetres beyond the 
proximal clamp. The haemodynamic effects of clamping and unclamping the aorta have 
been investigated since the mid-20th century as these effects are major contributors to the 
development of post-operative organ dysfunction (see below). Sequential clamping of the 
aorta remains an effective strategy for reducing ischaemic times. As the aorta is replaced 
from the proximal to the distal extent of the lesion, the aortic clamp is moved sequentially to 
lower positions along the graft to restore perfusion to newly reattached branch vessels. After 
the proximal anastomosis is completed using a non-absorbable continuous suture, the aortic 
clamp is repositioned onto the graft, flow restored to the left subclavian artery and the 
remainder of the aneurysm is opened longitudinally. An open distal anastomosis completes 
the repair.  
As an alternative to the “clamp and sew” technique described above, left heart bypass can 
be used selectively to provide distal aortic perfusion during the repair. In this technique the 
aorta is opened longitudinally and separated from the oesophagus. Stay sutures are applied 
to the aneurysm wall, and haemostasis obtained by oversewing any bleeding intercostal or 
bronchial arteries. Blood salvage is accomplished using a cell-saving device, while blood 
may be re-infused using a rapid infuser system. The length of aorta that is replaced is 
dependent upon as assessment of the aneurysm at the time of exploration. Once adequate 
haemostasis is obtained, an appropriately sized, woven Dacron tube graft is anastomosed to 
the proximal aorta with a running polypropylene suture. The graft is then cut in a bevelled 
fashion to accommodate the intercostal arteries. Re-implantation of patent, lower intercostal 
arteries (T8 through T12) is also performed. The distal anastomosis is completed and the 
graft flushed. The aortic clamps are slowly removed, and suture lines checked for 
haemostasis. The patient is weaned from left heart bypass once the rectal or bladder 
temperature reached 36°C. Protamine is usually administered and the atrial and femoral 
cannulae removed.  
4.3 Complications of open descending TAA repair 
Although recent advances in surgical techniques have improved the outcome of open 
descending TAA repair, significant mortality and morbidity is still encountered. Twenty 
seven percent of patients experience respiratory complications with prolonged 
postoperative ventilation (longer than 48 hours) and 11% require tracheostomy. Available 
data demonstrates that pre-operative renal insufficiency and the extent of the aneurysm are 
important predictors of respiratory complications (Etz et al, 2007). Paraplegia is the most 
devastating sequel to TAA repair. Debate still pervades the optimal approach to peri-
operative spinal cord protection. Early experimental data showed that aortic clamping 
increased CSF pressure which is now kept less than 10 mmHg for 3 days postoperatively by 
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appropriate drainage through a CSF catheter. After removal of the drain delayed neurologic 
deficit should prompt its reintroduction to reduce CSF pressure (Estrera et al, 2003). The use 
of atrio-femoral bypass may have a protective effect in reducing paraplegia (Svennson et al, 
1993). Subsequent to this latter study, other authors have reported encouraging results in 
reducing paraplegia rates by using only the clamp and sew for open descending TAA repair 
(Coselli et al, 2004). However, in a recent study involving 347 patients who had undergone 
descending open TAA repair and were specifically analyzed using propensity score analysis, 
the authors concluded that left heart bypass did not reduce paraplegia during repair (Coselli 
et al 2004). Although the overall incidence of paraplegia is low at 2.6%, it can be concluded 
from the available literature that simple clamp and sew technique can be performed safely 
with acceptable results. The incidence of acute renal failure after open descending TAA 
repair is 3-14%. If subsequent dialysis is required, patient mortality may rise to 30-60%. The 
risk of renal failure also increases if shunting and bypass techniques are not utilised. Aside 
from the techniques outlined above mannitol may also improve post-operative renal 
function by increasing renal perfusion and by acting as a free radical scavenger.  
A recent meta-analysis by Jonker et al conclusively showed the reduced rates of cardiac 
complications following minimally invasive TAA repair when compared to open repair. 
(Jonker et al, 2010). The incidence of myocardial infraction was 11.1% following open repair 
compared to 3.5% after TEVAR. The reported incidence of stroke after open TAA repair 
varies between 2-18% (Moon et al, 2007). Again in their systemic review Jonker et al showed 
that the TEVAR reduced the incidence of stroke (4.1% TEVAR versus 10.2% open repair). It 
is important note that many of these studies have assessed total complications in the 
particular patient groups and clinically some patients with invariably suffer more than one 
complication.  
5. Aneurysm repair in the modern era 
5.1 Minimally invasive aortic aneurysm repair 
In accord with the advancements in general surgery, the late 1990’s witnessed the 
pioneering of thorascopic and laparoscopic aortic aneurysm repair. Unfortunately the 
introduction and advancement of endovascular techniques have overshadowed and 
perhaps forestalled major development of these surgical approaches. A brief overview 
follows. 
5.2 Thorascopic TAA repair 
The premise for the development of thorascopic TAA repair was to minimize surgical 
trauma and aid improved patient outcome relative to open TAA (Fukada et al, 2002). The 
use of thoracoscopy in thoracic surgery is known to decrease post-thoracotomy pain and 
lead to enhanced patient recovery (Dajczman et al, 1991; Kirby et al, 1993). The literature 
consists of only limited case reports and case series detailing the technique of thorascopic 
descending TAA repair although the advent of endovascular techniques have impaired the 
major development of this facet of aortic aneurysm repair, thorascopy have been invaluable 
for the field of thoracic surgery. Historically thorascopic TAA repair was not attempted in 
humans over concern of prolonged aortic cross-clamp time necessitated by a minimally 
invasive procedure. As discussed above, during open descending TAA repair, the duration 
of the aortic clamp period, intercostal artery reimplantation critical to spinal cord blood flow 
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commenced when the cross-clamp is applied. By maintaining distal aortic perfusion during 
aortic reconstruction, LHB reduces spinal and visceral ischaemic time and prevents many of 
the complications seen after open AAA repair. Aortic control is established using the 
familiar proximal and distal paradigm using appropriate vascular clamps. It is vital at this 
stage to allow the important lower intercostal arteries to be perfused from below during of 
arterial construction of the proximal anastomosis and decrease the spinal cord ischemic time. 
This period requires carefully maintenance of normal proximal aortic pressure.  
Vascular clamps are placed on the aortic arch between the left common carotid and left 
subclavian arteries. A vascular clamp is also applied to the left subclavian artery. The aorta 
is opened longitudinally and divided circumferentially a few centimetres beyond the 
proximal clamp. The haemodynamic effects of clamping and unclamping the aorta have 
been investigated since the mid-20th century as these effects are major contributors to the 
development of post-operative organ dysfunction (see below). Sequential clamping of the 
aorta remains an effective strategy for reducing ischaemic times. As the aorta is replaced 
from the proximal to the distal extent of the lesion, the aortic clamp is moved sequentially to 
lower positions along the graft to restore perfusion to newly reattached branch vessels. After 
the proximal anastomosis is completed using a non-absorbable continuous suture, the aortic 
clamp is repositioned onto the graft, flow restored to the left subclavian artery and the 
remainder of the aneurysm is opened longitudinally. An open distal anastomosis completes 
the repair.  
As an alternative to the “clamp and sew” technique described above, left heart bypass can 
be used selectively to provide distal aortic perfusion during the repair. In this technique the 
aorta is opened longitudinally and separated from the oesophagus. Stay sutures are applied 
to the aneurysm wall, and haemostasis obtained by oversewing any bleeding intercostal or 
bronchial arteries. Blood salvage is accomplished using a cell-saving device, while blood 
may be re-infused using a rapid infuser system. The length of aorta that is replaced is 
dependent upon as assessment of the aneurysm at the time of exploration. Once adequate 
haemostasis is obtained, an appropriately sized, woven Dacron tube graft is anastomosed to 
the proximal aorta with a running polypropylene suture. The graft is then cut in a bevelled 
fashion to accommodate the intercostal arteries. Re-implantation of patent, lower intercostal 
arteries (T8 through T12) is also performed. The distal anastomosis is completed and the 
graft flushed. The aortic clamps are slowly removed, and suture lines checked for 
haemostasis. The patient is weaned from left heart bypass once the rectal or bladder 
temperature reached 36°C. Protamine is usually administered and the atrial and femoral 
cannulae removed.  
4.3 Complications of open descending TAA repair 
Although recent advances in surgical techniques have improved the outcome of open 
descending TAA repair, significant mortality and morbidity is still encountered. Twenty 
seven percent of patients experience respiratory complications with prolonged 
postoperative ventilation (longer than 48 hours) and 11% require tracheostomy. Available 
data demonstrates that pre-operative renal insufficiency and the extent of the aneurysm are 
important predictors of respiratory complications (Etz et al, 2007). Paraplegia is the most 
devastating sequel to TAA repair. Debate still pervades the optimal approach to peri-
operative spinal cord protection. Early experimental data showed that aortic clamping 
increased CSF pressure which is now kept less than 10 mmHg for 3 days postoperatively by 
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appropriate drainage through a CSF catheter. After removal of the drain delayed neurologic 
deficit should prompt its reintroduction to reduce CSF pressure (Estrera et al, 2003). The use 
of atrio-femoral bypass may have a protective effect in reducing paraplegia (Svennson et al, 
1993). Subsequent to this latter study, other authors have reported encouraging results in 
reducing paraplegia rates by using only the clamp and sew for open descending TAA repair 
(Coselli et al, 2004). However, in a recent study involving 347 patients who had undergone 
descending open TAA repair and were specifically analyzed using propensity score analysis, 
the authors concluded that left heart bypass did not reduce paraplegia during repair (Coselli 
et al 2004). Although the overall incidence of paraplegia is low at 2.6%, it can be concluded 
from the available literature that simple clamp and sew technique can be performed safely 
with acceptable results. The incidence of acute renal failure after open descending TAA 
repair is 3-14%. If subsequent dialysis is required, patient mortality may rise to 30-60%. The 
risk of renal failure also increases if shunting and bypass techniques are not utilised. Aside 
from the techniques outlined above mannitol may also improve post-operative renal 
function by increasing renal perfusion and by acting as a free radical scavenger.  
A recent meta-analysis by Jonker et al conclusively showed the reduced rates of cardiac 
complications following minimally invasive TAA repair when compared to open repair. 
(Jonker et al, 2010). The incidence of myocardial infraction was 11.1% following open repair 
compared to 3.5% after TEVAR. The reported incidence of stroke after open TAA repair 
varies between 2-18% (Moon et al, 2007). Again in their systemic review Jonker et al showed 
that the TEVAR reduced the incidence of stroke (4.1% TEVAR versus 10.2% open repair). It 
is important note that many of these studies have assessed total complications in the 
particular patient groups and clinically some patients with invariably suffer more than one 
complication.  
5. Aneurysm repair in the modern era 
5.1 Minimally invasive aortic aneurysm repair 
In accord with the advancements in general surgery, the late 1990’s witnessed the 
pioneering of thorascopic and laparoscopic aortic aneurysm repair. Unfortunately the 
introduction and advancement of endovascular techniques have overshadowed and 
perhaps forestalled major development of these surgical approaches. A brief overview 
follows. 
5.2 Thorascopic TAA repair 
The premise for the development of thorascopic TAA repair was to minimize surgical 
trauma and aid improved patient outcome relative to open TAA (Fukada et al, 2002). The 
use of thoracoscopy in thoracic surgery is known to decrease post-thoracotomy pain and 
lead to enhanced patient recovery (Dajczman et al, 1991; Kirby et al, 1993). The literature 
consists of only limited case reports and case series detailing the technique of thorascopic 
descending TAA repair although the advent of endovascular techniques have impaired the 
major development of this facet of aortic aneurysm repair, thorascopy have been invaluable 
for the field of thoracic surgery. Historically thorascopic TAA repair was not attempted in 
humans over concern of prolonged aortic cross-clamp time necessitated by a minimally 
invasive procedure. As discussed above, during open descending TAA repair, the duration 
of the aortic clamp period, intercostal artery reimplantation critical to spinal cord blood flow 
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and the completeness of spinal cord reperfusion are risk factors for paraplegia. However, 
shortening aortic clamp time and complete reconstruction of the intercostal artery were 
considered problematic if visualisation were as restricted as the original pioneers of 
thorascopic TAA repair envisaged. However, the thorascopic approach would certainly 
reduce patient morbidity, post-thoracotomy pain and ventilatory complications (Dajczman 
et al, 1991).  
As with conventional open and endovascular repairs, preoperative radiological imaging is 
essential. Contrast CT and Magnetic Resonance Imaging (MRI) may help to prevent post-
operative paraplegia by visualizing the spinal artery of Adamkiewicz. The patient is placed 
in a right lateral decubitus position, as with open repair. The initial insertion site of the 
thoracoscope in the middle axillary line in the 4th intercostal space. A second thorascopic 
port is inserted through which a fan retractor is placed at a point 5 cm anterior to the first 
incision. Under direct thoracoscopic visualization of the TAA a mini-thoracotomy is made in 
the 7th intercostal space. This incision could be extended according to the location of the 
aneurysm. The third port placed in the 5th intercostal in the anterior axillary line is used for 
additional thorascopic views. The posterior surfaces of the aortic necks are dissected by the 
operator’s hand introduced through the mini-thoractomy to avoid injuring the hemi-azgous 
vein. Umbilical tapes are placed around the aortic necks. Femoro-femoral cardiopulmonary 
bypass may be used at this stage. Two custom-made vascular cross-clamps are introduced 
via the first port and a fourth puncture wound made 4 cm anterior to the edge of the mini-
thoractomy (Castronuovo et al, 2000). The aortic necks are transected after the placement of 
a proximal cross-clamp distal to the 9th intercostal space and a distal clamp. Video-assisted 
graft replacement of the aorta is performed with continuous sutures by conventional 
instruments. Single re-implantation of the artery of Adakiewicz by use of a side-arm graft 
can be considered if radiological imaging has been obtained (Yamada et al, 2000). The 
principal benefits of the technique is that it enables the thoractomy wound to be made 
smaller by introduction of aortic clamps through puncture wounds, and while enabling a 
more accurate determination of the intercostal space to be incised by pre-observation of the 
thoracic cavity using a thoracoscope. However these techniques have not progressed to the 
establishment of total thorascopic TAA repair.  
5.3 Laparoscopic AAA repair  
The gold standard in the treatment of AAA remains repair with a prosthetic graft through 
an open approach (Creech et al, 1966). In the last 10 years EVAR has become an established 
alternative as a result of low failure rates and reduced mortality in the short term (Brewster 
et al, 2002; Brewster et al, 2003). However, over longer follow-up, complications following 
EVAR such as endoleaks, endograft migration, occlusion, and aneurysm rupture (see below) 
have been reported leading to reintervention rates in the order of 10% to 34% of cases 
(Verhoeven et al, 2004; Sampram et al, 2003; Becquemin et al, 2004). While EVAR has been 
gaining widespread popularity, the laparoscopic technique (through either a fully 
laparoscopic or a laparoscopy-assisted approach) for AAA repair has been under 
development (Dion et al, 1993; Kline et al, 1998; Cerveira et al, 1999; Edoga et al, 1998). 
Laparoscopic AAA repair was developed to overcome specific technical challenges during 
open surgery, such as bowel manipulation, bleeding control, and, mainly, the performance 
of vascular anastomoses, which might jeopardize the procedure success rate (Kolvenbach et 
al, 2004; Coggia et al, 2004). In some instances the insertion of a hand inside the insufflated 
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abdominal cavity restores tactile feedback to the surgeon, who is able to locate the aneurysm 
neck and iliac arteries, thus adding to the visual evaluation of the anatomy and quality of 
the tissues. The internal hand also compensates for lack of the tri-dimensional vision 
encountered in laparoscopy. 
For total laparoscopic AAA repair the patients the patient is positioned at 45-degree right 
decubitus position. The abdomen is hyper-extended and draped from the right mid-





Fig. 5. The position of the operative surgeon and assistant for laparoscopic AAA repair. 
Figure 5 demonstrates the position of the operating team at the commencement of the 
procedure. The patient lies in the semi-decubitus position on the right. The operating surgeon 
(*) stands on the right of the patient. After retrocolic dissection the operating surgeon (*) 
stands on the left of the patient (lower panel) to perform endoaneurysmorrhaphy and 
laparoscopic anastomosis. (Taken from Chiu et al, 2008) 
Initially, a sub-umbilical incision is made and a Veress needle inserted into the abdominal 
cavity to create a carbon dioxide pneumoperitoneum. A laparoscopic port is then inserted. 
Two additional laparoscopic ports are inserted in the midline above and below the first one 
port. By using these three ports, the peritoneal cavity is inspected. In hand-assisted 
laparoscopic AAA repair a midline mini-laparotomy incision of approximately 7-8 cm is 
first made for insertion of a laparoscopic omni-port-site device. Through the omni-port, the 
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and the completeness of spinal cord reperfusion are risk factors for paraplegia. However, 
shortening aortic clamp time and complete reconstruction of the intercostal artery were 
considered problematic if visualisation were as restricted as the original pioneers of 
thorascopic TAA repair envisaged. However, the thorascopic approach would certainly 
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abdominal cavity restores tactile feedback to the surgeon, who is able to locate the aneurysm 
neck and iliac arteries, thus adding to the visual evaluation of the anatomy and quality of 
the tissues. The internal hand also compensates for lack of the tri-dimensional vision 
encountered in laparoscopy. 
For total laparoscopic AAA repair the patients the patient is positioned at 45-degree right 
decubitus position. The abdomen is hyper-extended and draped from the right mid-





Fig. 5. The position of the operative surgeon and assistant for laparoscopic AAA repair. 
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(*) stands on the right of the patient. After retrocolic dissection the operating surgeon (*) 
stands on the left of the patient (lower panel) to perform endoaneurysmorrhaphy and 
laparoscopic anastomosis. (Taken from Chiu et al, 2008) 
Initially, a sub-umbilical incision is made and a Veress needle inserted into the abdominal 
cavity to create a carbon dioxide pneumoperitoneum. A laparoscopic port is then inserted. 
Two additional laparoscopic ports are inserted in the midline above and below the first one 
port. By using these three ports, the peritoneal cavity is inspected. In hand-assisted 
laparoscopic AAA repair a midline mini-laparotomy incision of approximately 7-8 cm is 
first made for insertion of a laparoscopic omni-port-site device. Through the omni-port, the 
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non-dominant hand of the surgeon is introduced into the abdominal cavity without any loss 
of insufflation. After the mini-laparotomy is performed, a laparoscopic port is placed in the 
epigastrium. With their non-dominant hand, the surgeon gently pushes bowel loops toward 
the right side of the abdominal cavity aided by tilting the operating table to the right and in 
the Trendelenburg position (not exceeding 30°). 
Whether total laparoscopic or hand assisted AAA repair is used the initial dissection and 
mobilisation of the descending and sigmoid colon is carried out. The paracolic gutter is 
incised to expose the retroperitoneum and the splenic flexure detached from the splenic 
hilum. The descending mesocolon is dissected medially leaving Gerota’s fascia, the ureter 
and gonadal vein intact. Following the landmark of the gonadal vein, the dissection is 
performed cephalic to the renal vein. The surgeon and assistant then move to the left side of 
the patient (Figure 5).  
Three additional laparoscopic ports are then inserted. Three sutures serve as stay sutures to 
hold the left hemicolon apron. The traction sutures and right decubitus position help 
exposure of the retroperitoneal space. A laparoscopic fan retractor is used to keep the 
visceral organs away from the dissection. The aneurysmal neck and bilateral common iliac 
arteries can be isolated to facilitate the clamping of the aorta. The lumbar arteries behind the 
aneurysm and the IMA can be visualised, clipped and divided. Heparin is given prior to 
aortic clamping. Two additional laparoscopic ports are inserted for laparoscopic vascular 
clamps. A stab incision over the aneurysm allows assessment of the amount of collateral 
flow. The aorta is transected. The entire aneurysm is dissected free using electrocautery. A 
segment of Dacron graft is inserted into the abdomen and the proximal anastomosis 
between the aorta and the prosthesis is performed under direct vision with conventional but 
long instruments, according to the technique described by Oscar Creech (Creech et al, 1966). 
The proximal anastomosis is carried out using a 15 cm suture staring from the far side and 
running the dorsal aspect of the anastomosis. The other suture is used to finish the 
remaining anastomosis. The distal anastomosis is performed in the same way. The 
laparoscopic clamps are then removed. Afterward, the IMA is sewn or re-implanted, 
depending on left colon vascularisation. The aneurysm wall and the posterior parietal 
peritoneum are closed to cover the prosthesis in the conventional manner. Laparoscopic 
AAA repair has been applied to the repair of even complex AAA such as juxta-renal repair 
(Coggia et al, 2008).Although there remain proponents within centres performing 
laparoscopic AAA repairs routinely, it is likely that the approach will remain a niche in the 
field of surgical options for AAA. 
6. Endovascular aneurysm repair (EVAR) 
In tandem with a global movement towards minimally invasive techniques in all branches 
of surgery, endovascular techniques have become the treatment of choice for many 
aneurysmal conditions of the aorta reinforced by the mortality of open aneurysm repair. 
The concept centres on the endoluminal deployment of a covered stent graft which 
effectively shields the aneurysm wall from systemic arterial pressure and thereby, 
prevents aneurysm rupture. Since the first published report of stent graft implantation for 
AAA in humans in 1991 suggested that this approach was feasible (Parodi et al, 1991), a 
surge in both the number of EVARS performed and technological improvements in stent 
graft design account for a steady upward trend in stent graft use as reflected in 
administrative databases. Indeed, some consider EVAR to be the procedure of choice for 
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AAA (Cowan et al, 2006; McPhee et al, 2007). The pace of technological evolution of 
EVAR has been rapid in comparison to the two millennia required for the development of 
successful open aneurysm repair. 
Diffusion of this technology, although widespread, has been met with both enthusiasm and 
scepticism. Advocates of traditional open surgical techniques maintain that EVAR is costly 
and that long-term outcomes for patients are inferior. Rather than relying on sutures to 
provide fixation, as in open repair, endovascular stent grafts rely on radial forces of self-
expanding stents for fixation or self expand in concert with active fixation using hooks or 
barbs at the proximal aorta fixation site. With longer follow-up now being achieved after 
EVAR, >97% 5-year and >94% 9-year rupture-free survival has been observed (Brewster et 
al, 2006). Pre-procedural planning using CT as its backbone is the most critical component of 
a technically successful EVAR. Advances in imaging have had a major role in the 
development of these complex endovascular procedures: CT images are reconstructed on 
three dimensional imaging work-stations and ‘centreline of flow’ reconstructions are used to 
design the customised endoprotheses (Figure 6).  
 
 
Fig. 6. Three-dimensional volume rendering reconstruction of a computed tomography 
angiogram performed before (left) and after (right) implantation of a four-branch endograft 
to treat a type III thoracoabdominal aneurysm. The bridging stents between the branches 
and the four target vessels are implanted from a brachial approach (Taken from Haulon et 
al, 2011). 
Furthermore, intra-operative imaging can now incorporate on-table CT with 3-D 
reconstruction to improve the accuracy of graft placement and decrease fluoroscopy time 
and contrast media volumes. EVAR is a great advance but one must not lose sight of the fact 
that from a purely technical standpoint, open aneurysm repair is a superior operation. 
EVAR has been adapted for the treatment of AAA (herein termed EVAR) and TAA 
(TEVAR). Each procedure is discussed below.  
 
Aneurysmal Disease of the Thoracic and Abdominal Aorta 
 
34
non-dominant hand of the surgeon is introduced into the abdominal cavity without any loss 
of insufflation. After the mini-laparotomy is performed, a laparoscopic port is placed in the 
epigastrium. With their non-dominant hand, the surgeon gently pushes bowel loops toward 
the right side of the abdominal cavity aided by tilting the operating table to the right and in 
the Trendelenburg position (not exceeding 30°). 
Whether total laparoscopic or hand assisted AAA repair is used the initial dissection and 
mobilisation of the descending and sigmoid colon is carried out. The paracolic gutter is 
incised to expose the retroperitoneum and the splenic flexure detached from the splenic 
hilum. The descending mesocolon is dissected medially leaving Gerota’s fascia, the ureter 
and gonadal vein intact. Following the landmark of the gonadal vein, the dissection is 
performed cephalic to the renal vein. The surgeon and assistant then move to the left side of 
the patient (Figure 5).  
Three additional laparoscopic ports are then inserted. Three sutures serve as stay sutures to 
hold the left hemicolon apron. The traction sutures and right decubitus position help 
exposure of the retroperitoneal space. A laparoscopic fan retractor is used to keep the 
visceral organs away from the dissection. The aneurysmal neck and bilateral common iliac 
arteries can be isolated to facilitate the clamping of the aorta. The lumbar arteries behind the 
aneurysm and the IMA can be visualised, clipped and divided. Heparin is given prior to 
aortic clamping. Two additional laparoscopic ports are inserted for laparoscopic vascular 
clamps. A stab incision over the aneurysm allows assessment of the amount of collateral 
flow. The aorta is transected. The entire aneurysm is dissected free using electrocautery. A 
segment of Dacron graft is inserted into the abdomen and the proximal anastomosis 
between the aorta and the prosthesis is performed under direct vision with conventional but 
long instruments, according to the technique described by Oscar Creech (Creech et al, 1966). 
The proximal anastomosis is carried out using a 15 cm suture staring from the far side and 
running the dorsal aspect of the anastomosis. The other suture is used to finish the 
remaining anastomosis. The distal anastomosis is performed in the same way. The 
laparoscopic clamps are then removed. Afterward, the IMA is sewn or re-implanted, 
depending on left colon vascularisation. The aneurysm wall and the posterior parietal 
peritoneum are closed to cover the prosthesis in the conventional manner. Laparoscopic 
AAA repair has been applied to the repair of even complex AAA such as juxta-renal repair 
(Coggia et al, 2008).Although there remain proponents within centres performing 
laparoscopic AAA repairs routinely, it is likely that the approach will remain a niche in the 
field of surgical options for AAA. 
6. Endovascular aneurysm repair (EVAR) 
In tandem with a global movement towards minimally invasive techniques in all branches 
of surgery, endovascular techniques have become the treatment of choice for many 
aneurysmal conditions of the aorta reinforced by the mortality of open aneurysm repair. 
The concept centres on the endoluminal deployment of a covered stent graft which 
effectively shields the aneurysm wall from systemic arterial pressure and thereby, 
prevents aneurysm rupture. Since the first published report of stent graft implantation for 
AAA in humans in 1991 suggested that this approach was feasible (Parodi et al, 1991), a 
surge in both the number of EVARS performed and technological improvements in stent 
graft design account for a steady upward trend in stent graft use as reflected in 
administrative databases. Indeed, some consider EVAR to be the procedure of choice for 
 
The Evolution of Aortic Aneurysm Repair: Past Lessons and Future Directions 
 
35 
AAA (Cowan et al, 2006; McPhee et al, 2007). The pace of technological evolution of 
EVAR has been rapid in comparison to the two millennia required for the development of 
successful open aneurysm repair. 
Diffusion of this technology, although widespread, has been met with both enthusiasm and 
scepticism. Advocates of traditional open surgical techniques maintain that EVAR is costly 
and that long-term outcomes for patients are inferior. Rather than relying on sutures to 
provide fixation, as in open repair, endovascular stent grafts rely on radial forces of self-
expanding stents for fixation or self expand in concert with active fixation using hooks or 
barbs at the proximal aorta fixation site. With longer follow-up now being achieved after 
EVAR, >97% 5-year and >94% 9-year rupture-free survival has been observed (Brewster et 
al, 2006). Pre-procedural planning using CT as its backbone is the most critical component of 
a technically successful EVAR. Advances in imaging have had a major role in the 
development of these complex endovascular procedures: CT images are reconstructed on 
three dimensional imaging work-stations and ‘centreline of flow’ reconstructions are used to 
design the customised endoprotheses (Figure 6).  
 
 
Fig. 6. Three-dimensional volume rendering reconstruction of a computed tomography 
angiogram performed before (left) and after (right) implantation of a four-branch endograft 
to treat a type III thoracoabdominal aneurysm. The bridging stents between the branches 
and the four target vessels are implanted from a brachial approach (Taken from Haulon et 
al, 2011). 
Furthermore, intra-operative imaging can now incorporate on-table CT with 3-D 
reconstruction to improve the accuracy of graft placement and decrease fluoroscopy time 
and contrast media volumes. EVAR is a great advance but one must not lose sight of the fact 
that from a purely technical standpoint, open aneurysm repair is a superior operation. 
EVAR has been adapted for the treatment of AAA (herein termed EVAR) and TAA 
(TEVAR). Each procedure is discussed below.  
 
Aneurysmal Disease of the Thoracic and Abdominal Aorta 
 
36
6.1 Anaesthetic considerations for TEVAR & EVAR 
Anaesthesia for TEVAR must accommodate the potential risk of conversion of the operation 
to open TAA repair. The risk of open conversion of TEVAR is decreasing with 
improvements in endoluminal prostheses and increased surgical expertise. Pre-operative 
assessment for TEVAR has tended to address the typical issues relating to general 
anaesthesia in a vascular patient. TEVAR should be classified as a high risk surgical 
procedure. The intra-operative anaesthetic goals during TEVAR are to provide 
haemodynamic stability while preserving cardiac, spinal and splanchnic blood flow. In 
addition, the maintenance of intra-vascular volume, adequate tissue oxygenation and body 
temperature is required. Accordingly, both general and regional anaesthetic techniques have 
been used successfully in the treatment of patients with descending TAA When combined 
with neurological monitoring and trans-oesophageal echocardiography (TOE). Care must be 
taken to ensure tachycardia and hypertension is avoided as this may impair spinal cord 
perfusion. The use of new self-deploying stents has meant that earlier manoeuvres such as 
ventricular asystole (Dorros et al, 1996) and ventricular fibrillation (Kahn et al, 1998) are not 
required for a ‘still’ operating field. Whilst an endoluminal balloon is being used to ‘seal’ the 
aortic wall after stent deployment (see below), a patient may experience significant 
haemodynamic stress, especially if baseline cardiac function is poor. Vasopressors and 
inotropes must be available to manage haemodynamic instability. Cardiac complications are 
the most common serious peri-operative adverse events of EVAR (Prissen et al, 2004) and 
the most common cause of late death (EVAR Trial 1, 2005). Hence patient selection must 
include careful risk stratification of co-morbidities. The Society for Vascular Surgery of 
America has recommended a medical co-morbidity grading system for EVAR that 
emphasizes cardiac, pulmonary, and renal status but also includes hypertension and patient 
age as relevant risk factors. This scoring system aids in patient selection and provides a 
framework for uniform data collection patterns intended to facilitate analysis of outcomes 
for EVAR. When a decision is made to proceed with EVAR, it can be performed under 
general anaesthesia, local aesthetic with sedation, epidural, or spinal block. Again for a 
patient undergoing EVAR the very small risk of conversion to open repair must be 
accommodated in operation planning. 
6.2 EVAR for TAA (TEVAR) 
Non-invasive repair of descending TAA has become particularly attractive but to justify its 
use the associated mortality and morbidity rates need to be equal to or better than those of 
open surgical repair. Dake et al reported the first endovascular TEVAR in 1994 (Dake et al, 
1994) which ushered in a new era in the treatment of thoracic aortic disease. TEVAR is 
emerging as the preferred treatment strategy in a majority of patients, as increasing data 
suggests that it may be performed with lower peri-operative morbidity and mortality rates 
with similar mid-term survival, when compared with standard open TAA repair (Bavaria et 
al, 2007; Jackson et al, 2007). However, anatomic constraints, principally related to required 
endograft landing/seal zones and the suitability of femoral and iliac access vessels for 
endograft introduction excludes a significant number of patients, many of whom are not 
ideal candidates for open surgery (Jackson et al 2007). With regard to landing zones, both 
length and diameter must be considered with a required seal zone length of ≥2 to 2.5 cm for 
all available devices. The endografts are usually oversized by 10% to 15%, and thus, the 
adequate seal zone diameter ranges from 18 to 42 mm depending on the device used. 
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Conventional TEVAR seal zones generally extend from zone 2 to zone 4 using a landing 
zone map.  
 
 
Fig. 7. The landing zones required for TEVAR. 
Fig. 7 demonstrates the aortic landing zone map devised by Ishimaru. Conventional TEVAR 
landing zones are between zone 2 just distal to the left common carotid artery, and zone 4 to 
the level of the celiac axis. Distal landing zones in zone 4 may be preformed in conjunction 
with visceral debranching procedures (Ishimura 2004). 
In this manner, endograft coverage may span regions of thoracic aorta between the left 
common carotid (CCA) and coeliac axis. The coeliac axis may occasionally be covered if 
necessary to achieve an adequate distal seal. Coeliac coverage is generally safe in situations 
in which the celiac artery is small in diameter and the SMA large and the gastroduodenal 
artery patent which will feed the coeliac distribution after coeliac coverage. Furthermore, if 
the right hepatic artery originates from the SMA, coeliac coverage should be well tolerated. 
Other seal zone considerations include the absence of excessive thrombus or calcification, 
which might impair endograft apposition to the aortic wall. For conventional TEVAR, the 
endografts are generally introduced via the femoral vessels, although introduction via the 
iliac arteries or even the infra-renal aorta may be necessary in some cases if the femoral 
vessels are unsuitable because of inadequate size or heavy calcification. The proximity of the 
oesophagus to the aorta in the intra-thoracic and upper abdominal regions makes TOE an 
attractive imaging modality for guiding placement of the endograft and detecting endoleaks 
after endograft deployment (see below). Precise placement of the endograft is essential to 
ensure exclusion of the aneurysmal sac from aortic flow. The endograft system can be 
clearly visualised in the aorta, from guidewire insertion, to balloon inflation and stent 
expansion. Aside from TOE, intra-operative CT and/or fluoroscopy can also be used to 
monitor the endograft system.  
6.3 EVAR for AAA (EVAR) 
Despite the reduction in mortality rates of open AAA repair from 20 to 5% in the past 30 
years (Rickenbach et al, 2004) there are still several complications associated with this 
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approach as illustrated above. It remains an invasive procedure with mortality rates rising 
sharply in those with co-morbid disease such as coronary artery disease and renal failure 
while recovery can be protracted resulting in reduced quality of life. Such problems 
combined with the high number of patients for whom open AAA was contraindicated 
prompted Volodos et al in 1991 to report their clinical experience of using self-fixing 
synthetic remote endoprosthetics for aorta reconstruction (Volodos et al, 1991). In the same 
year Parodi et al reported repair of AAA in five subjects using an endovascular approach 
with a modified stent and graft material (Parodi et al, 1991). The stent graft system reported 
by Parodi was initially developed and patented by Lazarus in 1987 (Lazarus et al, 
1987).Although in these early studies reflux was found at the distal end of the graft which 
necessitated re-intervention, EVAR was established as a feasible treatment for AAA and 
more importantly safe for the patient.  
The basic design of all endografts is similar: the aortic aneurysm is crossed by a tubular graft 
that has a wide diameter (~20-36 mm) and supported by stents along its length. The tube 
either bifurcates into two smaller diameter stent grafts that fit into the iliac arteries, or it 
decreases in size to locate in one iliac artery. Due to rapid commercialisation there are 
numerous EVAR devices available on the world wide market. The feasibility of EVAR like 
TEVAR depends mainly on anatomic factors that represent the important predictors of 
success. Aside from the indications of either an asymptomatic aneurysm of appropriate 
maximal diameter, or a small aneurysm with features putting it at increased risk of rupture, 
patients being considered for EVAR must fulfil several anatomic criteria. These include 1) 
ilio-femoral access vessels that will allow safe insertion and deployment of the device, 
adequate seal, and sufficient length to provide axial support for the graft and 2) an infra-
renal aortic neck of adequate length, limited angulation, and appropriate diameter. These 
features, as well as the presence or absence of thrombus and calcium at each level of fixation 
are evaluated using CT. Anatomic selection criteria for EVAR are based principally on 
characteristics of the proximal infra-renal neck, aneurysm sac and iliac arteries. An 
unfavourable neck anatomy is the most frequent cause for exclusion from EVAR (Iezzi et al, 
2001). The guidelines for EVAR are constantly being redefined, mostly as a result of 
increasingly operator experience and improvement in stent-graft technology. Although, 
with new technology the number of patient’s eligible for EVAR will increase, complex aortic 
anatomy will be a significant limitation, at least for the foreseeable future and is likely to 
ensure that open AAA repair will continue to form an essential part of vascular surgery.  
EVAR, as with TEVAR, begins by the surgeons gaining access to both femoral arteries 
typically through small groin incisions, although a totally percutaneous approach has been 
reported with low complication rates and high incidence of technical success (Lee et al, 
2007). Therefore, both the femoral and iliac arteries must be patent, have as little tortuosity 
as possible, and one of them must allow a catheter, up to 24 French (Fr) (8 mm) in diameter, 
to be introduced to the aorta. In some patients with AAA the arteries are too small to allow 
access (Velazquez et al, 2001). In addition some patients have concomitant vascular disease, 
so the femoral and iliac arteries can be arteriosclerotic or tortuous which denies access (Wolf 
et al, 2001). Calcification may also compromise passage of the stent delivery sheath. After 
bilateral access is obtained, a marking angiogram is typical to confirm pre-operative CT 
measurements and identify the exact location of the lowest renal artery. Most devices follow 
with ipsilateral main body insertion and deployment at the infra-renal neck, wire 
cannulation of the contralateral "gate," contralateral limb deployment, balloon angioplasty to 
fully expand the device, and completion angiography. Technical success is achieved when 
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there has been successful access to the arterial system using a remote site, successful 
deployment of a patent stent graft the stent graft with secure proximal and distal fixation 
and absence of either a type I or type III endoleak (Chaikof et al, 2002). Patients who 
undergo EVAR or TEVAR need regular clinical follow-up with appropriate imaging for the 
remainder of their lives because of the potential for stent graft migration and other causes of 
sac repressurization that put the patient at risk of aneurysm rupture. CT is the gold standard 
for follow-up imaging. Concerns with using CT for follow-up include the cumulative effects 
of radiation exposure and the effect of repetitive administration of intravenous contrast on 
renal function. MRangiography is an alternative for follow-up of most endograft devices but 
is costly, time consuming, and not universally available. Duplex ultrasound is preferable but 
bears the limitations of relatively small numbers of accredited vascular ultrasound 
technicians and the risk of inter-operator variability. Wireless pressure monitoring of the 
aneurysm sac using a small sensor implanted at the time of EVAR has been proposed as an 
alternative to other imaging modalities, but no long-term studies currently demonstrate its 
efficacy in preventing AAA rupture after EVAR (Kurosawa et al, 2007). Efforts to find the 
optimal method for minimizing the frequency and inconvenience for the patient of follow-
up visits while maximizing freedom from aneurysm-related death are ongoing. The first 
generation stents were suitable only for treating infra-renal aortic aneurysms with a long 
narrow neck, but subsequent device evolution has led to the situation where few aortic 
aneurysms cannot be treated by endovascular means. Continued development of grafts is 
likely to lead to application of the technique to increasing numbers of complex AAA’s.  
6.4 Complications of TEVAR & EVAR 
Many adverse events may accompany EVAR as it is a technically complex procedure 
typically performed on a high-risk, elderly patient population. This is particularly true of 
patients undergoing TEVAR. Hence, although the incidence of paraplegia is lower with 
TEVAR, it remains one of its most dreaded complications. The aetiology probably differs 
from that encountered after open surgery in that no aortic cross-clamping is required and 
most likely arises secondary to coverage of important intercostal or other collateral arteries 
supplying the spinal cord. Some institutions have introduced CSF drainage as described 
above for open TAA repair (Fuchs et al, 2003). However CSF catheters have their own 
related morbidity in the form of meningitis, CSF leak and epidural haematomas. In patients 
with high risk of spinal ischaemia additional intra-operative neurological monitoring with 
trans-cranial motor evoked potentials and/or somatosensory evoked potentials are useful.  
Blood loss following EVAR can be difficult to quantify, as it is often lost around the sheaths 
and catheters and can be retroperitoneal in the case of EVAR if an injury to femoral or iliac 
vessels occurs. In addition, TEVAR involves the liberal use of radiographic contrast to assist 
in appropriate deployment of the graft, ensure exclusion of the aneurysmal sac and 
determine branch vessel patency. The administration of radio-contrast media can lead to 
acute kidney injury which is usually reversible albeit its development is associated with 
adverse outcomes (Rudnick et al, 2008). There is no specific treatment for radio-contrast 
induced acute renal failure other than supportive management although preventive 
measures such as hydration with isotonic sodium bicarbonate and administration of the 
antioxidant acetylcyteine may reduce the risk (Merten et al, 2004).  
Myocardial responses to aortic cross-clamping are well documented. The degree of 
cardiovascular and systemic effects depends on the level at which the cross-clamp is 
applied. The higher the clamp is placed, the greater the haemodynamic disturbance. Unlike 
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approach as illustrated above. It remains an invasive procedure with mortality rates rising 
sharply in those with co-morbid disease such as coronary artery disease and renal failure 
while recovery can be protracted resulting in reduced quality of life. Such problems 
combined with the high number of patients for whom open AAA was contraindicated 
prompted Volodos et al in 1991 to report their clinical experience of using self-fixing 
synthetic remote endoprosthetics for aorta reconstruction (Volodos et al, 1991). In the same 
year Parodi et al reported repair of AAA in five subjects using an endovascular approach 
with a modified stent and graft material (Parodi et al, 1991). The stent graft system reported 
by Parodi was initially developed and patented by Lazarus in 1987 (Lazarus et al, 
1987).Although in these early studies reflux was found at the distal end of the graft which 
necessitated re-intervention, EVAR was established as a feasible treatment for AAA and 
more importantly safe for the patient.  
The basic design of all endografts is similar: the aortic aneurysm is crossed by a tubular graft 
that has a wide diameter (~20-36 mm) and supported by stents along its length. The tube 
either bifurcates into two smaller diameter stent grafts that fit into the iliac arteries, or it 
decreases in size to locate in one iliac artery. Due to rapid commercialisation there are 
numerous EVAR devices available on the world wide market. The feasibility of EVAR like 
TEVAR depends mainly on anatomic factors that represent the important predictors of 
success. Aside from the indications of either an asymptomatic aneurysm of appropriate 
maximal diameter, or a small aneurysm with features putting it at increased risk of rupture, 
patients being considered for EVAR must fulfil several anatomic criteria. These include 1) 
ilio-femoral access vessels that will allow safe insertion and deployment of the device, 
adequate seal, and sufficient length to provide axial support for the graft and 2) an infra-
renal aortic neck of adequate length, limited angulation, and appropriate diameter. These 
features, as well as the presence or absence of thrombus and calcium at each level of fixation 
are evaluated using CT. Anatomic selection criteria for EVAR are based principally on 
characteristics of the proximal infra-renal neck, aneurysm sac and iliac arteries. An 
unfavourable neck anatomy is the most frequent cause for exclusion from EVAR (Iezzi et al, 
2001). The guidelines for EVAR are constantly being redefined, mostly as a result of 
increasingly operator experience and improvement in stent-graft technology. Although, 
with new technology the number of patient’s eligible for EVAR will increase, complex aortic 
anatomy will be a significant limitation, at least for the foreseeable future and is likely to 
ensure that open AAA repair will continue to form an essential part of vascular surgery.  
EVAR, as with TEVAR, begins by the surgeons gaining access to both femoral arteries 
typically through small groin incisions, although a totally percutaneous approach has been 
reported with low complication rates and high incidence of technical success (Lee et al, 
2007). Therefore, both the femoral and iliac arteries must be patent, have as little tortuosity 
as possible, and one of them must allow a catheter, up to 24 French (Fr) (8 mm) in diameter, 
to be introduced to the aorta. In some patients with AAA the arteries are too small to allow 
access (Velazquez et al, 2001). In addition some patients have concomitant vascular disease, 
so the femoral and iliac arteries can be arteriosclerotic or tortuous which denies access (Wolf 
et al, 2001). Calcification may also compromise passage of the stent delivery sheath. After 
bilateral access is obtained, a marking angiogram is typical to confirm pre-operative CT 
measurements and identify the exact location of the lowest renal artery. Most devices follow 
with ipsilateral main body insertion and deployment at the infra-renal neck, wire 
cannulation of the contralateral "gate," contralateral limb deployment, balloon angioplasty to 
fully expand the device, and completion angiography. Technical success is achieved when 
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there has been successful access to the arterial system using a remote site, successful 
deployment of a patent stent graft the stent graft with secure proximal and distal fixation 
and absence of either a type I or type III endoleak (Chaikof et al, 2002). Patients who 
undergo EVAR or TEVAR need regular clinical follow-up with appropriate imaging for the 
remainder of their lives because of the potential for stent graft migration and other causes of 
sac repressurization that put the patient at risk of aneurysm rupture. CT is the gold standard 
for follow-up imaging. Concerns with using CT for follow-up include the cumulative effects 
of radiation exposure and the effect of repetitive administration of intravenous contrast on 
renal function. MRangiography is an alternative for follow-up of most endograft devices but 
is costly, time consuming, and not universally available. Duplex ultrasound is preferable but 
bears the limitations of relatively small numbers of accredited vascular ultrasound 
technicians and the risk of inter-operator variability. Wireless pressure monitoring of the 
aneurysm sac using a small sensor implanted at the time of EVAR has been proposed as an 
alternative to other imaging modalities, but no long-term studies currently demonstrate its 
efficacy in preventing AAA rupture after EVAR (Kurosawa et al, 2007). Efforts to find the 
optimal method for minimizing the frequency and inconvenience for the patient of follow-
up visits while maximizing freedom from aneurysm-related death are ongoing. The first 
generation stents were suitable only for treating infra-renal aortic aneurysms with a long 
narrow neck, but subsequent device evolution has led to the situation where few aortic 
aneurysms cannot be treated by endovascular means. Continued development of grafts is 
likely to lead to application of the technique to increasing numbers of complex AAA’s.  
6.4 Complications of TEVAR & EVAR 
Many adverse events may accompany EVAR as it is a technically complex procedure 
typically performed on a high-risk, elderly patient population. This is particularly true of 
patients undergoing TEVAR. Hence, although the incidence of paraplegia is lower with 
TEVAR, it remains one of its most dreaded complications. The aetiology probably differs 
from that encountered after open surgery in that no aortic cross-clamping is required and 
most likely arises secondary to coverage of important intercostal or other collateral arteries 
supplying the spinal cord. Some institutions have introduced CSF drainage as described 
above for open TAA repair (Fuchs et al, 2003). However CSF catheters have their own 
related morbidity in the form of meningitis, CSF leak and epidural haematomas. In patients 
with high risk of spinal ischaemia additional intra-operative neurological monitoring with 
trans-cranial motor evoked potentials and/or somatosensory evoked potentials are useful.  
Blood loss following EVAR can be difficult to quantify, as it is often lost around the sheaths 
and catheters and can be retroperitoneal in the case of EVAR if an injury to femoral or iliac 
vessels occurs. In addition, TEVAR involves the liberal use of radiographic contrast to assist 
in appropriate deployment of the graft, ensure exclusion of the aneurysmal sac and 
determine branch vessel patency. The administration of radio-contrast media can lead to 
acute kidney injury which is usually reversible albeit its development is associated with 
adverse outcomes (Rudnick et al, 2008). There is no specific treatment for radio-contrast 
induced acute renal failure other than supportive management although preventive 
measures such as hydration with isotonic sodium bicarbonate and administration of the 
antioxidant acetylcyteine may reduce the risk (Merten et al, 2004).  
Myocardial responses to aortic cross-clamping are well documented. The degree of 
cardiovascular and systemic effects depends on the level at which the cross-clamp is 
applied. The higher the clamp is placed, the greater the haemodynamic disturbance. Unlike 
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open aortic surgery, TEVAR does not involve extended periods of aortic occlusion. 
Although the balloon is usually deflated within 15-20 seconds during TEVAR, patients with 
coronary artery disease or left ventricular dysfunction may respond poorly and run a high 
risk of myocardial ischaemia.  
The above complications of EVAR procedure relate to the peri- and post-operative period. 
One of the most common adverse events following EVAR is the need for a secondary 
intervention. Data from the EUROpean collaborators on Stent/graft Techniques for Aortic 
Aneurysm Repair (EUROSTAR) registry of 2846 patients treated from December 1999 until 
December 2004 revealed that EVAR resulted in a cumulative incidence of secondary 
interventions of 6.0%, 8.7%, 12%, and 14% at 1, 2, 3, and 4 years, respectively (Hobo et al, 
2006). Secondary interventions are typically performed when the aneurysm has become 
repressurized because of incomplete exclusion of blood flow from the sac. The term 
"endoleak" was created in 1996 to describe this complication (White et al, 1996). An endoleak 
is defined as the persistence of blood flow outside the lumen of the endograft but within an 
aneurysm sac or adjacent vascular segment treated by the graft (White et al, 1996; Gonzalez-
Fajardo et al, 2002). Endoleaks may occur because of misplacement or poor sizing of an 
endograft, endograft fatigue and displacement or distortion of the endograft material. These 
latter factors represent device failure which in the modern era has largely been overcome as 
a result of device development. Endoleaks have been classified into types I to IV based upon 
the underlying cause and anatomical site of origin. Each is discussed below. 
Persistent flow around the attachment sites (proximal or distal) of the endograft due to 
inadequate or ineffective seal at the graft ends is classified as a type I endoleak. Type I 
endoleaks may occur in up to 24% of patients following TEVAR is the most frequently 
encountered, usually results from technical error and may eventually result in graft failure. 
Type I endoleaks usually require additional stent-graft deployment. .which may increase 
complication rates and adversely affect patient quality of life. Type I and type III endoleaks 
(see below) are treated immediately to halt peri-graft flow or flow between modular 
components. 
An endoleak may also occur because of retrograde flow into the aneurysmal sac from a 
patent collateral branch vessel (type II endoleak) and is not of major concern. The endoleak 
usually resolves spontaneously after 6 months. Type II endoleaks are typically managed 
expectantly with intervention reserved for persistent endoleaks in the presence of aneurysm 
sac enlargement. The presence of a persistent type II endoleak for ≥ 6 months, however, has 
been associated with aneurysm enlargement, increased rate of secondary interventions, and 
even aneurysm rupture (Fairman et al, 2006; Jones et al, 2007). Secondary interventions can 
range from diagnostic angiography to endograft removal with conversion to open repair. 
Flow into the aneurysmal sac because of leakage between modular segments of an endograft 
is classified as a type III endoleak. This is probably more common in the thoracic aorta 
because of greater haemodynamic stress causing early or late graft material fatigue. 
Management via the endovascular route using a covered stent to reline the failing endograft 
is usually appropriate. A related cause of endoleak and potential complication of EVAR is 
device failure. The integrity of stent graft materials and maintenance of proper positioning 
within the aneurysm are critical in preventing pressurization of the aneurysm sac and 
rupture. Material failure includes fracture of any of the metallic components of the stent 
graft, including stents, hooks, or barbs, or tears in the fabric component of the stent graft. 
Loss of proper stent graft position can occur for many reasons. Material failure, inadequate 
proximal or distal seal zone, aneurysm remodelling after EVAR, or features of the vessel, 
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such as thrombus or calcium, that limit stent purchase, have all been implicated in the 
migration of stent grafts. Each of these modes of failure must be analyzed within the context 
of their clinical significance. A stent fracture that leaves the graft fabric intact and is not in a 
critical region for maintaining fixation would likely need only follow-up, whereas modular 
component separation resulting in a large type III endoleak will require urgent intervention 
to restore stent graft integrity. 
Flow detected in the aneurysmal sac by completion angiography may occur due to porous 
graft material. This is termed a type IV endoleak and may be difficult to distinguish from 
other types of graft leakage. Its diagnosis is made after exclusion of any other identifiable 
source of endoleak. Type IV endoleaks rarely occurs with modern stent graft design.  
Type V endoleaks or ‘endoleak of undefined origin’ (endotension), although still reported 
(Iyer et al, 2007), but are much less frequent after modification of the Gore Excluder device in 
2004 to a low-permeability expanded polytetrafluoroethylene layer (Tanski et al, 2007). 
Endotension is the continued pressurisation of the sac with subsequent sac enlargement in 
the absence of an apparent endoleak. It is may be caused by pressure transmission through a 
sealed of thrombosed endoleak (Kamineni et al, 2004). Controversy surrounds the nature of 
this type of endoleak and its management. An increase in aneurysm size can occur with 
endotension, but if there is no demonstrate endoleak or the aneurysm is shrinking in size, 
additional intervention is usually not required. Several procedures are possible: open 
replacement of the graft, wrapping the endograft with a new graft at laparotomy, and 
endovascular relining of the stent-graft. Conversion to open repair usually treats 
endotension satisfactorily (Lin et al, 2003).  
Stent fatigue and fracture are also a problem following endovascular procedures. Ten per 
cent of all stent grafts have fractured within 4 years (Jacobs et al, 2003). The fracture of a 
stent strut may lead to a Type III endoleak, or if the attachment barbs and hooks fracture, 
the stent graft may migrate to form a Type I endoleak. Many stents allow initial deployment 
which allows partial re-positioning, as no repositioning can be performed when the graft is 
fully deployed. Inaccurate deployment will also lead to the increased use of extenders, thus 
increasing the probability of Type III endoleak (Zairns et al, 2003). Although many of the 
stents grafts do allow some manoeuvrability post-implantation, this is mostly in the form of 
moving the stent down the aorta. Thus if barbs/anchors have been deployed, too much 
movement may itself cause dissection of the artery. Kinking caused by fracture of the stent 
or insufficient support given to the graft can result in obstructed of a bifurcated limb 
(Corbett et al, 2008) which often leads to the need for endovascular re-intervention being 
required. EVAR device migration remains a major problem. Fixation devices (endostaplers) 
along with new stent graft designs may be important in preventing graft migration. Such 
approaches appear to work in animal models with relatively thin, non-diseased aortas (Arko 
et al, 2005). 
The primary goal of EVAR is aneurysm exclusion and depressurisation. However continued 
pressurisation secondary to endoleaks or endotension can be associated with late aneurysm 
rupture with a reported incidence of one per cent (Cho et al, 2004). Diagnosis of rupture 
after EVAR can be problematic. Female gender and adverse anatomy with short wide and 
angulated infra-renal necks may be predisposing factors (Brewster et al, 2006). The mortality 
for late rupture is variable and reported between 43-83%.  
As discussed above, aorto-duodenal fistula (ADF) is an abnormal communication between the 
aorta and usually the fourth part of the duodenum which constitutes a rare but life-threatening 
complication of aneurysm repair. Until recently, they were primarily associated with open 
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open aortic surgery, TEVAR does not involve extended periods of aortic occlusion. 
Although the balloon is usually deflated within 15-20 seconds during TEVAR, patients with 
coronary artery disease or left ventricular dysfunction may respond poorly and run a high 
risk of myocardial ischaemia.  
The above complications of EVAR procedure relate to the peri- and post-operative period. 
One of the most common adverse events following EVAR is the need for a secondary 
intervention. Data from the EUROpean collaborators on Stent/graft Techniques for Aortic 
Aneurysm Repair (EUROSTAR) registry of 2846 patients treated from December 1999 until 
December 2004 revealed that EVAR resulted in a cumulative incidence of secondary 
interventions of 6.0%, 8.7%, 12%, and 14% at 1, 2, 3, and 4 years, respectively (Hobo et al, 
2006). Secondary interventions are typically performed when the aneurysm has become 
repressurized because of incomplete exclusion of blood flow from the sac. The term 
"endoleak" was created in 1996 to describe this complication (White et al, 1996). An endoleak 
is defined as the persistence of blood flow outside the lumen of the endograft but within an 
aneurysm sac or adjacent vascular segment treated by the graft (White et al, 1996; Gonzalez-
Fajardo et al, 2002). Endoleaks may occur because of misplacement or poor sizing of an 
endograft, endograft fatigue and displacement or distortion of the endograft material. These 
latter factors represent device failure which in the modern era has largely been overcome as 
a result of device development. Endoleaks have been classified into types I to IV based upon 
the underlying cause and anatomical site of origin. Each is discussed below. 
Persistent flow around the attachment sites (proximal or distal) of the endograft due to 
inadequate or ineffective seal at the graft ends is classified as a type I endoleak. Type I 
endoleaks may occur in up to 24% of patients following TEVAR is the most frequently 
encountered, usually results from technical error and may eventually result in graft failure. 
Type I endoleaks usually require additional stent-graft deployment. .which may increase 
complication rates and adversely affect patient quality of life. Type I and type III endoleaks 
(see below) are treated immediately to halt peri-graft flow or flow between modular 
components. 
An endoleak may also occur because of retrograde flow into the aneurysmal sac from a 
patent collateral branch vessel (type II endoleak) and is not of major concern. The endoleak 
usually resolves spontaneously after 6 months. Type II endoleaks are typically managed 
expectantly with intervention reserved for persistent endoleaks in the presence of aneurysm 
sac enlargement. The presence of a persistent type II endoleak for ≥ 6 months, however, has 
been associated with aneurysm enlargement, increased rate of secondary interventions, and 
even aneurysm rupture (Fairman et al, 2006; Jones et al, 2007). Secondary interventions can 
range from diagnostic angiography to endograft removal with conversion to open repair. 
Flow into the aneurysmal sac because of leakage between modular segments of an endograft 
is classified as a type III endoleak. This is probably more common in the thoracic aorta 
because of greater haemodynamic stress causing early or late graft material fatigue. 
Management via the endovascular route using a covered stent to reline the failing endograft 
is usually appropriate. A related cause of endoleak and potential complication of EVAR is 
device failure. The integrity of stent graft materials and maintenance of proper positioning 
within the aneurysm are critical in preventing pressurization of the aneurysm sac and 
rupture. Material failure includes fracture of any of the metallic components of the stent 
graft, including stents, hooks, or barbs, or tears in the fabric component of the stent graft. 
Loss of proper stent graft position can occur for many reasons. Material failure, inadequate 
proximal or distal seal zone, aneurysm remodelling after EVAR, or features of the vessel, 
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such as thrombus or calcium, that limit stent purchase, have all been implicated in the 
migration of stent grafts. Each of these modes of failure must be analyzed within the context 
of their clinical significance. A stent fracture that leaves the graft fabric intact and is not in a 
critical region for maintaining fixation would likely need only follow-up, whereas modular 
component separation resulting in a large type III endoleak will require urgent intervention 
to restore stent graft integrity. 
Flow detected in the aneurysmal sac by completion angiography may occur due to porous 
graft material. This is termed a type IV endoleak and may be difficult to distinguish from 
other types of graft leakage. Its diagnosis is made after exclusion of any other identifiable 
source of endoleak. Type IV endoleaks rarely occurs with modern stent graft design.  
Type V endoleaks or ‘endoleak of undefined origin’ (endotension), although still reported 
(Iyer et al, 2007), but are much less frequent after modification of the Gore Excluder device in 
2004 to a low-permeability expanded polytetrafluoroethylene layer (Tanski et al, 2007). 
Endotension is the continued pressurisation of the sac with subsequent sac enlargement in 
the absence of an apparent endoleak. It is may be caused by pressure transmission through a 
sealed of thrombosed endoleak (Kamineni et al, 2004). Controversy surrounds the nature of 
this type of endoleak and its management. An increase in aneurysm size can occur with 
endotension, but if there is no demonstrate endoleak or the aneurysm is shrinking in size, 
additional intervention is usually not required. Several procedures are possible: open 
replacement of the graft, wrapping the endograft with a new graft at laparotomy, and 
endovascular relining of the stent-graft. Conversion to open repair usually treats 
endotension satisfactorily (Lin et al, 2003).  
Stent fatigue and fracture are also a problem following endovascular procedures. Ten per 
cent of all stent grafts have fractured within 4 years (Jacobs et al, 2003). The fracture of a 
stent strut may lead to a Type III endoleak, or if the attachment barbs and hooks fracture, 
the stent graft may migrate to form a Type I endoleak. Many stents allow initial deployment 
which allows partial re-positioning, as no repositioning can be performed when the graft is 
fully deployed. Inaccurate deployment will also lead to the increased use of extenders, thus 
increasing the probability of Type III endoleak (Zairns et al, 2003). Although many of the 
stents grafts do allow some manoeuvrability post-implantation, this is mostly in the form of 
moving the stent down the aorta. Thus if barbs/anchors have been deployed, too much 
movement may itself cause dissection of the artery. Kinking caused by fracture of the stent 
or insufficient support given to the graft can result in obstructed of a bifurcated limb 
(Corbett et al, 2008) which often leads to the need for endovascular re-intervention being 
required. EVAR device migration remains a major problem. Fixation devices (endostaplers) 
along with new stent graft designs may be important in preventing graft migration. Such 
approaches appear to work in animal models with relatively thin, non-diseased aortas (Arko 
et al, 2005). 
The primary goal of EVAR is aneurysm exclusion and depressurisation. However continued 
pressurisation secondary to endoleaks or endotension can be associated with late aneurysm 
rupture with a reported incidence of one per cent (Cho et al, 2004). Diagnosis of rupture 
after EVAR can be problematic. Female gender and adverse anatomy with short wide and 
angulated infra-renal necks may be predisposing factors (Brewster et al, 2006). The mortality 
for late rupture is variable and reported between 43-83%.  
As discussed above, aorto-duodenal fistula (ADF) is an abnormal communication between the 
aorta and usually the fourth part of the duodenum which constitutes a rare but life-threatening 
complication of aneurysm repair. Until recently, they were primarily associated with open 
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AAA repair occurring at a rate 2% (Bertges et al, 2003). It is believed that local infection leads 
to intestinal necrosis and subsequent fistula formation. Endotension may also be a 
contributory factor. Treatment of ADF is graft removal, revascularisation and intestinal repair.  
7. Evidence for type of aneurysm repair: In a nutshell 
7.1 Open versus laparoscopic AAA repair 
Reviews of published large series of open AAA repair demonstrate consistent short-term 
(30-day) outcomes: death, 2-5%; myocardial infarction, 2-8%; renal failure, 2-5%; pneumonia, 
5%; bleeding, 2-4%; leg ischaemia 1-4%; colon ischaemia, 1-2%; and length of stay 5 to 10 
days (Lerderle et al, 2000, Johnston et al, 1998, Huber et al, 2007, Richardson et al, 1991). The 
short term morbidity and mortality are offset by a low rate of adverse long-term (10 or more 
years) outcome that include anastomotic aneurysm, 4-10%; graft infection 1-2% and 
thrombosis, 3% (Biancari et al, 2002; Hallet et al, 1997; Schermehorn et al, 2008). These 
figures have been used as the benchmark against which the newer, minimal invasive repairs 
have been judged.  
The follow-up results of laparoscopic AAA repair seem to indicate a better post-operative 
course when compared with standard open repair. Retrospective comparisons with open 
surgically treated cases are unreliable because the groups are not matched or randomized 
and are thus subject to the influence of uncontrolled variables. The advantages of the 
laparoscopic approach over the open surgical approach are likely to be real. Indeed total 
laparoscopic aortic surgery based on data from the reported laparoscopic AAA repair 
literature reports better outcomes in terms of post-operative stay when compared to hand-
assisted laparoscopic surgery and open repair (Coggia et al, 2004). However with the advent 
of EVAR and the pace of technological development the randomized prospective trials 
required to assess laparoscopic and open AAA repair have not been performed. 
Laparoscopic AAA repair has thus largely become marginalised because of the wide 
adoption of EVAR.  
7.2 Open versus EVAR repair 
In modern aortic surgery the question has centred largely on the potential benefits of EVAR 
in comparison to open repair. Retrospective studies based on large administrative databases 
comparing open repair with EVAR document impressive superiority of EVAR in early 
patient outcomes (Schermehorn et al, 2008; Lee et al, 2004; Hua et al, 2005). This advantage 
of EVAR is all the more impressive when one considers that the EVAR was in general 
performed upon older and sicker patients. These results have been confirmed in the 
randomised trials, EVAR-1 and the Dutch Randomized Endovascular Aneurysm 
Management (DREAM) (Greenhalgh et al, 2004; Prissen et al, 2004). Additionally, two 
randomized European trials comparing EVAR to open surgery and one randomized trial 
comparing EVAR to no intervention were published in 2005 (Blankensteijn et al, 2005; EVAR 
Trial 1, 2005; EVAR Trial 2, 2005). The DREAM trial, randomised 351 patients with 
asymptomatic AAAs >5 cm in diameter with suitable stent graft anatomy to open surgery or 
EVAR. This study suggested a 30-day benefit in mortality favouring EVAR (Prissen et al, 
2004). The trend toward an early mortality advantage was lost, however, 12 months into the 
2-year study follow-up (Blankensteijn et al, 2005).  
The second trial, from the United Kingdom, EVAR 1, was similar to DREAM in comparing 
EVAR to open surgery in patients with suitable stent graft anatomy and aneurysm size 5.5 
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cm (EVAR Trial 1, 2005). This study randomized 1082 patients. EVAR 1 more clearly 
demonstrated an early peri-operative mortality benefit for EVAR (Greenhalgh et al, 2004). 
Blood product use and length of hospital stay also favoured EVAR. In contrast, the primary 
end point of all-cause mortality did not show a lasting benefit for EVAR at the 4-year study 
conclusion, although aneurysm-related death was decreased (EVAR Trial 1, 2005). 
Complication rates and re-intervention rates were much higher for stent graft repair than for 
open repair. EVAR trial 2 (EVAR Trial 2, 2005) randomized 338 patients >60 years of age 
with aneurysms 5.5 cm who were deemed unfit for open surgical repair to EVAR or no 
intervention (EVAR Trial 2, 2005). Between the two arms of the study, 142 patients died 
during follow-up, which correlated to a 64% overall mortality by Kaplan–Meier estimates at 
4 years. This study was complicated by long delays in EVAR after randomization and a 27% 
patient crossover rate from the no intervention group. In the final analysis, no benefit to 
EVAR over medical management was detected in either overall mortality or aneurysm-
related mortality for patients unfit for open surgery.  
Ongoing in the United States is the Open Versus Endovascular Repair (OVER) trial, a 9-year 
study that began in 2002 comparing endovascular aneurysm repair with standard open 
surgery using a multi-centre randomized trial through the Department of Veteran Affairs 
Cooperative Study Group (Lederle et al, 2006). In comparison with EVAR, open AAA repair 
has a highly significant 2- to 3-fold increase in mortality, a 1.5- to 2-fold increase in major 
morbidity, a 12-fold increase in blood transfusion requirement and a 2-fold increase in 
length of stay and discharge to a long-term care facility.  
In conclusion, although early outcome data provided a compelling case for EVAR the 
outlook became clouded when long term outcomes were considered. This finding is even 
more pertinent when it is considered that both EVAR 1 and DREAM showed that EVAR 
was associated with a 4-fold increase in long-term (2-4 years) complications and a 3-fold 
increase in the need for re-intervention (Greenhalgh et al, 2005; Blankensteijn et al, 2005). 
Quality of life is heavily in favour of EVAR especially in the weeks and months immediately 
following the procedure. However after 6 months and longer quality of life is documented 
to be better in patients with open repair (Greenhalgh et al, 2005; Prissen et al, 2004a; Prissen 
et al, 2004b). This is likely related to the greater need for radiological surveillance with 
EVAR. However although earlier studies suggested that EVAR was not cost-effective (Jonk 
et al, 2007; Prissen et al, 2007) more recent data from the National Institute for Clinical 
Excellence (NICE) in the United Kingdom suggests EVAR is cost effective (Hay et al, 2009). 
In addition, the long-term outcomes of EVAR are not fully understood. Indeed a 7- to 8-fold 
increase in aneurysm-related death after 5 years of follow-up has been observed in good-
risk patients treated with EVAR in comparison with open repair (Eliason et al, 2009).  
7.3 EVAR for small aneurysms 
Whereas randomized clinical trials have focused on establishing the proper use of EVAR for 
larger aneurysms, its application for the treatment of small aneurysms is still an area of 
controversy. Early open aneurysm repair for aneurysms <5.5 cm in diameter does not confer 
a long-term survival advantage (Lederle et al, 2002; UK small aneurysm trial, 2002). 
However, retrospective analysis of the large EUROSTAR database revealed that EVAR for 
aneurysms with diameters between 4.0 cm and 5.4 cm had lower incidence of type I 
endoleak and improved cumulative freedom from aneurysm-related death relative to two 
comparison groups with aneurysm diameters of 5.5 to 6.4 cm and 6.5 cm (Peppelenbosch et 
al, 2004). Level 1 evidence is lacking at this time, but the Positive Impact of EndoVascular 
 
Aneurysmal Disease of the Thoracic and Abdominal Aorta 
 
42
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Options for Treating Aneurysms EarLy (PIVOTAL) and Comparison of Surveillance versus 
Aortic Endografting for Small Aneurysm Repair (CAESAR) trials were initiated in an 
attempt to provide such evidence (Cao et al, 2005). Both are device specific, randomize 
patients with smaller aneurysms to EVAR or surveillance, and use an FDA-approved 
Medtronic device or the Cook Zenith device, respectively. Until the results of these trials are 
published, the optimal management of small aneurysms remains ambiguous and a patient-
specific approach that takes into account aneurysm morphology, biology, and patient co-
morbidities should be used. 
7.4 Open versus TEVAR for TAA 
TEVAR benefit to risk ratio is even greater than that encountered with EVAR although 
TEVAR is more expensive than EVAR. In comparison to open surgery it is associated with 
significant reduction in blood transfusion requirements, major complications, ITU and 
hospital length of stay (Murphy et al, 2009). However the total hospital costs are 2-fold 
higher and the cost margin minus 34% in comparison with plus 6.2% for open repair 
(Ramagnoli et al, 2009). The extra costs for TEVAR were usually a result of the use of 
multiple devices to treat extensive aneurysms. Clearly, in elderly patients and in those at 
high risk for open repair, TEVAR is an excellent surgical option for repair. With continuing 
evaluation of endovascular techniques, comparisons with open repair will be made. 
Recently, the results from the combined experience of EUROSTAR and the United Kingdom 
Thoracic Endograft registries have been published (Leurs et al, 2004). From this report, 
overall 30-day mortality was 5.4% for elective cases, and paraplegia was 4% after aneurysm 
stenting; 1-year follow-up was obtained for 45% of patients of the entire cohort with an 80% 
survival for aneurysmal disease. Others have reported similar early results (Mitchell et al, 
1999; Greenberg et al, 2000; White et al, 2004; Najibi et al, 2002, Hansen et al, 2004; 
Lambrechts et al, 2003). It remains striking that even with no aortic occlusion during 
endovascular stenting, neurologic deficit was still significant, ranging as high as 12% (with 
stroke as high as 7%). The overall long-term survival was 79%, 76%, 64%, and 35% at 1, 2, 5, 
and 10 years, respectively after open TAA repair (Svensson et al, 1993). In addition, freedom 
from reoperation for distal aortic related condition was 96% at 13 years. Early (1 to 2 years) 
survival with endovascular stenting has been reported from 73% to 81% with freedom from 
reintervention at 54% at almost 4 years (Mitchell et al, 1999). This report confirms that open 
repair for descending thoracic aortic repair remains durable for the long term and does not 
require multiple reinterventions. Two clinical trials have compared TEVAR with open 
surgery. The first published in 2002 compared 19 patients with 10 historical controls. The 
mean length of ITU stay and hospital stay were better in the TEVAR group. This study 
however was not randomised and follow up was limited (Najibi et al, 2002). The second 
(non-randomized) study also reported that 30 day mortality was better in the TEVAR group 
with fewer complications (Bavaria et al, 2007). However the two year survival was similar in 
both groups. A recent Cochrane review concluded that although such evidence may suggest 
that endovascular repair can be appropriate in selected patients, high quality studies are 
needed to produce generalisable conclusions (Abraha et al, 2009).  
8. The future of aortic aneurysm repair 
Aortic surgery has evolved at an exponential rate in the last five decades. The future lies in 
how we further develop these technologies to improve patient outcome. With the advent of 
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screening programmes it is likely in the immediate future that the need for surgery will 
increase. How to apply these technologies for maximal patient benefit will be the future 
challenge to the vascular surgeon. In the next decade we can expect continuing 
improvements in endovascular device design to include the treatment of supra-renal and 
thoraco-abdominal aneurysms. The role of open repair is likely to diminish raising questions 
on whether centralization of complex open aortic surgery will be required.. Surgeons will 
need to have efficient follow-up protocols and evaluate the new stent-grafts in order to 
continue the advance of aortic aneurysm surgery.  
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1. Introduction 
Abdominal aortic aneurysms (AAA) are a well-recognized cause of morbidity and mortality 
in older persons. The 20th century has lead to many overall advances in surgery and 
specifically the management of complex and often lethal disease processes. In the early part 
of last century, advances in anesthesia and critical care allowed for the surgical management 
of AAA via the open approach, which is to this day still considered by many to remain the 
gold standard of repair. In the latter part of the last century further advances and innovative 
thinking led to the minimally invasive endovascular treatment of many AAAs. 
Endovascular abdominal aortic aneurysm repair (EVAR) has pioneered the treatment of 
more complex aortic disease and now with greater then 20 years since its début it is in many 
centers the preferred treatment. There is no longer a feasibility question; these devices have 
been proven to be safe and efficacious with less perioperative morbidity and mortality than 
traditional open repair.  
In an attempt to improve the world literature and make comparisons more possible amongst 
the many evolving studies underway globally a need for some commonality in the reporting 
of results was recognized. The reporting standards for AAA repair, both for endovascular and 
for open repair have been formulated into guidelines first extended in 1997 and then later 
updated in 2002. These standards outline the generally measured characteristics touched on by 
many of the studies reporting on the treatment of aortic aneurismal disease. Included are the 
common patient characteristics involved in atherosclerotic disease such as tobacco use, 
hyperlipidemia, hypertension, diabetes mellitus, renal insufficiency, chronic obstructive 
pulmonary disease, carotid occlusive disease, other associated aneurismal disease and 
anesthesia risk as outlined by the American Society of Anesthesiology Risk Classification 
(ASA). These guidelines also address characteristics unique to aneurismal disease known as 
the anatomical risk factors, such as aortic neck length and angulation as well as access vessels 
where included with a grading system. Outcome measures of clinical success and the 
definition of terms such as endotension and endoleak were included. The current devices have 
gone through several generations of advancement, alteration and modification which has 
addressed many of the device specific criterions that where offered and for the most part has 
addressed, and continue to address these limitations as innovation in the field continues. 
With further advances and longer length follow up periods many of the earlier unanswered 
questions are being addressed however in doing so new questions have arisen and the 
persistent question since the inception of EVAR remains a point of controversy to this day, 
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1. Introduction 
Abdominal aortic aneurysms (AAA) are a well-recognized cause of morbidity and mortality 
in older persons. The 20th century has lead to many overall advances in surgery and 
specifically the management of complex and often lethal disease processes. In the early part 
of last century, advances in anesthesia and critical care allowed for the surgical management 
of AAA via the open approach, which is to this day still considered by many to remain the 
gold standard of repair. In the latter part of the last century further advances and innovative 
thinking led to the minimally invasive endovascular treatment of many AAAs. 
Endovascular abdominal aortic aneurysm repair (EVAR) has pioneered the treatment of 
more complex aortic disease and now with greater then 20 years since its début it is in many 
centers the preferred treatment. There is no longer a feasibility question; these devices have 
been proven to be safe and efficacious with less perioperative morbidity and mortality than 
traditional open repair.  
In an attempt to improve the world literature and make comparisons more possible amongst 
the many evolving studies underway globally a need for some commonality in the reporting 
of results was recognized. The reporting standards for AAA repair, both for endovascular and 
for open repair have been formulated into guidelines first extended in 1997 and then later 
updated in 2002. These standards outline the generally measured characteristics touched on by 
many of the studies reporting on the treatment of aortic aneurismal disease. Included are the 
common patient characteristics involved in atherosclerotic disease such as tobacco use, 
hyperlipidemia, hypertension, diabetes mellitus, renal insufficiency, chronic obstructive 
pulmonary disease, carotid occlusive disease, other associated aneurismal disease and 
anesthesia risk as outlined by the American Society of Anesthesiology Risk Classification 
(ASA). These guidelines also address characteristics unique to aneurismal disease known as 
the anatomical risk factors, such as aortic neck length and angulation as well as access vessels 
where included with a grading system. Outcome measures of clinical success and the 
definition of terms such as endotension and endoleak were included. The current devices have 
gone through several generations of advancement, alteration and modification which has 
addressed many of the device specific criterions that where offered and for the most part has 
addressed, and continue to address these limitations as innovation in the field continues. 
With further advances and longer length follow up periods many of the earlier unanswered 
questions are being addressed however in doing so new questions have arisen and the 
persistent question since the inception of EVAR remains a point of controversy to this day, 
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namely who should undergo endovascular treatment and who should under go standard 
open repair. A significant hindrance has been the lack of ability to compare these studies 
head to head and gain useful and usable information from them. The reporting standards 
conceived by the Society for Vascular Surgery (SVS) were an attempt to make such 
comparisons more uniform for just this reason.  
As well as reporting standards in individual studies being a goal of the SVS reporting 
standards guidelines the drive for successful management of AAA as well as many other 
diseases has been taken up by the clinical and administrative bodies of large organizations 
such as the Veterans Healthcare system and the American Collage of Surgeons based on the 
VA model. “Soon after introduction of endovascular aneurysm repair (EVAR), with Food 
and Drug Administration device approval in 1999, robust electronic NSQIP (National 
Surgical Quality Improvement Program) records immediately began to capture individual 
facility performances and outcomes for both types of AAA repair. The NSQIP data center 
provided actual and risk-adjusted analyses for both procedures semiannually. These 
analyses have been used by its executive board to provide recommendations, often based on 
site visits, to improve outcomes.” 1,2 Data bases like these have been adopted and pioneered 
by other countries as well and continue to add to the knowledge bases with the goal of 
efficient, high-quality care 2. 
However, in the face of all of the published standards no one accepted method is used and 
continued publications of standards and measuring techniques can still be found in both the 
world literature and in the Journal of vascular surgery such as the recently published 
Validation of a new standardized method to measure proximal aneurysm neck angulation 3 
and the recently reported attempt by the French health agency Agence Française de Sécurité 
Sanitaire des Produits de Santé (AFSSAPS) to determine criteria for the best surgical 
approach. The high-risk AFSSAPS criteria were however not predictive of postoperative 
mortality and the authors stated that these should not be used to determine the choice of 
treatment technique. Other criteria therefore need to be established to determine whether 
open or EVAR repair should be used. 4  
In the ever evolving field of AAA treatment there has not been an acceptance of the reporting 
standards, which makes interpretation difficult to a certain extent, but by the common nature 
of the studies there does tend to be overlap in the reporting making it possible to draw 
conclusions all be it in a non-standardized fashion from the recently reported studies.  
2. EVAR vs open repair: Basic variables in decision making  
There are three basic modalities, which are generally accepted and widely available for the 
management of abdominal aortic aneurysms. These include observation alone, also known 
as best medical treatment (BMT), Standard or open repair which is the oldest surgical 
method and for this reason considered by many to be the gold standard, which can be done 
either by a transperitoneal, or via the retroperitoneal incision, and the endovascular 
approach (EVAR). There are other options, which are available at some institutions and 
represent variations on and combinations of the above approaches, these include 
laparoscopic abdominal aortic repair and hybrid procedures. Of the 3 commonly available 
and accepted modalities outlined above, EVAR is the newest and most rapidly progressive 
in terms of technological innovation and industry driven advancements. 
The decision on the specific modality for optimal treatment has long been a matter of 
controversy, and continues to be so to this day. When planning the optimal treatment for 
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AAA there are 3 commonly considered variables. The first thing to consider is the size of the 
aneurysm. There is a well-established correlation between rupture risk and the maximal 
transverse size of the aorta and rupture5. Second is the anatomy or morphology of the aorta. 
All devices have guidelines for use under the Food and Drug Administration (FDA) which 
where created to assist the clinician in determining anatomical acceptability of the device to 
ensure the optimal outcome. In the past there has been a 20-60% reported suitability 
following the information for use guidelines (IFU) 6,7 however with advancing technology 
the delivery systems for these devices have gotten smaller, with hydrophilic coats and the 
devices themselves have become larger with different configurations which has greatly 
expanded the anatomic criteria for the use of these devices. Devices used outside of the 
FDA-IFU guidelines have been associated with increased complication rates and adherence 
to these guidelines as much as possible is recommended. 8-11 
The third variable commonly considered is perhaps the most challenging and can impact 
the other two variables to varying extents when trying to formulate an appropriate 
operative strategy. This variable is the patient. Multiple considerations on multiple levels 
often cloud ones judgment and make this a subjective rather then an objective decision. The 
elements going into this equation range widely from the patients co-morbidities and other 
illnesses are in determining whether they are “fit” for surgery or “high risk”, to whether the 
patient will follow up and be compliant with surveillance imaging, to what the patients 
expectations and knowledge are about the purposed intervention to outside influences such 
as the wishes, knowledge-base and influence family, friends and loved ones have. Putting 
all of these patient variables together is often a difficult and arduous task that can greatly 
influence the treatment modality chosen perhaps more then any other variable outlined.  
3. Size 
The anatomical size, in transverse diameter, has long been established as one of the main 
indications for treatment vs. observation. The commonly accepted size for the initiation of 
intervention is 5.5 cm based on several landmark publications and the accepted risk of 1% 
rupture below this threshold. A threshold diameter of 5.5 cm has been the point of 
separation commonly used based on the United Kingdom Small Aneurysm trial 5 and the 
US Veterans Administration Aneurysm Detection and Management 12 Study. These trials 
showed no benefit in overall survival to early repair over continued observation for AAAs 
less then 5.5 cm in diameter, and demonstrated an annual rupture risk for such small AAAs 
(4.0 cm to 5.4 cm) to be low approximately 1%. These studies where based on open 
aneurysm intervention. The natural history, despite the treatment threshold, of aneurysms is 
to continue to grow and then eventually to rupture. In the United Kingdom Small 
Aneurysm Trial 5, over 60% of those initially assigned to surveillance had AAA repair by 4 
years, and most of those with greater then 5.0 cm AAAs had a repair within 1 year. As a 
result, many clinicians have dropped the threshold for intervention for AAAs to 5.0 cm in 
diameter. It is more appropriate to think of size as an indication of when to consider, not 
whether to consider AAA repair. However when to treat endovascularly remained an open 
question EVAR has been reported to achieves better outcomes in smaller AAAs 13 and the 
importance of size in EVAR outcomes has been recently underscored by an analysis of the 
European Collaborators on Stent-Graft Techniques for Abdominal Aortic Aneurysm Repair 
(EUROSTAR) database, which showed a statistically significant correlation between size (4.0 
to 5.4 cm versus 5.5 to 6.4 cm versus >6.5 cm diameter) and all five outcomes studied (Type 
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as best medical treatment (BMT), Standard or open repair which is the oldest surgical 
method and for this reason considered by many to be the gold standard, which can be done 
either by a transperitoneal, or via the retroperitoneal incision, and the endovascular 
approach (EVAR). There are other options, which are available at some institutions and 
represent variations on and combinations of the above approaches, these include 
laparoscopic abdominal aortic repair and hybrid procedures. Of the 3 commonly available 
and accepted modalities outlined above, EVAR is the newest and most rapidly progressive 
in terms of technological innovation and industry driven advancements. 
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the delivery systems for these devices have gotten smaller, with hydrophilic coats and the 
devices themselves have become larger with different configurations which has greatly 
expanded the anatomic criteria for the use of these devices. Devices used outside of the 
FDA-IFU guidelines have been associated with increased complication rates and adherence 
to these guidelines as much as possible is recommended. 8-11 
The third variable commonly considered is perhaps the most challenging and can impact 
the other two variables to varying extents when trying to formulate an appropriate 
operative strategy. This variable is the patient. Multiple considerations on multiple levels 
often cloud ones judgment and make this a subjective rather then an objective decision. The 
elements going into this equation range widely from the patients co-morbidities and other 
illnesses are in determining whether they are “fit” for surgery or “high risk”, to whether the 
patient will follow up and be compliant with surveillance imaging, to what the patients 
expectations and knowledge are about the purposed intervention to outside influences such 
as the wishes, knowledge-base and influence family, friends and loved ones have. Putting 
all of these patient variables together is often a difficult and arduous task that can greatly 
influence the treatment modality chosen perhaps more then any other variable outlined.  
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separation commonly used based on the United Kingdom Small Aneurysm trial 5 and the 
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less then 5.5 cm in diameter, and demonstrated an annual rupture risk for such small AAAs 
(4.0 cm to 5.4 cm) to be low approximately 1%. These studies where based on open 
aneurysm intervention. The natural history, despite the treatment threshold, of aneurysms is 
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result, many clinicians have dropped the threshold for intervention for AAAs to 5.0 cm in 
diameter. It is more appropriate to think of size as an indication of when to consider, not 
whether to consider AAA repair. However when to treat endovascularly remained an open 
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1 endoleak, total mortality, aneurysm-related death, conversion to open repair, and post-
EVAR rupture) 14 15 . Endovascular repair has been shown to be safer than open surgical 
repair in patients with large aneurysms, prompting a randomized trial of early endovascular 
repair vs surveillance in patients with small aneurysms16. In the PIVOTAL trial the 
researchers randomly assigned 728 patients with 4 to 5 cm AAAs to early endovascular 
repair (366 patients) or ultrasound surveillance (362 patients), and Concluded the early 
treatment with endovascular repair and rigorous surveillance with selective aneurysm 
treatment as indicated both appear to be safe alternatives for patients with small AAAs, 
protecting the patient from rupture or aneurysm-related death for at least 3 years 16. In the 
Comparison of Surveillance Versus Aortic Endografting for Small Aneurysm Repair 
(CAESAR) Trial the researchers randomly assigned patients with AAA of 4.1-5.4 cm in a 1:1 
ratio, to receive immediate EVAR or surveillance by ultrasound and computed tomography 
(CT) and repair only after a defined threshold (diameter ≥5.5 cm, enlargement >1 cm /year, 
symptoms) was achieved. Between 2004 and 2008, 360 patients (early EVAR = 182; 
surveillance = 178) were enrolled. They reported that mortality and rupture rates in AAA 
<5.5 cm are low and no clear advantage was shown between early or delayed EVAR 
strategy. However, within 36 months, three out of every five small aneurysms under 
surveillance might grow to require repair and one out of every six might lose feasibility for 
EVAR. Concluding that surveillance is safe for small AAA if close supervision is applied.17 
Depending on interpretation and resources this information may help determine when to 
treat patients with smaller AAA at an earlier stage. Further, it has been suggested that the 
threshold in women be even lower (e.g., 4.5 cm in diameter) based on women’s relatively 
smaller aortic dimensions, which appear to play a role in their higher risk of rupture and its 
attendant mortality and in their 18 lower anatomical suitability for EVAR 14,18,19  
While in the past there was “no disagreement about appropriate treatment for large AAAs 
in patients with unsuitable anatomic characteristics that preclude EVAR, these patients 
should have conventional open repair, which has been reported to have low morbidity and 
mortality rates14. The advancement of technology has steadily whittled away at these 
anatomic criteria and continues to push the safe and acceptable anatomical criteria further 
into what was once considered to be the experimental or anatomically unacceptable range. 
With this push and the increasing use and availability of the EVAR technology there has 
been an over all shift in the general clinical practice in many institutions towards the 
implantation of EVAR, with less and less consideration being given to the surgically fit 
patient. This has led many clinicians to consider EVAR as the first line treatment for AAA 
regardless of the patient’s characteristics, such as fitness for surgery, or ability to undergo a 
large abdominal procedure. In many ways this is the trend first set out by the laparoscopic 
revolution that swept through general surgery some 20-30 years ago. It is rare now to see an 
open cholecystectomy, and rarer still to see this as a planned first line intervention. The open 
cholecystectomy is often reserved for the failed laparoscopic approach. So to, it would 
appear, is the fate of open abdominal reconstruction. While EVAR Has boasted well-
documented benefits20-22 over open repair including a reduction of aneurysm-related 
mortality, a decrease in perioperative cardiopulmonary complications as well as of 
hemorrhage, graft infection and colonic ischemia, as well as reduced patient trauma, 
reduced hospital stays and faster recovery 20. Even in the face of the EVAR 1 data suggesting 
that After 12 months there was negligible difference in Health Related Quality of Life 
(HRQL) between the two groups (EVAR vs Open) 23. The obvious benefits noted clinically 
by the patient and surgeons alike have propelled EVAR forward despite all oppositions. 
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While the above benefits are well documented and the trends outlined it is more apparent 
that obtaining similar results with less pain and less procedure are the true drivers behind 
EVAR. The argument against EVAR citing the need for long follow up and the possibility 
for re-intervention as a downside is far out weighed by the realization of both clinicians and 
patients alike that a little “check-up” every year or 6 months trumps a week in the hospital 
and a possible ICU stay for all concerned. Cost is a driving negative force, but if the same 
results are obtainable with less pain, people, especially Americans will put up with nothing 
less. Re-interventions often sited as a complication of EVAR are viewed by many patients as 
simply tune-ups, and despite the extensive reports documenting reintervention as a 
negative or down side to EVAR these are often well tolerated and the surgical conversion 
and explantation of EVAR has become much like the open cholecystectomy.  
The shift and trend is now towards EVAR first both in clinicians and patients minds. The 
drive has been both evidence based and human nature. When looking at an AAA needing 
repair most surgeons’ in this era first check to see if the patient is an EVAR candidate. 
Almost all other criteria are secondary. If the patient is young and could undergo a big open 
operation the surgeon and the patients’ response is more and more commonly becoming 
“why” from the sociological point of view. The argument has been posed that a young 
patient is generally a productive member of society and no matter how well they do with 
open repair, arguably given EVAR they would rejoin the work force much sooner and even 
in the face of continued “check-ups” and possible intermittent “tune-ups” they would still 
be a more productive, over a longer period of time then where they to undergo a open 
procedure with its associated recovery time and potential risks.  
4. The high risk patient 
The management of AAA in patients considered to be high-risk remains a challenge. While 
EVAR was initially studied in this group as an alternative to the open procedure in patients 
that where considered unfit for the open surgical intervention the pendulum has now 
swung in the opposite direction. Initially the question of feasibility was addressed using this 
patient population, now that feasibility is no longer a question and EVAR has been well 
established as an acceptable method for aneurysm treatment the consideration of 
appropriateness has come into question.  
The EVAR-2 Trial which used the cohort of patients that where excluded for the EVAR-1 
trial as mentioned earlier concluded after a mean 4 years of follow up that EVAR had a 
considerable 30-day operative mortality in patients already unfit for open repair of their 
aneurysm. EVAR did not improve survival over no intervention and was associated with a 
need for continued surveillance and reinterventions, at substantially increased cost. 
Ongoing follow-up and improved fitness of these patients is a priority24 published in 2005.  
Endovascular aneurysm repair (EVAR) is associated with superior short-term mortality 
rates but unclear long-term results and has not been shown to improve survival in patients 
unfit for open repair (OR)25. A group using the Swedish vascular registry conducted 
population-based study with the aim evaluating the outcome after elective EVAR compared 
with OR in a high-risk patient cohort. They reported that elective OR of aortic aneurysms 
seems to have a better outcome compared with EVAR in this specific, population-based, 
high-risk patient cohort after adjusting for covariates, and that they cannot confirm the 
benefit of EVAR from previous registry studies concluding that in clinical practice, OR may 
be at least as good as EVAR in high-risk patients fit for surgery. 25(Swedish study) 
 
Aneurysmal Disease of the Thoracic and Abdominal Aorta 
 
58
1 endoleak, total mortality, aneurysm-related death, conversion to open repair, and post-
EVAR rupture) 14 15 . Endovascular repair has been shown to be safer than open surgical 
repair in patients with large aneurysms, prompting a randomized trial of early endovascular 
repair vs surveillance in patients with small aneurysms16. In the PIVOTAL trial the 
researchers randomly assigned 728 patients with 4 to 5 cm AAAs to early endovascular 
repair (366 patients) or ultrasound surveillance (362 patients), and Concluded the early 
treatment with endovascular repair and rigorous surveillance with selective aneurysm 
treatment as indicated both appear to be safe alternatives for patients with small AAAs, 
protecting the patient from rupture or aneurysm-related death for at least 3 years 16. In the 
Comparison of Surveillance Versus Aortic Endografting for Small Aneurysm Repair 
(CAESAR) Trial the researchers randomly assigned patients with AAA of 4.1-5.4 cm in a 1:1 
ratio, to receive immediate EVAR or surveillance by ultrasound and computed tomography 
(CT) and repair only after a defined threshold (diameter ≥5.5 cm, enlargement >1 cm /year, 
symptoms) was achieved. Between 2004 and 2008, 360 patients (early EVAR = 182; 
surveillance = 178) were enrolled. They reported that mortality and rupture rates in AAA 
<5.5 cm are low and no clear advantage was shown between early or delayed EVAR 
strategy. However, within 36 months, three out of every five small aneurysms under 
surveillance might grow to require repair and one out of every six might lose feasibility for 
EVAR. Concluding that surveillance is safe for small AAA if close supervision is applied.17 
Depending on interpretation and resources this information may help determine when to 
treat patients with smaller AAA at an earlier stage. Further, it has been suggested that the 
threshold in women be even lower (e.g., 4.5 cm in diameter) based on women’s relatively 
smaller aortic dimensions, which appear to play a role in their higher risk of rupture and its 
attendant mortality and in their 18 lower anatomical suitability for EVAR 14,18,19  
While in the past there was “no disagreement about appropriate treatment for large AAAs 
in patients with unsuitable anatomic characteristics that preclude EVAR, these patients 
should have conventional open repair, which has been reported to have low morbidity and 
mortality rates14. The advancement of technology has steadily whittled away at these 
anatomic criteria and continues to push the safe and acceptable anatomical criteria further 
into what was once considered to be the experimental or anatomically unacceptable range. 
With this push and the increasing use and availability of the EVAR technology there has 
been an over all shift in the general clinical practice in many institutions towards the 
implantation of EVAR, with less and less consideration being given to the surgically fit 
patient. This has led many clinicians to consider EVAR as the first line treatment for AAA 
regardless of the patient’s characteristics, such as fitness for surgery, or ability to undergo a 
large abdominal procedure. In many ways this is the trend first set out by the laparoscopic 
revolution that swept through general surgery some 20-30 years ago. It is rare now to see an 
open cholecystectomy, and rarer still to see this as a planned first line intervention. The open 
cholecystectomy is often reserved for the failed laparoscopic approach. So to, it would 
appear, is the fate of open abdominal reconstruction. While EVAR Has boasted well-
documented benefits20-22 over open repair including a reduction of aneurysm-related 
mortality, a decrease in perioperative cardiopulmonary complications as well as of 
hemorrhage, graft infection and colonic ischemia, as well as reduced patient trauma, 
reduced hospital stays and faster recovery 20. Even in the face of the EVAR 1 data suggesting 
that After 12 months there was negligible difference in Health Related Quality of Life 
(HRQL) between the two groups (EVAR vs Open) 23. The obvious benefits noted clinically 
by the patient and surgeons alike have propelled EVAR forward despite all oppositions. 
 
Abdominal Aortic Aneurysms: Changing Paradigms in Treatment 
 
59 
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simply tune-ups, and despite the extensive reports documenting reintervention as a 
negative or down side to EVAR these are often well tolerated and the surgical conversion 
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EVAR was initially studied in this group as an alternative to the open procedure in patients 
that where considered unfit for the open surgical intervention the pendulum has now 
swung in the opposite direction. Initially the question of feasibility was addressed using this 
patient population, now that feasibility is no longer a question and EVAR has been well 
established as an acceptable method for aneurysm treatment the consideration of 
appropriateness has come into question.  
The EVAR-2 Trial which used the cohort of patients that where excluded for the EVAR-1 
trial as mentioned earlier concluded after a mean 4 years of follow up that EVAR had a 
considerable 30-day operative mortality in patients already unfit for open repair of their 
aneurysm. EVAR did not improve survival over no intervention and was associated with a 
need for continued surveillance and reinterventions, at substantially increased cost. 
Ongoing follow-up and improved fitness of these patients is a priority24 published in 2005.  
Endovascular aneurysm repair (EVAR) is associated with superior short-term mortality 
rates but unclear long-term results and has not been shown to improve survival in patients 
unfit for open repair (OR)25. A group using the Swedish vascular registry conducted 
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This prompted a Department of Veteran Affairs analysis citing that “recent results after 
endovascular abdominal aortic aneurysm repair (EVAR) have brought into question its 
value in patients deemed at high-risk for surgical intervention.”26 The Department of 
Veteran Affairs (VA) National Surgical Quality Improvement Program (NSQIP) is the 
largest prospectively collected and validated United States surgical database representing 
current clinical practice. Utilizing this database a study was designed to evaluate outcomes 
after elective EVAR performed in high-risk veterans. This retrospective review analyzed 
2296 pts (EVAR, n = 788; open, n = 1580) who underwent elective aneurysm repair from 
May 2001 to December 2004 and met the high risk criteria. High-risk criteria analyzed 
included age > or =60 years, American Society of Anesthesiology (ASA) classification 3 or 4, 
and the comorbidity variables of history of cardiac, respiratory, or hepatic disease, cardiac 
revascularization, renal insufficiency, and low serum albumin level. The primary end points 
were 30-day and 1-year all-cause mortality.26 The investigators concluded that veterans 
deemed high-risk for surgical therapy, outcomes after elective EVAR are excellent, and the 
procedure is relatively safe in this special patient population. Our retrospective data 
demonstrate that patients with considerable medical comorbidities and infrarenal 
abdominal aortic aneurysms benefit from and should be considered for primary 26 EVAR.  
Another American group conducted an interesting study in response the the EVAR-2 
publication to determine the outcome in the United States after endovascular repair (EVAR) 
of infrarenal abdominal aortic aneurysms (AAAs) in patients at high-risk for open surgery. 
They independently audited, high-compliance, chart-verified data sets, and compared those 
results with open surgery. Interestingly in an attempt for head to head comparability they 
defined High-risk to match the EVAR-2 trial and included age of > or =60 years with 
aneurysm size of > or =5.5 cm, plus at least one cardiac, pulmonary, or renal comorbidity. 
They then analyzed data from five multicenter investigational device exemption clinical 
trials leading to Food and Drug Administration (FDA) approval finding 565 EVAR patients 
that met the high-risk criteria, and 61 OPEN patients that met high-risk criteria. Primary 
outcome comparisons included AAA-related death, all-cause death, and aneurysm rupture. 
Secondary measures were endoleak, AAA sac enlargement, and migration. 
After analysis they concluded that endovascular repair of large infrarenal AAAs in 
anatomically suited high-surgical-risk patients using FDA-approved devices in the United 
States is safe and provides lasting protection from AAA-related mortality. EVAR mortality 
remained comparable with OPEN up to 4 years.27  
An Italian group animalized their data to determine the best treatment for high-risk patients 
with abdominal aortic aneurysms (AAA) using the ASA classification guidelines and found 
a total 375 patients who underwent AAA repair, 168 (45%) belonged in ASA classes III and 
IV (85 OPEN and 83 EVAR). After analysis they concluded that except patients with small 
aneurysms (< 6 cm), in whom the risk of death at 1-year due to comorbidities exceeds the 
risk of a ruptured aneurysm, all patients at high surgical risk (ASA class IV) benefit from 
AAA repair. Patients with small aneurysms must undergo strict surveillance to assess 
growth and aneurysmal wall changes to prevent unexpected rupture.28  
Another American investigation looked at The 2001-2004 Nationwide Inpatient Sample in a 
direct response to EVAR-2 hypothesizing that The nationwide in-hospital mortality for 
patients with the highest risk undergoing EVAR in the United States is lower than that 
reported in EVAR trial 2. They found that 65 502 EVARs were performed with an in-hospital 
mortality of 2.2%. Risk-adjusted in-hospital mortality rates ranged from 1.2% to 3.7% 
compared to the substantial in-hospital mortality after EVAR (9%) reported in EVAR 2. 
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They concluded that The EVAR procedure is currently being performed in the United States 
with low in-hospital mortality, even in patients with the highest risk. Therefore, EVAR 
should not be denied to high-risk patients with abdominal aortic aneurysms in the United 
States on the basis of the level I evidence from the United Kingdom study. 29  
Another group utilizing Department of Veteran Affairs data attempted to further 
investigate this issue by examining the influence of age, aneurysm size, and patient fitness 
on suitability for endovascular aortic aneurysm repair. They examined 186 male patients 
referred for evaluation of nonruptured AAAs. Suitability for EVAR was determined by 
neck anatomy, iliac artery morphology, and total aortic aneurysm angulation and 
tortuosity according to the clinicians' experience and current practice. They found that 
aortic neck length (odds ratio [OR]=1.2, 95% confidence interval [CI] 1.1-1.2) and diameter 
(OR=0.78, 95% CI 0.63-0.96) were the only independent predictors for EVAR suitabilityn 
and concluded that Overall, EVAR suitability is not influenced by age, aneurysm size, or 
patient fitness.30 
5. The elderly and ethics  
5.1 The elderly  
The elderly group is a cohort is not well documented in the world literature with relation to 
management of AAA. There are few large series in this population which may reflect a 
unique survivability in this population. The average life expectancy has been steadily 
increasing world wide. The United Nations World Population Prospective 2006 revision 
showed an average life expectancy from birth in the united states of 77.4 from 2000-to-2005 
and predicted an increase to 78.2 from 2005-to-2010 and to 78.9 for 2010-to-2015. Due to the 
increasingly aging populations of the industrialized countries, the prevalence of vascular 
disorders is increasing, with an emerging patient subgroup of 80 years and older 
(octogenarians), often multi-morbid with an increased risk of anaesthesiological and 
surgical complications 31. Abdominal aortic aneurysms (AAAs) occur in approximately 5% 
of the population older than 50 years and up to 10% within the male population over 80 
years 32. According to the United Nations World Population Prospective 2006 revision 
globally, the number of persons aged 60 years or over is expected nearly to triple, increasing 
from 673 million in 2005 to 2 billion by 2050. Over the same period, the share of older 
persons living in developing countries is expected to rise from 64 per cent in 2005 to nearly 
80 per cent in 2050. A recent analysis of the nationwide sample of intact AAA repairs from 
2001 to 2006 demonstrated a 69% increase in the total number of asymptomatic AAA repairs 
in patients more than 85 years of age in comparison to their younger counterparts 33. 
Moreover the estimated life expectancy of a centenarian in the United States in 2004 was 2.3 
years. (National Vitals Statistics System. Available at: http://www.cdc.gov/ 
nchs/data/nvsr/nvsr56/nvsr56_09.pdf. Accessed June 10, 2010.) 
The Question of age as a defining category of AAA repair becomes more difficult when 
analyzing the outcomes of the studies in the literature, many of which demonstrate favorable 
outcomes. Numerous articles have reported acceptable results for octogenarians treated with 
both open and endovascular techniques. 34. Open repair of AAAs in octogenarians has been 
associated with increased life expectancy in comparison to untreated AAAs 35. With respect to 
treatment of AAA mortality rate, while higher than in younger patients, is acceptable in 
carefully selected octogenarians 36. While other investigators looking at EVAR vs. Open repair 
concluded that there was no difference in the long-term survival benefit between open repair 
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They concluded that The EVAR procedure is currently being performed in the United States 
with low in-hospital mortality, even in patients with the highest risk. Therefore, EVAR 
should not be denied to high-risk patients with abdominal aortic aneurysms in the United 
States on the basis of the level I evidence from the United Kingdom study. 29  
Another group utilizing Department of Veteran Affairs data attempted to further 
investigate this issue by examining the influence of age, aneurysm size, and patient fitness 
on suitability for endovascular aortic aneurysm repair. They examined 186 male patients 
referred for evaluation of nonruptured AAAs. Suitability for EVAR was determined by 
neck anatomy, iliac artery morphology, and total aortic aneurysm angulation and 
tortuosity according to the clinicians' experience and current practice. They found that 
aortic neck length (odds ratio [OR]=1.2, 95% confidence interval [CI] 1.1-1.2) and diameter 
(OR=0.78, 95% CI 0.63-0.96) were the only independent predictors for EVAR suitabilityn 
and concluded that Overall, EVAR suitability is not influenced by age, aneurysm size, or 
patient fitness.30 
5. The elderly and ethics  
5.1 The elderly  
The elderly group is a cohort is not well documented in the world literature with relation to 
management of AAA. There are few large series in this population which may reflect a 
unique survivability in this population. The average life expectancy has been steadily 
increasing world wide. The United Nations World Population Prospective 2006 revision 
showed an average life expectancy from birth in the united states of 77.4 from 2000-to-2005 
and predicted an increase to 78.2 from 2005-to-2010 and to 78.9 for 2010-to-2015. Due to the 
increasingly aging populations of the industrialized countries, the prevalence of vascular 
disorders is increasing, with an emerging patient subgroup of 80 years and older 
(octogenarians), often multi-morbid with an increased risk of anaesthesiological and 
surgical complications 31. Abdominal aortic aneurysms (AAAs) occur in approximately 5% 
of the population older than 50 years and up to 10% within the male population over 80 
years 32. According to the United Nations World Population Prospective 2006 revision 
globally, the number of persons aged 60 years or over is expected nearly to triple, increasing 
from 673 million in 2005 to 2 billion by 2050. Over the same period, the share of older 
persons living in developing countries is expected to rise from 64 per cent in 2005 to nearly 
80 per cent in 2050. A recent analysis of the nationwide sample of intact AAA repairs from 
2001 to 2006 demonstrated a 69% increase in the total number of asymptomatic AAA repairs 
in patients more than 85 years of age in comparison to their younger counterparts 33. 
Moreover the estimated life expectancy of a centenarian in the United States in 2004 was 2.3 
years. (National Vitals Statistics System. Available at: http://www.cdc.gov/ 
nchs/data/nvsr/nvsr56/nvsr56_09.pdf. Accessed June 10, 2010.) 
The Question of age as a defining category of AAA repair becomes more difficult when 
analyzing the outcomes of the studies in the literature, many of which demonstrate favorable 
outcomes. Numerous articles have reported acceptable results for octogenarians treated with 
both open and endovascular techniques. 34. Open repair of AAAs in octogenarians has been 
associated with increased life expectancy in comparison to untreated AAAs 35. With respect to 
treatment of AAA mortality rate, while higher than in younger patients, is acceptable in 
carefully selected octogenarians 36. While other investigators looking at EVAR vs. Open repair 
concluded that there was no difference in the long-term survival benefit between open repair 
 
Aneurysmal Disease of the Thoracic and Abdominal Aorta 
 
62
and EVAR in 150 octogenarians. 37 With attention to the population of octogenarian-to-
nonagenarians (age range 80-95) Prenner et al report a series of 322 patients that underwent 
elective EVAR from January 1997 to November 2007. The mean age was 84 years +/- 3.4 years. 
They reported a perioperative 30-day mortality rate of 3.1% with a mean follow-up of 25.7 
months. Freedom from aneurysm-related mortality was 95.4% at 1 year and 92.9% at 5 years. 
They concluded that EVAR in octogenarians is associated with high procedural success and 
low perioperative morbidity and mortality. 38 
In the Nonagenarian population Halpern et al report the largest retrospective review of 
EVAR over a 10-year period. While this remains a small cohort of only 23 patients. The 
mean age was 91.5 (range 90-94) and the perioperative mortality was only 4.3%. There were 
no aneurysm-related deaths beyond the 30-day postoperative period. They also reported 
that the mean survival beyond 30 days was 800 +/-459 days following EVAR. These results 
suggest that despite their advanced age, these patients benefit from EVAR with low 
morbidity, low mortality, and mean survival exceeding 2.4 years. Survival appears best in 
those patients with ≤5 comorbidities. With or without symptoms, patients over the age of 90 
should be considered for EVAR 39. Another relatively large study from a single institution 
analysis of endovascular repair (EVAR) in nonagenarians analyzed 18 nonagenarians (age 
range 90-95). They reported 100% technical success with a mortality rate of 5.6%, 41.2% and 
58.3% at 30 days, 365 days, and 2 years, respectively. Mean survival of the 11 patients who 
expired beyond the first 30 days was 17.5 months. EVAR is safe in nonagenarians despite 
their advanced age and significant surgical risk factor profile. The procedure can be 
performed with excellent technical success and a low rate of perioperative complications. 
However, mortality rates after 30 days are significant. The substantial long-term mortality 
raises the question of possible treatment futility in this unique population. While age should 
not be a contraindication for EVAR, recommendations for the procedure should be based on 
individual patient selection. 40 In a recent review Demirel and colleges examined Vascular 
Surgery in the Elderly and made Recommendations for Clinical Practice. They state that 
with suitable morphology of the aneurysm, endovascular aneurysm repair (EVAR) is the 
therapy of choice for abdominal aortic aneurysm (AAA). In elderly patients unfit for open 
repair and with a life expectancy of less than 4 years, EVAR does not offer any survival 
benefit compared with no intervention. In such patients, conservative therapy should be 
taken into consideration 31 
5.2 The ethical dilemma 
The ethical dilemma of age is mirrored on every level of patient treatment and the decision for 
any surgery. The question of age however perhaps underscores these considerations more 
strongly then any other patient related characteristics because the emphasis must be placed on 
the individual. There are patients that are in the most advanced chronological category that are 
much healthier from a physiological stand point then some patients that are very much 
younger in years. This gives rise to the concept of physiological age of the patient, which is far 
more important then the chronological age when considering surgery. The ethical discussion 
in the health care arena centers around 4 main concepts. These briefly outlined are as fallows. 
First are the basic ethical principals of beneficence and nonmaleficence. These state that the 
procedure or treatment in question should be beneficial and not do harm. While this is often 
not totally possible it may be extended in thought and practice to have the potential benefits 
out weigh the potential risks. Second is the principal of autonomy. This simply stated is the 
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patents right to make decisions for themselves and has been expanded in modern medicine to 
be the basis of the informed consent. Given all of the information available and a clear 
understanding of the first principal the patient has the right to guide his or her own care. The 
third principle is that of justice. This principle brings into account the population or 
community as a whole. It is concerned with the allocation of limited vital healthcare recourses 
and whom these should be made available to. The dichotomy of this prospective, simply 
stated, is should valuable resources be adjudicated to the largest amount of people that could 
benefit from them or on the people that need them most. The final issue is the respect for 
human life. This brings into account religion, cultural beliefs, and moral values both of the 
individual and of society and may differ around the world.  
Abdominal aortic aneurysms (AAAs) occur in approximately 5% of the population older than 
50 years and up to 10% within the male population over 80 years. (Cosford PA, Leng GC. 
Screening for abdominal aortic aneurysm. Cochrane Database Syst Rev 2007;2:CD002945.)  
Schwarze et al5 analyzed a nationwide sample of intact AAA repairs from 2001 to 2006 and 
demonstrated a 69% increase in the total number of asymptomatic AAA repairs in patients 
more than 85 years of age in comparison to their younger counterparts. 33  
6. Nonagenarians 
Jim et al6 reported a single institution analysis of endovascular repair (EVAR) in 
nonagenarians. The study analyzed 18 nonagenarians (age range 90-95) and reported 100% 
technical success with a mortality rate of 5.6%, 41.2% and 58.3% at 30 days, 365 days, and 2 
years, respectively. Mean survival of the 11 patients who expired beyond the first 30 days 
was 17.5 months. They concluded that EVAR is safe in nonagenarians despite their 
advanced age and significant surgical risk factor profile. 34  
Halpern et al reported a largest retrospective review of nonagenarians that underwent 
EVAR over a 10-year period. They analyzed 23 patients with mean age of 91.5 (range 90-94) 
and reported a perioperative mortality of 4.3%. There were no aneurysm-related deaths 
beyond the 30-day postoperative period. Mean survival beyond 30 days was 800 +/- 459 
days following EVAR. Their results demonstrated nonagenarians’ benefit from EVAR with 
low morbidity, low mortality, and survival exceeding 2.2 years despite their advanced age 
and, therefore, they should be considered for EVAR with or without symptoms. 39  
7. Octogenarians-to-nonagenarians 
A series of 322 patients that underwent open and EVAR in octogenarians and 
nonagenarians (age range 80-95) was reported by Stuart Prenner and colleagues.8 The 
perioperative 30- day mortality rate was 3.1% with a mean follow-up of 25.7 months. 
Freedom from aneurysm-related mortality was 95.4% at 1 year and 92.9% at 5 years. Their 
results demonstrated EVAR in octogenarians is associated with low rates of perioperative 
morbidity and mortality and low long-term aneurysm-related mortality despite the high 
rates of comorbidities in these patients. 38 
8. The ruptured aneurysm  
An interesting and natural advancement to endovascular technology has resulted in another 
group not previously mentioned which has benefited from EVAR with increasingly 
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promising results in the literature. This is the rupture population. EVAR has now been used 
with excellent results in some centers not only for prevention rupture, but also for the 
treatment of ruptured abdominal aortic aneurysms, and is now growing in acceptance as a 
life saving procedure. Foster and collogues reviewed the literature to answer the question 
whether a policy for endovascular repair as the primary mode of treatment for ruptured 
abdominal aortic aneurysms (rAAAs) would improve outcomes. They reviewed One 
thousand three hundred and twenty-eight papers and concluded that conclude that, within 
the limitations of the published literature to date, endovascular repair as the primary 
treatment for rAAA is achievable and appears to be associated with favorable mortality over 
open repair with appropriate case selection. 41 More recently Bosch et al reviewed their 
results from April 2002 until March 2008 from a single center in the Netherlands comparing 
their open to their EVAR experience in the ruptured setting and concluded that In EVAR-
suitable patients, an absolute perioperative mortality reduction of 25.5% of rEVAR over 
open surgery was found, which was still present at 6 months of follow-up. These data 
suggest that rEVAR is a superior treatment option for EVAR-suitable patients with an rAAA 
compared with an open surgery. 42  Setacci and the university of Siena group reported that 
despite this evidence, EVAR for rAAA remains prerogative of few centers worldwide. In 
conclusion only larger study or registry could assest the real role of EVAR in the 
management of rAAA. 43 In an attempt to further explore this question Davenport et al from 
the University of Kentucky examined the Thirty-day NSQIP database outcomes of open 
versus endoluminal repair of ruptured abdominal aortic aneurysms. They identified A total 
of 427 patients the majority of which (76.8%) underwent open repair. However in review of 
the data they found that composite 30-day morbidity risk is lower after EVAR vs open 
repair of rAAA. Open repair is associated with increased transfusion requirements. 
Performance of EVAR in rAAA patients with favorable anatomy could potentially result in 
improved outcome as compared with open repair. 44  
9. Inherent problems in study design  
In the era of clinical and research based medicine otherwise known as evidence based 
medicine a great deal of positive information and tools to assist in clinical judgment have 
been generated. However along with the need for research to both explain what we do and 
document its positive or negative effects there has evolved an overwhelming amount of 
information. This information is not free of error and in even the gold standard randomized 
control study can be manipulated. While these statistical acrobatics are generally not 
malicious in intent a lot can ride on the outcome of study both with respect to surgical and 
to a broader extent medical decision making and to the bottom line of reimbursement which 
drive the hospitals and clinics. Whatever the reason it is important to recognize that in 
particular many of the “land mark studies” in AAA have a very serious problem associated 
with their general design, despite the fact that superficially these appear to represent the 
“gold standard.” These studies are the randomized clinical trials (RCTs) offering an 
observation/no treatment (OBS/NoRx) arm as control and which are focused on the 
management of a condition with potentially life-threatening consequences, however small 
the risk, often experience a significant rate of crossover to treatment by those randomized to 
the OBS/NoRx arm. 45 this type of design was initially designed for Medication and drug 
testing. Intent-to-treat data analytic strategy was developed for drug trials in which some 
patients dropped out (after 10-12 weeks) before receiving full treatment. To determine 
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whether the full treatment worked, you could just use the subjects who completed treatment 
when analyzing outcome data for these studies. Hence preserving data for the statistical 
analysis, however in a life threatening, or perceived life threatening condition, where there 
can be no “blinding” of the patient this type of design often leads to a significant degree of 
error in the form of the cross over effect. The frequency with which patients cross over may 
either confound the outcomes of these trials and/or undermine the acceptance of 
conclusions based on an intent-to-treat analysis, which should not be used in this situation. 
45 Yet the very fabric on which a great many of our clinical decisions are based is from just 
such studies. Studies of abdominal aortic aneurysms with this design that exemplify this 
dilemma, with crossovers ranging from 27% to over 60% include EVAR II, UKSAT, ADAM, 
and PIVOTAL. Results of these trials are frequently used as level I medical evidence and 
their potential impact on clinical decision-making and reimbursement can be quite 
significant and long-lasting. 45  
10. Analysis of available studies 
In 2005 the findings from the United Kingdom EVAR 1 Trial where released in the British 
journal, the Lancet titled “Endovascular aneurysm repair versus open repair in patients with 
abdominal aortic aneurysm (EVAR trial 1): randomized controlled trial”. This randomized 
controlled trial prospectively randomized 1082 patients aged 60 years or older who had 
aneurysms of at least 5.5 cm in diameter and who had been referred to one of 34 hospitals 
proficient in the EVAR technique. The patients were both anatomically suitable for EVAR 
and fit for an open repair to EVAR or open repair cohorts. 24 The primary endpoint was all-
cause mortality at 4 years and EVAR and OPEN were found to be similar in this regard, 
with mortality rates of approximately 28% (hazard ratio, 0.90; 95% CI, 0.69–1.18; P = 0.46). 
One of the secondary endpoints, AAA-related death, showed a 3% advantage to EVAR, 
which was maintained for 4 years (perioperative mortality: EVAR 1.7% versus OPEN 4.7%; 
midterm mortality: EVAR 26% versus OPEN 29%). Other secondary endpoints showed that 
patients undergoing EVAR had a much higher complication rate (41% versus 9%, P < 
0.0001) and reintervention rate (20% versus 6%) than those having OPEN. Mean hospital 
(not total) costs were roughly estimated to be about 30% higher in the EVAR group. 
Additionally, at 12 months follow-up, there was no difference in healthrelated quality of life. 
The Authors concluded that Compared with open repair, EVAR offers no advantage with 
respect to all-cause mortality and HRQL, is more expensive, and leads to a greater number 
of complications and reinterventions. However, it does result in a 3% better aneurysm-
related survival. The continuing need for interventions mandates ongoing surveillance and 
longer follow-up of EVAR for detailed cost-effectiveness assessment. 
However a closer examination of the statistical breakdown of the EVAR 1 protocol raises 
several issues with regards cohort assignments. Of the 1082 patients ultimately randomized 
from the original 4799 persons assessed for the study, 453 were assigned to EVAR and 539 
were assigned to open repair. Thus, only 23% of those assessed for eligibility were 
ultimately randomized. This eliminated close to two thirds of the candidates from the EVAR 
group. Reasons for exclusion included AAA was considered too small for repair in 9%; the 
AAA morphology was unsuitable for EVAR in 54%, and the patients were unfit for open 
repair in 1.5%. Adding further confusion is the all cause mortality. As demonstrated in the 
EVAR cohort where 10 patients died while waiting EVAR, in effect they where randomized 
to this group, but never availed the benefit of the intervention. Another 15 patients 
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promising results in the literature. This is the rupture population. EVAR has now been used 
with excellent results in some centers not only for prevention rupture, but also for the 
treatment of ruptured abdominal aortic aneurysms, and is now growing in acceptance as a 
life saving procedure. Foster and collogues reviewed the literature to answer the question 
whether a policy for endovascular repair as the primary mode of treatment for ruptured 
abdominal aortic aneurysms (rAAAs) would improve outcomes. They reviewed One 
thousand three hundred and twenty-eight papers and concluded that conclude that, within 
the limitations of the published literature to date, endovascular repair as the primary 
treatment for rAAA is achievable and appears to be associated with favorable mortality over 
open repair with appropriate case selection. 41 More recently Bosch et al reviewed their 
results from April 2002 until March 2008 from a single center in the Netherlands comparing 
their open to their EVAR experience in the ruptured setting and concluded that In EVAR-
suitable patients, an absolute perioperative mortality reduction of 25.5% of rEVAR over 
open surgery was found, which was still present at 6 months of follow-up. These data 
suggest that rEVAR is a superior treatment option for EVAR-suitable patients with an rAAA 
compared with an open surgery. 42  Setacci and the university of Siena group reported that 
despite this evidence, EVAR for rAAA remains prerogative of few centers worldwide. In 
conclusion only larger study or registry could assest the real role of EVAR in the 
management of rAAA. 43 In an attempt to further explore this question Davenport et al from 
the University of Kentucky examined the Thirty-day NSQIP database outcomes of open 
versus endoluminal repair of ruptured abdominal aortic aneurysms. They identified A total 
of 427 patients the majority of which (76.8%) underwent open repair. However in review of 
the data they found that composite 30-day morbidity risk is lower after EVAR vs open 
repair of rAAA. Open repair is associated with increased transfusion requirements. 
Performance of EVAR in rAAA patients with favorable anatomy could potentially result in 
improved outcome as compared with open repair. 44  
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management of a condition with potentially life-threatening consequences, however small 
the risk, often experience a significant rate of crossover to treatment by those randomized to 
the OBS/NoRx arm. 45 this type of design was initially designed for Medication and drug 
testing. Intent-to-treat data analytic strategy was developed for drug trials in which some 
patients dropped out (after 10-12 weeks) before receiving full treatment. To determine 
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can be no “blinding” of the patient this type of design often leads to a significant degree of 
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either confound the outcomes of these trials and/or undermine the acceptance of 
conclusions based on an intent-to-treat analysis, which should not be used in this situation. 
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such studies. Studies of abdominal aortic aneurysms with this design that exemplify this 
dilemma, with crossovers ranging from 27% to over 60% include EVAR II, UKSAT, ADAM, 
and PIVOTAL. Results of these trials are frequently used as level I medical evidence and 
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longer follow-up of EVAR for detailed cost-effectiveness assessment. 
However a closer examination of the statistical breakdown of the EVAR 1 protocol raises 
several issues with regards cohort assignments. Of the 1082 patients ultimately randomized 
from the original 4799 persons assessed for the study, 453 were assigned to EVAR and 539 
were assigned to open repair. Thus, only 23% of those assessed for eligibility were 
ultimately randomized. This eliminated close to two thirds of the candidates from the EVAR 
group. Reasons for exclusion included AAA was considered too small for repair in 9%; the 
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repair in 1.5%. Adding further confusion is the all cause mortality. As demonstrated in the 
EVAR cohort where 10 patients died while waiting EVAR, in effect they where randomized 
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randomized to the EVAR group had OPEN repair. Three of these deaths were directly 
ascribed to AAA rupture. In the OPEN group, there were 13 deaths, of which 7 had 
ruptured AAAs and 18 patients received EVAR. This demonstrates a significant cross-over 
effect between the groups and further clouds the final analysis. The average delay from 
randomization to actual treatment was 57 days, despite a mean AAA size of 6.7 cm, which 
provides a likely explanation for the high pretreatment rupture rates. The increased 
availability of devices and the “off-the shelf” combinations in most large center stocks as 
well as the more expedient progression from diagnosis to treatment in the United states as 
well as many other countries world wide make delayed treatment extremely unlikely or 
even unacceptable in this day and age.  
Another problem with the initial reporting in EVAR 1 is that only 24% of participants’ data 
were included in the 4-year cutoff point for analysis, with 72% being still alive and 
uncensored at 4 years. Indeed, 25.3% of the open cohort and 21.6% of the EVAR cohort were 
ASA class 1; thus, this trial represented relatively healthy individuals 46 view of the above, 
these results, although contributory to the current body of knowledge, really only represent 
midterm outcomes.  
In 2010 the United Kingdome EVAR trial investigators produced a subsequent analysis in 
the publication of Endovascular versus open repair of abdominal aortic aneurysm in the 
New England journal of medicine. Here the United Kingdome EVAR trial investigators 
examined their data from 1999 through 2004 at 37 hospitals in the United Kingdom. They 
randomly assigned 1252 patients with large abdominal aortic aneurysms (> or = 5.5 cm in 
diameter) to undergo either endovascular or open repair; 626 patients were assigned to each 
group. Patients were followed for rates of death, graft-related complications, 
reinterventions, and resource use until the end of 2009. In this group the initial 1082 patients 
included in a planned midterm analysis that was reported in 2005 and an additional 170 
patients who were enrolled between January 2004 and August 2004, who were not included 
in the midterm analysis. There were no significant differences between the two treatment 
groups with respect to baseline characteristics. The patients in EVAR 1 were randomly 
assigned to undergo either open repair or endovascular repair. Patients were encouraged to 
undergo repair within 1 month after randomization, although such scheduling was not 
always possible for logistic or other reasons. 47 Despite this the For patients undergoing 
aneurysm repair, the median time from randomization to surgery was 44 days (interquartile 
range, 29 to 70) in the endovascularrepair group and 35 days (interquartile range, 20 to 57) 
in the open-repair group 47. Representing, again, a delay that would still be considered 
unacceptable by many. Of the 12 patients in the endovascular-repair group who did not 
undergo aneurysm repair, 7 died within 6 months after randomization (3 as a result of 
rupture), 3 became physically ineligible, 1 declined surgery, and 1 became anatomically 
unsuitable because of a change in the shape of the aorta. Of the 24 patients in the open-
repair group who did not undergo aneurysm repair, 7 died within 6 months after 
randomization (3 as a result of rupture), 7 became physically ineligible, 8 declined surgery 
(of whom 3 died), and 2 had an unknown reason (of whom 2 died). 47 They report that the 
30-day operative mortality was 1.8% in the endovascular-repair group and 4.3% in the open-
repair group (adjusted odds ratio for endovascular repair as compared with open repair, 
0.39; 95% confidence interval [CI], 0.18 to 0.87; P=0.02). The endovascular-repair group had 
an early benefit with respect to aneurysm-related mortality, but the benefit was lost by the 
end of the study, at least partially, because of fatal endograft ruptures (adjusted hazard 
ratio, 0.92; 95% CI, 0.57 to 1.49; P=0.73). By the end of follow-up, there was no significant 
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difference between the two groups in the rate of death from any cause (adjusted hazard 
ratio, 1.03; 95% CI, 0.86 to 1.23; P=0.72). The rates of graft-related complications and 
reinterventions were higher with endovascular repair, and new complications occurred up 
to 8 years after randomization, contributing to higher overall costs. 47 
In response to these findings Jetty et al in their manuscript Long-term outcomes and 
resource utilization of endovascular versus open repair of abdominal aortic aneurysms in 
Ontario. This retrospective analysis was based on hospital discharge abstracts. They 
examined all patients who underwent elective AAA repair between April 2002 and March 
2007. Clinical outcomes included time to all-cause death and discharge to a nursing home or 
long-term care facility. Resource utilization outcomes included imaging utilization, hospital 
utilization, and reintervention rates. They identified 6461 patients underwent treatment of 
nonruptured AAAs, comprising 888 EVARs and 5573 open repairs. EVAR patients were 
older and had more comorbidities. The adjusted mortality was significantly lower in the 
EVAR group at 30 days (adjusted odds ratio [adj-OR], 0.34; 95% confidence interval [95% 
CI], 0.20-0.59), but long-term mortality was similar (adj-OR, 0.95; 95% CI, 0.81-1.05). EVAR 
patients were significantly less likely to be discharged to a nursing home or other chronic 
care facility (adj-OR, 0.55; 95% CI, 0.41-0.74). Imaging utilization as well as urgent and 
vascular readmissions were significantly higher in the EVAR group. However, the EVAR 
group had a significantly shorter length of stay and less intensive care unit use for the index 
hospitalization and decreased hospital length of stay during follow-up. There was a trend 
toward a slightly increased risk of reintervention with EVAR (adj-OR, 1.3; 95% CI, 0.98-
1.75).They concluded that compared with open repair, EVAR significantly reduced short-
term but not long-term mortality. The EVAR patients spent less time in health institutions, 
including long-term care facilities, but underwent more imaging studies. Future 
improvements in EVAR could result in further decreases in reinterventions and subsequent 
radiologic monitoring.48 . 
The Dutch DREAM trial was similar to EVAR 1 in that it was a prospective randomized 
study comparing EVAR to OPEN among patients with AAAs 5 cm or greater in diameter 
who were fit for open repair, but the number recruited was significantly smaller in this trial 
than in EVAR 1—only 351 patients. This study initially reported its 30-day mortality 
endpoint but it also performed a composite endpoint analysis of mortality and moderate or 
severe complications. Much like EVAR 1, there was a roughly 3% advantage to EVAR in 
perioperative mortality (EVAR 1.2% versus OPEN 4.6%), and interestingly, even though at 1 
year the all-cause mortality was not different (EVAR 20.4% versus OPEN 20.3%), AAA-
related death was higher for OPEN at 2 years (EVAR 2.1% versus OPEN 5.7%). Health-
related quality-of-life measures were improved at 6 months in patients having EVAR; 
however, they were equivalent thereafter. Also, significantly higher costs were again 
documented in the EVAR cohort. The authors’ conclusion was that the “Initial mortality 
advantage was lost at one year because of non-aneurysm related deaths.”  
The Dream trial was also updated in 2010 with a follow up carried out to 6 years titled 
Long-Term Outcome of Open or Endovascular Repair of Abdominal Aortic Aneurysm 
published in the New England Journal of medicine. Here they conducted a long-term, 
multicenter, randomized, controlled trial comparing open repair with endovascular repair 
in 351 patients with an abdominal aortic aneurysm of at least 5 cm in diameter who were 
considered suitable candidates for both techniques. They randomly assigned 178 patients to 
undergo open repair and 173 to undergo endovascular repair. The primary outcomes were 
rates of death from any cause and reintervention. Six years after randomization, the 
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repair group who did not undergo aneurysm repair, 7 died within 6 months after 
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difference between the two groups in the rate of death from any cause (adjusted hazard 
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cumulative survival rates were 69.9% for open repair and 68.9% for endovascular repair 
(difference, 1.0 percentage point; 95% confidence interval [CI], −8.8 to 10.8; P = 0.97). The 
cumulative rates of freedom from secondary interventions were 81.9% for open repair and 
70.4% for endovascular repair (difference, 11.5 percentage points; 95% CI, 2.0 to 21.0; P = 
0.03). Further more similar to the original trial Six patients did not undergo aneurysm repair 
after randomization: four declined treatment (three in the open-repair group and one in the 
endovascular-repair group), one died from a ruptured abdominal aortic aneurysm before 
undergoing open repair, and one died from pneumonia before undergoing endovascular 
repair. There were eight in-hospital deaths after open repair and two after endovascular 
repair. The median follow-up was 6.4 years (range, 5.1 to 8.2). All patients were followed for 
5 years, 79% for 6 years, and 53% for 7 years. The completeness of follow-up was 99.3% 
(11,589/11,673 months) for open repair and 99.7% (11,193/11,232 months) for endovascular 
repair. At the date of censoring, 106 patients had died during followup after hospital 
discharge (51 in the open-repair group and 55 in the endovascular-repair group). Five years 
after randomization, CT was performed in approximately one fourth of patients in the open-
repair group and in almost all patients in the endovascular-repair group. They concluded 
that Six years after randomization, endovascular and open repair of abdominal aortic 
aneurysm resulted in similar rates of survival. The rate of secondary interventions was 
significantly higher for endovascular repair. 49 
Although the DREAM trial was criticized for being underpowered, and drawing this 
conclusion, most of its findings were in concert with EVAR 1, And subsequently validated in 
comparison to the EuroStar registry by Leurs el at. Here the Data of 177 patients of the 
DREAM trial with randomization to EVAR and 856 patients selected in the EUROSTAR-
registry were compared. Baseline characteristics were comparable between the EUROSTAR-
cohort and EVAR-arm of the DREAM-trial. The 36-month survival-rate was 87.6% for EVAR-
arm in the DREAM-trial similar to the 86.8% found in this EUROSTAR-study population. The 
freedom of secondary procedures reached after 3 years 85.7%, and 86.9% in the DREAM and 
EUROSTAR-cohort, respectively. They concluded that comparable characteristics and 
outcomes between patients of comparable risk class of the EUROSTAR-registry and the 
EVAR-cohort of the DREAM-trial. This demonstrates the following: first, the EUROSTAR-data 
provide reliable information, and further comparisons of registry data with patients treated by 
conventional AAA surgery may be justified. Secondly, the various outcomes of the 
randomised DREAM trial appear generalisable, as it agrees with observations in a broad 
common practice derived database. 50 In summary, both EVAR 1 and DREAM showed no 
difference their primary endpoint of overall mortality but both demonstrated about a 3% 
advantage for EVAR in perioperative and AAA-related death, at 4 and 2 years, respectively, 
with similar results over long-term analysis. Complications, reinterventions, and costs were 
much higher in the studies’ EVAR cohorts, with no improvements seen in health-related 
quality-of-life measures lasting beyond the initial period. 
11. EVAR 2 trial 
EVAR 2 utilized patients that where excluded fro the EVAR1 trial who were considered to 
be physically ineligible for open repair but who were candidates for endovascular repair 
were offered enrollment in the EVAR 2 trial 24,47. Citing that Endovascular aneurysm repair 
(EVAR) to exclude abdominal aortic aneurysm (AAA) was introduced for patients of poor 
health status considered unfit for major surgery. The investigators instigated EVAR trial 2 to 
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identify whether EVAR improves survival compared with no intervention in patients unfit 
for open repair of aortic aneurysm. In this randomized controlled trial of 338 patients aged 
60 years or older who had aneurysms of at least 5.5 cm in diameter and who had been 
referred to one of 31 hospitals in the UK. They assigned patients to receive either EVAR 
(n=166) or no intervention (n=172). Primary endpoint was all-cause mortality, with 
secondary endpoints of aneurysm-related mortality, health-related quality of life (HRQL), 
postoperative complications, and hospital costs. Analyses were by intention to treat. The 30-
day operative mortality in the EVAR group was 9% (13 of 150, 95% CI 5-15) and the no 
intervention group had a rupture rate of 9.0 per 100 person years (95% CI 6.0-13.5). By end 
of follow up 142 patients had died, 42 of aneurysm-related factors; overall mortality after 4 
years was 64%. There was no significant difference between the EVAR group and the no 
intervention group for all-cause mortality (hazard ratio 1.21, 95% CI 0.87-1.69, p=0.25). There 
was no difference in aneurysm-related mortality. The mean hospital costs per patient over 4 
years were UK pound sterling 13,632 in the EVAR group and pound sterling 4983 in the no 
intervention group (mean difference pound sterling 8649, SE 1248), with no difference in 
HRQL scores. This data evoked several interpretations and conclusions at variance with 
those proposed by the trialists, who basically concluded that there was no mortality 
advantage to EVAR in managing large AAAs in patients unfit for open repair and, since this 
treatment modality costs much more than observation alone, a policy of no treatment was 
endorsed. The paradox here is that it is precisely for such high-risk patients that EVAR was 
first proposed, as a lower risk alternative to open repair, yet the EVAR 2 trial appeared to 
refute this expectation, concluding it to be no better than no treatment! 14 Interestingly, the 
reported 30- day mortality rate of 9% for EVAR and the 4-year mortality of 64% are both 
much higher than previously reported in high-risk patient cohorts, and, while these 
observations provided a basis for much criticism, the published results of EVAR 2 have 
clearly complicated patient and provider decision-making, in addition to potentially 
influencing policymaking and reimbursement practices. 
As an Update to the 2005 Lancet publication EVAR 2 was further examined in the 2010 
publication tilted Endovascular repair of aortic aneurysm in patients physically ineligible 
for open repair. Presented in the New England Journal of Medicine. From 1999 through 2004 
at 33 hospitals in the United Kingdom, 404 patients with large abdominal aortic aneurysms 
(> or = 5.5 cm in diameter) who were considered to be physically ineligible for open repair 
where randomly assigned to undergo either endovascular repair or no repair; 197 patients 
were assigned to undergo endovascular repair, and 207 were assigned to have no 
intervention. Patients were followed for rates of death, graft-related complications and 
reinterventions, and costs until the end of 2009. The 30-day operative mortality was 7.3% in 
the endovascular-repair group. The overall rate of aneurysm rupture in the no-intervention 
group was 12.4 (95% confidence interval [CI], 9.6 to 16.2) per 100 person-years. Aneurysm-
related mortality was lower in the endovascular-repair group (adjusted hazard ratio, 0.53; 
95% CI, 0.32 to 0.89; P=0.02). This advantage did not result in any benefit in terms of total 
mortality (adjusted hazard ratio, 0.99; 95% CI, 0.78 to 1.27; P=0.97). A total of 48% of patients 
who survived endovascular repair had graft-related complications, and 27% required 
reintervention within the first 6 years. During 8 years of follow-up, endovascular repair was 
considerably more expensive than no repair (cost difference, 9,826 pounds sterling [U.S. 
$14,867]; 95% CI, 7,638 to 12,013 [11,556 to 18,176]). The Trialists presented a similar 
conclusion to there first publication stating that in this randomized trial involving patients 
who were physically ineligible for open repair, endovascular repair of abdominal aortic 
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cumulative survival rates were 69.9% for open repair and 68.9% for endovascular repair 
(difference, 1.0 percentage point; 95% confidence interval [CI], −8.8 to 10.8; P = 0.97). The 
cumulative rates of freedom from secondary interventions were 81.9% for open repair and 
70.4% for endovascular repair (difference, 11.5 percentage points; 95% CI, 2.0 to 21.0; P = 
0.03). Further more similar to the original trial Six patients did not undergo aneurysm repair 
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endovascular-repair group), one died from a ruptured abdominal aortic aneurysm before 
undergoing open repair, and one died from pneumonia before undergoing endovascular 
repair. There were eight in-hospital deaths after open repair and two after endovascular 
repair. The median follow-up was 6.4 years (range, 5.1 to 8.2). All patients were followed for 
5 years, 79% for 6 years, and 53% for 7 years. The completeness of follow-up was 99.3% 
(11,589/11,673 months) for open repair and 99.7% (11,193/11,232 months) for endovascular 
repair. At the date of censoring, 106 patients had died during followup after hospital 
discharge (51 in the open-repair group and 55 in the endovascular-repair group). Five years 
after randomization, CT was performed in approximately one fourth of patients in the open-
repair group and in almost all patients in the endovascular-repair group. They concluded 
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aneurysm resulted in similar rates of survival. The rate of secondary interventions was 
significantly higher for endovascular repair. 49 
Although the DREAM trial was criticized for being underpowered, and drawing this 
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identify whether EVAR improves survival compared with no intervention in patients unfit 
for open repair of aortic aneurysm. In this randomized controlled trial of 338 patients aged 
60 years or older who had aneurysms of at least 5.5 cm in diameter and who had been 
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(n=166) or no intervention (n=172). Primary endpoint was all-cause mortality, with 
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intervention group for all-cause mortality (hazard ratio 1.21, 95% CI 0.87-1.69, p=0.25). There 
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intervention group (mean difference pound sterling 8649, SE 1248), with no difference in 
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intervention. Patients were followed for rates of death, graft-related complications and 
reinterventions, and costs until the end of 2009. The 30-day operative mortality was 7.3% in 
the endovascular-repair group. The overall rate of aneurysm rupture in the no-intervention 
group was 12.4 (95% confidence interval [CI], 9.6 to 16.2) per 100 person-years. Aneurysm-
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95% CI, 0.32 to 0.89; P=0.02). This advantage did not result in any benefit in terms of total 
mortality (adjusted hazard ratio, 0.99; 95% CI, 0.78 to 1.27; P=0.97). A total of 48% of patients 
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considerably more expensive than no repair (cost difference, 9,826 pounds sterling [U.S. 
$14,867]; 95% CI, 7,638 to 12,013 [11,556 to 18,176]). The Trialists presented a similar 
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Aneurysmal Disease of the Thoracic and Abdominal Aorta 
 
70
aneurysm was associated with a significantly lower rate of aneurysm-related mortality than 
no repair. However, endovascular repair was not associated with a reduction in the rate of 
death from any cause. The rates of graft-related complications and reinterventions were 
higher with endovascular repair, and it was more costly. Suggesting that observation alone 
should be considered in patients unfit for open repair which redecorates many of the same 
arguments previously invoked by the fist publication.  
In response to the initial EVAR 2 study data an American group from the University of 
Texas Southwestern Medical Center performed a Population-based, cross-sectional study 
analysis to look at The nationwide in-hospital mortality for patients with the highest risk 
undergoing EVAR in the United States they closely matched the time period of EVAR 2 
reviewing the 2001-2004 Nationwide Inpatient Sample identifying EVAR procedures for 
nonruptured abdominal aortic aneurysms. Risk stratification was based on comorbidities 
and the Charlson comorbidity index, a validated predictor of in-hospital mortality after 
abdominal aortic aneurysms repairs. Weighted univariate and logistic regression analyses 
were used to determine the association between comorbidity measures and risk-adjusted in-
hospital mortality. They found that During the 4-year period, 65502 EVARs were performed 
with an in-hospital mortality of 2.2%. Risk-adjusted in-hospital mortality rates ranged from 
1.2% to 3.7%. Stratified analyses, including only elective EVAR procedures, revealed that in-
hospital mortality was significantly higher in patients with the most severe comorbidities 
(1.7%) vs those with lower comorbidity (0.4%; P<.001). Patients with high risk had only a 
1.6-fold increased risk of adjusted in-hospital mortality (odds ratio, 1.6; 95% confidence 
interval, 1.2-2.2) compared with patients with low risk. They concluded that the EVAR 
procedure is currently being performed in the United States with low in-hospital mortality, 
even in patients with the highest risk. Therefore, EVAR should not be denied to high-risk 
patients with abdominal aortic aneurysms in the United States on the basis of the level I 
evidence from the United Kingdom study. 29 
12. United States experiences with EVAR in high-risk cohorts 
Randomized clinical trials had been lacking in the United States, which prompted the V.A. 
trilists to launch an investigation comparing endovascular to open abdominal aneurysm 
repair, which was recently published in JAMA. A randomized, multicenter clinical trial of 
881 veterans, over the age of 49 years, from 42 Veterans Affairs Medical Centers with AAA 
that were at least 5 cm in size, or associated with an iliac aneurysm of 3 at least 3 cm in size, 
or had rapid expansion over a 6-to-12 month period who were candidates for both elective 
endovascular repair and open repair of AAA. This ongoing report detailed the time period 
between October 15, 2002, and October 15, 2008 Elective endovascular (n=444) or open 
(n=437) repair of AAA. Multiple variables and data points where extensively collected 
which included the main outcome measures, procedure failure, secondary therapeutic 
procedures, length of stay, quality of life, erectile dysfunction, major morbidity, and 
mortality. The mean follow-up was 1.8 years after which the American investigators 
concluded that short-term outcomes after elective AAA repair, perioperative mortality was 
low for both procedures and lower for endovascular than open repair. The early advantage 
of endovascular repair was not offset by increased morbidity or mortality in the first 2 years 
after repair. Longer-term outcome data are needed to fully assess the relative merits of the 2 
procedures. The overall study has id still underway with the primary outcome of long-term 
(5-9 years) all-cause mortality (October 15, 2002-October 15, 2011) and has not yet been 
 
Abdominal Aortic Aneurysms: Changing Paradigms in Treatment 
 
71 
completed. (Outcomes Following Endovascular vs Open Repair of Abdominal Aortic 
Aneurysm)51  
13. Remaining controversies 
Several issues remain unresolved and to a certain extent have been touched on already in 
this chapter. A clear and comparable system that is widely accepted and used for AAA 
reporting would greatly forward the global knowledge base and increase understanding 
and transparency. The issues with randomized control tried and the intention to treat arm 
have been discussed above. While this practice may improve statistics it does not improve 
the real numbers that clinicians need when trying to evaluate a patient and determine a 
care-plan strategy. Another issue is the all cause mortality arm of many studies. This, like 
the intention to treat, may provide more numbers for statistical analysis and to a certain 
extent some comparability and useful information however it has been confused in certain 
situations with aneurysm related death, which would be a much more useful piece of 
information to know about in the clinical setting.  
Aneurysm-related death can only be accurately determined by directly witnessed objective 
information, e.g., postmortem examination or rupture seen on an imaging study prior to 
death14. This however is difficult to obtain with decreasing numbers of autopsies being 
performed, deaths outside of the hospital and incomplete communication amongst 
healthcare systems. One possible solution would be a requirement in study designs for all 
participants to undergo a postmortem fine cut cat-scan however this has not yet been done. 
This would have the added benefit of having the patient locked into the system so to speak 
and could perhaps increase the autopsy rates. Another problem with AAA-related death 
outside of the abouve mentioned situation is that, taken alone, is a soft endpoint and one, 
which tends to preserve any initial/perioperative mortality advantage of one method of 
repair over another, with respect to aneurysm treatment 12 The data set would have likely 
been very different in the interpretation of the United Kingdom small aneurysm and 
Aneurysm Detection and Management trials if AAA-related death had been used as the 
primary end- point, rather than all-cause mortality. This was the goal of the Positive Impact 
of endoVascular Options for Treating Aneurysm early trial, or PIVOTAL trial which used as 
its primary endpoints aneurysm rupture and AAA-related deaths at up to 36 months after 
randomization52 This trial was recently completed after enrolling 728 patients (13.3% 
women; mean age, 71 +/- 8 years) with 4 to 5 cm AAAs to early endovascular repair (366 
patients) or ultrasound surveillance (362 patients). Rupture or aneurysm-related death and 
overall mortality in the two groups were compared during a mean follow-up of 20 +/- 12 
months. The investigators concluded Early treatment with endovascular repair and rigorous 
surveillance with selective aneurysm treatment as indicated both appear to be safe 
alternatives for patients with small AAAs, protecting the patient from rupture or aneurysm-
related death for at least 3 years16. Which provided useful information with regards to the 
size at which aneurysms should be treated with EVAR vs. surveillance. However there was 
still a significant cross-over rate from surveillance to the interventional arm Among patients 
randomized to surveillance, 31% underwent aneurysm repair during the course of the 
study16 Cross over-over rates provide useful information as long as the setting is not in the 
intention to treat model as outlined above45 The crossover rates in the PIVOTAL trial where 
about ½ that of the original UKSAT trial53. In the recently published mid-term results of the 
European-based 17-site Comparison of surveillance vs Aortic Endografting for Small 
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aneurysm was associated with a significantly lower rate of aneurysm-related mortality than 
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and the Charlson comorbidity index, a validated predictor of in-hospital mortality after 
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were used to determine the association between comorbidity measures and risk-adjusted in-
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patients with abdominal aortic aneurysms in the United States on the basis of the level I 
evidence from the United Kingdom study. 29 
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that were at least 5 cm in size, or associated with an iliac aneurysm of 3 at least 3 cm in size, 
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endovascular repair and open repair of AAA. This ongoing report detailed the time period 
between October 15, 2002, and October 15, 2008 Elective endovascular (n=444) or open 
(n=437) repair of AAA. Multiple variables and data points where extensively collected 
which included the main outcome measures, procedure failure, secondary therapeutic 
procedures, length of stay, quality of life, erectile dysfunction, major morbidity, and 
mortality. The mean follow-up was 1.8 years after which the American investigators 
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low for both procedures and lower for endovascular than open repair. The early advantage 
of endovascular repair was not offset by increased morbidity or mortality in the first 2 years 
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have been discussed above. While this practice may improve statistics it does not improve 
the real numbers that clinicians need when trying to evaluate a patient and determine a 
care-plan strategy. Another issue is the all cause mortality arm of many studies. This, like 
the intention to treat, may provide more numbers for statistical analysis and to a certain 
extent some comparability and useful information however it has been confused in certain 
situations with aneurysm related death, which would be a much more useful piece of 
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This would have the added benefit of having the patient locked into the system so to speak 
and could perhaps increase the autopsy rates. Another problem with AAA-related death 
outside of the abouve mentioned situation is that, taken alone, is a soft endpoint and one, 
which tends to preserve any initial/perioperative mortality advantage of one method of 
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Aneurysm Repair (CAESAR) of small AAAs (4.1-5.4 cm) for surveillance or EVAR with the 
Zenith stent-graft with the primary endpoint of all-cause mortality at 54 months. However 
they included information on Aneurysm-related mortality, aneurysm rupture and major 
morbidity rates which where similar perhaps indicating a trend towards interpretable 
information17 Inline with the information provided by the PIVOTAL trial they authors 
conclude that Mortality and rupture rates in AAA <5.5 cm are low and no clear advantage 
was shown between early or delayed EVAR strategy. However, within 36 months, three out 
of every five small aneurysms under surveillance might grow to require repair and one out 
of every six might lose feasibility for EVAR. Surveillance is safe for small AAA if close 
supervision is applied. 17 However a clear recommendation can not yet be made on the size 
for which small aneurysms should be treated, and we are left with the interpretation that 
aneurysms as seen above and in many other studies have the natural history to continue to 
increase in size and that many patients in the observation arm of trials, 27% to over 60% ( 
EVAR II, UKSAT, ADAM, PIVOTAL), crossovers to the treatment arm45.  
Further controversy revolves around large AAA greater then 5.5 cm and the question of 
treatment in the healthy patient vs the infirmed or unfit for open surgery patients as 
discussed above. Though the question is somewhat being answered by the trends in AAA 
management in clinical practice. Studies using large administrative databases in the United 
States have documented a trend whereby the majority of patients undergoing elective 
abdominal aortic aneurysm (AAA) repair in the United States are being repaired using 
endovascular techniques54 In a recently published single center study from the United States 
investigators retrospectively analyzed non-suprarenal AAA repairs between January 1, 
1996, and December 31, 2008. Patients were stratified by endovascular AAA repair (EVAR) 
or open repair and the presence or absence of rupture. During a 13-year period, 721 patients 
underwent AAA repair, comprising 410 (56.9%) with EVAR and 311 (43.1%) with open 
repair. This study included a time period prior to the availability of EVAR 1996 through the 
period when EVAR became widely available 2008, and showed that between 2005 and 2008, 
average EVAR use increased to 84%. 55 This is exemplary of the increased use of EVAR over 
open AAA. Another group analyzed Medicare Part B data sets for 2001 through 2006 with 
respect to open vs endovascular AAA repair. A total of 31,965 OSRs for AAA were 
performed in Medicare beneficiaries in 2001, dropping to 15,665 by 2006 (-51%). In contrast, 
EVAR was carried out in 11,028 instances in 2001, increasing to 28,937 by 2006 (+162%). The 
utilization rate per 100,000 for OSR dropped from 90 to 42 (a rate decrease of 48) during the 
study period, while the rate for EVAR increased from 31 to 77 (a rate increase of 46)56. The 
investigators drew the obvious conclusion that the newer, less invasive, and less risky 
procedure (EVAR) is replacing the older and more invasive procedure (OSR) to a 
considerable degree56. In another study looking at large national administrative in-hospital 
database to compare utilization and age-specific outcomes between open repair (OAR) and 
endovascular (EVAR) repair for the treatment of abdominal aortic aneurysm (AAA). The 
estimated number of elective AAAs treated with EVAR increased from 11,171 in 2001 to 
21,725 in 2006 (P = .003). The number of elective AAAs treated with OAR declined from 
17,784 to 8451 during the same period (P < .001). By 2006, EVAR was more frequently used 
than OAR for patients of all ages. Compared with the younger age groups, patients aged 
>or=85 years had a significant increase in the total number of asymptomatic AAA repairs, 
driven almost entirely by an increase in the use of EVAR 33. These authors noted that as 
short-term surgical outcomes are consistently improving for patients undergoing AAA 
repair, elective EVAR has replaced OAR as the more common method of repair in the 
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United States. The introduction of this technology has been rapidly adopted, particularly for 
the oldest-old surgical patients, aged >or=85 years, who previously may not have been 
offered surgical intervention for asymptomatic AAA. 33 This being said there are still 
significant unknowns with respect to long term out comes of EVAR despite the trend 
outlined above. The rapid improvements in EVAR design and deliverability have lead to 
changes in the anatomical criteria, and expanded usage. The EVAR device of today is very 
different then that of 10 years ago, however the outcomes data for “long-term follow up” is 
based on these older devices. The durability of these devices is a question that is difficult to 
answer, as this has been a constantly moving target as improvements to devices are made. 
Despite the increasing trend to treat all comers with EVAR, or at least the majority, the 
longitudinal data is not available or appropriate to make a solid recommendation. The 
durability of open grafts is proven with by the test of time there relatively low-tech nature 
and static design, this can however not be said about the endograft and the question of 
placing an endograft in a relatively young or fit patient with the concern that they may out-
live the life of the endograft has not yet been answered.  
Physician bias and training as well add to the difficulty in patient decision-making. As 
EVAR has gained in popularity open surgical repair has decreased and younger surgeons 
have less experience with open repair. The experience gained in many training programs 
has been that of difficult AAA repair in patients with unsuitable anatomy, which are 
relatively uncommon. To add to this dilemma as EVAR devices improve the pool of 
anatomically unfit patients decrease. Another issue is that AAA is no longer solely treated 
by surgeons and the decision to treat or observe a patient might be made on the clinicians 
inability to provide both the endovascular and open services.  
14. Recommendations for the up-to-date patient decision-making with 
respect to the repair of abdominal aortic aneurysms 
Based on the available literature and the global experience with larger studies and data-base 
analysis the general principles governing patient selection can be suggested as follows:  
(1) in medically fit patients with AAAs large enough to justify consideration of intervention, 
current-day EVAR is preferable for those with suitable anatomy and with comorbidities 
likely to limit their longevity commensurate with the estimated durability of the device 
used. The argument for EVAR in all patients with suitable anatomy has been extended by 
some prominent figures in the vascular surgery community at recent meetings. The 
suggestion here is that even the first generation devices have been shown to be durable over 
time and that with current improvements in device and delivery system that the longevity 
of these devices has been clearly demonstrated. On the other hand, good risk patients with a 
projected longevity clearly beyond the known limits of device durability should receive 
OPEN, has been a standard approach. While this is an acceptable statement, there is no  
 
question that EVAR is less invasive, has a faster recovery time and a shorter hospitalization 
period. The aspect that has generally been looked over is that in a young, fit patient that is a 
productive member of society, despite their likely ability to heal and continue working with 
either approach is more likely to be able to do so in a more expeditious way following an 
endovascular strategy. 57 
(2) High-risk patients with large AAAs, who are unfit for OPEN, first deserve intensive 
treatment of their comorbidities, followed by EVAR, if they improve, and continued 
observation if they do not. Here a difficult decision has to be made which brings up 
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Aneurysm Repair (CAESAR) of small AAAs (4.1-5.4 cm) for surveillance or EVAR with the 
Zenith stent-graft with the primary endpoint of all-cause mortality at 54 months. However 
they included information on Aneurysm-related mortality, aneurysm rupture and major 
morbidity rates which where similar perhaps indicating a trend towards interpretable 
information17 Inline with the information provided by the PIVOTAL trial they authors 
conclude that Mortality and rupture rates in AAA <5.5 cm are low and no clear advantage 
was shown between early or delayed EVAR strategy. However, within 36 months, three out 
of every five small aneurysms under surveillance might grow to require repair and one out 
of every six might lose feasibility for EVAR. Surveillance is safe for small AAA if close 
supervision is applied. 17 However a clear recommendation can not yet be made on the size 
for which small aneurysms should be treated, and we are left with the interpretation that 
aneurysms as seen above and in many other studies have the natural history to continue to 
increase in size and that many patients in the observation arm of trials, 27% to over 60% ( 
EVAR II, UKSAT, ADAM, PIVOTAL), crossovers to the treatment arm45.  
Further controversy revolves around large AAA greater then 5.5 cm and the question of 
treatment in the healthy patient vs the infirmed or unfit for open surgery patients as 
discussed above. Though the question is somewhat being answered by the trends in AAA 
management in clinical practice. Studies using large administrative databases in the United 
States have documented a trend whereby the majority of patients undergoing elective 
abdominal aortic aneurysm (AAA) repair in the United States are being repaired using 
endovascular techniques54 In a recently published single center study from the United States 
investigators retrospectively analyzed non-suprarenal AAA repairs between January 1, 
1996, and December 31, 2008. Patients were stratified by endovascular AAA repair (EVAR) 
or open repair and the presence or absence of rupture. During a 13-year period, 721 patients 
underwent AAA repair, comprising 410 (56.9%) with EVAR and 311 (43.1%) with open 
repair. This study included a time period prior to the availability of EVAR 1996 through the 
period when EVAR became widely available 2008, and showed that between 2005 and 2008, 
average EVAR use increased to 84%. 55 This is exemplary of the increased use of EVAR over 
open AAA. Another group analyzed Medicare Part B data sets for 2001 through 2006 with 
respect to open vs endovascular AAA repair. A total of 31,965 OSRs for AAA were 
performed in Medicare beneficiaries in 2001, dropping to 15,665 by 2006 (-51%). In contrast, 
EVAR was carried out in 11,028 instances in 2001, increasing to 28,937 by 2006 (+162%). The 
utilization rate per 100,000 for OSR dropped from 90 to 42 (a rate decrease of 48) during the 
study period, while the rate for EVAR increased from 31 to 77 (a rate increase of 46)56. The 
investigators drew the obvious conclusion that the newer, less invasive, and less risky 
procedure (EVAR) is replacing the older and more invasive procedure (OSR) to a 
considerable degree56. In another study looking at large national administrative in-hospital 
database to compare utilization and age-specific outcomes between open repair (OAR) and 
endovascular (EVAR) repair for the treatment of abdominal aortic aneurysm (AAA). The 
estimated number of elective AAAs treated with EVAR increased from 11,171 in 2001 to 
21,725 in 2006 (P = .003). The number of elective AAAs treated with OAR declined from 
17,784 to 8451 during the same period (P < .001). By 2006, EVAR was more frequently used 
than OAR for patients of all ages. Compared with the younger age groups, patients aged 
>or=85 years had a significant increase in the total number of asymptomatic AAA repairs, 
driven almost entirely by an increase in the use of EVAR 33. These authors noted that as 
short-term surgical outcomes are consistently improving for patients undergoing AAA 
repair, elective EVAR has replaced OAR as the more common method of repair in the 
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United States. The introduction of this technology has been rapidly adopted, particularly for 
the oldest-old surgical patients, aged >or=85 years, who previously may not have been 
offered surgical intervention for asymptomatic AAA. 33 This being said there are still 
significant unknowns with respect to long term out comes of EVAR despite the trend 
outlined above. The rapid improvements in EVAR design and deliverability have lead to 
changes in the anatomical criteria, and expanded usage. The EVAR device of today is very 
different then that of 10 years ago, however the outcomes data for “long-term follow up” is 
based on these older devices. The durability of these devices is a question that is difficult to 
answer, as this has been a constantly moving target as improvements to devices are made. 
Despite the increasing trend to treat all comers with EVAR, or at least the majority, the 
longitudinal data is not available or appropriate to make a solid recommendation. The 
durability of open grafts is proven with by the test of time there relatively low-tech nature 
and static design, this can however not be said about the endograft and the question of 
placing an endograft in a relatively young or fit patient with the concern that they may out-
live the life of the endograft has not yet been answered.  
Physician bias and training as well add to the difficulty in patient decision-making. As 
EVAR has gained in popularity open surgical repair has decreased and younger surgeons 
have less experience with open repair. The experience gained in many training programs 
has been that of difficult AAA repair in patients with unsuitable anatomy, which are 
relatively uncommon. To add to this dilemma as EVAR devices improve the pool of 
anatomically unfit patients decrease. Another issue is that AAA is no longer solely treated 
by surgeons and the decision to treat or observe a patient might be made on the clinicians 
inability to provide both the endovascular and open services.  
14. Recommendations for the up-to-date patient decision-making with 
respect to the repair of abdominal aortic aneurysms 
Based on the available literature and the global experience with larger studies and data-base 
analysis the general principles governing patient selection can be suggested as follows:  
(1) in medically fit patients with AAAs large enough to justify consideration of intervention, 
current-day EVAR is preferable for those with suitable anatomy and with comorbidities 
likely to limit their longevity commensurate with the estimated durability of the device 
used. The argument for EVAR in all patients with suitable anatomy has been extended by 
some prominent figures in the vascular surgery community at recent meetings. The 
suggestion here is that even the first generation devices have been shown to be durable over 
time and that with current improvements in device and delivery system that the longevity 
of these devices has been clearly demonstrated. On the other hand, good risk patients with a 
projected longevity clearly beyond the known limits of device durability should receive 
OPEN, has been a standard approach. While this is an acceptable statement, there is no  
 
question that EVAR is less invasive, has a faster recovery time and a shorter hospitalization 
period. The aspect that has generally been looked over is that in a young, fit patient that is a 
productive member of society, despite their likely ability to heal and continue working with 
either approach is more likely to be able to do so in a more expeditious way following an 
endovascular strategy. 57 
(2) High-risk patients with large AAAs, who are unfit for OPEN, first deserve intensive 
treatment of their comorbidities, followed by EVAR, if they improve, and continued 
observation if they do not. Here a difficult decision has to be made which brings up 
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questions of ethical and moral responsibility. While the exact nuances of are left to the 
practitioner to decide the cautionary note here is not do something like EVAR, or any 
procedure for that matter, just because it can be done. While this was the patient population 
in which EVAR was initially studied and designed in we have proven feasibility and this 
question has been answered. One must look closely at the quality of life and life expectancy 
as well as comorbidities to make this decision.  
(3) Patients with small AAAs deserve continued surveillance, with the threshold diameter 
being 5.0 cm diameter for males (based on the UKSAT trial follow-up data cited) and even 
lower, (4.5 cm diameter) for female patients, based on their relatively smaller anatomical 
dimensions, their attendant higher risk of rupture and higher rupture mortality, and a lower 
anatomical suitability for EVAR. This being said there appears to be some role in repair of 
smaller aneurysms in certain patient and closer or more frequent follow up in others. The 
opportunity for such early decision-making should be afforded by the recently approved 
national AAA screening program under Medicare, with screening having been shown to not 
only be cost effective for older men 58 but also for women as well 57  
15. Conclusions 
Trusting as we do in the inevitable progress of newer technology, we believe that, in the 
future, the great majority of AAAs will be repaired via EVAR. This trend has been 
demonstrated and to a certain degree the pendulum has been set in motion. EVAR in many 
institutions world wide is the preferred mode of treatment and the first choice procedure. 
The de- vices will continue to improve, as will deployment techniques, and hopefully, 
patient selection will be driven more by evidence than a biased view of the options. EVAR is 
recommended for most patients with large AAAs and “suitable anatomy,” specifically those 
who are deemed to be poor risk for open repair and/or have a limited life expectancy. Based 
on the data we have presented and contrary to the conclusions of EVAR 2, we also 
recommend EVAR for high-risk patients who respond to an intensive treatment of their 
comorbidities. Ultimately, patient and physician choice must take precedence when 
deciding between EVAR and no treatment in those with unsuitable anatomy for EVAR who 
are also unfit for open repair. The treatment of AAA like the treatment of many modern 
diseases needs to be individualized to the patient taking into account the many complex 
social and physiological considerations to formulate an appropriate management strategy  
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The standard treatment for an ascending aorta aneurysm is radical resection and 
interposition of a tubular prosthesis.  
Involvement of other adjacent structures has dictated the employment of more complex 
surgical techniques. The surgical treatment of concomitant disease of the aortic valve, aortic 
root and ascending aorta started in 1968 with Bentall and De Bono (Bentall & De Bono, 
1968), who applied a new surgical technique bearing their names and that represents the 
standard surgical technique for this pathology. With this technique, the valve, aortic root 
and ascending aorta are resected, replaced with a prosthetic valvular conduit, and the 
coronary vessels are anastomised to the tubular prosthesis. Nowadays, this represents a 
widely accepted surgical strategy to treat concomitant disease at the three mentioned 
structures. Minimally invasive procedures have been reported in the treatment of these 
patients as well (Perrotta et al., 2008; Perrotta & Lentini, 2009). 
In contrast, treatment of moderate ascending aorta dilatation associated with aortic valvular 
disease and with or without mild involvement of the aortic root is still controversial, 
especially in high risk patients (Bahnson, 1982; Prenger et al., 1994; Svensson et al., 1992). 
While it is usually accepted that ascending aorta dilatation beyond 5 cm should be surgically 
replaced, opinions on the treatment below this limit are divided (Ergin et al., 1999). In older 
and high surgical risk patients, several conservative surgical techniques on the ascending aorta 
have been proposed, such as the “waistcoat” aortoplasty, the simple aortoplasty, the “S” shape 
aortoplasty and the “wrap” aortoplasty (Robicsek & Thubrikar, 1994; Mueller et al., 1997). 
Radical resection of the ascending aortic aneurysm is needed in order to eliminate all the 
pathologic tissue of the aorta damaged by degenerative processes, such as cystic 
medionecrosis, aterosclerosis, and inflammatory processes. Lack of resecting part of the 
degenerative tissue may predispose to new aneurysmatic dilatation.  
2. Histology and pathophisiology in aortic aneurysms 
In the presence of mild to moderate dilatation of the ascending aorta associated with aortic 
valve disease, it may be difficult to ascertain if the dilatation is secondary to the 
hemodynamic alterations produced by the valvulopathy or by a disease of the aortic wall. 
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Preoperative and intraoperative studies may help to evaluate the structure of the aortic wall 
in relation to its thickness, elasticity and endothelium continuity. This can be done through a 
macroscopic analysis or through an intraoperative histopathologic evaluation on a cryostatic 
section of the aortic wall (Roman et al., 1989; Imaizumi et al., 1982). 
The most frequent histological finding in patients with dilatation of the ascending aorta is 
cystic medionecrosis. However, results from histology may be very different and it is often 
difficult to distinguish the primary cause of dilatation (Mueller et al., 1997; Schlatmann & 
Becker, 1997a, 1997b; Hirst & Gore, 1976). In cystic medionecrosis it is possible to observe 
necrosis of the smooth muscular cells and a mucoid degeneration of the media, with 
accumulation of amorphic mucopolysaccaridic material in the vessel wall. Several authors 
(Schlatmann & Becker, 1997a; Klima et al., 1983) have observed that this is not a specific 
finding in patients with aortic ectasia and that positive-alcian basophile material is also 
present in the media of normal aortas. Furthermore, they noticed that the aortic alterations 
and their entities are mostly related to the patient’s age and that there are more quantitative 
than qualitative differences between the analysed sections of normal aortas and the 
aneurysmatic or dissected ones. With aging, in normal aortas it is possible to observe 
fragmentation of the elastine, fibrosis, reduction of muscular cells and mucopolysaccarides. 
This may suggest that histological alterations in the aortic wall are not the expression of a 
degenerative disease, but the consequence of the metabolic activity of the media as a 
response to hemodynamic stress. With time, the hemodynamic stress prevails on the 
metabolic reparative processes. This process happens faster in patients with hereditary 
connective diseases (i.e. Marfan syndrome), in which the metabolic reparative mechanism is 
genetically malfunctioning.  
Giving strength to the theory of hemodynamic stress, is the observation that the dilatation is 
more frequently localized on the lateral segment of the ascending aorta and on the aortic 
arch. The hemodynamic stress can be associated with an aortic valve disease. In these 
patients, a dilatation of the ascending aorta of various entities has been observed regardless 
of the presence of degenerative disease (Carrel et al., 1991). 
Patients with a mild or moderate dilatation of the ascending aorta in association with an 
aortic valve disease often undergo only aortic valve replacement (Prenger et al., 1994; 
Natsuaki et al., 1998), believing it is not necessary to replace the ascending aorta. In patients 
with aortic valve stenosis, the replacement of the aortic valve, reducing systolic blood flow 
produced by the valve stenosis, eliminates the hemodynamic turbulence in the ascending 
aorta (Yearwood et al., 1989; Jarchow & Kincaid, 1961; Stein & Sabbah, 1976). Similarly, the 
surgical correction of an aortic valve insufficiency reduces the systolic hypertension and the 
diastolic ventricular turbulences, restoring the normal blood pressure and blood flow (Stein 
& Sabbah, 1976; Laske et al., 1996). In both situations the hemodynamic stress on the aortic 
wall is reduced (Schlatmann & Becker, 1997b; Crawford et al., 1988). 
However, the removal of hemodynamic factors may not be sufficient to prevent further 
dilatation of the ascending aorta, and further dilatation may slowly progress according to 
the Laplace law (Natsuaki et al., 1998; Milano et al., 1998). For this reason, several surgical 
techniques of aortoplasty have been proposed in order to prevent this occurrence; some 
techniques modify only the aortic diameter without reinforcing (McCready & Pluth, 1979) 
the vessel, others instead reinforce (Robicsek, 1982) the vessel to prevent redilatation. 
The efficacy of this technique is still under question since complications and redilatation 
may occur at follow up. These controversial results may be related to the extreme 
heterogeneity of the enrolled patients in the literature reports; some had aneurysms of the 
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ascending aorta without aortic valve disease, others ascending aorta dissection or Marfan 
disease (Robicsek & Thubrikar, 1994; Carrel et al., 1991; Natsuaki et al., 1998; Barnett et al., 
1995). These last clinical conditions are usually associated with a high frequency of 
redilatation (Kouchoukos et al., 1986; Carrel et al., 1993; Lawrie et al., 1993). For this reason, 
an accurate selection of patients and a correct surgical indication is mandatory in patients 
who are candidates for aortoplasty surgery. 
3. Conservative treatment of an ascending aorta aneurysm 
The conservative surgical treatment for an ascending aorta aneurysm takes its origin not as 
an elective treatment of mild or moderate dilatation of the ascending aorta, but as a surgical 
alternative to the traditional radical technique of resection with a tubular (Wheat et al., 1964; 




Fig. 1. Dilatation of the ascending aorta. The patient is cannulated according to standard 
technique; the arterial cannula is placed into the ascending aorta or aortic arch, while the 
venous cannula is in the right atrium. The ascending aorta is clamped before the 
brachiocephalic truncus. The aortic vent can be positioned according to the surgeon’s 
preference.  
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It was McCready and Pluth (McCready & Pluth, 1979), who in 1979 reported the first 
conservative surgical technique for the treatment of an aneurysm of the ascending aorta, the 
so-called “simple aortoplasty”(Figure 2). They proposed an oval and longitudinal resection 
of the anterior wall of the ascending aorta. The aortotomy was sutured with a continuous 
double layer suture and in some cases reinforced by Teflon strips. In 1982, Robicsek 
(Robicsek, 1982) suggested his technique of aortoplasty, the so-called “external grafting” or 
“aortic wrap” (Figure 3), for the treatment of small aneurysms of the abdominal and thoracic 
aorta, and fusifom dilatation of the ascending aorta with associated valvular disease. The 
surgical procedure is similar to the one proposed by McCready, with an oval and 
longitudinal resection of the ascending aorta. The aorta is then reinforced by the application 
of a tubular prosthesis around the ascending aorta. The prosthesis is incised longitudinally 
and shaped around the vessel. The prosthesis is then stabilized by placing three sutures. 
 
 
Fig. 2. “Simple aortoplasty”. The ascending aorta is incised longitudinally and then an oval 
and longitudinal resection of the anterior wall of the ascending aorta is performed. The 
aortotomy can be sutured with a continuous double layer suture, or can be reinforced with 
Teflon felts. 
 




Fig. 3. “Aortic wrap aortoplasty”. The surgical procedure is similar to the “simple 
aortoplasty”. The aorta is then reinforced by the application of a tubular prosthesis around 
the ascending aorta. The prosthesis is incised longitudinally and shaped around the vessel. 
The prosthesis is then stabilized by placing three sutures at the level of the three 
commissures.   
The results reported in the literature, both for the simple aortoplasty and for the aortic 
wrapping, are heterogeneous. However, most report advantages in using a conservative 
approach rather than radical surgery in selected cases (Carrel et al., 1991; Barnett et al., 
1995). 
The aortic cross clamp time and the extracorporeal circulation time are usually shorter, and 
this may represent an important factor in older patients requiring additional cardiac surgical 
procedures (Robicsek & Thubrikar, 1994; Mueller et al., 1997; Baumgartner et al., 1998). 
Results from studies reporting on conservative treatment of the ascending aorta are 
summarized in the next paragraph. 
4. Results from previous published studies 
Egloff (Egloff et al., 1982), in his study, compared the results of aortoplasty surgery (both 
simple aortoplasty and wrapping technique) with radical surgery. He found that the 
incidence of cerebrovascular thromboembolic events is higher in patients undergoing 
radical surgery that in those undergoing conservative surgery. However, it should be 
mentioned that in his report, Egloff included a heterogeneous study population. Half of the 
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patients had an acute or chronic ascending aorta dissection, while the other half had a 
dilatation of the ascending aorta of various entities and not always associated with an aortic 
valve disease. In 15% of the patients the aneurysm was related to Marfan syndrome, while 
in 4% of the population the aneurysm was related to syphilitic disease. There was not a 
specific indication for the type of surgery performed in relation to the specific pathology. 
This lack of specific indication may partly explain the higher incidence of redilatation of the 
ascending aorta after aortoplasty than after radical surgery.  
Carrel (Carrel et al., 1991) reported the results of 291 patients who underwent cardiac 
surgery and concomitant surgery on the ascending aorta. The surgical procedures employed 
were aortic remodeling and external wall support in 164 patients, composite graft 
replacement in 81 patients and supracoronary graft in 46 patients. Elective, urgent and 
emergent operations were included in the study. The overall mortality was 4.8%, and he 
showed good results, at both medium and long term. Compared to the graft replacement 
and supracoronary graft, the aortoplasty group had the lowest early mortality rates (1.8% vs 
9.8% vs 6.4%). The 5 and 10 year survival in the groups of patients undergoing aortic 
remodelling and external wall support, supracoronary graft and composite graft were, 
respectively, 93.5%, 82% and 80% and 83.8%, 73% and 67%. The incidence of reoperation at 
10 years was 3.6% versus 2.4 %, respectively, in the group of patients that underwent 
conservative surgery and in the group with composite graft. The incidence of postoperative 
bleeding was higher in patients undergoing radical surgery rather than conservative 
surgery. 
Barnett (Barnett et al., 1995) in 1995 evaluated the effectiveness of tailoring aortoplasty used 
to treat fusiform aneurysms of the ascending aorta. He reviewed results on 17 patients, of 
which nine had tailoring aortoplasty alone, and eight patients had aortoplasty and Dacron 
wrapping. In his study the author included patients with aortic valve disease associated 
with an aneurysm of the ascending aorta, with sizes ranging from 5 to 8 cm, confined to the 
tubular portion of the ascending aorta that narrowed to a normal diameter in the distal 
ascending aorta and with a normal diameter of the sinuses of Valsalva. All the patients 
underwent concomitant cardiac surgery procedures. The actuarial survival at 1 and 10 years 
was 81% and 63%, respectively. He concluded that in selected cases, tailoring aortoplasty 
can achieve long-term results comparable to those of resection and graft replacement of 
fusiform ascending aortic aneurysms. At the follow up (mean 4.4 years), the ascending aorta 
was studied with chest radiography alone without reporting any redilatation of the 
ascending aorta. This represents a limiting factor of the study, since the diagnosis of 
redilatation is important for defining the technique efficacy.  
Mueller (Mueller et al., 1997), in 1997, reported on 17 consecutive patients treated by 
unsupported aortoplasty for an aneurysm of the ascending aorta associated with aortic 
valve disease. Twelve patients had predominantly regurgitation of the aortic valve, and 5 
patients had stenosis. The ascending aorta diameter ranged from 5 to 5.5 cm. In 6 elderly 
and high-risk patients, the aorta was between 5.5 and 6 cm in diameter. He reported a 
hospital mortality of 12%. Survival at 7 years was 86.7%. Recurring aortic aneurysms, 
requiring reoperation, developed in 4 patients after a mean time of 63 months, with an 
event-free survival at 7 years of 41%. All of these 4 patients had aortic valve regurgitation 
and cystic medial necrosis. The author concludes that the high recurrence of aorta ascending 
aneurysm after aortoplasty in patients with aortic valve regurgitation is due to an intrinsic 
deficiency of the aortic wall. 
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In 1998 Baumgartner (Baumgartner et al., 1998) developed a modification of the reduction 
aortoplasty procedure as a modified “Z-plasty” (Figure 4) without the use of additional 
external prosthetic wrapping material. The aortoplasty was performed when moderately 
sized ascending aortic aneurysms were encountered during concomitant cardiac operations. 
The incision was S-shaped and on the lateral aspect of the ascending aorta, with biased 
excision of tissue predominantly in the bends of the "S". The aorta was then sutured using a 
double running suture. The procedure was performed in 23 patients with moderate 
ascending aorta aneurysms, the mean diameter being 5.0±0.7 cm, and not involving the 
sinuses of Valsalva; none had Marfan syndrome. Sixteen patients were studied with 
echocardiography at a mean follow-up of 9.9±12.6 months. Their mean intraoperative 
postreduction diameter was 2.9±0.65 cm, at the follow-up the aorta was 3.1±0.45 cm (p = 
NS). Of these, seven had a mean follow-up of 22.1±9.2 months. Their mean postreduction 
diameter of 2.9±0.5 cm increased to 3.1±0.35 cm (NS). The author says that this simple 
technique places stress on the suture line in a favorable orientation, it appears to have good 
mid-term results and it is best suited to moderately sized aneurysms. 
 
 
Fig. 4. “Z-plasty” aortoplasty. The incision of the ascending aorta is based on an “S-shape 
incision” and on the lateral aspect of the ascending aorta, with biased excision of tissue 
predominantly in the bends of the "S". The aorta is then sutured using a double running 
suture.  
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patients had an acute or chronic ascending aorta dissection, while the other half had a 
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In 2002 Bauer (Bauer et al., 2002) reported of a total of 115 patients (36 female, 79 male) with 
bicuspid aortic valve and dilatation of the ascending aorta who underwent reduction 
aortoplasty alone or in combination with another cardiac procedure. In 106 patients (group 
I), reduction aortoplasty, “simple aortoplasty”, was performed without additional external 
prosthetic support of the aortic wall. In the remaining 9 patients (group II), the aorta was 
externally supported by wrapping the ascending aorta with a prosthetic graft. None of the 
patients had characteristics of Marfan syndrome, as this surgical technique should be 
considered contraindicated in patients with this syndrome. The patients were 
postoperatively studied with CT and echocardiography during a mean follow-up time of 40 
months (range 12 to 144 months). No reoperations on the ascending aorta or aortic valve 
during the follow-up period were reported. The 5-year survival rate was 94%±3.1%. During 
the late follow-up, a significant increase (> 4 mm) of the ascending aortic diameter was 
found in 9 patients (8.9%) from group I and in none from group II. The author observed that 
a factor that influenced the redilatation was the early postreduction diameter. He suggested 
that to avoid redilatation, the diameter of the ascending aorta should be reduced to 35 mm 
or less or the aorta should be supported externally by a tubular graft. 
Viganó (Viganó et al., 2002), in 2002, reported the description of a different conservative 
surgery on the ascending aorta, named “end-to-end anastomosis” (Figure 5), designed for 
patients undergoing a ministernotomy approach for ascending aortic aneurysm with minor 
involvement of the sinotubular junction. He reported on 45 patients with a diagnosis of 
chronic ascending aorta aneurysm, including also patients with type A aortic dissection. To 
reduce the aneurysmatic section of the aorta he suggested performing two circumferential 
aortotomies: the first at the level of the sinotubular junction and the second at the distal 
border of the aneurysm. At this stage aortic valve surgery could be performed, if needed. 
The resulting resected wall is a cuneiform segment of the ascending aorta, that if opened on 
its anterior aspect, assumes a typical butterfly shape. Finally the two ends of the ascending 
aorta are sutured together with a running suture, eventually reinforced by Teflon strips. 
Patients were studied with computed tomography and echocardiography. During the 
follow-up period (23.7±12.3 months) a very low redilatation rate (1 of 43; 2.3%) and no 
incidence of pseudoaneurysm were reported; 1 patient required reoperation.  
 
 
Fig. 5. After clamping the ascending aorta, distally to the aneurysm, the aorta is opened and 
then resected between two circumferential aortotomies: first at level of sinotubular junction 
and second at distal edge of aneurysm (1). Two ends of aorta, without tension, are finally 
sutured with a continuous (2). 
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Later, Masetti (Masetti et al., 2004), in a smaller series of patients undergoing “end-to-end 
anastomosis” suggested a modification of the previously described technique with the aim to 
facilitate the surgical approach. The horizontal aorta is largely mobilized, mainly by dissecting 
the first portion of supra-aortic trunks and by dissecting pericardial reflections adjacent to the 
inferior vena cava and left atrium. Then, after clamping the ascending aorta and resecting the 
aneurysm by two circumferential aortotomies, the two aortic ends may be sutured together 
with a reduced tension. The patients were postoperatively studied with CT scan during a 
median follow-up time of 72 months per patient (10.5±102.7 months). At the follow-up, the 
mean aortic diameters showed no statistically significant enlargement when compared with 
the findings of aortic contrast CT scan at discharge. The author concludes that cuneiform 
resection of the aorta ascendens and end-to-end ansastomosis provides effective long-term 
outcomes. This technique should be used only in patients with ascending aorta aneurysm 
associated with structural aortic valve disease. Patients with Marfan syndrome or other 
inherited connective tissue disorders should be not considered for this treatment. 
Gaeta (Gaeta et al., 2009), in a recent report focused on some surgical details of the “end to end 
technique”, reported on specific anatomic indications for this type of surgery. He recommended 
a preoperative CT scan spatial reconstruction of the thoracic aorta. The ideal candidate for this 
technique has “an elongated aorta in the antero-lateral wall; the postero-medial wall is usually 
restrained by the pulmonary artery and it maintains the original length”. 
Cotrufo (Della Corte et al., 2003; Cotrufo et al., 2003), in 2003, reported the results of 73 
patients with a non-complicated dilatation of the ascending aorta associated with aortic 
valve structural disease, who underwent aortic valve replacement and “waistcoat 
aortoplasty”; some of these patients underwent plication of the sinuses of Valsalva as well. 
The surgical indication for associated aortoplasty was an aortic ratio >1.5 at either sinusal, 
tubular, or both levels. The aorta was incised longitudinally, starting from the aortic clamp 
towards the commissure between the right coronary sinus and the non-coronary sinus. At 
above 2 cm before reaching the commissure, the incision was deflected at an angle of 90° 
and continued towards the commissure between the left coronary and the non-coronary 
sinus. A triangular resection of the dilated aortic wall was then obtained by extending the 
incision from above the commissure to the distal end of the incision.  At this point, surgery 
on the aortic valve was performed according the surgeon’s preference. In patients with 
associated dilatation of the aortic sinuses, in order to treat the dilatation of the aortic sinuses 
and to remodel the aortic root geometry, each stitch bite placed on the aortic annulus, 
included the redundant subcoronary portion of the aortic wall. When implanting the 
prosthesis, and drawing the stitches tight, a bidimensional, longitudinal and radial plication 
of the three sinuses was achieved, thereby reducing the distance between the coronary ostia 
and the aortic annulus. The aorta was reconstructed using a double layer technique termed a 
“waistcoat aortoplasty”. A first suture line fixed the right posterolateral free edge of the 
resection to the inner surface of the anterior wall, leaving a 1 to 2 cm wide anterior lap. The 
anterior lap was then used to cover and reinforce the neo-aortic wall, and its free margin 
was sutured on the right posterior wall (Figure 6 to 8). At follow-up, the ascending aorta 
was studied with echocardiography. The author reports that a significant postoperative 
reduction of Valsalva sinuses, sinustubular and ascending aorta diameters were found 
compared to the preoperative values. In 53 patients at a mean follow-up of 33.8±10.2 
months, there was no significant enlargement of the aorta compared to 48 h postoperatively 
(P=0.32, P=0.15, P=0.38 respectively). Furthermore, no cases of postoperative aneurysm or 
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aortic valve complications were recorded and the sinus plication did not interfere with the 
prosthesis leaflet movements. The author assesses that the “waistcoat aortoplasty”, reducing 
the diameter of the ascending aorta and reinforcing the aortic wall, is indicated only in 
asymmetric dilatation of the ascending aorta associated with primary structural aortic valve 
disease; while in symmetrical dilatation a radical surgery is recommended. 
 
 
Fig. 6. “Waistcoat aortoplasty”. The aorta is longitudinally incised, starting from the clamp 
towards the commissure between the right coronary sinus and the non-coronary sinus. At 
above 2 cm before reaching the commissure, the incision is deflected at an angle of 90° and 
continued towards the commissure between the left coronary and the non-coronary sinus 
(1). The native aortic valve is excised (2). 
 
 
Fig. 7. The prosthetic valve is implanted (1). The sutures to anchor the aortic valve are 
driven in through the subcoronary aortic wall and out through the annulus. When 
implanting the prosthesis, there is a longitudinal plication of the sinuses (2). 
 




Fig. 8. A triangular resection of the dilated aortic wall is obtained by extending the incision from 
above the commissure to the distal end of the incision (1). The right edge of the aortotomy is 
sutured to the inner surface of the anterior wall with a suture line starting from the right 
coronary ostium (2). The suture line continues longitudinally leaving a 2 cm wide anterior lap 
(3). The remaining anterior lap is sutured to cover and to reinforce the aortic wall (4). 
In 2004, Arsan (Arsan et al., 2004) reported on 62 consecutive patients that underwent 
treatment for ascending aorta aneurysm by reduction aortoplasty and external wrapping 
during cardiac concomitant procedures. The mean preoperative aortic diameter was 
52.7±0.5 mm and the diameter of the ascending aorta was greater than 45 mm in all patients. 
Mean follow-up time was 39.6±18.0 months (range 8 to 78 months). No mortality was 
registered during a 30-day period. The hospital mortality was 1.6%, one patient died as 
result of septic multiple-organ failure. Comparing the aortic diameter before surgery (AD1), 
aortic diameter in early postoperative (AD2) and aortic diameter during the late 
postoperative period (AD3), reduction aortoplasty of the ascending aorta with external 
wrapping resulted in a significant reduction of the ascending aorta diameter in all patients 
(AD1 versus AD2 and AD3, p=0.000).  There was also a statistically significant difference 
between the ascending aortic diameters measured during early and late follow-up (AD2 
versus AD3, p=0.000). Although this increase was statistically significant, all measurements 
of the follow-up period in groups AD2 and AD3 were still within the normal range. The 
author concluded that external wrapping of the aorta offers excellent results with very low 
mortality and morbidity, and it can be regarded as a safe and effective method for the 
treatment of ascending aortic aneurysm in selected patients. However, the patients should 
be carefully monitored for redilatation after the procedure. 
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The same author (Arsan, 2004) reported as well on 4 high-risk patients who underwent off-
pump reduction aortoplasty and concomitant myocardial revascularization. In these 
patients, the diameter of the ascending aorta was less than 6 cm and there were no 
calcification, atherosclerotic penetrating ulcers, or suspicion of dissection. The author 
routinely performs an external wrapping technique without incising or excising the diseased 
aorta, a “sandwich technique”. The tubular graft is tailored to the diseased aorta 
longitudinally using separate, full-thickness U sutures. This technique can be performed 
easily even on the beating heart in high risk patients in order to prevent complications. 
According to the author, this technique could be the procedure of choice in selected high-
risk cases for the treatment of borderline ascending aortic aneurysms in patients undergoing 
coronary revascularization.  
Polvani (Polvani et al., 2006), in 2006, published a study where he evaluated the midterm 
follow-up of unsupported aortoplasty and determined predictors of redilatation. He 
reported on 68 patients with dilatation of the ascending aorta treated by unsupported 
reduction aortoplasty in combination with other cardiac procedures. Indication for surgery 
was an aortic diameter between 40 and 50 mm for younger patients and up to 60 mm for 
older patients or in high risk patients, with the aim to reduce aortic cross-clamp and 
perfusion times. Mean follow-up time was 2.9±1.7 years. The overall perioperative mortality 
rate was 1.5%. Overall survival estimates at 3 and 6 years were 93.3%±4.5% and 89.3%±5.9%, 
respectively. Ascending aorta redilatation occurred in 5 patients (7.5%). The actuarial 
freedom from redilatation at 3 and 6 years was 97.7%±2.3% and 79.8%±8.4%, respectively. 
The actuarial freedom from reoperation at 3 and 6 years was 100% and 86.3%±7.5%, 
respectively. Only preoperative diameter was a significant predictor of redilatation, using 
multivariate stepwise logistic regression analysis. In the author’s experience, unsupported 
aortoplasty resulted in a safe and effective technique with low mortality, low morbidity, and 
few late complications for selected chronic aneurysm of the ascending aorta with diameters 
less than 55 mm. A diameter greater than 55 mm is an independent risk factor for 
redilatation, and it should be considered a contraindication to this procedure and may be 
considered an indication to the Dacron graft support.  
Walker (Walker et al., 2007), in 2007, investigated the postoperative stability and preservation 
of the physiologic elasticity of the reconstructed ascending aorta (Windkessel function). He 
collected the results of 97 patients who underwent aortoplasty without external stabilization, 
for a moderate enlargement of the ascending aorta up to 5 cm, as a concomitant procedure 
during cardiac surgery. Patients with Marfan syndrome, aneurysms of the sinus of Valsalva, 
aneurysms of the aortic arch and patients with an infective origin of the aneurysm were 
excluded. Hospital mortality was 3%. At 32 months follow-up, fifty-four patients agreed to be 
examined by computed tomographic scan (determination of the aortic diameter) and 
transthoracic echocardiography (determination of the Windkessel function). Mean dilatation 
during the time from early postoperative measurement to follow-up was 0.17 cm (±0.27 cm; CI 
0.09 to 0.25 cm). In six patients with a follow-up of 60 months who had both early and late 
postoperative diameter assessment, the mean postoperative dilatation was 0.04 cm (±0.15 cm; 
CI 0.11 to 0.20 cm). By transthoracic echography, the diastolic-systolic augmentation 
(Windkessel function) of the ascending aorta was confirmed, with a median amplitude value 
of 0.25 cm (range, 0 to 1.1 cm). These results were compared with data from patients who 
received a tubular graft on the ascending aorta. They had only minor diameter changes during 
systole and diastole: median 0.06 cm (range, 0 to 0.12 cm). The systolic augmentation of 
patients with aortoplasty was 250% in comparison with those who received a tubular graft on 
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the ascending aorta (CI 157% to 375%). The author concludes that aortoplasty without external 
support is a valid treatment in patients with moderate dilatation of the ascending aorta and 
preserves the Windkessel function of the ascending aorta. 
In 2007, Feindt (Feindt et al., 2007), in a retrospective study, analyzed the results of a cohort 
of 50 patients who underwent size-reducing ascending aortoplasty with external wrapping. 
The maximum diameter of the ascending aorta in this group was measured between 45 and 
65 mm without dilation of the sinotubular junction and aortic arch. Aortoplasty was 
associated with other cardiac procedures such as aortic valve replacement in 47 cases. The 
procedure was performed with low hospital mortality (2%) and a low postoperative 
morbidity. Computer tomographic and echocardiographic diameters were significantly 
smaller after reduction (55.8±9 mm down to 40.51 (±6.2 mm (CT), p < 0.002; 54.1±6.7 mm 
preoperatively down to 38.7±7.1 mm (echocardiography), p < 0.002), with stable 
performance at follow-up (mean follow-up time: 70 months, complete in 31 patients). The 
authors concluded that ascending aorta aortoplasty with external reinforcement is a safe 
procedure with excellent long-term results and that it is a therapeutic option in patients with 
poststenotic dilatation of the aorta, without dilatation of the sinotubular junction.  
Belov (Belov et al., 2009), in 2009, compared the early results and late outcome in two groups 
of patients. Group 1 had prosthetic ascending aorta replacement, while group 2 had 
reduction aortoplasty and external wrapping. All had a diameter of the ascending aorta ≥5 
cm and a sinus of Valsalva diameter <4.5 cm. Group 1 had longer cardiopulmonary bypass 
time, higher reoperation for bleeding and higher mortality. None of the patients in group 2 
needed reoperation due to ascending aorta redilatation nor significant enlargement of the 
Valsalva sinuses during the follow-up. According to Belov, the main criterion for 
performing or not performing an aortoplasty with external wrapping on the ascending aorta 
should only be the diameter at the level of the Valsalva sinuses, rather than the ascending 
aorta maximal diameter. He considered a diameter <4.5 cm at the Valsalva sinuses as an 
appropriate condition for performing a reduction aortoplasty. On the other hand, important 
enlargement of the ascending aorta usually leads to aortic root dilatation; reduction 
aortoplasty with external wrapping may be impossible in these circumstances.  
In the same year, Zhang (Zhang et al., 2010) published his report of 71 patients with 
fusiform ascending aortic aneurysms and aortic valve disease who underwent reinforced 
reduction aortoplasty associated with aortic valve replacement (RRA group, n 32) or 
ascending aortic replacement combined with aortic valve replacement (AAR group, n 39). 
Patients requiring other concomitant cardiac procedures were excluded, as well patients 
with Marfan syndrome. The mean follow-up time was 3 years and 4 months. The 
cardiopulmonary bypass time, the aortic cross clamp time and the length of stay were 
higher in the AAR group than in the RRA group. The overall survival rate in all patients 
was 88.6%±4.5% at 5 years. The 5-year survival rate was 90.7%±6.4% in the RRA group and 
87.0%±6.3% in the AAR group. There were no reoperations on the aorta or aortic valve in all 
patients during follow-up. In both groups, the aorta was studied at the level of the aortic 
sinuses and proximal aortic arch, and no significant differences between the postoperative 
and late follow-up diameters were found in the RRA and in the AAR groups.  
In 2009, Haddad (Haddad et al., 2009) published an article in which he analyzed the results 
of 6 high risk patients, with a Euroscore between 11 and 19, with ascending aortic aneurysm 
and aortic valve disease, who underwent reduction aortoplasty with external wrapping 
associated with the aortic valve replacement. The inclusion criteria were: patients with aortic 
valve disease with surgical indication, ascending aortic diameter >5.5 cm, EuroSCORE >6 
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The same author (Arsan, 2004) reported as well on 4 high-risk patients who underwent off-
pump reduction aortoplasty and concomitant myocardial revascularization. In these 
patients, the diameter of the ascending aorta was less than 6 cm and there were no 
calcification, atherosclerotic penetrating ulcers, or suspicion of dissection. The author 
routinely performs an external wrapping technique without incising or excising the diseased 
aorta, a “sandwich technique”. The tubular graft is tailored to the diseased aorta 
longitudinally using separate, full-thickness U sutures. This technique can be performed 
easily even on the beating heart in high risk patients in order to prevent complications. 
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aneurysms of the aortic arch and patients with an infective origin of the aneurysm were 
excluded. Hospital mortality was 3%. At 32 months follow-up, fifty-four patients agreed to be 
examined by computed tomographic scan (determination of the aortic diameter) and 
transthoracic echocardiography (determination of the Windkessel function). Mean dilatation 
during the time from early postoperative measurement to follow-up was 0.17 cm (±0.27 cm; CI 
0.09 to 0.25 cm). In six patients with a follow-up of 60 months who had both early and late 
postoperative diameter assessment, the mean postoperative dilatation was 0.04 cm (±0.15 cm; 
CI 0.11 to 0.20 cm). By transthoracic echography, the diastolic-systolic augmentation 
(Windkessel function) of the ascending aorta was confirmed, with a median amplitude value 
of 0.25 cm (range, 0 to 1.1 cm). These results were compared with data from patients who 
received a tubular graft on the ascending aorta. They had only minor diameter changes during 
systole and diastole: median 0.06 cm (range, 0 to 0.12 cm). The systolic augmentation of 
patients with aortoplasty was 250% in comparison with those who received a tubular graft on 
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the ascending aorta (CI 157% to 375%). The author concludes that aortoplasty without external 
support is a valid treatment in patients with moderate dilatation of the ascending aorta and 
preserves the Windkessel function of the ascending aorta. 
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65 mm without dilation of the sinotubular junction and aortic arch. Aortoplasty was 
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procedure was performed with low hospital mortality (2%) and a low postoperative 
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smaller after reduction (55.8±9 mm down to 40.51 (±6.2 mm (CT), p < 0.002; 54.1±6.7 mm 
preoperatively down to 38.7±7.1 mm (echocardiography), p < 0.002), with stable 
performance at follow-up (mean follow-up time: 70 months, complete in 31 patients). The 
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procedure with excellent long-term results and that it is a therapeutic option in patients with 
poststenotic dilatation of the aorta, without dilatation of the sinotubular junction.  
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should only be the diameter at the level of the Valsalva sinuses, rather than the ascending 
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In the same year, Zhang (Zhang et al., 2010) published his report of 71 patients with 
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Patients requiring other concomitant cardiac procedures were excluded, as well patients 
with Marfan syndrome. The mean follow-up time was 3 years and 4 months. The 
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patients during follow-up. In both groups, the aorta was studied at the level of the aortic 
sinuses and proximal aortic arch, and no significant differences between the postoperative 
and late follow-up diameters were found in the RRA and in the AAR groups.  
In 2009, Haddad (Haddad et al., 2009) published an article in which he analyzed the results 
of 6 high risk patients, with a Euroscore between 11 and 19, with ascending aortic aneurysm 
and aortic valve disease, who underwent reduction aortoplasty with external wrapping 
associated with the aortic valve replacement. The inclusion criteria were: patients with aortic 
valve disease with surgical indication, ascending aortic diameter >5.5 cm, EuroSCORE >6 
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and age over 60 years; the mean diameter of the sinotubular junction was 36 mm. The 
exclusion criteria were: presence of dissections of the ascending aorta and Marfan 
syndrome. At follow-up (28 months), the actuarial survival rate was 100%, and none of 
patients needed reoperation. The author concludes that, despite the limitations of the study 
(small sample of patients, mid-term follow-up, selected and not random population), the 
reduction aortoplasty associated with external wrapping and aortic valve replacement is a 
therapeutic option with promising midterm results in high surgical risk patients with 
ascending aortic aneurysm and aortic valve disease. 
In a recent article published in 2010, Hwang (Hwang et al., 2010), in his series of 88 patients, 
evaluates the long-term results of aortoplasty performed with aortic valve surgery and 
compared the results in patients with bicuspid aortic valve with those in patients with 
tricuspid aortic valve. Indication for aortoplasty was a moderately dilated ascending aorta 
with a diameter between 40–50 mm. Patients with combined aortic root dilatation (diameter 
of the sinus of Valsalva greater than 5 cm and/or displaced coronary ostia distal to the sino-
tubular junction), and patients with systemic connective tissue disease were excluded. 
Operative mortality was 1.1%. The overall 10-year survival rate was 91.1%. No patients 
suffered from aorta-related complications such as aortic dissection, rupture or aortic 
reoperation. At follow-up of 74 months per patient, a CT scan was performed to evaluate the 
ascending aorta. The mean diameter of the repaired aorta was 37.8±4.3 mm and none had a 
diameter greater than 5 cm. The author assesses that the reduction ascending aortoplasty for 
a moderate ascending aortic aneurysm combined with aortic valve disease can be performed 
with low periprocedural risks and good long-term results. 
Recently, Ang (Ang et al., 2010) reported on the early impact of aortic wrapping in patients 
undergoing aortic valve replacement with mild to moderate ascending aorta dilatation. An 
important finding of this study refers to “the reduction of the diameter and reversed 
remodeling of the aorta not only at the site of dilatation but also proximally and distally to 
the aortic wrapping”. These results suggest that “correction of dimensions of a dilated 
ascending aorta at an early stage, and before irreversible anatomical changes take place, 
results in the rapid reversed remodeling of the rest of the aorta, probably due to the 
restoration of normal blood flow haemodynamics”.  
5. Discussion and conclusions 
From the above mentioned studies we see that aortoplasty with or without external wrapping 
or simple wrapping alone may represent a surgical alternative for mild to moderate ascending 
aorta dilatation in high risk patients. However, some points should be addressed.  
The aortoplasty reduces the diameter of the ascending aorta and therefore reduces the 
tension on the aortic wall, but it does not reinforce the wall in itself. Blood ejected by the left 
ventricle hits an area of the ascending aorta, which after aortoplasty is less elastic and rather 
more fibrotic due to the formation of a scar on the suture line. Areas of the ascending aorta 
previously involved in the dilatation are still weakened by the hemodynamic stress trauma 
(Mueller et al., 1997; Robicsek, 1995). This mechanism could explain aneurysm recurrence 
observed after “simple aortoplasty” (Mueller et al., 1997; Egloff et al., 1982). Therefore, 
aortoplasty, even if it eliminates the aneurysm, may sometimes prove insufficient to prevent 
recurrence. 
Furthermore, simple aortoplasty may not be appropriate to treat patients with concomitant 
aortic root aneurysm (Mueller et al., 1997; Barnett et al., 1995). In order to reconstruct 
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physiologically the ascending aorta, the wall of the ascending aorta is incised longitudinally 
and an elliptical portion of the aortic wall is then removed. From its nature, the edges of the 
elliptical shape progressively reduce their width at the extremities. Using this technique, it 
could be difficult to extend the reductive aortoplasty to the sinuses of Valsalva. These 
limitations are not overcome by the technique suggested by Baumgartner (Baumgartner et al., 
1998); this technique is applicable to reduce the diameter of the ascending aorta, but it does not 
reinforce the aortic wall and it cannot be used to reduce a dilatation of the sinuses of Valsalva.  
Not unanimous is the consensus regarding the “external grafting technique” suggested by 
Robicsek. Incertitude is raised by the use of a prosthetic graft to reinforce the aortic root 
(Cooley, 1982; Gott, 1994).  Gott (Gott, 1994) has observed that this technique does not offer 
an adequate reinforcement of the aortic root, although Robicsek has indicated the dilatation 
of the sinuses of Valsalva and dilatation of the ascending aorta in patients with Marfan 
syndrome as pathologies treatable by external grafting. 
The tubular prosthetic graft should be adequately positioned in order to not compress the 
coronary ostia and compromise cardiac perfusion (Robicsek & Thubrikar, 1994;  Robicsek , 
1982; Barnett et al., 1995). Often, when a dilatation of the aortic root is present, the coronary 
ostia are dislocated distally and away from the annulus (Bahnson, 1982; Barnett et al., 1995; 
Gott, 1994; Lewis et al., 1992). They take origin from the distal part of the aneurysm. The 
remaining section of the aortic root under the coronary ostia remains, in these cases, 
unsupported. 
An adequate anchoring of the tubular graft is important to prevent complications.  Neri and 
colleagues (Neri et al., 1999) reported on 2 patients who developed false aneurysm of the 
ascending aorta after 7 and 11 years, respectively. Histological examination of the aortic wall 
underlying the reinforcement cuff revealed extensive wall degeneration. Dhillon and 
associates (Dhillon et al., 1986) observed late ruptures after wrapping of aortic aneurysms. 
In all 3 cases, the aortic wall had been eroded. Usually the border between the wrapped 
segment and the native aortic wall might be under high pressure, resulting in dissection and 
erosion of the native intima, producing a weakening of the aortic wall both proximally and 
distally. Akgun (Akgun et al., 2010) reported an aortic root aneurysm in a patient who 7 
years earlier underwent a reduction aortoplasty with external wrapping.  Bauer (Bauer et al., 
2003) found, in 1 patient, that the dacron wrapping had become dislocated by moving to the 
distal part of the ascending aorta, creating a sharp fold at the inner curve of the vessel. In 
this region he noted an extreme rarefaction of the aortic wall with impending rupture. To 
prevent late complications such as coronary compression, redilatation of the ascending aorta 
due to dislocation of the wrap, secure anchoring of the prosthetic wrap to the aorta is 
mandatory. Furthermore, to avoid alterations of the aortic wall, the prosthetic wrapping has 
to be well fitted to prevent the creation of folds, which may become areas of high 
mechanical stress. 
Limitations of the wrapping technique without aortoplasty, the “sandwich technique”, are 
that the available vascular graft prostheses may be insufficient in diameter to fit a large 
ascending aorta (Ergin et al., 1999; Carrel et al., 1991). The vascular prostheses have a crimped 
fabric, which allows the prostheses to be moderately bent without angulations. When trying 
to fit a straight prosthesis in a curvilinear aorta, the prosthesis develops wrinkles in the aortic 
concavity.  The wrinkles of the prosthesis may be responsible for erosion of the aortic wall 
with a resulting risk of rupture. Thus aortic wrapping could become more dangerous than 
dilatation itself. Tappainer (Tappainer et al., 2007) suggested a new technique for wrapping 
of the ascending aorta in association with aortic valve replacement. Usually, the aortic wrap 
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is constructed before aortic cross-clamping. The vascular dacron prosthesis is cut into two 
halves of 6 cm length. Both halves are opened longitudinally with a curved cut. Thus two 
dacron sheets are obtained from the prosthesis, each of them having one concave and one 
convex side. Finally, the sheets are joined by suturing the two convex sides together and the 
two concave sides together. A curved dacron hose 5 cm in diameter is obtained for external 
wrapping of the ascending aorta (Figure 9). After surgery on the aortic valve, the posterior 
aspect of the ascending aorta is freed completely from the pericardial reflection up to the 
innominate artery. In this way, the custom-built prosthesis is easily inserted for wrapping the 
ascending aorta. After closing the aortotomy and releasing the aortic clamp, the prosthesis is 
pulled down to cover the suture line and fixed with few adventitial stitches. No solid 
transmural stitches are usually needed with this technique because the curved prosthesis fits 
the curved ascending aorta. Similarly, after decannulation, the prosthesis is pulled up to 
cover the cannulation site. With this technique, the whole ascending aorta is covered by the 
prosthesis without wrinkles or bends. 
Thus, reduction aortoplasty seems to be a safe procedure and to give good postoperative 
outcomes. It could be a viable alternative to conventional aortic root replacement or 
interposition tube grafting in some selected patients. The underground wall disorder should 
be an aortic valve stenosis. Patients with cystic medial necrosis, connective disorders and 
ascending aorta dissections are not candidates for reduction aortoplasty; furthermore no 
calcifications or atherosclerotic penetrating ulcers should affect the aortic wall; aneurysms 
with an infective origin are to be excluded from this type of treatment. The dilatation should 
be localized only on the ascending aorta, between the sinotubular junction and not 
extending beyond the innominate artery and the aortic arch. The ascending aorta should be 
moderately dilated with a diameter of up to 5.5 cm. Patients with an ascending aorta larger 
than 5.5 cm could benefit from a reduction aortoplasty if they are older and at high surgical 
risk. As an appropriate condition for reduction aortoplasty, the diameter at the sinus of 
Valsalva should be up to 4.5 cm. The intra-operative reduction of the aorta should be to 3.5 
cm. The external wrapping should be anchored to minimize the risk of dislocation and it 
should be shaped anatomically on the ascending aorta. 
 
 
Fig. 9. Drawing of custom-made prosthesis preparation (1). Custom-made prosthesis before 
insertion (2). 
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is constructed before aortic cross-clamping. The vascular dacron prosthesis is cut into two 
halves of 6 cm length. Both halves are opened longitudinally with a curved cut. Thus two 
dacron sheets are obtained from the prosthesis, each of them having one concave and one 
convex side. Finally, the sheets are joined by suturing the two convex sides together and the 
two concave sides together. A curved dacron hose 5 cm in diameter is obtained for external 
wrapping of the ascending aorta (Figure 9). After surgery on the aortic valve, the posterior 
aspect of the ascending aorta is freed completely from the pericardial reflection up to the 
innominate artery. In this way, the custom-built prosthesis is easily inserted for wrapping the 
ascending aorta. After closing the aortotomy and releasing the aortic clamp, the prosthesis is 
pulled down to cover the suture line and fixed with few adventitial stitches. No solid 
transmural stitches are usually needed with this technique because the curved prosthesis fits 
the curved ascending aorta. Similarly, after decannulation, the prosthesis is pulled up to 
cover the cannulation site. With this technique, the whole ascending aorta is covered by the 
prosthesis without wrinkles or bends. 
Thus, reduction aortoplasty seems to be a safe procedure and to give good postoperative 
outcomes. It could be a viable alternative to conventional aortic root replacement or 
interposition tube grafting in some selected patients. The underground wall disorder should 
be an aortic valve stenosis. Patients with cystic medial necrosis, connective disorders and 
ascending aorta dissections are not candidates for reduction aortoplasty; furthermore no 
calcifications or atherosclerotic penetrating ulcers should affect the aortic wall; aneurysms 
with an infective origin are to be excluded from this type of treatment. The dilatation should 
be localized only on the ascending aorta, between the sinotubular junction and not 
extending beyond the innominate artery and the aortic arch. The ascending aorta should be 
moderately dilated with a diameter of up to 5.5 cm. Patients with an ascending aorta larger 
than 5.5 cm could benefit from a reduction aortoplasty if they are older and at high surgical 
risk. As an appropriate condition for reduction aortoplasty, the diameter at the sinus of 
Valsalva should be up to 4.5 cm. The intra-operative reduction of the aorta should be to 3.5 
cm. The external wrapping should be anchored to minimize the risk of dislocation and it 
should be shaped anatomically on the ascending aorta. 
 
 
Fig. 9. Drawing of custom-made prosthesis preparation (1). Custom-made prosthesis before 
insertion (2). 
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Aortic Valve Sparing Operation 
Júlia Čanádyová and Aleš Mokráček 
Department of Cardiac Surgery, Regional Hospital České Budějovice, 
Czech Republic 
1. Introduction 
A standard approach in the surgical treatment of severe aortic regurgitation and/or aortic 
root dilatation is Bentall procedure, it means replacement of the aortic valve and ascending 
aorta with a composite graft including mechanical or biological valve. The original 
technique described by Bentall and De Bono in 1968 (5). This is a „safe“ method with low 
mortality, but patients have to accept the disadvantages of lifelong anticoagulation and 
comercial valvular prosthesis, such as higher risk of tromboembolic complications, bleeding, 
endocarditis and also rapid degeneration of biological prosthesis (28). 
The alternative technique for the patients with aortic root dilatation and/or ascending aorta 
aneurysm and aortic valve incompetence, causing by outward displacement of the 
commissures is the aortic valve-sparing operation (24). The technique of aortic root 
remodeling first described by Sarsam and Yacoub and technique of aortic valve 
reimplantation first described by David and Feindel in 1993 (33,9). The both techniques 
preserve the native aortic valve and partialy dynamic native aortic valve annulus, which 
may have hemodynamic benefits over a rigid prosthetic valve stent. The major benefits are 
freedom from anticoagulation treatment, relative resistance to infection compared with 
prosthetic valves and maybe better resistance against the premature degenerative changes 
of the bioprosthesis (multifactorial etiology). A major drawback is the increased risk of early 
failure of reconstructed valve cause the valve incompetence and needing the early 
reoperation (24).  
Aortic valve sparing operations were developed to preserve native tricuspid aortic valve 
without gross structural defects and absence of severe cusp prolapse or assymetry (9). In 
recent years, surgeons gaining more and more experience and skills and indications were 
liberally expanded to include older and also younger patients, patients with bicuspid valves, 
aortic valves with cusp prolapse, Marfan patients, patients with acute type A dissection, 
endocarditis and reoperation (1,14,26,19,18). Future and longer follow up will show us the 
best solutions for each of these categories. 
2. Operative technique 
For choosing the right type of valve sparing operation is important to assess the pathology 
of the leaflets, aortic root and asending aorta. Our approach based on the functional 
classification of aortic regurgitation linked to the pathophysiologic mechanism and desribed 
by El Khoury (tab. 1, tab. 2) (6,16).  
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1. Introduction 
A standard approach in the surgical treatment of severe aortic regurgitation and/or aortic 
root dilatation is Bentall procedure, it means replacement of the aortic valve and ascending 
aorta with a composite graft including mechanical or biological valve. The original 
technique described by Bentall and De Bono in 1968 (5). This is a „safe“ method with low 
mortality, but patients have to accept the disadvantages of lifelong anticoagulation and 
comercial valvular prosthesis, such as higher risk of tromboembolic complications, bleeding, 
endocarditis and also rapid degeneration of biological prosthesis (28). 
The alternative technique for the patients with aortic root dilatation and/or ascending aorta 
aneurysm and aortic valve incompetence, causing by outward displacement of the 
commissures is the aortic valve-sparing operation (24). The technique of aortic root 
remodeling first described by Sarsam and Yacoub and technique of aortic valve 
reimplantation first described by David and Feindel in 1993 (33,9). The both techniques 
preserve the native aortic valve and partialy dynamic native aortic valve annulus, which 
may have hemodynamic benefits over a rigid prosthetic valve stent. The major benefits are 
freedom from anticoagulation treatment, relative resistance to infection compared with 
prosthetic valves and maybe better resistance against the premature degenerative changes 
of the bioprosthesis (multifactorial etiology). A major drawback is the increased risk of early 
failure of reconstructed valve cause the valve incompetence and needing the early 
reoperation (24).  
Aortic valve sparing operations were developed to preserve native tricuspid aortic valve 
without gross structural defects and absence of severe cusp prolapse or assymetry (9). In 
recent years, surgeons gaining more and more experience and skills and indications were 
liberally expanded to include older and also younger patients, patients with bicuspid valves, 
aortic valves with cusp prolapse, Marfan patients, patients with acute type A dissection, 
endocarditis and reoperation (1,14,26,19,18). Future and longer follow up will show us the 
best solutions for each of these categories. 
2. Operative technique 
For choosing the right type of valve sparing operation is important to assess the pathology 
of the leaflets, aortic root and asending aorta. Our approach based on the functional 
classification of aortic regurgitation linked to the pathophysiologic mechanism and desribed 
by El Khoury (tab. 1, tab. 2) (6,16).  
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Type I Normal appearing cusps with FAA dilatation 
Ia Ascending aorta dilatation (starting at the sinotubular junction) 
Ib Valsalva sinuses and sinotubular junction dilatation 
Ic Funcional aortic annulus dilatation 
Id Cusp perforation 
Type II Cusp prolapse 
Type III Cusp retraction and thickening 
Table 1. Functional classification of aortic regurgitation. 
Aortic root is functional unit consist with two major components: the leaflets and the 
functional aortic annulus (FAA). It is a classification of the different mechanism of aortic 
insuficiency that allows the surgeons to define and categorize pathological findings and 
























































(secondary) SCA  STJ annuloplasty
SCA SCA 
Table 2. The functional classification of aortic regurgitation linked to the pathophysiologic 
mechanism. (STJ- sinotubular junction; SCA- subcommissural annuloplasty). 
Echocardiographic examination 
Crucial and very important is echocardiography examination. All patients underwent 
preoperative transthoracic (TTE) and transesophageal echocardiography (TEE) and 
intraoperative TEE. Severity of aortic regurgitation was classified according to four grades 
using semiquantitative criteria. Leaflets morphology and motion were described in order to 
determine which leaflet was prolapsing. Also the quality of the cusp tissue (the presents of 
sclerosis or calcification, cusp damage), the level of coaptation, the length of the free margin 
of the leaflets, hight of the cusp and the anatomy of the aortic root were assessed. (Fig. 1, 
Fig. 2., Fig. 3.) 
For long-term durability is important to respect some echocardiographic signs : 
 preoperative the leaflet coaptation is minimally 6 mm above the annulus 
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 the length of free margin is maximal 50% longer than  diameter of the annulus (Fig. 1.) 
 after the operation the coaptation area is completely above inferior edge of prosthesis 










Fig. 2. Annulus, Valsalva sinuses and STJ dilatation. 
 
Aneurysmal Disease of the Thoracic and Abdominal Aorta 
 
102 
Type I Normal appearing cusps with FAA dilatation 
Ia Ascending aorta dilatation (starting at the sinotubular junction) 
Ib Valsalva sinuses and sinotubular junction dilatation 
Ic Funcional aortic annulus dilatation 
Id Cusp perforation 
Type II Cusp prolapse 
Type III Cusp retraction and thickening 
Table 1. Functional classification of aortic regurgitation. 
Aortic root is functional unit consist with two major components: the leaflets and the 
functional aortic annulus (FAA). It is a classification of the different mechanism of aortic 
insuficiency that allows the surgeons to define and categorize pathological findings and 
























































(secondary) SCA  STJ annuloplasty
SCA SCA 
Table 2. The functional classification of aortic regurgitation linked to the pathophysiologic 
mechanism. (STJ- sinotubular junction; SCA- subcommissural annuloplasty). 
Echocardiographic examination 
Crucial and very important is echocardiography examination. All patients underwent 
preoperative transthoracic (TTE) and transesophageal echocardiography (TEE) and 
intraoperative TEE. Severity of aortic regurgitation was classified according to four grades 
using semiquantitative criteria. Leaflets morphology and motion were described in order to 
determine which leaflet was prolapsing. Also the quality of the cusp tissue (the presents of 
sclerosis or calcification, cusp damage), the level of coaptation, the length of the free margin 
of the leaflets, hight of the cusp and the anatomy of the aortic root were assessed. (Fig. 1, 
Fig. 2., Fig. 3.) 
For long-term durability is important to respect some echocardiographic signs : 
 preoperative the leaflet coaptation is minimally 6 mm above the annulus 
 
Aortic Valve Sparing Operation 
 
103 
 the length of free margin is maximal 50% longer than  diameter of the annulus (Fig. 1.) 
 after the operation the coaptation area is completely above inferior edge of prosthesis 










Fig. 2. Annulus, Valsalva sinuses and STJ dilatation. 
 















Fig. 3b. Condition after aortic valve reimplantation. 
2.1.1 Ascending aorta replacement 
Supracommisural ascending aorta replacement with tube dacron prosthesis is indicated in 
patients with isolated dilatation of sinotubular junction (STJ) and ascending aorta, where the 
severe aortic insuficiency is due to changes in root geometry and outward displacement of 
the commissures. Restoration of a normal diameter of STJ is important and obviosly enough 
to correct the aortic incompetence. (Fig. 4.) 
We prefer to use 10% (2 or 3 mm) bigger diameter of prosthesis than native aortic annulus 
measured by echogardiographic examination (in diastola) and by Hegar dilator during the 
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Fig. 4. Ascending aorta replacement. 
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2.1.2 The remodeling technique (Yacoub) 
Remodeling is physiologic reconstruction of the aortic root. This approach preserves the 
anatomy and the function of the Valsalva sinuses. According to our opinion and experience 
of other surgeons, it is not a suitable method for patients with dilated annulus, because of 
lack of annulus support and there is a tendency toward progressive aortic insuficiency. (34) 
Remodeling (sec operation. Yacoub) - aortic bulbus, diseased sinuses, including the ST 
junction and necessary part of the ascending aorta were trimming,  leaving only 4-5 mm of 
the aortic wall at the base of aortic leaflets and annulus. The coronary arteries were prepared 
for a button reimplantation in standard manner. Subsequently, vascular prosthesis was 
prepared - Gelweave Valsalva prosthesis (Vascutec Ltd., UK) by trimming to obtain three 
tongue-shaped extensions (neosinuses) that are then sutured to the aortic annulus at the line 
of the attachment of the cusps. (Fig. 7.) Prosthesis size was derived from the size of annulus 
measured by echogardiographic examination and also we used a Hegar dilator or the size of 
the graft is based on the diameter of sinotubular junction (STJ). The prosthesis was 
subsequently chosen by 10% higher compared to the native annulus or equal to the diameter 
of STJ. The prosthesis was fixed to the rim of the sinuses with three running polypropylene 
4-0 stitches. Stitches were placed up to the base of leaflets – that we consider crucial for long-
term durability. We use of stentless valvular sizer (Toronto SPV) for measurement of extent 
of circumference for each sinus and after that we individualizate the extent of each neosinus 
on vascular prosthesis. (Fig. 5.) Coronary arteries buttons were sewn end to side into the 
prosthesis with polypropylene 6-0 stitches and the prosthesis was anastomosed to the distal 






Fig. 5. The use of stentless valvular sizer (Toronto SPV).  
(Photo is from the author´s archive) 
 




Fig. 6. The measurement of diameter annulus by Hegar dilator.  
(Photo is from the author´s archive) 
 
 
Fig. 7. Remodeling of the aortic root. 
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2.1.3 The reimplantation technique (David) 
Reimplantation (surgery sec. David I) – the surgical procedure followed the steps originally 
described by David and Feindel. (9). 
Detailed description of the techniques (aortotomy and exposure, aortic root preparation, 
prosthesis sizing, proximal suture line, prosthesis preparation and fixation, valve 
reimplantation) mentioned Boodhwani et al. (6).  
Briefly the aorta is transected 1 cm above the sinotubular junction starting above the non-
coronary sinus. Three full-thickness 4-0 polypropylene traction sutures are placed at the level of 
the three commissures. Very important is to externally dissect the aortic root as low as possible, 
started along the non-coronary sinus and continued towards the left and right commissures and 
leaflet with respect the external anatomical limitations (insertion of the root into the ventricular 
muscle). The diseased sinuses of Valsalva are then resected leaving approximately 3-5 mm of 
the aortic wall attached. Then the coronary buttons are prepared. (Fig. 9.) 
We prefer the Valsalva prosthesis with neo-sinuses (13), which was prepared by „scaloping“ 
in areas of commissures to the depth 1 cm according to valve anatomy.  
The diameter of the graft was about 50% smaller than the average length of the free margins 
of the aortic cusps. If there is some discrepancy, we could repare a leaflets too. 
Then the coronary arteries buttons and aortic valve were prepared in the same manner as in 
remodeling.  
Proximal anastomosis is bilayer. The first layer of multiple horizontal mattress sutures of 2-0 
polyester are passed from the inside to the outside of the left ventricle outflow tract 
circumferentially below the nadir of aortic annulus and following the scalloped shape of the 
aortic annulus along the muscular interventricular septum. The second layer of the stitches 
attached the remaining sinuses into the graft using three 4-0 polypropylene sutures. 
Important is to achieve correct cusp geometry and sufficient height of commissural 
resuspension within the prosthesis at the level of the new sinutubular junction. (Fig. 8., Fig. 
9., Fig. 10.) Than the coronary arteries were implanted and the distal anastomosis between 
the graft and the native ascending aorta was performed using running 4-0 Prolen suture. 
(Fig. 11., Fig. 12., Fig. 13., Fig. 14.) 
 
 
Fig. 8. Reimplantation of the aortic valve. 
 




Fig. 9. A-root dilatation, B-resection of diseased Valsalva sinuses with preparing coronary 
artery buttons. C, D-reimplantation of the aortic valve into the prosthesis, E, F- distal 
anastomosis between the graft and the native ascending aorta. 
 
 
Fig. 10. Reimplantation of the valve into the prosthesis. (Photo is from the author´s archive) 
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Fig. 10. Reimplantation of the valve into the prosthesis. (Photo is from the author´s archive) 
 








Fig. 11. Hole preparation by electrocautery for coronary artery button reimplantation.  






Fig. 12. The implantation of the coronary artery button end to side into the prosthesis.  
(Photo is from the author´s archive) 
 





Fig. 13. Venous graft sewn  into the prosthesis.  
(Photo is from the author´s archive) 
 
 
Fig. 14. The distal anastomosis between the graft and the native ascending aorta.  
(Photo is from the author´s archive) 
2.1.4 Replacement of the non-coronary aortic sinus (Wheat) 
Indicated in patients with isolated non-coronary aortic sinus dilatation (exceptionally two 
sinuses). In our practise is the non-coronary sinus the most diseased sinus in case of 
nondegenerative diseases (atherosclerosis). The diseased non-coronary sinus and ascending 
aorta were replaced by a scalloped shape dacron tubular graft. (Fig. 15.) 
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Fig. 14. The distal anastomosis between the graft and the native ascending aorta.  
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Fig. 15. Replacement of the noncoronary aortic sinus. 
2.1.5 Cusp repair technique 
Cusp perforation 
When the leaflet defect is too large for direct closure with a running locked suture of 6-0 
polypropylene, an autologous pericardial patch is used. The patch size is larger than the 
defect area to avoid any restriction of the repaired leaflet (26,15,27,10). (Fig. 16.) 
 
 
Fig. 16. Patch repair. 
 




Caused by dilatation of the sinutubular junction (STJ) and increased mechanical stress on 
the free margin of the cusp. Most often located in the commissural areas and may be repared 
with a double layer of 6-0 PTFE suture along the free margins or by pericardial patch (11). 





















Fig. 17. Pericardial patch repair of the defect located in the commisural area.  
(Photo is from the author´s archive) 
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Fig. 17. Pericardial patch repair of the defect located in the commisural area.  
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Fig. 18. Free margin reinforcement. 
Leaflet prolapse 
Is frequent cause of aortic insuficiency. The etiology is multiple-is frequent in bicuspid aortic 
valve, in patients with connective tissues diseases (Marfan syndrome), in chronic aortic root 
aneurysm. Acute leaflet prolapse can occur in patients with acute type A dissection, trauma. 
El Khoury et al. detaily desribed 4 different techniques of leaflet prolapse repair. (15,16,27). 
 Central leaflet plication with 6-0 polypropylene suture 
 Triangular resection 
This two techniques are indicated when the leaflets are thin and flexible. 
 Free margin resuspension with running suture of Gore-Tex 7-0 (Fig. 18.) 
 Autologous pericardial patch repair 
This techniques are prefered in case of poor quality of leaflets with thickening. 
Kerchove et. al had a very good results with 146 patients with cusp prolapse corrected with 
this technique. During the initial hospitalization only two patients required reoperation for 
reccurent aortic insuficiency (AI). At 4 years freedom from reoperation and from reccurent 
AI (grade >2) was 94 ± 5% and 91 ± 7% respectively. (26) 
3. Discussion 
For long term durability and good results of the operation is essential to achieve a coaptation 
cusp area type A. Harringer et al. confirmed a direct correlation between early development 
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and progression of aortic regurgitation and the type of coaptation area after the 
reconstruction of the valve on transthoracic echocardiography – tab. 3. (21).  The authors 
confirmed the association between type B and C coaptation area and faster progression of 
aortic regurgitation compared with patients who had the type A of coaptation area. (p<0,05, 
C versus A in early postoperative period, p<0,001, C versus A and B after 1 year). Fig. 19. (21) 
 
Type A  Coaptation area completely above inferior edge of prosthesis 
Type B  Coaptation area at inferior edge of prosthesis 
Type C  Coaptation area >= 2 mm below lower edge of prosthesis 
Table 3. Type of coaptation area (Hannover classification). 
 
 
Fig. 19. Significance of aortic insuficiency. 
If we decided to perform a reconstructive surgery of the aortic valve we have to answer 3 
basic questions. Which type of surgery we perform, which type and size of prosthesis we 
use. 
In the case of a limited expansion and dilatation of sinuses and ascending aorta the 
remodeling technique described by Yacoub is chosen. This technique seems more 
physiological. Restoration of the aortic sinuses provide a proper opening and closing 
velocities of the valve leaflets, with reducing their mechanical stress. (13). On the other hand 
remodeling is associated with higher risk of early reccurence of aortic regurgitation. The 
reason is lack of annular support. 
If the dilatation affects the sinuses, including the annulus, we prefer reimplantation 
technique described by David, which provide more effective stabilization and external 
support of the annulus and better long term durability. 
If one or maximum two sinuses are affected our decision is a created a neo-sinus by tailoring 
the graft with a tongue of tissue that is sutured directly to the aortic annulus replacement 
this part of aortic root with prosthesis. 
Furthermore, we must decide what type of prosthesis we use-Dacron tube graft or 
prosthesis with neo sinuses. Aybek et al. showed that the tubular graft should have a greater 
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reason is lack of annular support. 
If the dilatation affects the sinuses, including the annulus, we prefer reimplantation 
technique described by David, which provide more effective stabilization and external 
support of the annulus and better long term durability. 
If one or maximum two sinuses are affected our decision is a created a neo-sinus by tailoring 
the graft with a tongue of tissue that is sutured directly to the aortic annulus replacement 
this part of aortic root with prosthesis. 
Furthermore, we must decide what type of prosthesis we use-Dacron tube graft or 
prosthesis with neo sinuses. Aybek et al. showed that the tubular graft should have a greater 
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rate of opening and closing of the valve and shorter times compared with native root and 
reimplantation into the prosthesis with neo sinuses. Similarly the distance between the 
cusps and graft wall during the systole was smallest. (9). 
Also Leyh et al. (28) observed that near normal opening and closing characteristics can be 
achieved by a technique that preserves the shape and independent mobility of the sinuses of 
Valsalva. There is a theoretical assumption that neo sinuses (created by any method) will 
extend the durability of valve. But clinical differences in the intermediate term follow-up 
were clearly demonstrated. 
De Paulis et al. introducing modified Dacron conduit (Gelweave Valsalva, Sulzer Vascutek, 
Renfrewshire, Scotland) that on implantation recreates sinuses of Valsalva of normal shape 
and dimension, providing a sufficient gap that should avoid any contact between the open 
leaflet and the Dacron wall. (34,13). 
On the other hand, very good results with reimplantation technique into the Dacron tube 
graft achieve colleques in Hannover (24). In the 11 year interval a total of 284 patients 
operated on with an average follow up was 44 months (0-130 months). The number of 
reoperations for recurrent significant aortic regurgitation was only 11 patients. Only Marfan 
syndrome be considered as a risk factor for reoperation. 
We also prefer the Vascutek Valsalva prosthesis which we prepare by parcial or complete 
scalloping. 
For the good result of the operation is also important the size of prosthesis. Most authors 
derived it from the diameter of the annulus and length of the free margin of the leaflets in a 
relationship and in relation to type of valve preserving technique (remodeling or 
reimplantation). An interesting insight provides Maselli et al. (29), which is based on the 
consideration that in the case of native valve even when fully valve open in a systole 
remains space several millimeters between the leaflets and the wall of the aorta. Results of 
their simulations suggest that the ideal graft oversizing in respect the final aortic annulus 
diameter is +7 mm for a standard graft and +3 mm for the Valsalva grafts. It is very simply 
solution, available in every situation. We prefer to derive the size of prosthesis measured 
preoperatively by echocardiographic examination and perioperatively by Hegar dilator. 
Prosthesis is chosen by 10% greater for remodeling. For reimplantation technique in patients 
with severe dilatation of the annulus the free-edge length of the leaflet was measured in the 
short-axis view by tracing the leaflet outline.  The parameters were determined in the closed 
valve and in the open valve. The size of the prosthesis was chosen by 50% less. 
From 2002 to 2009, 37 patients underwent aortic valve sparing operations in our 
department. Mean age was 58 ± 9 (range 21 to 77) years. Of the 37 patients, 24 were male 
(64.8%) and 13 female (35.2%). 
The average degree of aortic regurgitation was 2.9 ± 0.5, ejection fraction of the left ventricle 
was 56% ± 9. The average size of aortic annulus was 26,4 ± 2,6 mm, aortic root 50,6 ± 7,4 mm, 
sinotubular junction was 43,7 ± 5,1 mm and the ascending aorta 51,2 ± 6,8 mm. 32 (86,5%) 
patients underwent the reimplantation of the aortic valve according to the technique 
described by David, 2 (5,4%) patients underwent the remodeling procedure and 3 (8,1%) 
patients had a replacement of the noncoronary sinus descibed by Wheat.  
Chronic ascending aortic aneurysm was present in 23 patients (62.2%), acute aortic 
dissection type A in 13 patients (35.1%) and chronic type A dissection in 1 patient (2.7%). 4 
patients (10.8%) had Marfan syndrome and bicuspid aortic valve was present in 2 patients 
(5.4%).  
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Reoperation of the reconstructed vlave was required in 4 patients. One patient (with chronic 
aneurysm of the ascending aorta) has coaptation area type B in perioperative TEE and 
anatomical effects of the operation was not therefore prognostically optimal. In another 
patient, with Marfan syndrome, operated on for acute dissection, there was an abrupt aortic 
regurgitation 2 years after primary surgery because tearing one of the commissure. Second 
patient with Marfan syndrome and chronic ascending aorta aneurysm was reoperated after 
4 years. The last patient with chronic aneurysm, and copatation area type A was reoperated 
after 3 years. It is considered that this type of procedures in carefully selected patients is safe 
and the mild-term follow-up is satisfactory.  
3.1 Specific acces in the management of selected group of patients  
3.1.1 Marfan syndrom 
Composite replacement of the aortic valve and ascending aorta (Bentall procedure) is a 
standard approach in patients with Marfan syndrome associated with excellent long term 
outcomes. The major disadvantage are complications related to long-term anticoagulation 
treatment in young individuals. This is the main reason for increasing interest for preserve 
the native aortic valve. 
Karck and associates (25) compare the results of aortic valve sparing reimplantation (45 
patients) and aortic root replacement with mechanical valve conduits (74 patients) in 
patients with Marfan syndrome. The results during the mean follow up of 30 months (range 
1-94 months) for patients undergoing aortic valve reimplantation and mean follow up 114 
months for patients undergoing composite grafting were comparable. Freedom from 
reoperation and death after 5 years postoperatively was 84% and 96% in patients after vlave 
reimplantation and 92% and 89% in patients after Bentall procedure. 
De Oliveira et al. (30) examine the long-term results of surgery for aortic root aneurysm in 
patients with Marfan syndrome. 44 patients underwent aortic root replacement and 61 
patients underwent aortic valve sparing operations (remodeling/reimplantation). Freedoms 
from reoperation on aortic valve in patients with Marfan syndrome after aortic valve 
sparing operations was 100% et 5 and 10 years and in patients after aortic valve replacement 
92±5% and 75±9%  at 5 and 10 years. 
Kallenbach from Hannover, Germany (23), did not observe any difference in short-term 
outcomes in patients with Marfan syndrome between the reimplantation technique and 
replacement with composite conduit. 
A great supporter of the operation by the Bentall is Hagl from New York (20). He evaluates 
the results of 142 patients younger than 65 years (32% younger than 40 years, 58% between 
40-60 years and 10% 60-65 years old) operated on by Bentall technique. Event-free interval 
was observed in a set of 0.85/5 years and 0.78/8 years. The gold standard in this age group 
the authors consider surgery by Bentall and prefer it before valve sparing operations. 
3.1.2 Bicuspid aortic valve  
A particular problem is the valve sparing operations for bicuspid aortic valve associated 
with aortic regurgitation, particularly in young patients.  
Alsoufi and coworkers (2) presents the results of 71 patients with bicuspid valves and aortic 
regurgitation who were treated by remodeling, reimplantation or isolated aortic leaflets 
repair. Risk of reccurence of aortic regurgitation was greater in isolated leaflets repair as 
compared to remodeling/reimplantation. However, the risk of aortic regurgitation and the 
risk of reoperation and aortic valve replacement (in case of bicuspid aortic valve) is higher 
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than the remodeling/reimplantation of the tricuspid valve in the same workplace. The risk 
of bleeding or thromboembolic complications are minimal, but the risk of significant aortic 
regurgitation (3+/4) is 56% 8 years.  
The largest published series on aortic valve repair for aortic insufficiency due to prolapse of 
bicuspid aortic valve came from Cleveland Clinic. Casselman and colleagues reported on 94 
patients with a mean age of 38 years. The freedom from reoperation was 84% at 7 years. (7). 
The only risk factor predictive of reoperation was residual aortic insufficiency at the time of 
repair.  
Aicher and associates (3) reported a 5year freedom from recurrent aortic insufficiency of 
96%, and a freedom from reoperation of 98% after the remodeling procedure in patients 
with incompetent bicuspid aortic valve and dilated aortic root. 
Our insitutional approach in patients with bicuspid valves is  very cautious. From our own 
experience we know that they are technically feasible very often. It is even possible to say 
that the correction of prolapse in bicuspid valve is simpler than the tricuspid valve. The 
problem we see in long term durability.  
Robicsek et al. (32) showed that in bicuspid valve is never possible to achieve physiological 
flow and is always greater stress on the cusps in comparison with symmetrical tricuspid 
aortic valves. Therefore, very often we prefer a valve replacement. But this is a controversial 
topic with many opinions both for and against.  
3.1.3 Aortic dissection type A 
Acute dissection of the ascending aorta (Stanford classification type A) requires emergent 
surgical intervention to prevent life-threatening complications. The valve sparing techniques 
are innovative approach for patients in whom the aortic leaflets and annulus does not 
involved. Minor extension of the dissection into the aortic root with near normal size of the 
sinuses led to conventional valve sparing techniques using Teflon felts and glue. Severe 
extension of dissection including fragile tissue or aneurysmatic dilatation of more than 4,5 to 
5 cm diameter of the dissected root favour valve sparing root replacement by the 
remodeling or reimplantation techniques. (17,18,19,8,31). Advantages of preservation of the 
native aortic valve are avoidance of a life-long anticoagulation treatment in mechanical 
valve replacement and facilitating the thrombotic obliteration of the false lumen. Persistent 
patency of the false lumen leads to the aneurysm formation, which has been associated with 
reduced late survival. 
Erasmi et al. (19) reviewed 36 patients with acute aortic dissection type A who underwent 
aortic valve sparing operations. Only 3 patients required reoperation during the mean follow 
up 7,3 years (after remodeling technique) upon for redetachement of one commissure. All 3 
reoperations have been associated with the use of GRF glue (at reoperation they found the 
necrotic and fragile tissues, which led to anastomotic dehiscences). 
Also Casselman et al. (8) revealed the use of fibrinous glue and presence of an aortic valve 
annulus more than 27 mm as independent risk factors for aortic root reoperation. 
Kallenbach et al. presents (24) excellent results in 53 patients with acute aortic dissection 
type A and valve sparing operations, only 2 patients required reoperation of the 
reconstructed aortic vlave, both because endocarditis. 
Preliminary results of valve sparing techniques for type A dissection in a small series were 
encouraging with low hospital mortality, and aoutcome is comparable to patients treated 
with a Bentall procedure. But follow up is short and we have to wait for long term results. 
 




Aortic valve sparing operations extend the spectrum of treatment options for aortic 
regurgitation. They provide excellent results and are associated with very low rates of valve-
related complications. However, as they are technically demanding operations, only 
surgeons with extensive experience in aortic surgery should perform them.  
The reimplantation technique with the Gelweave Valsalva prosthesis is our procedure of 
choice for patients with aortic root aneurysm, including the annulus dilatation with absence 
or minimal damages of aortic leaflets. 
Long-term follow up of more number of patients are needed to confirm the eligibility of 
using this method in our daily practise. 
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exist, evidence from both prospective and retrospective reviews demonstrate the feasibility 
and potential benefit of rEVAR. There is mounting evidence showing EVAR to be a safer, 
less invasive alternative to open surgery with the potential to significantly reduce in-
hospital mortality and morbidity in EVAR suitable candidates despite the inherent biases 
that accompany the comparison. 
2. A Standardized approach to endovascular repair of ruptured abdominal 
aortic aneurysms 
To successfully treat patients with ruptured AAA using endovascular means, the practicing 
institution must have resources to support a multidisciplinary team approach to managing 
patients with ruptured AAA. Strict protocols from the emergency room to discharge 
planning need to be put in place to streamline patient throughput. A comprehensive 
protocol should address the following issues – appropriate triage and expedient imaging in 
the emergency department; equipment needs and necessities of the operating suite; a 
systematic approach to post-operative care and the management of the most common post-
operative complications; a method for ensuring that the protocol includes the most up-to-
date evidence-based measures; and finally, a delineation of required ancillary resources. 
Figure 1 below illustrates a proposed protocol for the management of patients with a 
suspected ruptured AAA.  
A well organized team of vascular specialists should be able to address any ruptured AAA 
that is admitted to the hospital at any time of day or night. In order to accomplish this goal, 
the team must be multidisciplinary, familiar with working with each other in the context of 
AAAs, and have enough trained members to include 24 hour per day, 365 days per year 
coverage. While not an exhaustive list, the specialties required of the vascular team are 
vascular surgeons, vascular anesthesiologists familiar with both open and endovascular 
ruptured AAAs, vascular scrub nurses or technicians who have experience in both open 
operations and endovascular interventions, critical care nurses, surgical intensivists who are 
familiar with endovascular interventions, radiology technicians well versed in rapid CT 
protocols for delineating AAA anatomy, emergency medicine physicians familiar with 
ruptured AAA pre-operative requirements, a liaison in the blood bank familiar with 
massive resuscitation (should the case need to convert to open), and bed control managers 
with authority to free up appropriate ICU resources. 
Ideally there should be an up-to-date inventory management system so that missing or 
damaged equipment are known of with enough lead time to permit transfer of the patient to 
a hospital with appropriate and working resources. As with the often acknowledged “door-
to-balloon” time with myocardial infarction, hospitals must seek to minimize the time from 
diagnosis to aortic control. This includes a standardized approach to activating a dedicated 
team, including experienced surgeons facile with both endovascular and open techniques, 
anesthesiologists, nursing staff, and radiology technicians. These individuals must be 
experienced in performing both EVAR and open aortic repair. In a recent international, 
collective report of rEVAR performed by 49 centers worldwide, it was noted that staff 
availability and skills were a major determinant of whether a rupture AAA patient would be 
treated by EVAR or open repair (Veith et al., 2009). Additionally, it is advisable to have a 
method for the emergency room physician to put the team on notice, at the time a ruptured 
AAA is first suspected.  
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Fig. 1. Proposed protocol for rEVAR. 
2.1 In the emergency room - Diagnosis and triage  
When a ruptured AAA is suspected in the emergency room, the “aneurysm reflex” must be 
avoided where, historically, patients are aggressively resuscitated and then taken urgently 
to the operating room. There is evidence to suggest that a more controlled, thoughtful but 
expeditious approach is feasible and likely beneficial. For one, allowing “permissive 
hypotension” by limiting the resuscitation to maintain a detectable blood pressure (SBP 
>80mmHg) and maintaining mental status can help minimize ongoing hemorrhage and 
allow for expeditious imaging via computed tomography (CT).  
The need for preoperative CT imaging prior to EVAR for ruptured AAA continues to be 
debated. Most centers consider such screening to be mandatory both for purposes of 
confirming the diagnosis as well as for morphological assessment. A few centers have 
developed protocols that provide for intraoperative assessment without CT delay using 
angiography or intravascular ultrasound. Realistically, time is usually available to send 
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patients for CT evaluation without undue risk. Current data suggests that the majority of 
patients with ruptured AAA have time to undergo a CT scan. The majority of patients who 
are admitted to the hospital with ruptured AAA survive for a number of hours. In 2004 
Lloyd et al., examined the time to death in patients with ruptured AAA who did not 
undergo treatment. Their findings indicated that 88% (49 of 56) of patients died >2 hours 
after admission with diagnosis of ruptured AAA. The median time from the onset of 
symptoms to admission to the hospital was 2.5 hours, and the interval between hospital 
admission and death was 10 hours.  
2.1.1 Diagnosis and determination of anatomic suitability 
Although the diagnosis of rupture AAA is generally made by CT, it is important to consider 
that a history along with abdominal palpation has a sensitivity of between 90-97% for 
patients who eventually have an operation. Once the diagnosis is suspected and the vascular 
team activated, the next step is to triage hemodynamically unstable patients (SBP < 
80mmHg) to the operating room, and hemodynamically stable (SBP > 80mmHg) patients to 
the CT scanner. Given the potential for rapid and significant deterioration, it is paramount 
for ruptured AAA patients to have priority for the CT scanner. CT is vital in confirming the 
diagnosis and properly delineating the aortoiliac anatomy for EVAR suitability. At most 
centers, 2 hours is ample time to obtain a CT scan to assess suitability for EVAR. In the case 
of patients who present with true hemodynamic instability, the decision must be made to 
either attempt to assess the morphology, and hence the candidacy for EVAR, without axial 
imaging using modalities available in the procedural suite or to commit to open 
reconstruction.  
Investigators have begun to evaluate the use of fixed C-arm imaging systems and advanced 
rendering softwares in the hybrid operating room to generate three-dimensional roadmaps 
and perform computed tomographic (CT) imaging. Eide et al used the Siemens DynaCT to 
generate a CT immediately following EVAR and compared those images to a standard CT 
angiogram performed on a standard 16 slice multidetector CT (MDCT) scanner. The authors 
noted no statistical differences between the intra-operative C-arm generated completion 
DynaCT and the postoperative MDCT. When evaluating the preoperative anatomic 
assessment capability in EVARs however, Nordon et al found that DynaCT provided 
inferior visualization of mural thrombus and calcification and underestimates vessel size. 
Further studies assessing CT capability of fixed C-arms in the operating room are currently 
underway; and as imaging technology and software continue to evolve, it will not be long 
before accurate three-demensional roadmaps can be rendered "on-table" to expedite 
assessment of anatomic suitability for EVAR.  
Anatomic suitability has been reported in between 60% to 80% of patients presenting with a 
rupture AAA (Mehta, 2009). The range is accounted depending on strict versus liberal 
adherence to the generally acknowledged criteria – aortic neck length greater than or equal 
to 15 mm, infrarenal neck diameter less than or equal to 32 mm, aortic neck angulation less 
than 60 degrees, and need for both iliac arteries to be greater than 5 mm in diameter to 
achieve an optimal infrarenal fixation (Chaikof et al., 2009). Advancements in endograft 
technology continue to push the indications for use (IFU) and determination of anatomic 
suitability is generally dependent upon the judgment and comfort of the vascular surgeon. 
Accepting normally unsuitable anatomy has led a number of investigators to develop the 
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concept of endovascular damage control, which accepts a suboptimal radiographic result in 
exchange for temporizing the emergency. In short, some patients will still require 
laparotomy for failed EVAR or for the treatment of abdominal compartment syndrome. The 
damage control approach can only be adopted provided patients consent to undergo 
vigilant late follow-up examination and understand the potential need for “preventative 
maintenance”.  
2.1.2 Triage 
In the hemodynamically unstable patient taken directly to the operating suite, each 
respective institution should determine whether or not to proceed directly to an open 
operation, or alternatively attempt to determine anatomic suitability fluoroscopically or via 
intravascular ultrasound. The determination of whether a patient is hemodynamically 
unstable should not be made on an ad hoc basis, but should be explicit within the protocol 
beforehand. The determination of instability is based upon the level of physiologic 
compromise that the surgeons, anesthesiologists, emergency medicine physicians, and 
intensivists are comfortable and experienced with handling. In the recent 2009 survey by 
Veith et al., centers providing rEVAR reported a wide range of hemodynamic criteria for 
when a patient was too unstable to be offered EVAR:  
1. All comers, regardless of hemodynamics, receive attempt at EVAR 
2. Systolic blood pressure (SBP) <90 mm Hg 
3. SBP <80 mm Hg 
4. SBP <70 mm Hg 
5. Similar SBP lower limits as above but with requirement that the level is sustained 
6. SBP <50 mm Hg 
7. Any SBP measurement <90 mm Hg and/or who had contained ruptures 
While not stated in the Veith et al. survey, it has previously been reported that cardiac arrest 
is an automatic indication to proceed directly to open repair (Alsac et al., 2005).  
2.1.3 Resuscitation 
Clear endpoints of resuscitation should be determined when designing a standardized 
approach to rEVAR. Currently, limited resuscitation also called hypotensive or damage 
control resuscitation (DCR) has fallen back into vogue. The concept was first documented 
during World War I when poor outcomes were reported in battlefield patients with 
intravenous fluid administration (Cannon, 1818). With the recent conflicts in Iraq and 
Afghanistan, DCR has been extensively studied by both military and civilian trauma 
surgeons. In one study of civilian trauma patients it was found that limited resuscitation 
with a goal of maintaining systolic BP at 90 mmHg, use of isotonic intravenous fluids were 
limited and fresh frozen plasma (FFP) and packed red blood cells (PRBC) were transfused in 
a 1:1 ratio. This retrospective study found a nearly 20% decrease in 30 day mortality as well 
as a 50% decrease in ICU length of stay and overall hospital length of stay utilizing DCR.  
Considering the age demographic of most patients presenting with rupture AAA, a study of 
more than 3,000 trauma patients at the Cedars-Sinai Medical Center concluded that 
“judicious fluid resuscitation is especially important in the elderly [age >70 years]” because 
the use of crystalloid volumes greater than 3 liters is associated with an 8.6 fold decrease in 
survival (Ley et al., 2011). Although no studies directly address the issue of survival and 
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limited resuscitation in rupture AAA, one Dutch feasibility study found that hypotensive 
resuscitation with a goal SBP of 50-100 mm Hg was achievable in the majority (54%) of cases 
(van der Vliet et al., 2007). 
2.1.4 Additional preoperative considerations 
The goal of standardizing a preoperative management scheme for patients with ruptured 
AAA should be to make the diagnosis and get the patient safely to the operating room in 20-
30 minutes. Some considerations to allow for expediency are (1) if at all possible, avoid 
central lines, namely femoral lines, and arterial lines (2) EKG, Chest X-rays, and Ultrasound 
should be avoided unless the diagnosis is in question (3) an agreed upon goals for 
permissive hypotension or limited resuscitation, (4) the ability to start advanced-level real 
time hemodynamic monitoring to minimize delays once the patient arrives at the operating 
suite. 
2.2 In the operating room - Equipment and technical considerations 
It is the authors' belief that a hybrid operating suite, which incorporates both the ability to 
do advanced endovascular interventions as well as traditional open operations, is essential 
to successfully treating ruptured AAAs. Furthermore, logistics require that the operative 
suite be stocked with wide range of graft sizes and types, balloons, sheaths, wires, and 
catheters. While the imaging quality of the cardiac catheterization lab is equal to that of a 
hybrid operating room, the primary advantage of hybrid operating rooms is that they 
permit the surgeon to emergently convert to an open procedure without the need to bring in 
additional equipment. Routine utilization of hybrid operating rooms should provide for a 
more liberal policy “EVAR first”, while maintaining the option to institute an open repair 
should circumstances require. 
2.2.1 Inventory 
Concerning inventory management, there are two important considerations. First, there 
should be stocks of sheaths, wires, and catheters to fit various sizes of patients. There should 
also be a variety of sizes of aortic occlusion balloons, a power-injector, redundant back-ups 
for fluoroscopic equipment. A stock of endografts to match the largest aortic neck diameter 
and the shortest aneurysm length with a variety of iliac extensions for most AAA anatomic 
variations as well as a stock of Palmaz stents should be readily available. The second, and 
perhaps more important consideration, is that the inventory and functional status of all 
required equipment is must be known at all times. Because ruptured AAA are 
unpredictable, it must be known as soon as possible whether vital equipment (e.g. the 
power injector) is in disrepair so that the patient may be transferred to a hospital with the 
ability to carry out the intervention. 
2.2.2 Anesthesia and aortic control 
In rEVAR, aortic control can be performed under local anesthesia via percutaneous 
approach in experienced hands or general anesthesia and femoral artery cut-down. Use of 
local anesthesia helps to avoid the hemodynamic changes associated with muscle relaxation 
and general anesthesia. The significant inflammatory response related to cytokine release 
may be blunted with EVAR. Large doses of heparin can be avoided as well. While less 
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invasive, the percutaneous approach suffers several physiologic, mechanical, and logistic 
limitations. Physiologically, it may be difficult to quickly and accurately palpate a femoral 
pulse in a patient who is hemodynamically unstable or undergoing permissive hypotension. 
This maybe obviated by the use of ultrasound guided access. From a device standpoint, the 
most common stents require at least an 18F sheath and may pose problems depending on 
patient anatomy. Logistically, cut-downs are almost invariably faster. As such, it is the 
recommendation of the authors to forego attempts at totally percutaneous access in any 
patient who is not hemodynamically stable, awake, and unable to cooperate with the 
operating room personnel. 
2.2.3 Aortic occlusion balloons  
After gaining access, an aortic occlusion balloon (AOB) is advanced via a 12-14Fr (45 cm) 
sheath placed into the juxtarenal aorta and advanced to the level of the supraceliac aorta. 
The aortic occlusion balloon is inflated as needed to maintain hemodynamic stability. A 
liberal usage policy with regard to AOB is recommended because of the difficulty associated 
with insertion at later points in the intervention. In one case series, the use of AOB was 
reported at 27% (Riesenman et al., 2008). It is important to remember to deflate the balloon 
just prior to stent deployment to prevent entrapment of the balloon between the graft and 
the aorta. This short period without aortic occlusion is usually insignificant to the patient’s 
hemodynamics (Mehta et al., 2010).  
2.2.4 Adjunctive procedures 
The operating surgeon must be able to handle the need for unexpected adjunctive 
procedures as in the emergent setting, preoperative planning can be less than ideal. One 
such procedure that should be in the surgeon's armamentarium is knowledge and comfort 
in utilizing Palmaz stents to repair type I endoleaks (one of the most common operative 
complications of rEVAR). Further the surgeon should be comfortable with hybrid cases. For 
instance, if the decision is made to use an aortouni-iliac (AUI) graft or to convert a 
bifurcated stent graft to an AUI (as has been reported in 16% of patients), the surgeon 
should be comfortable performing both the primary EVAR and the femorofemoral bypass 
(Mehta et al., 2010). 
3. Post-operative care considerations 
The immediate post-operative considerations include the ability to monitor patients for the 
most common complications e.g. abdominal compartment syndrome. This necessitates a 
protocol re-activation of the operative team in the event of an emergent requirement to take 
the patient back to the OR. 
3.1 Abdominal compartment syndrome 
Abdominal compartment syndrome (ACS) is a significant complication resulting from a 
ruptured AAA. The pathophysiology is multifactorial resulting from existing 
retroperitoneal hematoma, ongoing, coagulopathic bleeding from aortic collaterals (lumbar 
and inferior mesenteric arteries from the disrupted aneurysm sac), and profound shock 
associated with ruptured AAA, which induce a systemic inflammatory response (SIRS) with 
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limited resuscitation in rupture AAA, one Dutch feasibility study found that hypotensive 
resuscitation with a goal SBP of 50-100 mm Hg was achievable in the majority (54%) of cases 
(van der Vliet et al., 2007). 
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30 minutes. Some considerations to allow for expediency are (1) if at all possible, avoid 
central lines, namely femoral lines, and arterial lines (2) EKG, Chest X-rays, and Ultrasound 
should be avoided unless the diagnosis is in question (3) an agreed upon goals for 
permissive hypotension or limited resuscitation, (4) the ability to start advanced-level real 
time hemodynamic monitoring to minimize delays once the patient arrives at the operating 
suite. 
2.2 In the operating room - Equipment and technical considerations 
It is the authors' belief that a hybrid operating suite, which incorporates both the ability to 
do advanced endovascular interventions as well as traditional open operations, is essential 
to successfully treating ruptured AAAs. Furthermore, logistics require that the operative 
suite be stocked with wide range of graft sizes and types, balloons, sheaths, wires, and 
catheters. While the imaging quality of the cardiac catheterization lab is equal to that of a 
hybrid operating room, the primary advantage of hybrid operating rooms is that they 
permit the surgeon to emergently convert to an open procedure without the need to bring in 
additional equipment. Routine utilization of hybrid operating rooms should provide for a 
more liberal policy “EVAR first”, while maintaining the option to institute an open repair 
should circumstances require. 
2.2.1 Inventory 
Concerning inventory management, there are two important considerations. First, there 
should be stocks of sheaths, wires, and catheters to fit various sizes of patients. There should 
also be a variety of sizes of aortic occlusion balloons, a power-injector, redundant back-ups 
for fluoroscopic equipment. A stock of endografts to match the largest aortic neck diameter 
and the shortest aneurysm length with a variety of iliac extensions for most AAA anatomic 
variations as well as a stock of Palmaz stents should be readily available. The second, and 
perhaps more important consideration, is that the inventory and functional status of all 
required equipment is must be known at all times. Because ruptured AAA are 
unpredictable, it must be known as soon as possible whether vital equipment (e.g. the 
power injector) is in disrepair so that the patient may be transferred to a hospital with the 
ability to carry out the intervention. 
2.2.2 Anesthesia and aortic control 
In rEVAR, aortic control can be performed under local anesthesia via percutaneous 
approach in experienced hands or general anesthesia and femoral artery cut-down. Use of 
local anesthesia helps to avoid the hemodynamic changes associated with muscle relaxation 
and general anesthesia. The significant inflammatory response related to cytokine release 
may be blunted with EVAR. Large doses of heparin can be avoided as well. While less 
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invasive, the percutaneous approach suffers several physiologic, mechanical, and logistic 
limitations. Physiologically, it may be difficult to quickly and accurately palpate a femoral 
pulse in a patient who is hemodynamically unstable or undergoing permissive hypotension. 
This maybe obviated by the use of ultrasound guided access. From a device standpoint, the 
most common stents require at least an 18F sheath and may pose problems depending on 
patient anatomy. Logistically, cut-downs are almost invariably faster. As such, it is the 
recommendation of the authors to forego attempts at totally percutaneous access in any 
patient who is not hemodynamically stable, awake, and unable to cooperate with the 
operating room personnel. 
2.2.3 Aortic occlusion balloons  
After gaining access, an aortic occlusion balloon (AOB) is advanced via a 12-14Fr (45 cm) 
sheath placed into the juxtarenal aorta and advanced to the level of the supraceliac aorta. 
The aortic occlusion balloon is inflated as needed to maintain hemodynamic stability. A 
liberal usage policy with regard to AOB is recommended because of the difficulty associated 
with insertion at later points in the intervention. In one case series, the use of AOB was 
reported at 27% (Riesenman et al., 2008). It is important to remember to deflate the balloon 
just prior to stent deployment to prevent entrapment of the balloon between the graft and 
the aorta. This short period without aortic occlusion is usually insignificant to the patient’s 
hemodynamics (Mehta et al., 2010).  
2.2.4 Adjunctive procedures 
The operating surgeon must be able to handle the need for unexpected adjunctive 
procedures as in the emergent setting, preoperative planning can be less than ideal. One 
such procedure that should be in the surgeon's armamentarium is knowledge and comfort 
in utilizing Palmaz stents to repair type I endoleaks (one of the most common operative 
complications of rEVAR). Further the surgeon should be comfortable with hybrid cases. For 
instance, if the decision is made to use an aortouni-iliac (AUI) graft or to convert a 
bifurcated stent graft to an AUI (as has been reported in 16% of patients), the surgeon 
should be comfortable performing both the primary EVAR and the femorofemoral bypass 
(Mehta et al., 2010). 
3. Post-operative care considerations 
The immediate post-operative considerations include the ability to monitor patients for the 
most common complications e.g. abdominal compartment syndrome. This necessitates a 
protocol re-activation of the operative team in the event of an emergent requirement to take 
the patient back to the OR. 
3.1 Abdominal compartment syndrome 
Abdominal compartment syndrome (ACS) is a significant complication resulting from a 
ruptured AAA. The pathophysiology is multifactorial resulting from existing 
retroperitoneal hematoma, ongoing, coagulopathic bleeding from aortic collaterals (lumbar 
and inferior mesenteric arteries from the disrupted aneurysm sac), and profound shock 
associated with ruptured AAA, which induce a systemic inflammatory response (SIRS) with 
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increased capillary permeability and hemodynamic compromise (Mehta M., 2005). The 
incidence of ACS after rupture AAA is as high as 18% and carries with it a 7 fold increased 
risk of death (Mehta et al, 2010). Additionally, ACS is a major contributor to post operative 
acute renal failure and intestinal ischemia. However, both acute renal failure and intestinal 
ischemia can occur outside of the setting of ACS. Risk factors include massive blood 
transfusions, intraoperative coagulopathy and use of aortic occlusion balloons. The debate is 
still ongoing as to the best method for diagnosing ACS. The various options center around 
some combination of clinical exam findings and bladder pressure measurements. By 
whatever criteria, the treatment has remained decompressed laparotomy.  
4. Current data on endovascular repair of ruptured aortic aneurysms 
The evidence to support EVAR for ruptured AAAs is largely drawn from results of single-
center case series, systematic reviews, and more recently, population-based studies arising 
from the United States. Although encouraging mortality rates are published, significant 
biases exist. First, a direct comparison between EVAR and open surgery for ruptured AAA 
is difficult as not all patients are anatomically suitable for EVAR. Secondly, unstable patients 
are by in large, directed toward traditional open repair. In a recent retrospective 
institutional review, Lee et al. identified this selection bias in that hemodynamically 
unstable patients tended to undergo open repair even when potentially anatomically 
suitable for rEVAR (Lee et al., 2008). Such observations may be alluding to the fact that 
patients stable enough to undergo CT are already a self-selecting cohort compared to those 
that are in extremis and cannot proceed to preoperative imaging. As experience increases 
with EVAR, however, hemodynamic stability may not factor as much into repair selection or 
else may push the choice toward rEVAR for unstable patients as access and balloon 
occlusion can be rapidly attained to stop hemorrhage. Despite the inherent biases that exist 
in studying the outcomes of rEVAR, evidence to support an EVAR first approach to 
managing ruptured AAAs continues to mount.  
Select studies in the literature representing current data on rEVAR are summarized in Table 
1 below. Many institutions that have adopted the rEVAR first approach have seen 
significant benefits. Of the single-center experience observational studies, the most recent 
report by Starnes et al. comparing outcomes before and after implementation of a rEVAR-
first protocol, showed that their overall 30-day mortality fell from 54.2% to 18.5% (Starnes et 
al., 2009). On a larger scale, outcomes of implementing a rEVAR first protocol was reviewed 
in a large co-operative multicenter cohort study by Veith et al. in 2009 spanning 49 
institutions in 13 countries. The study showed superiority of EVAR over open repair in 
terms of 30-day mortality (rEVAR 21.2% vs. Open repair 35.8%) when collectively analyzed 
not accounting for differences in practice variability; most centers limited the use of rEVAR 
to “stable” patients or those with “contained” ruptures (Veith et al., 2009). The study re-
examined the results of 13 centers that were committed to performing rEVAR for all 
ruptured cases despite hemodynamic instability. These centers were usually those with 
larger volume experiences. The report showed a median 30 day mortality of 19.7% with 
EVAR and 36.3% with open surgery (P<0.0001). The power of the study is significant (1037 
cases) to support rEVAR as a better treatment to managing ruptured AAAs, however, with 
no defined standard of practice in any participating centers and with this being a purely an 
observational study, the evidence is till at best level 2b.  
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Author, Date and 
Country 
Study Type Key Results 
Starnes et al., (2009), 
J Vasc Surg, USA 
Retrospective cohort study 
(level 2b) 
Mortality reduction from 57.8% to 35.3% [absolute 
risk reduction 22.5%; odds ratio (OR) of 0.40] 
Veith et al., (2009), 
Ann Surg, USA 
Retrospective multi-center 
cohort study (level 2b) 
30-day mortality amongst EVAR repair=21.2% 30-
day mortality amongst open- repairs=35.8% 
In centers treating 24–62 rAAA overall 
mortality=21.0% (range 7–39%).  
30-day mortality amongst centers using EVAR for 
11–18 rAAA per annum=22.5% (range 6–43%).  
30-day mortality for centers performing EVAR on 
5–10 rAAA per annum=30%.  
30-day mortality for centers performing EVAR on 
1–4 rAAA per annum=35% 
Karkos et al., (2009), 
Arch Surg, Greece 
Systematic review of non-
randomized observational 
studies (level 2a) 
Meta-analysis of 19 studies reporting results of 
concurrent open-repair, pooled mortality after 
open-repair = 44.4% (95% CI, 40.0–48.8%), and 
pooled overall mortality for endovascular or open 
repair= 35% (95% CI, 30–41%)  




cohort study (level 2b) 
Mortality=45.1% EVAR vs. 52.4% open-repair 
(P=0.21) Length of stay not significantly different 
between EVAR and open-repair groups 
Giles et al., (2009),  
J Endovasc Ther, 
USA 
Multicenter cohort study 
(level 2b) 
Mortality=24% EVAR vs. 36% open-repair (P<0.05) 
Visser et al., (2009), 
J Vasc Surg, 
Netherlands 
Multi-center prospectively- 
recruited cohort study 
(level 2b) 
Thirty-day mortality=26% EVAR vs. 40% open-
repair (P=0.06) 
Sadat et al., (2009), 
Eur J Vasc Endovasc 
Surg, UK 
Prospective cohort study 
(level 2b) 
Group 1=17 eEVAR, 29 open repairs, 4 palliated 
(after the introduction of rEVAR), Group 2=54 
underwent open repair and 17 were palliated 
Significant differences in 30-day operative 
mortalities between the two groups 13% in Group 
1 vs. 39% in Group 2 (P=0.0003) 
Verhoeven et al., 
(2008), J Vasc Surg, 
Netherlands 
Prospective cohort study 
(level 2b) 
Mortality after EVAR=13.9% vs. 28.1% open-repair 
(P=0.092) No significant difference in mortality 
over 25 months follow- up between EVAR and 
open- repair 
Ockert et al., (2007), 
J Endovasc Ther, 
Germany 
Retrospective cohort study 
(level 2b) 
30-day mortality=31% in both groups (P=1.0). 
Morbidity rate=55.2% EVAR vs. 62% open-repair 
(P=0.9) 
Hinchliffe et al., 
(2006), Eur J Vasc 
Endovasc Surg, UK 
Single center RCT (level 1b) 30-day intention-to-treat mortality=53% rEVAR vs. 
53% open-repair  
Moderate or severe operative complications=77% 
EVAR vs. 80% amongst open-repair. Renal 
complications=55% EVAR vs. 8% open-repair 
(P=0.02)  
4 patients died prior to surgery 
Table 1. List of current data on endovascular repair of ruptured AAA. 
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increased capillary permeability and hemodynamic compromise (Mehta M., 2005). The 
incidence of ACS after rupture AAA is as high as 18% and carries with it a 7 fold increased 
risk of death (Mehta et al, 2010). Additionally, ACS is a major contributor to post operative 
acute renal failure and intestinal ischemia. However, both acute renal failure and intestinal 
ischemia can occur outside of the setting of ACS. Risk factors include massive blood 
transfusions, intraoperative coagulopathy and use of aortic occlusion balloons. The debate is 
still ongoing as to the best method for diagnosing ACS. The various options center around 
some combination of clinical exam findings and bladder pressure measurements. By 
whatever criteria, the treatment has remained decompressed laparotomy.  
4. Current data on endovascular repair of ruptured aortic aneurysms 
The evidence to support EVAR for ruptured AAAs is largely drawn from results of single-
center case series, systematic reviews, and more recently, population-based studies arising 
from the United States. Although encouraging mortality rates are published, significant 
biases exist. First, a direct comparison between EVAR and open surgery for ruptured AAA 
is difficult as not all patients are anatomically suitable for EVAR. Secondly, unstable patients 
are by in large, directed toward traditional open repair. In a recent retrospective 
institutional review, Lee et al. identified this selection bias in that hemodynamically 
unstable patients tended to undergo open repair even when potentially anatomically 
suitable for rEVAR (Lee et al., 2008). Such observations may be alluding to the fact that 
patients stable enough to undergo CT are already a self-selecting cohort compared to those 
that are in extremis and cannot proceed to preoperative imaging. As experience increases 
with EVAR, however, hemodynamic stability may not factor as much into repair selection or 
else may push the choice toward rEVAR for unstable patients as access and balloon 
occlusion can be rapidly attained to stop hemorrhage. Despite the inherent biases that exist 
in studying the outcomes of rEVAR, evidence to support an EVAR first approach to 
managing ruptured AAAs continues to mount.  
Select studies in the literature representing current data on rEVAR are summarized in Table 
1 below. Many institutions that have adopted the rEVAR first approach have seen 
significant benefits. Of the single-center experience observational studies, the most recent 
report by Starnes et al. comparing outcomes before and after implementation of a rEVAR-
first protocol, showed that their overall 30-day mortality fell from 54.2% to 18.5% (Starnes et 
al., 2009). On a larger scale, outcomes of implementing a rEVAR first protocol was reviewed 
in a large co-operative multicenter cohort study by Veith et al. in 2009 spanning 49 
institutions in 13 countries. The study showed superiority of EVAR over open repair in 
terms of 30-day mortality (rEVAR 21.2% vs. Open repair 35.8%) when collectively analyzed 
not accounting for differences in practice variability; most centers limited the use of rEVAR 
to “stable” patients or those with “contained” ruptures (Veith et al., 2009). The study re-
examined the results of 13 centers that were committed to performing rEVAR for all 
ruptured cases despite hemodynamic instability. These centers were usually those with 
larger volume experiences. The report showed a median 30 day mortality of 19.7% with 
EVAR and 36.3% with open surgery (P<0.0001). The power of the study is significant (1037 
cases) to support rEVAR as a better treatment to managing ruptured AAAs, however, with 
no defined standard of practice in any participating centers and with this being a purely an 
observational study, the evidence is till at best level 2b.  
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Country 
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Retrospective cohort study 
(level 2b) 
Mortality reduction from 57.8% to 35.3% [absolute 
risk reduction 22.5%; odds ratio (OR) of 0.40] 
Veith et al., (2009), 
Ann Surg, USA 
Retrospective multi-center 
cohort study (level 2b) 
30-day mortality amongst EVAR repair=21.2% 30-
day mortality amongst open- repairs=35.8% 
In centers treating 24–62 rAAA overall 
mortality=21.0% (range 7–39%).  
30-day mortality amongst centers using EVAR for 
11–18 rAAA per annum=22.5% (range 6–43%).  
30-day mortality for centers performing EVAR on 
5–10 rAAA per annum=30%.  
30-day mortality for centers performing EVAR on 
1–4 rAAA per annum=35% 
Karkos et al., (2009), 
Arch Surg, Greece 
Systematic review of non-
randomized observational 
studies (level 2a) 
Meta-analysis of 19 studies reporting results of 
concurrent open-repair, pooled mortality after 
open-repair = 44.4% (95% CI, 40.0–48.8%), and 
pooled overall mortality for endovascular or open 
repair= 35% (95% CI, 30–41%)  




cohort study (level 2b) 
Mortality=45.1% EVAR vs. 52.4% open-repair 
(P=0.21) Length of stay not significantly different 
between EVAR and open-repair groups 
Giles et al., (2009),  
J Endovasc Ther, 
USA 
Multicenter cohort study 
(level 2b) 
Mortality=24% EVAR vs. 36% open-repair (P<0.05) 
Visser et al., (2009), 
J Vasc Surg, 
Netherlands 
Multi-center prospectively- 
recruited cohort study 
(level 2b) 
Thirty-day mortality=26% EVAR vs. 40% open-
repair (P=0.06) 
Sadat et al., (2009), 
Eur J Vasc Endovasc 
Surg, UK 
Prospective cohort study 
(level 2b) 
Group 1=17 eEVAR, 29 open repairs, 4 palliated 
(after the introduction of rEVAR), Group 2=54 
underwent open repair and 17 were palliated 
Significant differences in 30-day operative 
mortalities between the two groups 13% in Group 
1 vs. 39% in Group 2 (P=0.0003) 
Verhoeven et al., 
(2008), J Vasc Surg, 
Netherlands 
Prospective cohort study 
(level 2b) 
Mortality after EVAR=13.9% vs. 28.1% open-repair 
(P=0.092) No significant difference in mortality 
over 25 months follow- up between EVAR and 
open- repair 
Ockert et al., (2007), 
J Endovasc Ther, 
Germany 
Retrospective cohort study 
(level 2b) 
30-day mortality=31% in both groups (P=1.0). 
Morbidity rate=55.2% EVAR vs. 62% open-repair 
(P=0.9) 
Hinchliffe et al., 
(2006), Eur J Vasc 
Endovasc Surg, UK 
Single center RCT (level 1b) 30-day intention-to-treat mortality=53% rEVAR vs. 
53% open-repair  
Moderate or severe operative complications=77% 
EVAR vs. 80% amongst open-repair. Renal 
complications=55% EVAR vs. 8% open-repair 
(P=0.02)  
4 patients died prior to surgery 
Table 1. List of current data on endovascular repair of ruptured AAA. 
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Large national databases have also been used to examine the differences between open 
and endovascular repair for ruptured AAA. Egorova et al. examined the databases of 4 
large states from 2000 to 2003 and found, even in those earlier years, that mortality in 290 
rEVAR patients was lower than in 5508 open repair patients (39% versus 48%, p<0.005) 
(Egorova et al., 2008). Analysis of another large nationwide inpatient sample from 2001 to 
2006 showed the increase in the use of EVAR for ruptured AAAs increased over time 
(5.9% in 2001 to 18.9% in 2006, P < .0001) while overall ruptured AAA rates remained 
constant (Mcphee et al., 2009). In reviewing the database, the investigators showed that 
rEVAR had lower overall in-hospital mortality than open repair (31.7% vs 40.7%, P < 
.0001). The benefit of rEVAR, when stratified by institutional volume, was found to be 
augmented in that study. Investigators also found that rEVAR patients had a shorter 
length of stay (11.1 vs 13.8 days, P < .0001), higher discharges to home (65.1% vs 53.9%, P 
< .0001), and lower cost of care ($108,672 vs $114,784, P < .0001) (Mcphee et al., 2009). 
Although these large datasets give convincing arguments to support rEVAR, reports from 
population-based studies are misleading because they are not able to control for 
significant confounders of patient physiology and morphology. In addition, it is not 
known whether these studies are applicable outside the United States. The study, 
however, noted that because of the technical requirements of the procedure, the impact of 
annual volume on outcomes of ruptured AAA repairs is an important factor that cannot 
be assessed by single institutional series.  
It has been shown that there is a significant relationship between higher surgeon and 
hospital volume and improved patient outcomes after open surgical repair for ruptured 
AAA (Dimick et al., 2002). Mcphee et al found a clear mortality advantage directly related to 
all volume measures analyzed: annual elective open repair volume, annual elective EVAR 
volume, and annual RAAA volume. For each of these metrics, mortality decreased 
significantly as annual surgical volume increased. The absolute mortality benefit was most 
pronounced when analyzed according to elective EVAR volume; institutions in the high 
elective EVAR volume ( > 40 per year) had an absolute mortality decrease of >15%(Mcphee 
et al., 2009). In the multicenter study by Veith et al, rEVAR related mortality is seen to be 
dependent upon the institutional volume of rEVARs performed. In centers treating 24–62 
ruptured AAAs per year, the collective mortality rate reported is 21.0% (range 7–39%); 30-
day mortality amongst centers performing 11-18 rEVARs per year is 22.5% (range 6–43%); 
30-day mortality for centers performing 5–10 rEVARs per year is 30% (range 21-30%); 30-
day mortality for centers performing 1–4 rEVARs per year is 35. In fact, a study by Giles et 
al. in 2009 showed lower mortality rates in higher volume hospitals for both open repairs 
and rEVAR, and a very large difference in endovascular outcomes. As such, the authors 
concluded that regionalization of referrals of ruptured AAA patients to high-volume centers 
preferentially may improve overall national outcomes.  
The study by Hinchliffe et al from 2006 is the only paper published to date reporting level 1 
evidence comparing rEVAR to open repair. This single-center a randomized control trial 
(RCT) study showed a higher EVAR related mortality compared to those reported in 
observational studies and did not find any overall survival advantage in the mid- to long-
term with EVAR compared to open repair (Hinchliffe et al., 2006). Of those patients 
enrolled, 53% were deemed suitable for EVAR. The prerequisite for CT-scanning, 
interestingly, did not delay definitive surgery. As only 32 patients were enrolled, the 
study lacked sufficient power to provide definitive recommendations but did show that it 
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is possible to recruit patients to a randomized trial of open repair and EVAR in patients 
with ruptured AAA.  
More randomized studies have since commenced. The Amsterdam (Acute Endovascular 
Treatment to Improve Outcome of Ruptured Aortoiliac Aneurysms [Ajax]) trial 
(ISRCTN66212637) recruited 80 patients, and being underpowered, showed no significant 
difference in primary combined end point of 30-day mortality and serious morbidity. 
Recruitment for the trial has therefore been extended. The Ruptured Aorta-Iliac Aneurysms: 
Endo vs Surgery (ECAR) trial (NCT00577616) is currently underway and both AJAX and 
ECAR have been designed to recruit only the most stable patients, all of whom will be 
anatomically suitable for EVAR. One can argue that randomization of patients after CT 
scanning will not delineate the role of an rEVAR first strategy compared to open repair on 
an intention-to-treat basis. In consideration, the UK study Immediate Management of the 
Patient with Rupture: Open Versus Endovascular repair (IMPROVE) aneurysm trial 
(ISRCTN 48334791) will randomize patients at the time of diagnosis of ruptured AAA, either 
to immediate CT scan and endovascular repair whenever anatomically suitable 
(endovascular first), or to open repair, with CT scan being optional (normal care). The trial is 
set on a background of guidelines for emergency care, CT scanning and anesthesia, which 
incorporate the protocol of permissive hypotension. Recruitment started in October 2009 
and 600 patients are required to show a 14% survival benefit at 30 days (primary outcome) 
for the endovascular first policy.  
With the given evidence to date, the only reasonable conclusion that can be drawn is that the 
role of rEVAR in the management of patients with ruptured AAA remains to be proven. 
Due to the lack of quality data, determining the subgroup of patients that will truly gain 
benefit from rEVAR remains to be elucidated and we will have to await the results of level 1 
evidence to answer this question. 
5. Conclusion  
Despite the inherent biases, information is emerging to suggest that there is a clear role for 
EVAR for ruptured AAA in select patients. There are a number of clear advantages to the 
endovascular approach given patient suitability. Patients undergoing EVAR can be treated 
using local anesthesia, which helps avoid the hemodynamic changes associated with muscle 
relaxation and general anesthesia. In addition, the morbidity associated with dissecting the 
aortic neck, damage to peri-aortic structures, and bleeding, can be avoided. The current 
literature has demonstrated decreased procedure times, reduced blood loss, and improved 
overall and intensive care unit lengths of stay following EVAR for ruptured AAA when 
compared to open surgery, but also suggests that these results are seen in select centers with 
adequate EVAR and open experience; supporting a direction towards regionalization of care 
and the management of all ruptured AAAs in large vascular centers. The routine use of 
EVAR for ruptured AAAs, however, remains to be proven with forthcoming level 1 
evidence. 
The technology behind stentgrafts continues to evolve and will further the potential for 
improved patient survival. If rEVAR can significantly reduce the mortality rate of patients 
presenting to hospital with ruptured AAA, the management of ruptured AAA would have 
to change as well as the organization and delivery of emergency and vascular services. The 
capability of performing rEVARs requires significant investment in institutional 
infrastructure. If feasible, however, the implementation of rEVAR capability and protocols 
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Large national databases have also been used to examine the differences between open 
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is possible to recruit patients to a randomized trial of open repair and EVAR in patients 
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could potentially benefit all types of repairs as the awareness and response to the arrival of a 
ruptured aneurysm patient is streamlined.  
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1. Introduction 
Abdominal aortic aneurysm, with its incidence approaching approximately 8% in the 
population, accounts for more than 8,000 deaths annually in the United States. It is a 
multifactorial disease associated with atherosclerosis. Age, male gender, smoking, and the 
family history of abdominal aortic aneurysm are thought to be the risk factors for the 
disease (Ashton et al., 2002, Fleming et al., 2005). The natural history of abdominal aortic 
aneurysm is characterized by the progressive enlargement of the aneurysm, which 
ultimately leads to the rupture and the subsequent death of the patient. 
The aorta wall consists of a thin intima, a thick tunica media, and an adventitia, composed 
of endothelium for a thin intima, smooth muscle layers for a thick tunica media, and a 
connective tissue including the vasa vasorum and nervi vascularis for the adventitia, 
respectively. The wall of aorta is particularly vulnerable to an injury owing to the 
continuous exposure to high pulsate blood pressure and shear stress. Once degenerated 
which most commonly occurs by atherosclerosis, cystic medial necrosis, a condition in 
which the collagen and elastic fibers in the tunica media of the aorta are degenerated and 
replaced by the mucoid connective tissues, will immediately take place. It will 
subsequently result in the circumferential weakness, dilatation, and as a consequence, the 
development of aneurysm. The other etiological conditions that lead to the development 
of aneurysm include some hereditary basis such as Marfan’s and Ehlers-Dnlos 
syndromes, the infection including syphilis and tuberculosis, and vasculitis associated 
with autoimmune diseases such as Takayasu’s arteritis and rheumatoid arthritis (White et 
al., 1993, Shah et al., 1997). 
The prognosis of abdominal aortic aneurysm is strongly correlated with the size of 
aneurysm, and the risk of rupture is 1-2% for 5 years for an aneurysm less than 5cm in 
diameter, whereas it is more than 20-40% for those more than 5cm in diameter. Hence, an 
elective operation is indicated if the diameter of aneurysm is >5.5cm (Sakalihasan et al., 
2005). 
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2. Treatment options for abdominal aortic aneurysm: Endovascular 
abdominal aortic aneurysm repair (EVAR) 
Traditionally, abdominal aortic aneurysm had been treated with prophylactic open surgical 
repair, which usually had required the surgical procedure consisting of the cross-clamping 
of the aorta for more than 30 minutes. It exerted a profound impact on the peri-operative 
mortality of those with pre-existing impaired ventricular function and reduced coronary 
reserve through the increases in arterial blood pressure, systemic vascular resistance, and 
the reduction of cardiac output. In addition, ischemic complications may subsequently take 
place following a cross-clamping of aorta such as occlusive mesenteric ischemia, acute 
tubular necrosis of the kidneys, and paraplegia (Lloyd et al., 1996). 
In 1991, Parodi and co-workers reported the first clinical application of endovascular 
surgery, namely endovascular aortic aneurysm repair (hereafter referred to as EVAR), for 
abdominal aortic aneurysm repair (Parodi et al., 1991). It has revolutionized the traditional 
approach for the treatment of abdominal aortic aneurysm. The prominent advantage of this 
approach is its less invasiveness as compared with the traditional open surgical abdominal 
aortic reconstruction, which is particularly suitable for those who are considered to unfit for 
open surgical abdominal aortic aneurysm reconstruction owing to their serious pre-existing 
comorbidities (EVAR trial participants, 2005). This approach has enabled to reconstruct 
abdominal aortic aneurysm surgically without the large incisions of abdominal walls and 
the prolonged aortic cross-clamp times, and with the significantly less blood loss and fluid 
shifts. The technique commonly is undertaken with the bilateral groin incisions to obtain an 
access to the common femoral arteries. Approximately two decades later since its first report 
in 1991, this approach has come to account for nearly a half of elective repairs of abdominal 
aortic aneurysm in the United States and in European countries (Shermerhorn et al., 2008). 
Currently, two large randomized controlled trials evaluating the efficacy and the safety of 
EVAR in terms of 30-day peri-operative mortality as well as its long term durability as 
compared with the standard open surgical vascular reconstructions are undergoing in 
European countries (Prinssen et al, 2004, Greenhalgh et al., 2004). One is conducted in 
Netherland and Belgium, and the other is undergoing in the United Kingdom. Interestingly, 
the results of both trials were quite similar with each other. Although the 30-day peri-
operative mortalities as well as the rate of complications were significantly lower in EVAR 
group than in the open surgical reconstruction group in both studies, the cumulative 
survival advantage of EVAR group over those with the open surgical reconstruction group 
had disappeared following 2 years after randomization (Blankensteijin et al., 2005, 
Greenhalgh et al., 2005). In addition, the rate of subsequent requirement of the secondary 
interventions was higher in EVAR group, and the quality of life as reported by the 
participants was also higher in the open repair group (Blankensteijin et al., 2005, Greenhalgh 
et al., 2005). 
The other study is also now undergoing in the United Kingdom comparing the efficacy and 
the safety of EVAR as compared with no intervention on those who were especially 
considered to unfit for open repair and excluded for that reason, and it revealed no 
cumulative survival benefit of EVAR over no intervention group, presumably owing to the 
serious comorbidities of the participants (EVAR trial participants, 2005). However, the 
similar study now undergoing in the United States showed the more prominent lower peri-
operative mortality in those who had undergone EVAR in highly comorbid participants, 
which suggests that EVAR, owing to its less invasive nature as compared with the standard 
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open repair, is particularly suitable for those who were considered to unfit for open repair 
owing to their serious comorbidities (Timaran et al., 2007). 
3. Anesthesia for endovascular aortic aneurysm repair 
Shortly after the introduction of EVAR in the treatment of abdominal aortic aneurysm, 
general anesthesia was preferentially used for the anesthetic management of EVAR because 
of the following reasons;  
1. The first generation device had required the induced hypotension technique during the 
deployment of the graft. 
2. The procedure times were often long. 
3. The considerable number of patients had required conversion to open repair during the 
EVAR procedure. 
However, as the second-generation fully stented modular stent graft had come to be widely 
used, which, through the refinement of the first-generation brand, do not require the 
induced hypotension technique during the deployment of the graft, and as the physicians 
had gained the experiences with newer generation devices, which subsequently resulted in 
the shorter procedure times, a variety of regional anesthesia techniques has come to be used. 
These techniques include paravertebral peripheral nerve block, spinal anesthesia, 
continuous spinal anesthesia, epidural and combined spinal anesthesia, and regional 
anesthesia. Owing to the serious comorbidities of the patients who are undergoing EVAR 
procedure, the use of less invasive anesthetic techniques for the anesthetic management of 
EVAR, such as regional anesthesia techniques, has been shown to result in the lower peri-
operative mortality, reduced ICU admission and stay, reduced hospital length of stay, and 
the reduced rate of early complications (Asakura et al. 2009b, Asakura, 2010a, Ruppert et al, 
2006, Verhoeven et al., 2005). 
The use of neuroaxial anesthesia including epidural and spinal anesthesia may have 
potentially beneficial effects on patients such as the suppression of the surgical stress, 
positive effect on post-operative nitrogen balance, and reduced blood loss, these advantages 
are often counterbalanced by the increased risk of developing subdural and epidural 
hematoma in patients undergoing EVAR who are frequently medicated with anticoagulants 
pre-operatively and with the use of heparin during the surgical procedure (Asakura et al. 
2008a, Asakura, et al. 2009b, Asakura, 2010a, Park et al., 2001). The incidence of 
development of hematoma associated with the use of neuroaxial anesthesia is relatively low 
and is estimated to be approximately 1:150,000-1:200,000 in normal individuals (Horlocker 
et al., 2000). Although it is difficult to precisely ascertain the relative risk of the incidence of 
subsequent development of epidural/subdural hematoma in the population who is 
undergoing anticoagulant therapy, the consensus statement regarding the use of neuroaxial 
anesthesia and the concomitant use of anticoagulant drugs has been recently provided from 
the American Society of Regional Anesthesia, given the considerable number of case reports 
published thus far reporting the development of epidural hematoma in whom an 
anticoagulation therapy was administered (Horlocker et al., 2010).  
Bleeding in the neuroaxial space which most commonly occurs in an epidural space due to 
the presence of prominent venous plexus, is a potentially catastrophic complication of 
neuroaxial anesthesia, and the only minor proportion of patients fully recovered 
neurologically after the prompt diagnosis and the immediate decompression laminectomy. 
Among 61 cases of spinal hematoma that had been previously reported in the review of 
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literature, 25 of those had received intravenous or subcutaneous injection of heparin. 
Furthermore, 5 additional cases had undergone vascular surgery, which means that they 
were treated with heparin intra-operatively (Vandermeulen et al. 1994). Hence, nearly a half 
of reported cases were associated with the use of heparin. Although the use of neuroaxial 
anesthesia in patients who are going to receive heparin is not totally contraindicated, the 
consensus statement suggests that the careful cautions must be paid in patients receiving 
neuroaxial anesthesia who are treated with anticoagulant medications (Horlocker et al. 
2010). 
4. Peripheral nerve block; an alternative for neuroaxial anesthesia in the 
anesthetic management of EVAR 
An alternative regional anesthesia technique that can be used is peripheral nerve blockade 
(PNB), which has been shown to provide an effective unilateral analgesia with a fewer 
serious neurological complications even with the use of heparin (Asakura, et al, 2008a, Gray, 
2006). Historically, the technique of peripheral nerve block appeared in the early 20th 
century, but the needle advancement was guided by mostly the knowledge of anatomy. 
Hence, the rate of success was limited, and it was somewhat like an art of the skilled hands. 
However, as a result of the advance of ultrasound machine technology (Asakura, et al., 
2008b), the anesthesiologists come to perform peripheral nerve block with more than 90% 
rate of success virtually without any complications. As such, ultrasound-guided peripheral 
nerve block has come to gain popularity recently worldwide (Marhofer et al. 2007). 
4.1 Lumbar plexus block for the anesthetic management of EVAR 
During the surgical procedure of EVAR, skin incisions are made in the groin areas to gain 
the access to the common iliac arteries. The nerve to the lower extremity and groin areas 
are supplied from the lumbar and sacral plexus (Fig.1). The plexus runs between the 
psoas major muscle and the quadrates lumborum muscle which is termed as the psoas 
compartment. The lumbar plexus is formed from ventral rami with L1-4 in addition to the 
various types of additional contribution from T12 and L5. The branches of lumbar plexus 
form iliohypogastric, ilioinguinal, genitofemoral, lateral femoral cutaneous, femoral, and 
obturator nerves. The first lumbar ventral ramus supplies iliohypogastric and ilioinguinal 
nerves. The genitofemoral and the lateral femoral cutaneous nerves originate from the 
second ramus. The femoral nerve is formed from the united ventral rami of L2-4. From the 
anterior division of L2-4, the obturator nerve is formed. The psoas compartment block is 
usually performed by advancing the needle into the space between the psoas major and 
the quadrates lumborum muscles, and the once the plexus is approached, a large volume 
of local anesthetics is injected which subsequently anesthetize the hip and anterolateral 
thigh. 
For the standard lumbar plexus block, the patient is usually placed in the lateral decubitus 
position, with the hip fixated and the operative side uppermost. The block is conducted by the 
standard nerve stimulation method (Asakura, et al., 2008a). A 21-gauge 100-mm-long needle is 
advanced perpendicular to the skin until it contacts to the transverse process of the 5th lumbar 
spine. A nerve stimulator is set to deliver 0.5-1.0mA current impulse at 2Hz. By further 
advancing the needle, the localization of the lumbar plexus is confirmed by identifying the 
contraction of the quadriceps femoris (Asakura, et al., 2008a, Capdevila, et al., 2002). 
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Fig. 1. A schematic presentation of the lumbar and the sacral plexus. 1) lateral femoral 
cutaneous nerve; 2) femoral nerve; 3) psoas major muscle; 4) obturator nerve; 5) inguinal 
ligament. 
Following the confirmation of the negative aspiration of blood and the cerebrospinal fluids, a 
large volume of local anesthetics are usually injected. The procedure has been traditionally 
carried out by the nerve stimulation method under the confirmation of the landmarks of the 
body. After confirming the top of the iliac crest, a line is drawn to the spinous process of the 4th 
lumbar spine. Classically, a textbook describes to advance the needle 5cm lateral to the midline 
of the spine on this line. However, a considerable number of serious complications associated 
with the use of lumbar plexus block, such as intrathecal injection, epidural injection, 
inadvertent vascular puncture, and retroperitoneal bleeding (Aida et al., 1996, Aveline et al., 
2004, Ludot, et al., 2008, Weller, et al., 2003) have been reported. These complications have, at 
least in part, resulted from the depth of the plexus inside the body, which also makes it 
difficult to perform ultrasound-guided lumbar plexus block partly owing to the presence of 
bony structures. In particular, the use of heparin during the surgical procedures of EVAR 
makes the retroperitoneal bleeding as the serious complication with the use of lumbar plexus 
block, although the complication is often self-limiting in contrast to the bleeding in neuroaxial 
space, which often results in the inreversible neurological damage. Hence, we analyzed the 
computed tomography of the consecutive patients in our facility that had undergone any 
elective surgery and characterized the precise localization of the lumbar plexus at the fourth 
lumbar spine level in the Japanese population.  
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In the study, axial transverse sections of computed tomography of the fourth lumbar spine 
level were used to measure the following distances; a distance from the skin to the 
transverse process, a distance from the skin to the lumbar plexus nervous trunks, a distance 
from the median sagital plane to the lumbar nerve trunks, and a distance from the skin to 
the lateral border of psoas major muscle (Fig.2). On the basis of cadaver study, the lumbar 
plexus was identified to run between the fleshy slip of the main part of psoas major and the 
accessory part of the psoas that constitutes the posterior part of the psoas major muscle 
(Kirchmair et al., 2001). These two parts of the muscle fuses to form the psoas major. The 
femoral nerve and the lateral femoral cutaneous nerve run inside a thin fascia at the level of 
the junction of the posterior third and the anterior two-thirds of the muscle. In the 
measurements made from the computed tomography, the junction of the posterior third and 
anterior two-third of the psoas major was used as the plane of the femoral nerve (Fig.3). 
 
 
Fig. 2. The following variables were measured; 1)The distance from the skin to the 
transverse process, 2) The distance from the skin to the femoral nerve, 3) The distance from 
the median sagital line to the femoral nerve, 4) The distance from the median sagital line to 
the lateral border of the psoas major muscle.  
4.2 Anatomical localization of the lumbar plexus in the Japanese population 
Although several literatures have described the anatomical localization of lumbar plexus 
thus far, no similar information in the Japanese population is totally lacking (Farny et al., 
1994, Kirchmair et al., 2001). The present study was undertaken in order to precisely identify 
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the anatomical localization of the lumbar plexus in the Japanese population. The study 
included 100 Japanese adult patients (59 males and 41 females) who had undergone any 
elective surgical procedure in our facility. The measurements of the distance from the skin to 
the transverse process, the distance from the skin to the femoral nerve, the distance from the 
median sagital plane to the femoral nerve, and the distance from the median sagital plane to 
the lateral border of the psoas major muscle in the Japanese population are significantly 
smaller than those described previously in the Canadian population, which presumably had 
made the procedure to be complicated-prone one (Farny et al., 1994). In their report, the 
distance from the skin to the transverse process in the Canadian females was reported to be 
70±13mm and the distance from the skin to the transverse process in the Canadian males 
was 75±22mm.  
 
 
Fig. 3. Localization of the spinous process (SP), transverse process (TP), femoral nerve (FN), 
psoas major muscle (PM), and quadratus lumborum muscle (QL) on the computed 
tomography at the 4th lumbar spine level is shown. 
By contrast, in our hands, the same distance that corresponds to the Japanese male was 
49.32mm (median: 47, range: 30-72mm), and that corresponds to the Japanese female was 
48.41mm (median: 47, range: 25-86mm) (Fig.4). Similarly, the average distance from the skin 
to the femoral nerve in the Canadian males and females were reported to be 99±21mm and 
90±14mm, respectively, whereas that corresponds to the Japanese males was 66.6mm 
(median: 64, range: 64-90mm), and that to the Japanese female was 65.9mm (median: 66, 
range: 50-80mm) (Fig.5). The distance from the median sagital plane to the lateral border of 
the psoas muscle in the Canadian males and females were reported to be 72.7 ± 10mm and 
60 ± 8mm, whereas those correspond to the Japanese males and females were 54.88mm 
(median: 55, range: 47-64), and 49.31mm (median: 50; range: 34-67mm) (Fig.6). In addition, 
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although there was no description regarding the distance from the median sagital plane to 
the femoral nerve in the Canadian population, we measured those variables in the Japanese 
males and females. The distance from the median sagital plane to the femoral nerve in the 
Japanese male was 34.47mm (median: 35, range: 27-42mm), and that corresponds to the 






Fig. 4. The distance from the skin to the transverse process in the Japanese males (n=59) and 
the Japanese females (n=41). Results are expressed by the box-and-whisker plots. 
In the standard textbook in the field of anesthesiology, the needle is suggested to advance at 
the point 3cm caudal to the line connecting the both iliac crest and 5cm lateral to the median 
sagital line (Wedel et al., 2005). However, the average distance from the median sagital line 
to the lateral border of the psoas major muscle in the Japanese female is 49.31mm, and there 
is a substantial risk of peritoneal puncture in approximately a half of this population if the 
needle is advanced at the point described in the textbook. In addition, although the needle is 
suggested to advance until it contacts to the transverse process of the fifth lumbar spine, 
there is some possibility that the needle will not contact to the transverse process if it is 
advanced at the point where the textbook recommends.  
Moreover, the literature suggests that the nerve trunks are located approximately 
90(female)-99(male) mm deep inside the body in the Canadian population (Farny et al., 
1994). However, they are located far more superficial levels in the Japanese population 
(male; 66.6mm, female 65.9mm). Accordingly, there is a potential risk of peripheral nerve 
damage if the needle is advanced as suggested by the textbook. 
In the Japanese population, the nerve trunks are located approximately 30mm lateral from 
the median sagital line (male; 34.47mm, female; 32.63mm). Literature suggests that the 
development of inadvertent epidural spread occurs in approximately 9-16% of the patients, 
and this adverse event is attributable to the retrograde diffusion of the local anesthetics to 
the epidural space (Enneking, et al., 2005). Given the nearer distance from the median sagital 
line to the femoral nerve in the Japanese population than in the Caucasion population, it 
must be always kept in mind that the Japanese patients carry more risks of inadvertent 
epidural spread than those described in the textbook previously. 
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4.3 Examples that would develop serious complications following lumbar plexus 
block 
Followings are the typical examples of the Japanese patients who would develop serious 
complications if the needle would have advanced as suggested by the textbook. Figure 8 
shows the computed tomography at the 4th lumbar supine level from the 70-year-old female. 
In this case, if the needle is advanced 5cm laterally from the median sagital line into the 














Fig. 8. The computed tomography of a 70-year-old female at the 4th lumbar spine level. Note 
that if the needle had advanced as suggested by the textbook, it would have punctured the 
peritoneal cavity. 
Similarly, in cases which are shown in figure 9, 10, and 11, the inadvertent peritoneal 
puncture and possible colonic perforations would have developed if the needle had been 
advanced as suggested by the textbook. 
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Fig. 10. Computed tomography of the 4th lumbar spine level from a 70-year-old female. 
Similarly, the needle would have penetrated the peritoneal cavity if the needle had been 
advanced as suggested by the textbook. 
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Fig. 11. The computed tomography at the 4th lumbar spine from a 74-year-old female. 
In figure 12 and 13, the left kidney has descended as low as to the 4th lumbar supine level. In 
these cases, if the needle was advanced as suggested by the textbook, inadvertent renal 
puncture would have developed. 
In figure 14 and 15, inferior vena cava is present 3cm laterally from the median sagital line at 
the depth of 9cm from the skin. Thus, if the needle would have advanced 3cm laterally from 
the median sagital line, there would be the risk of inadvertent inferior vena cava puncture, 
which may result in serious consequences such as retroperitoneal hematoma, and 
inadvertent vascular injection of local anesthetics.  
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Fig. 12. Computed tomography of the 4th lumbar spine level from a 62-year-old female. 
 
 
Fig. 13. Computed tomography of the 4th lumbar spine level from a 62-year-old female. In 
these two cases, if the needle had been advanced as suggested by the textbook, an 
inadvertent renal puncture would have developed. 
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Fig. 14. The computed tomography at the 4th lumbar spine level from a 90-year-old female. 
Inferior vena cava is distended (indicated by the arrow), and there is a potential risk of 
inadvertent inferior vena cava puncture in this case. 
 
Fig. 15. The computed tomography at the 4th lumbar spine level from a 76-year-old female. 
In this case, inferior vena cava is laterally deviated (indicated by the arrow), and there is a 
potential risk of inadvertent inferior vena cava puncture. 
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From our observations, we suggest that the needle should be advanced 32 (female)-35 (male) 
mm laterally from the median sagital line in the Japanese population. If the needle puncture 
point is more than 5cm laterally from the median sagital line, there is a risk of inadvertent 
peritoneal puncture. In addition, the nerve trunks of lumbar plexus present at the depth of 
64-66mm inside the body from the skin.  
4.4 Ultrasound-guided lumbar plexus block 
Lastly, the possibility of ultrasound-guidance for lumbar plexus block is going to be 
discussed. With the aid of ultrasound, it has come to be feasible to directly visualize the 
peripheral nerves, the needle, and the spread of local anesthetics. The ultrasound-
guidance for peripheral nerve block has been shown to be efficacious in femoral nerve 
block, sciatic nerve block, brachial plexus block, and peripheral nerves of body trunks 
(Asakura, et al., 2010a, Asakura, et al., 2010b, Gray, 2006). However, bony structure has a 
high absorption coefficient of ultrasound, which makes the ultrasound-imaging of lumbar 
plexus limited in resolution, in addition to the location of nerve trunks deep inside the 
body. In general, the visualization of nerve structures by ultrasound requires the use of 
high frequency probes offering high-resolution images. However, the higher the 
frequency is, the smaller the penetration depth would be (Marhofer et al., 2007). In other 
words, for the blockade of nerves located deep inside the body, the ultrasound probes 
with lower frequency are required, which often are insufficient for offering high-
resolution images required for identifying nerve structures. In the standard textbook in 
the field of anesthesiology, there are subtitles dealing with ultrasound-guided 
supraclavicular and interscalene brachial plexus block, infraclavicular block, axillary 
block, ilioinguinal block, femoral nerve block, and sciatic nerve block, but no single 
description of ultrasound-guided lumbar plexus block (Gray, 2005). The first attempt to 
identify the structures of lumbar plexus by ultrasound using a curved array transducer 
with a frequency at 4 MHz appeared in 2001 using the healthy volunteers (Kirchmair et 
al., 2001). They reported the successful identification of psoas muscle, erector spinae, and 
quadratus lumborum muscle by ultrasonography but not the nerve structures of lumbar 
plexus. Shortly thereafter, an attempt of ultrasound-guided lumbar plexus block using 
cadavers appeared from the same group, which confirmed the feasibility and accuracy of 
ultrasound guidance in advancing the needle to the psoas major muscle, but again 
without identifying the nerve structures (Kirchmair et al., 2002). Hence, the knowledge of 
anatomical localization of the nerve structures of the lumbar plexus would appear to be 
the prerequisite for performing the “ultrasound-assisted” lumbar plexus block. In 2004, 
however, the successful identification of the nerve trunks of lumbar plexus in the 
pediatric cases has been reported (Kirchmair et al., 2004). The successful identification of 
the lumbar plexs in these pediatric cases had resulted from the superficial localization of 
the nerve trunks, which allowed the researchers to utilize the higher frequency (5-8MHz) 
transducer ultrasound equipments. So far, the direct visualization of the nerve trunks of 
lumbar plexus in adult cases appears to be unsuccessful. However, by combining the 
nerve stimulation in addition to the ultrasound assistance, the identification of lumbar 
plexus becomes feasible even in adult cases (Asakura et al., 2008a). More importantly, the 
direct visualization of the adjacent structures such as the kidneys by ultrasound may 
prevent an inadvertent renal puncture or peritoneal puncture and hence may reduce the 
incidence of the development of complications associated with the lumbar plexus block. 
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Endovascular aortic aneurysm repair has provided a substantial improvement in the peri-
operative patients’ outcome including 30-day peri-operative mortality as compared with the 
traditional open surgical vascular reconstruction largely owing to its less invasive nature, 
especially in those whom serious comorbidities are present. In order to reduce the 
substantial risks associated with the anesthesia for EVAR in such seriously comorbid 
patients, various attempts have thus far been made. Particularly, the use of loco-regional 
anesthesia technique is a promising way to reduce the risks associated with the use of 
general anesthesia, such as the reduction in the incidence of development of respiratory 
complications. However, obstacles have also been met especially with the use of neuroaxial 
anesthesia because of the increased risks of developing subdural/epidural hematoma. 
Peripheral nerve block is the possible promising alternative for the use of neuroaxial 
anesthesia. During the surgical procedures of EVAR, skin incisions are made in the groin 
areas in order to gain the access to the femoral arteries. Anesthesia at the groin areas can be 
obtained by the posterior lumbar plexus block, which is traditionally approached by the 
nerve stimulation method. In comparison with the Caucasian population, the nerve trunks 
of lumbar plexus are located far more superficial and far more close to the median sagital 
plane in the Japanese and possibly in Asian populations. In order to prevent the potential 
risks of inadvertent renal and peritoneal puncture as well as inadvertent epidural spread, 
the lumbar plexus block should be carried out with the assistance of ultrasound-guidance. 
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1. Introduction 
Abdominal aortic aneurysms (AAA) occur when weakened areas of the abdominal aortic 
wall result in a ballooning of the vessel. Endovascular repair of AAA (EVAR) has rapidly 
been integrated into clinical care worldwide as an alternative to open surgical repair. 
However, such a management is coupled with extended exposure to X-rays for 
intervention planning, manipulations of catheters and endovascular devices and 
documentation of the repair, as well as for long-term postoperative surveillance. The 
energy absorbed in the human body by X-rays causes ionizations triggering biochemical 
changes that may lead to death or modification of cells. Although many patients derive 
great benefit from such repairs, some may suffer radiation - induced harm (e.g. skin 
injuries and increased risk for future cancer), mainly due to the use of inappropriate 
equipment and, more often, due to poor operational practices (International Commission 
on Radiological Protection [ICRP], 2000). The three key principles of radiological 
protection, justification and optimization and application of dose limits, have to be 
applied in AAA management, as in any practice related to use of ionizing radiations. The 
radiological burden to both patient and staff has to be assessed at each facility, and if 
required, the employed practice has to be modified, to keep the risks as low as reasonably 
achievable, commensurate with the medical purpose.  
2. Dosimetric quantities 
The medical use of ionizing radiations has the potential to cause harm, as well as provide 
benefit. Most of the energy emitted from of the X-ray unit during aorta imaging is absorbed 
non-uniformly in the imaged sections of the patient’s body. The patient’s bed and the image 
receptor absorb another fraction of the emitted energy. An additional fraction, usually of the 
order of 20%, is scattered towards other directions, such as non imaged sections of the 
patient’s body and the staff present in the operation room.  
The estimation of the probability of induction of radiobiological effects, either acute or 
delayed, requires the assessment of quantity absorbed dose, D, at any point in the human 
body, i.e., the quotient of the energy imparted by ionizing radiation to a volume to the mass 
in the volume. This quantity is measured in grays, Gy (J/kg). Direct dose measurements at 
any point are impractical for most organs and tissues. Therefore, simulations of clinical 
practices are often carried out using physical or mathematical anthropometric phantoms 
coupled with the following quantities that are assessed in real-time during AAA repair:  
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practices are often carried out using physical or mathematical anthropometric phantoms 
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- dose at the interventional reference point, Do , i.e., the procedure cumulative absorbed 
dose in air at a specific point in space along the central beam axis, with no patient in 
place, i.e., this quantity, sometimes also referred as cumulative air kerma. does not 
include backscattering from the human body 
- dose area product, i.e., the cumulative product of the absorbed dose in air with the 
beam cross sectional area (this quantity is often referred as kerma area product, KAP, 
due to the marginal differences between the physical quantities kerma and absorbed 
dose in low energy X-ray radiation fields). This distance invariant quantity is related to 
the entire amount of energy delivered to the patient during the procedure. 
C-arm units used for fluoroscopically guided vascular interventions should to be equipped 
with a device called DAP (or KAP) meter, that tracks and displays dosimetric quantities on 
or near the operator’s imaging monitors both in real-time and cumulatively (FDA 
regulations enacted on June 2006, require all new fluoroscopic equipment to be equipped 
with a DAP meter, that is integrated into the unit, Conference of Radiation Control Directors 
[CRCPD], 2010). The meter consists of a large parallel plate ionization chamber located close 
to the exit window of the fluoroscopic head and connected with an electrometer. A rough 
estimation of Do and DAP can be obtained alternatively in some units using a build-in 
software (in practice, the software does not take into account possible temporal changes in 
the X-ray tube output per mA during its working life). The thus obtained dosimetric data as 
well as procedural and anatomical data, are often introduced off-line to software that allows 
the assessment of the mean value of absorbed dose in the various organs and tissues of the 
human body, but not on the spatial distribution of the dose in each of them. 
3. Radiobiological aspects 
The various biological effects that can be induced by ionizing radiations are divided in two 
groups, stochastic and deterministic. The former can be induced even after irradiations at 
low doses of irradiation; on the contrary, the latter can be induced only by high doses 
(International Commission of Radiological Protection [ICRP], 2007). However, controversy 
exists today regarding the risk of exposure to X-ray doses less than 100 mGy. Many 
mechanisms operated in cells and tissues are still evasive in this dose range. Some 
radiobiologists claim that extrapolation of high-dose to the low-dose region of the dose-
effect relationship may overestimate the risk (Feinendegen, el al, 2011). However, the 
current strategy to quantify the radiological risks in daily practice, assumes that both 
radiogenic cancer induction in exposed individuals attributed to mutations of somatic cells 
and heritable effects in their offspring attributed to mutations of reproductive cells, may 
occur at low doses. Risks of other non-cancer diseases following low dose irradiations, such 
cardiovascular disorders and vision impairment, still remain uncertain (ICRP, 2007). 
3.1 Stochastic effects  
Stochastic effects are those for which the probability of induction, but not their severity, is 
regarded as a function of dose without threshold. More specifically, epidemiological data on 
subjects irradiated with –X of –γ rays at doses >100 mGy indicate a linear relationship 
without threshold between the mean absorbed dose in a number of irradiated organs and 
tissues and the probability of cancer induction to them. Therefore, an increment of absorbed 
dose induces a proportional increment in risk at low doses. So far only two effects are 
considered to be stochastic, induction of malignant disease and heritable effects. In radiation  
 
Endovascular Repair: Radiation Risks 
 
157 
protection the quantity called effective dose, E, expressed in Sv (J/kg), is widely used as an 
estimator of the health detriment at low doses. 
The probability of induction of stochastic effects is related to the quantity effective dose, i.e., 
the weighted sum of the doses absorbed in a number of organs and tissues specified by 
ICRP, that their exposure may induce cancer or heritable effects. This quantity takes into 
account the fact that the induction probability and severity of radiobiological effects per unit 
dose are not identical in various parts of the body by weighting individual organs and 
tissues by the relative detriments. Nowadays, most countries base their legislation on the 
1990 ICRP recommendations (ICRP, 1990), that take into account the absorbed doses to 
gonads and to 21 organs or tissues. More specifically, a 0.20 organ weighting factor was 
assigned to gonads (testes or ovaries), 0.12 to red bone marrow, lung, stomach and colon, 
0.05 to five organs (urinary bladder, breast, liver, esophagus and thyroid), 0.01 to bone 
surface and skin, and 0.005 to ten organs or tissues (adrenals, brain, upper large intestine, 
small intestine, kidney, pancreas, spleen, thymus, uterus or prostate and muscle). ICRP 
assigned a nominal risk coefficient of 7.3% per Sv for the whole population and 5.6% per Sv 
for adult workers (18-64 years old).  
According to 1990 ICRP recommendations, the detriment-adjusted risk to patients that 
undergo a CT examination of the aorta, that results to a 14 mSv effective dose, is about 0.1% 
(=14 10-3 x 7.3%). Let’s assume that the examination has to be repeated three times. Taking 
into account that the fact that the risk increases linearly with dose and the hypothesis often 
made that that the time period over which the dose is given does not modify the risk, the 
three examinations result in a 0.3% risk. Similarly, the occupational radiological risk of an 
interventionist that gets an effective dose of 100 mSv due to his occupation over a 25 year 
period (4 mSv annually on the average) is estimated to be almost 0.6% (~100 10-3 x 5.6%).  
Recently ICRP updated its recommendations (ICRP, 2007). Among others, the number of 
organs/tissues that are taken into consideration for cancer induction was increased from 21 
to 27, the weighting factors were modified (for example, the nominal risk for heritable 
effects in adult workers up to second generation was reduced by a factor of eight) and the 
nominal risk coefficients for the whole population and for adult workers were reduced to 
5.7 % and 4.2% per Sv, respectively. Taking into account that most EVAR patients are past 
reproductive age and have serious underlying health problems, i.e., with life expectancy 
shortened as compared to whole population, deterministic injuries in patients are usually of 
greater concern than those of stochastic effects. 
3.2 Deterministic effects 
Deterministic effects, or tissue reactions, can be induced by X-ray doses of a few Gy from X-
rays to ovaries, testes, red bone marrow, skin, carotid arteries, brain and the eye lens (ICRP, 
1984, 2007). However, recently ICRP stated that “although uncertainty remains, medical 
practitioners should be made aware that the absorbed dose threshold for circulatory disease 
may be as low as 0.5 Gy to the heart or brain”. Doses higher than few Gy are required to 
induce deterministic effects to other organs, such as lungs, intestine and kidneys.  
The incidence of radiation induced injuries in patients is small when compared with the 
large number of fluoroscopy – guided procedures carried out world-wide, but their 
consequences can be devastating (Balter & Moses, 2007; ICRP, 2000). Therefore, practitioners 
should apply methods to avoid the induction of such effects and know how to recognize 
their signs. In addition, they have to communicate the radiation risk information to patients 
and provide them the opportunity to ask questions, whenever they deliver doses that could 
potentially induce them. 
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Early tissue reactions (on time scale less than about two months after irradiation) usually are 
the result of either inflammatory type reactions occurring as a result of cell permeability 
changes or sterilization of stem and progenitor cells. On the contrary, late tissue reactions 
(on time scale from months to many decades) may occur as a result of either the direct injury 
to the target tissue, or as a result of severe of early reactions (e.g., dermal necrosis as a result 
of epidermal denudation) or/and chronic infection. Late tissue reactions, such as excess 
cardiovascular disease that becomes clinically apparent only 10 to 20 years post-irradiation, 
have a long and dose-dependent latency period before their clinical expression, reducing 
thus the probability of induction in elderly patients. 
Although deterministic effects may appear in all body areas, the various tissues and organs 
have different tolerances. Once a threshold dose has been exceeded, the probability of 
induction and the severity of the effect increases with increasing dose. The threshold dose, 
TD1, i.e. the amount of radiation that is required to cause a specific observable effect in 1% of 
the exposed individuals, depends on a number of factors, such the irradiated tissue or 
organ, the type of response and the time over which the dose was given. TD1 usually 
increases with increase of the time over which the dose is given, or by dose fractionation, 
due to cellular repair and even repopulation. Therefore, increase of the interval between 
medical procedures that require “heavy” exposure of the same body region, if clinically 
acceptable, modifies the dose response relationship.  
The TD1 currently used values, such as those on skin reactions (Table 1) refer to healthy adults. 
No specific data have been proposed to be used for children and subjects with mutations in 
important DNA damage sensing or repairing genes (the homozygous form of ataxia 
telangiectasia gene, Fanconi anemia, and Bloom syndrome are typical examples), patients with 
diabetes, active connective tissue diseases (scleroderma, lupus erythematosus, etc), 
autoimmune disorders, and patients with disrupted skin due to surgery or burns.  
In most tissues and organs, responses are greater when the irradiated volumes are greater. 
This volume effect means that the threshold dose increases as the volume of the irradiated 
organ/tissue decreases. Cell migration, proliferation and differentiation of progenitor cells 
from the margins to the heavily irradiated tissue volume may explain this effect (Dilmanian 
et al., 2007). Paired organ, such as the kidneys, and organs with functional subunits 
arranged in parallel, such as elements in the liver, rather in series, such as elements in the 
spinal cord, can sustain partial inactivation without clinical signs of injury.  
3.2.1 Skin reactions 
Since the early 1990s reports of radiation-induced skin injuries to patients due to 
fluoroscopically guided medical procedures have steadily increased. The skin is the only 
organ, which is always exposed to primary radiation during X-ray imaging (the skin region 
of beam entrance is the region that gets the highest dose). Relative to other organs, skin is 
less liable to develop fatal cancer after irradiation (ICRP 1991, 1992, 2007). However, the 
thresholds for mild deterministic effects are relatively low compared other organs 
(International Atomic Energy Agency [IAEA], 1998). Therefore, only five months after the 
discovery of X-rays, serious skin damage was documented, three weeks after imaging the 
head of a child (Daniel, 1896; Tarbell et al., 1981). Since then, a vast literature has been 
published on skin injuries that may evolve slowly over time, extending from hours to years 
after irradiation, often with periods between them of none or few symptoms (Table 1).  
A minimum number of adjacent cells must be damaged by radiation to elicit skin injury 
(Peel & Hopwell, 1984; Dilmanian, et al., 2003). The dose-response relationship for each type 
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of skin damage due to X-ray irradiation (Table 1), as well as the kinetics of healing, depend 
on a large number of factors, such as protraction of irradiation or dose fractionation 
(potential of partial or full repair between fractions), size and location of the exposed area 
(the skin in the back of the trunk is considered to be of medium radiosensitivity), obesity, 
skin hydration status and coloration (light-colored skin is regarded to be most sensitive). 
The dose-response relationship is often modified in patients given some medications that 
may modify skin response, before, during, or even years post irradiation (Burris & Hurtig, 
2010; Camidge et al., 2001; Hymes et al., 2006). 
In general, the earlier the onset of clinical changes (Table 2) the more severe the pathology of 
the skin lesion (Muller & Meineke, 2010). Following skin irradiation some basal cells are 
destroyed. The remaining cells shed more quickly. Mitotic inhibition appears about 30 minutes 
after a single 4 to 5 Gy X-ray irradiation, followed by decrease in the proliferation of the 
germinal layer of the endothelium. No clinically observable skin reactions are expected to be 
induced following a single acute dose up to 2 Gy of X-rays (higher total doses can be tolerated 
following prolonged or fractionated irradiations). Pain, if occurs, does not occur immediate (as 
in thermal burns), but when it appears, it is sever and resistant to drugs (its evolution is 
regarded as a good indicator for the prognosis and prediction of local skin atrophy and even 
necrosis (Rojas-Palma, et al., 2009). Therefore, although skin injuries are not usually life 
threatening, the more severe lesions may result among others in chronic intractable pain and 
permanent disability, such as that related to amputation (IAEA, 1998, 2002).  
The earliest visible skin response that may appear is a transient skin erythema, (reddening), 
at the entrance site of the X-ray beam. It resembles to sunburn with no hair loss at this stage, 
in contrast to thermal burns, where early hair and tissue loss is observed (Table 2). The first 
wave of erythema may be accompanied by sensation of heat and itching. It may be seen 
from a few hours up to 48 h after irradiation at single X-ray doses above 2 Gy, when the 
exposed skin area is relatively large (as in EVAR where ~250 cm2 is a typical field area), and 
fades after few hours to two days. This injury is attributed to inflammation due cytokine 
activation and capillary dilation, thus increasing blood volume beneath epidermis and 
vascular permeability. This stage is followed by a latent one during which there are no 
apparent skin reactions, despite the subcellular processes that may take place. In daily 
clinical practice, the isolated or confluent prodromal patches in the skin of EVAR patients 
that received high local doses may go unnoticed, because they are anticipated to occur at the 
patient’s back, an area that patients could no easily see. However, if observed, they can 
serve as an alarm for possible more serious radiation reactions. In this case, the use of 
dermatoprotector creams is recommended (IAEA, 2002).  
 
effect TD1 (Gy) effect TD1(Gy) 
early transient eryrhema 2 dry desquemation 14 
temporary epilation 3 late erythema 15 
main erythema 6 dermal necrosis >15 
permanant epilation 7 moist desquamation 18 
dermal atrophy 10 ischemic dermal necrosis  18 
telangiectasia 10 secondary ulceration 24 
Table 1. Threshold acute X-ray doses (ED) for skin reactions in 1% of the subjects 
(protraction of dose over a period of 1-3 weeks results in higher TD1). 
 
Aneurysmal Disease of the Thoracic and Abdominal Aorta 
 
158 
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stage latency persistence symptoms 
prodromal minutes-hours 0.5 – 36 h erythema, pruritus 
manifestation  3 weeks 1- 2 weeks erythema, pruritus, bullae, ulcer 
subacute 16 weeks  months erythema, ulcer 
chronic years unlimited ulcer, keratosis, fibrosis, epidermal 
atrophy, teleangiectasia, angioma, 
alterations in pigmentation 
late >10 years unlimited angioma, basal and squamous, cell 
carcinoma 
Table 2. Clinical stages of skin reactions (IAEA, 2002). 
If the dose is sufficient, inflammatory processes prevail and a second hyperemic phase of 
more sustained erythema (second wave of erythema), may appear at two to four weeks after 
dosing of at least 3 to 6 Gy in adults, usually lasting 20 to 30 days (ICPR, 2007). The severity 
of erythema and the latent period are dose dependent. This erythema phase may appear 
even one week after an acute dose above 15 Gy, often accompanied by subepidermal blister 
formation due to apoptosis and necrotic destruction of the epidermis (Muller & Meineke, 
2010), heat sensation, itching, tenderness in the irradiated skin area and changes in 
pigmentation. However, if the dose is not much a greater than the threshold, the erythema 
fades after about 4 weeks (Koening et al., 2001). The third phase of erythema (third wave of 
erythema) may also be seen with an onset of about 8 to 20 weeks post-irradiation following 
a single irradiation of at least 15 Gy. This phase may vary in severity, but at its maximum is 
characterized with a dusky / mauve appearance. Recently, Rahimi et al. (2011) associated to 
radiation damage a square shaped burn observed in the back of a patient with abdominal 
aortic aneurysm during the second post-repair visit to the hospital. 
Two to three weeks after an acute X-ray dose exceeding the 4 Gy threshold (ICRP, 2007), 
epilation may occur due to damage in the base of the hair follicles (in some anatomic 
locations the TD1 could be higher than 4 Gy). Single acute doses from X-rays in excess of 7 to 
10 Gy may irreversibly reproductively sterilize or lead to apoptotic death the stem cells in 
hair follicles, resulting in permanent epilation (Koening et al., 2001; Kim et al., 2003). 
However, epilation is temporary following low radiation doses. Survival of basal and 
germinal matrix cells in the hair follicles may allow for hair re-growth (Geleijns et al., 2005) 
about 1.5 to 4 months post-irradiation. At the initial stage of re-growth, hair may be thinner 
(up to 30% reduction in diameter) and sparse, differing occasionally in pigmentation and 
structure from that before irradiation.  
Alopecia has been reported in literature to be induced in patients who underwent 
endovascular treatments for various clinical conditions, such as aneurysm (Foroozan et al., 
2008; Lee et al., 2004; Marti et al., 2008) and arteriovenous malformations (Fellman, 2011; 
Wen, et al., 2003) mainly in the skull, as well as in practitioners, such as hair loss reported at 
the lower legs of cardiologists (Wipper et al., 2005). Taking into account the locations of the 
X-ray entrance ports used in patients with aortic aneurysm and their age distribution, 
radiation induced hair loss is not as stressful as in other patients, such as those in young 
patients with malformations in the head or those with radiotherapy.  
The rate of gradual decline in cell density in the basal layer depends on the rate of epidermal 
turnover at the irradiated site. A 50% reduction of the normal basal cell density appears to 
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provide a stimulus to the remaining viable colonogenic stem cells to proliferate starting 
about 3 weeks post irradiation in pig skin, the model historically assumed to be the best one 
for human skin (Van de Aardeg et al., 1988). At relatively low doses the number of 
developing colonies will be adequate to unite into a single group, thus leading 3 to 6 weeks 
to dry desquamation, an atypical keratination of the skin (ICRP, 1992). If the X-ray dose 
exceeds 18 Gy, the reduced number of developing colonies may not cover the entire 
damaged area and cell loss will continue, leading to moist desquamation, i.e., loss of the 
epidermis. At this stage dermis is denuded, allowing serum from the deep cutaneous layers 
to be excreted (Koening et al., 2001) often responding with marked inflammation (the use of 
glucocorticoids and hydrocolloid dressings might be considered, as well as local infection 
prophylaxis and treatment). When the area of the irradiated skin is completely denuded of 
clonogenic epithelial cells, healing must occur totally as a result of division and migration of 
epithelial cells from the edges of the irradiated skin area. For all, but the very small radiation 
fields, the repopulation progresses slowly, thus exposing the skin to risk of secondary 
ulceration, at least 6 weeks post-irradiation (ICRP, 1992; Balter et al., 2010). Some radiation 
ulcers that were healed over time have a tendency to recur in the following months and 
years (Koenig et al., 2001). Other ulcers never heal completely even years after 
fluoroscopically guided interventions.  
In general, dermis presents clinically its response at a later stage than epidermis and may 
not reach its peak even after some years (Geleijns et al., 2005). Cutaneous reactions are 
attributed to complex interactions between antiproliferative and proinflammatory processes, 
involving a variety of cytokines, adhesion molecules, growth factors and their receptors 
(IAEA, 2002). Dermal ischaemia and necrosis may appear 6 to 8 weeks post-irradiation at 
doses of at least 20 to 25 Gy. These effects were preceded by loss of endothelial cells, 
microvascular damage, reduction in capillary density, edema and impaired lymphatic 
clearance (ICRP, 1992). Late skin damage is characterized by dermal atrophy, dermal tissue 
thinning, long-lasting telangioectasia (it appears at least 1 year after an acute X-ray dose of 
at least 10 Gy), cutaneous fibrosis characterized by an increase of collagen fibers, keratosis, 
and often by reduction in the linear dimensions of the irradiated area. The use of interferon 
gamma as an inhibitor of collagen can be considered.  
The various techniques for diagnosis and medical management of localized radiation injuries 
were reviewed by various organizations and investigators (IAEA, 2002; Rojas-Palmas et al., 
2009; Muller et al., 2010). For example, moist desquamation may require surgical intervention 
to remove irradiated dermal and subcutaneous tissue (Rojas-Palmas et al., 2009). 
3.2.2 Eye reactions 
The eye lens is one of the most radiosensitive tissues of the human body, not with respect to 
cancer induction but mainly to the induction of lens opacity. The potential of X-rays to 
produce cataracts was suggested only two years after their discovery (Merriam & Worgul, 
1983). Lens transparency depends on proper differentiation of fibre cells from a layer of 
epithelial cells in the lens anterior surface near its equator. The earliest lens change is the 
visualization of granular opalescent on the posterior lens capsule observed by slit lap 
examination followed by the appearance of small vocuoles (ICRP, 2007; Merriam & Worgul, 
1983), which, over time, aggregate to form larger opacities of great impact in vision. The 
time between irradiation and the clinical manifestation of eye damage varies from half a 
year after “heavy” exposures to many decades.  
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In the past, induction of vision-impairing cataract was considered as a deterministic effect 
with threshold of 5.0 Gy following a single brief exposure to X-rays and higher than 8 Gy 
following highly fractionated exposures (ICRP, 2000). Based on knowledge available on 
2007, ICRP reduced the TD1 for cataract formation to 1.5 Gy, stating, however, that “the 
Committee can not ultimately exclude cataract induction at even lower doses”. Recent 
studies indicated a significant association between exposure to lower doses and increased 
risk of cataract formation (Ainsbury et al., 2009; Chodick et al .,2008; Ciraj-Bjelac et al., 2010; 
Jacob, et al.; Shore et al., 2010, Worgul et al., 2007). For example, some investigators reported 
on increased cataract rate even after ~0.5 Gy, acute or fractionated; others found detectable 
lens changes even after only 0.1 Gy doses and some even proposed the use of a linear non-
threshold model (Chodick et al., 2008; Nakashima et al., 2006). Based on evidence available 
on April 2011, ICRP further reduced the threshold dose for the eye lens to 0.5 Gy. 
Τhose occupationally exposed during fluoroscopically guided procedures are at a risk of 
radiation-induced eye damage. For example, Vano et al. (2010) found a 3.2 relative risk of 
posterior subcapsular opacities in 116 interventional cardiologists versus unexposed 
individuals. Ciraj- Bjelac et al. (2010) found a 5.7 relative risk of posterior subcapsular 
opacities in 56 interventional cardiologists of average age 42 y, that received a mean 
cumulative dose to the lens 3.7 Gy versus unexposed matched individuals (prevalence 52% 
vs 9%). Therefore, precautions, such as protective glasses and X-ray tube positioning, have 
to be taken to protect the eyes of staff heavily involved in fluoroscopically guided 
interventional procedures, delaying thus opacity propagation and limiting future 
cumulative lens dose (Vano et al., 2008).  
3.2.3 Effects of antenatal exposure  
Embryo and fetus are highly radiosensitive during the entire gestation period. The possible 
biological effects due to prenatal irradiation were reviewed in ICRP Publication 90 (ICRP, 
2003). The type and the severity of the damage depend on the time of exposure relative to 
conception (ICRP, 2003, 2007; Brent, 2007). Chronic or fractionated irradiations to X-rays at a 
specific total dose are usually assumed to be four to ten times less risky than single acute 
doses.  
The life-time cancer risk after prenatal irradiation is assumed to be at most few times that of 
the population as a whole and not greater than that following exposure in early childhood 
(ICRP, 2007). For example, following an 100 mGy fetal dose there is a 99% chance that the 
exposed fetus will not develop childhood cancer or leukaemia. Animal experiments indicate 
higher radiosensitivy for cancer induction in females than in males and at late than early 
gestation periods (ICRP, 2003). However, it is not clear if these findings hold for humans. In 
addition, it is not possible to determine tissue/organ weighting factors of the conceptus, 
based on the currently available data. 
The risk for lethality of the developing organism is assumed to be highest during the first 
post-conception days (pre-implantation period). At this period the number of cells in 
humans increases from one, the zygote, to about 200. No observations are available at this 
gestational period in humans, as conception in not noticed at that time. Therefore, the 
current knowledge is based on animal models. At doses of few tens of mGy lethal effects are 
very infrequent. However, lethality reaches 50% for 1 Gy X-ray doses given at stages from 
the zygote to expanded blastocyte (ICRP, 2003). The currently available data provide no 
reason to believe that, if death does not occur at this stage, significant health effects may 
occur after birth, except if there is genetic predisposition for malformations (ICRP, 2007).  
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Human epidemiological studies and animal studies indicate that the in utero radiosensitivity 
for malformations (defects visible at birth) depends on gestation age and that the 
regenerative capacity decreases as differentiation of tissues and cells progresses It is 
currently believed that there is a dose threshold of about 100 mGy for malformation during 
the most radiosensitive period for such an effect, the period of major organogenesis (3 to 7 
weeks post-conception). Studies on rodents indicated the existence of a dose threshold for 
induction of intrauterine growth retardation of about 0.25 Gy following an X ray irradiation 
within a short time period during the most sensitive period that is advanced stages of 
organogenesis and 0.5 Gy during the less sensitive stages (ICRP, 2003). Therefore, for stage 
of peak sensitivity for fetal underweight differs from those for lethality and malformations. 
Nakasima, et al (1994) analyzing body habitus of age 18 years of in utero exposed atomic-
bomb survivors found a clear radiation effect on standing height, however in a later study 
(Nakashima, et al., 2005) they failed to find dependence of the effect on the gestational 
period at exposure, particularly among males. Neurobehavioral studies of animals exposed 
in utero demonstrate a threshold for behavioral effects at the same dose as for other 
teratological effects, i.e. 0.2 Gy (Brent, 2007). 
High radiation doses (1 to 2 Gy) of ionizing radiation to the developing human fetus may 
induce mental retardation and microcephaly (Brent, 2007). The susceptibility of the 
developing human to injury from prenatal exposure was clearly shown by Schull and Otake 
(1984, 1999). The human data related mainly to those exposed to radiation from the use 
nuclear weapons in Hiroshima and Nagasaki are in good agreement with data on animal 
models. Severe mental retardation may occur following prenatal irradiation. When the cases 
assumed to have non-radiation aetiology at the two Japanese towns were excluded (e.g. 
Down’s syndrome), threshold dose values of 0.55 Gy (95% confidence interval 0.3 to 0.6 Gy) 
and 0.87 Gy (95% confidence interval 0.3 to 1.1 Gy) were proposed for irradiations 8-15 and 
16-25 weeks post-conception, respectively, i.e. the major neuronogenetic periods of the 
developing human neocortex during which the developing brain expands very fast (ICRP, 
2000; Nowoakowski & Haeys, 2008). In addition, a decline in IQ values of about 25 IQ points 
per Gy was observed due to irradiation 8 to 15 weeks post-conception, resulting in very 
small detriment at X-ray doses less than 0.1 Gy. Irradiations 16 to 25 weeks pos-conception 
resulted in lower IQ decrement, 13 IQ points per Gy. From the other hand, there is no data 
supporting a similar damage, when the dose is given at a later gestation stage (ICRP, 2003, 
2007). 
4. Radiation protection in aneurysm repair 
Radiation dose and image quality strategies are important for ensuring a balance between 
cost and benefit. The question to ask in daily clinical practice is not “is this radiation-related 
procedure safe?” but “is this procedure needed to help the physicians provide the best 
medical treatment?” The practitioner has the responsibility to order / carry out the 
appropriate tests and interventions when justified by the presenting symptoms or concerns 
with the lowest cost consistent with the medical aim.  
In EVAR, as in any other type of fluoroscopy guided vascular intervention, both patient and 
staff radiation exposures are related to the dose at the interventional reference point (Do) 
or/and the dose area product (DAP) value. Patient data related to over AAA 1000 repairs 
are summarized in Table 3. The corresponding studies indicated that the vast majority of the 
patients were male with mean age 70 to 75 years and that the mean fluoroscopic time  
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Geijer, et al., 2005 24 72 28 72+45 60.1  390 mobile 
Kalef-Ezra et al., 
2009 62 74 23 42.5+25.6 37.4  227 mobile I 
Lipsitz, et al., 2000 47  39    360 mobile 
Present study 142 70 22 30+24 24.4  205 mobile II 
Weerakkody, et al., 
2008  96* 73 21*,++  150*  850*,++ mobile 
Weiss, et al., 2008 12  21 152   750 mobile 
Farrar, et al., 2005 121 74 24++     not specified 
Jones, et al., 2010 64 75 23 54+34    not specified 
Jones, et al., 2010 320 75 29 47 +28  1187  not specified 
Bannazadeh, et al., 
2009       729 stationary 
Blaszak, et al., 2009 61 71.5 23 381+285 355   stationary 
Geijer, et al., 2005  24+    600 + 2900+  stationary 
Kalef-Ezra, in 
press 6 72 12 192 205  1050 stationary 
Kuhelj, et al., 2010 152 71 21  154  440** stationary 
Panuccio, et al., 
2011++ 47 75 83 782 697 6300 2590 stationary 
* excluding data on seven patients,  ** median rather than mean value, 
PSD: peak skin dose,  + simulated procedures,  ++ thoracoabdominal aneurysms 
Table 3. Demographic data, fluoroscopy time and dosimetric quantities related to AAA 
repairs. 
per repair was about 20 min, with two exceptions, the studies by Lipsitz er al, and by Panuccio 
et al. (2011) who treated thoracoabdominal aneurysms. On the other hand, the spread of the 
DAP and the mean peak skin dose, (Dpeak) values were also large, even excluding the study by 
Pannuccio, et al. In addition, as in other types of vascular interventions, the spread of values at 
each facility was also large (65% is a typical value of the coefficient of variation) and their 
distributions were not Gaussian (the median is typically about 15% lower than the mean 
value). In the following paragraphs some of the factors related to the spread of the mean DAP 
values between facilities and between repairs carried out at each facility are discussed, as well 
as, some means to control the radiation burden. 
The currently acceptable errors in Do and DAP measurements are quite large, +35% by the 
Food and Drug Administration (FDA) and +50% by International Electrochemical 
Commission (IEC). In addition, there is no unique definition on the place of the 
interventional reference point along the central beam line. IEC defines it to be at 15 cm 
distance on the X-ray tube side (IEC, 2000), while FDA defines it at 30 cm distance from the 
image receptor, leading a factor of four difference in the displayed Do values in systems 
with 100 cm focus to distance. An additional source of error is the angular dependence of 
the X-ray beam attenuation on the patient’s bed (the calibration of the DAP meter is often 
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carried out at a geometry that differs from that used during AAA repair). Therefore, spatial 
attention is required when comparing values presented in various studies and/or 
correlating the displayed quantities with the mean or the peak doses in an organ or a tissue. 
4.1 Assessment of stochastic risk to patient 
The assessment of the effective dose related to AAA management is required to weigh the 
potential stochastic risks against the anticipated medical benefits. However, direct dose 
measurements are impractical for most organs and tissues. Thus, the assessment of mean 
doses absorbed by the organs and tissues of interest is usually made by introducing to a 
software some repair-related parameters (DAP, field size, data on patient’s body habitus, 
the anatomic location of the lesion, X-ray tube high voltage and filtration, etc.). The dose 
corresponding to each radiation field has to be assessed separately and then summed-up to 
calculate E (most investigators so far assumed that the location and the size of the X-ray 
beam and spectral distribution remained unchanged throughout repair, and neglected the 
influence of body shape and composition on dose distribution). Various investigators 
reported mean E to DAP ratios ranging between 0.14 and 0.25 mSv/Gy cm2 (Table 4) using 
the 1990 definition of E by ICRP. On the other hand, the mean E values shown in Table 4 
differ up to two orders of magnitude, with the lower ones being comparable to the effective 
dose resulting from three years of exposure to natural background radiation.  
 






Badger, et al., 2010 0.25 12  
Bannazadeh, et al., 2009 0.14 109 
Ho, et al., 2007 12.7  
Geijer, et al., 2005 0.14 10.5 8.7 
Kalef-Ezra, et al., in press 0.23 5.8 * 4.6 
Kalef-Ezra, et al., in press 0.23 6.6 **  
Kalef-Ezra, et al., in press 0.21 40 ***  
Weerakody, et al., 2008 0.18 27 
* mobile C-arm unit I,  ** mobile unit II,  *** stationary C-arm unit 
Table 4. Repair related effective dose. 
The excess life mortality after exposure to ionizing radiations at low doses decreases with 
increasing age (ICRP, 1991). It is about 4.8% per Sv in men exposed at age of 65 years, 2.6% 
and 1.1% per Sv in men exposed at 75 and 85 years, respectively, and slightly lower in 
women (3.9%, 2.9% and 0.9%, respectively). In case of uniform irradiation, leukemia is 
anticipated to be the main cause of death (almost 50% in men exposed at age of 70 years). 
Taking into account the age and sex distribution of EVAR patients (Table 3), an excess life 
mortality of 3.5% per Sv can be assumed. Therefore, the radiological health detriment of a 
repair requiring an effective dose of 10 mSv is about 3.5 10-4.  
Combining dosimetric data on 91 repairs carried out at Ioannina University Hospital (IUH) 
using a Pulsera mobile C-arm unit with a PC-based Monte Carlo software (Kalef-Ezra in 
press), it was found in that: 
- the mean E/DAP ratio was 0.23 mSv/Gy cm2 (range 0.17 to 0.31 mSv/Gy cm2), 
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carried out at a geometry that differs from that used during AAA repair). Therefore, spatial 
attention is required when comparing values presented in various studies and/or 
correlating the displayed quantities with the mean or the peak doses in an organ or a tissue. 
4.1 Assessment of stochastic risk to patient 
The assessment of the effective dose related to AAA management is required to weigh the 
potential stochastic risks against the anticipated medical benefits. However, direct dose 
measurements are impractical for most organs and tissues. Thus, the assessment of mean 
doses absorbed by the organs and tissues of interest is usually made by introducing to a 
software some repair-related parameters (DAP, field size, data on patient’s body habitus, 
the anatomic location of the lesion, X-ray tube high voltage and filtration, etc.). The dose 
corresponding to each radiation field has to be assessed separately and then summed-up to 
calculate E (most investigators so far assumed that the location and the size of the X-ray 
beam and spectral distribution remained unchanged throughout repair, and neglected the 
influence of body shape and composition on dose distribution). Various investigators 
reported mean E to DAP ratios ranging between 0.14 and 0.25 mSv/Gy cm2 (Table 4) using 
the 1990 definition of E by ICRP. On the other hand, the mean E values shown in Table 4 
differ up to two orders of magnitude, with the lower ones being comparable to the effective 
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using a Pulsera mobile C-arm unit with a PC-based Monte Carlo software (Kalef-Ezra in 
press), it was found in that: 
- the mean E/DAP ratio was 0.23 mSv/Gy cm2 (range 0.17 to 0.31 mSv/Gy cm2), 
 
Aneurysmal Disease of the Thoracic and Abdominal Aorta 
 
166 
- the red bone marrow and colon were the main contributors to E in male patients,  
- the image registration contribution to E was only 20%, 
- the effective dose was linearly correlated with fluoroscopy time, tfl, and body mass 
index (BMI), i.e., 
E (mSv) = - 7.24 + 0.298 tfl (min) + 0.237 BMI (kg/m2) 
The effective dose related to the repair itself is often lower than that related with the other 
aspects of AAA management. For example, a typical two-phase CT abdominal/pelvic 
angiography often requires about 20 mSv, i.e. few times higher than that of a repair itself 
carried out using a mobile unit. Therefore, various protocols for diagnostic / planning and 
postoperative follow-up imaging have been proposed to reduce both radiological and renal 
function deterioration risks. Dose reducing protocols related to post-operative imaging can 
be divided in three main groups:  
- application of less intensive follow-up procedures, including an optimized temporal 
spacing between CT scans (Dias, et al., 2009; Go, et al, 2008; Verhoeven, et al., 2011; 
White & McDonald, 2010; Zhou, 2011),  
- optimization of the CT scanning parameters (Diehm et al., 2008; Iezi et al, 2006,2009; 
Kalef-Ezra et al., in press; Kirby et al., 2007; Macari et al., 2006; Nakayama, et al., 2006; 
Sommer, et al., 2010; Wintersperger, et al., 2005), 
- replacement of CT imaging with alternative imaging / assessment techniques, that 
require lower or even no radiation dose, such as ultrasound or MRI imaging (Elkouri et 
al.; 2004, Manning, et al, 2008.; Sternbergh, et al., 2008; Ten Bosch, et al.; 2010; 
Tomlinson, et al, 2007, 2009; Truijers, et al., 2009). 
The application of the life-long protocol for AAA management at IUH with optimized post-
operative CT parameters resulted in a cumulative effective dose of almost 60 mSv (Kalef-
Ezra, in press), which leads to a 0.2% excess life-time mortality, using the 3.5% per Sv risk 
factor. However this value has be divided by a factor of two according to the current ICRP 
recommendations (ICRP, 2007) due to dose fractionation over many years, resulting in a life-
time mortality of 0.1%. 
4.2 Assessment of deterministic effects to patient 
On contrast to radiation-induced cancer that can be observed clinically after many years, 
deterministic reactions are often near-term radiation effects. In CT imaging the X-ray 
spectrum is harder than that used in AAA repair and the X-ray source rotates around the 
human body, dispersing thus the imparted energy to the body more uniformly and over 
larger volumes. Therefore, the induction of deterministic effects in AAA patients is mainly 
related to the repair itself and not to CT.  
If such effects occur, the most probable location is the skin at the patients’ back (Table 3). 
Damaging skin levels can be reached in a short time especially when obese patients are treated 
using short focus-skin distance, non-optimized fluoroscopic units and/or high image 
magnification factors. Therefore, each medical facility has to develop techniques to assess peak 
skin dose, PSD, and control it at levels below the threshold for induction of deterministic 
effects (Tables 1 and 2), taking into account that the same skin area may absorb additional 
doses due to other imaging procedures made within a relatively short time period.  
Skin dose mapping shows the overlapping fields and allows the accurate determination of 
PSD. Recently some manufactures of stationary fluoroscopic units introduced the use of 
software to calculate PSD combining the readings of the DAP meter with geometrical data 
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related to bed movements during the procedures, focus to table distances, beam 
angulations, etc. High sensitivity self-developing radiochromic films, such as reflective-type 
dosimetric gafchromic XR type films and arrays of thermoluminescent dosimeters (TLDs) 
have been used for direct 2D dose skin mapping by placing them between the surgical bed 
and patient’s back (Table 5). The extent of polymerization of the films, and thus the changes 
in their optical properties, are influenced by their dosing. TLDs emit light upon heating at 
any time after irradiation. Other types of dosimeters could be used, such as the scintillating 
ZnCd dosimeters and diodes. Slow photographic film, such as those use in radiation 
therapy, do not allow accurate determination of the dose distribution due to the large 
dependence of their response to X-ray spectrum. Currently there is no perfect dose mapping 
system available and each facility should use the best available indicator.  
TLD handling and processing are complex and time consuming and the cost of the 
equipment to process is high. In addition, there is a risk to miss with TLDs the region with 
the peak skin dose. On the other hand, one has to consider the cost of the radiochromic 
films, that can be used only once, the substantial dependence of their response on the X-ray 
spectrum and the fact that they cannot be read accurately until after their use, because they 
must undergo a time-consuming stabilization process (Kalef-Ezra et al., 2008, 2010). 
However, if concern is raised over skin dose, the radiochromic film can be removed from 
the bed during repair and examined by bare eye in normal light at the operation room for a 
rough dose assessment.  
Kuhelj, et al. (2010) analyzing the dosimetric data on 179 patients treated using a suboptimal 
mobile C-arm unit found a 0.44 Gy median PSD (range 0.12 to 2.7 Gy). Investigators at 
Cabridge reported a 0.85 Gy median PSD on 96 repairs (Weerakkody, et al. 2008; Walsh, et 
al., 2008). About 1/4 of their patients received PSD higher than 3.75 Gy and the maximum 
dose was 8.8 Gy (the authors excluded from the analysis data on seven additional repairs 
because the “values were orders of magnitude greater than typical values recorded”). 
Pannuccio, et al. (2011) reported on 47 patients that undergone thoracoabdominal aneurysm 
repair a 2.5 Gy mean PSD (in ten patients the dose was higher than 4.0 Gy, and the 
maximum value was 6.5 Gy). The most heavily irradiated areas were of 4 cm2 size and 
located at the central part of the back close to the kidneys. Despite the high PSDs found, no 
skin reactions were reported. On the contrary, Rahimi et al. (2011) related to radiation the 
acute gastrointestinal complications (nausea, diarrhea and abdominal pain) reported by an 
EVAR patient during the first post-repair visit. These symptoms were coupled with skin 
color alterations observed during the second visit. According to the authors “the procedure 
required about 56 min of fluoroscopic imaging time resulting in 6.8 Gy total radiation 
exposure”.  
Lower mean PSD values were reported by other investigators (Table 3). For example, Weiss et 
al. (2008) measured a 0.75 median value (range 0.27 to 1.25 Gy) in twelve repairs. Geijer, et al. 
(2005) analyzing data on 24 procedures calculated a 0.33 Gy median value (range 0.08 to 1.1 
Gy). Among the 204 patients treated with EVAR at IUH using mobile C-arm units, no patient 
received a peak dose exceeding 1.1 Gy. Therefore, in none of the repairs presented in these 
studies using mobile fluoroscopic units, PSD approached the threshold for any skin reaction. 
In daily clinical practice direct 2D dose skin mapping in all patients is considered to be a 
time and money consuming procedure. In addition, it does not provide real-time guidance 
to the operator on accumulated dose to adjust the employed techniques during repair, such 
as the use of dose spreading techniques, i.e. change of the X-source angle, while the 
intervention site is kept in the centre of the field of view (Johnson et al., 2001).  
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related to bed movements during the procedures, focus to table distances, beam 
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An empirically determined relationship between indications of meter and PSD obtained by 
direct measurements in a subgroup of patients in each facility can be used for this purpose 
(Kalef-Ezra, et al., 2009, 2010). This approach bypasses the accuracy limitations of the DAP 
indicators and many of the differences in employed imaging strategies. If no direct data is 
available at a facility, data from other facilities could be used as a rough estimation, keeping 
in mind that the relationship depends on a larger number of factors. The currently available 
data on the PSD to DAP ratio for AAA repairs vary between 3 and 7 mGy per Gy cm2 (Table 
5). Assuming a 6 mGy / Gy cm2 value, the restriction of the DAP below 333, 667 Gy cm2 
keeps PSD below the threshold for temporary erythema and epilation (Tables 1 and 2), 1.0, 
1.15 and 2.3 kGy cm2 below the threshold of main erythema reaction, permanent epilation 
and dry desquamation respectively, provided that no other imaging with X-rays is carried 
out within a short time period. Based on such findings a warning level (called also as 
triggering level) of 250 Gy cm2 can be used for the operator to consider modification of the 
imaging strategy during the repair of the specific patient. In practice the operator could be 
notified by the technical staff present in the room when the 150, 250, 350, 650 and 1000 Gy 
cm2 levels were reached. However, it is up the interventionist in charge to decide how to 
proceed, when a significant dose level has been crossed. 
To avoid the induction of skin injuries, practitioners should always seek to establish before 
repair whether the patients had previous imaging procedures or radiotherapy sessions, 
together with the estimated skin doses and the beam entrance sites (ICRP, 2000). In addition, 
monitoring and tracking of radiation doses in endovascular AAA management should to be 
carried out after repair (CRCPD, 2010). More specifically, the dose indications should to be 
recorded in the machine’s log book (physical or electronic) and reviewed immediately after 
repair to determine if the patient is at risk to develop skin injuries. The dosimetric data have 
to be recorded to the patient’s medical record, indicating the beam entry site. If some 
threshold is exceeded, such as 150 Gy cm2 (the level depends on national legislation and the 
local rules), the medical (or health) physicist in charge of the unit has to assess more 
accurately the doses and the associated risks. The facility radiation safety committee/ officer 
should periodically check the distribution of the dosimetric parameters, compare them over 
time and review one by one all repairs that exceeded some dose value, such as a PSD of 3.0 
Gy. In departments with “heavy” duty, the data have to be also analyzed according to the 










Geiger, et al., 2005 mobile angiographic 5.5 calculated 
Kalef-Ezra, et al., 2009 mobile I surgical 5.0 LiF:Mg,Ti TLD 
Kalef-Ezra, et al., 2011 mobile II angiographic 6.8 LiF:Mg,Ti TLD 
Kalef-Ezra, et al., 2011 mobile II angiographic 6.7 gafchromic XR-RV2 
Kuhelj, et al., 2010 stationary angiographic 3.5 gafchromic XR 
Panuccio, et al., 2011 stationary angiographic ~3 gafchromic 
Weiss, et al., 2008 mobile - ~5 gafchromic 
Weerakkody, et al., 
2008 mobile surgical ~6 calculated 
Table 5. Skin peak dose and its relationship with DAP. 
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All patients who potentially received a skin dose higher than some predetermined value, 
usually set at 3.0 Gy, should be closely monitored for potential serious skin injuries. The 
practitioner should arrange for the patient to be reviewed about two weeks after repair. The 
patient and family should to be informed of the possible symptoms and signs and instructed 
to check the patient’s skin during the first 48 h procedure (in case of out-patients) and once a 
week over the following five weeks. If radiation cannot be ruled out as the cause of skin 
lesion, the patient has to be referred to either a dermatologist or a radiation therapist, 
experienced in managing radiation injuries. In addition, patient’s personal physician should 
be informed to avoid procedures during subsequent two months, which could result in a 
substantial dose to the same skin area. Such actions are important because radiation injuries 
are often misdiagnosed and treated inappropriately.  
4.3 Determinants of patient’s radiation risks 
The potential risks of medical exposures to ionizing radiation must be balanced against the 
potential medical benefits of the procedures. Limiting potential radiological risk is essential, 
remembering the currently applied working hypothesis that there is no dose below which 
there is zero risk. In general radiation burden, besides the age and general clinical 
conditions of the patient, is influenced by a number of anatomical and technical factors, as 
well as to the education and training of the interventional team. Radiation protection can be 
ensured by appropriate design, procurement and commissioning of equipment, optimal 
operational technique and quality assurance backed by quality audit. In particular, the 
choice of the fluoroscopic unit to be used and the irradiation modes to be selected, have to 
be based primarily on the required level of image quality, ergonomic factors, financial costs, 
and associated radiological risks. The analysis of the influence of the various factors and the 
analysis of the accumulated experience may allow the selection of the optimum repair 
strategy. 
4.3.1 Equipment related factors 
Repairs can be carried out using angiographic units equipped with either low power 
generators, such as mobile C-arm fluoroscopic units widely used in operation theaters, or 
with high power stationary generators, such as those designed primarily for guidance in 
coronary artery interventions and located at radiology / cardiology suites. According to 
data shown in Table 3, the mean DAP per repair carried out using mobile units ranged 
between 30 and 152 Gy cm2. On the other hand, higher mean (192 to 782 Gy cm2) and 
median values (154 to 697 Gy cm2) were reported on repairs carried out using stationary 
units.  
To exclude the possible influence of the use of different protocols, few AAA repairs were 
carried out at IUH using a stationary 100 kW unit, an Allura 9C by Philips, at the lowest 
available mode (12.5 p/s fluoroscopy and registration rate 12.5 images/s and 11 mm Al 
equivalent filtration). The dosimetric data of these repairs was compared with those of 
repairs carried using a much cheaper mobile unit, a 7.5 kW Pulsera unit by the same 
manufacturer, selecting a registration rate of 3 images/s, and 50% of its maximum power 
during fluoroscopy in the majority of the patients, and avoiding magnified views. The 
repairs carried out with the stationary unit required on the average lower fluoroscopic time 
than those using the mobile one (Table 3). However, the use of the stationary unit resulted 
in an increase in both patient and personnel dose by a factor of about seven (this finding 
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dictated the early stop of repairs using the stationary unit). The increase was related in large 
part to the five-fold higher mean DAP rate during fluoroscopic imaging with the stationary 
unit and to the fact that registration contributed about 50% to total DAP, rather than only 
20% when the mobile unit was used, indicating the importance of the rate of registered 
images. Similarly to the present study (Table 3), Geijer et al. (2005) simulating a typical 
repair using a stationary high-power unit, reported that the replacement of the mobile unit 
with a stationary resulted in an eight-fold increase in DAP. 
Radiological burden, purchase and operation costs are not the only factors against the use of 
high power stationary units. AAA repairs performed at surgical theaters with mobile 
angiographic units are carried out in a more sterile environment, do not require the transfer 
of surgery and anesthesia equipment as well as staff to an often remote location in the 
hospital. In addition, repairs carried out under such conditions, could be easily changed 
during the procedure from enovascular to open repair, if required. Taking into account that 
AAA repairs are often time consuming, when such procedures are carried out in 
angiographic suite, an extra suite has to be kept free to carry out urgent cardiac procedures. 
Therefore, AAA repairs carried out using units designed for interventions in vessels of small 
diameter, such as the coronary arteries, have to be avoided. Hybrid units designed for 
interventions in both cardiac and non-cardiac vessels could be used, only if it is possible to 
adapt the operating parameters to the needs of AAA repair.  
Some mobile units may not meet the required criteria (e.g. adequate anode cooling rate, image 
quality, image processing capabilities). For example, two units made by the same 
manufacturer were tested at IUH under clinical conditions, a 3.15 kW Libra unit equipped 
with a stationary anode made of tungsten (W), two foci (0.6 and 1.4 mm, respectively), and a 
9” CsI/CCD image intensifier and a Pulsera unit equipped with a rotating W/Rh anode, foci 
0.3 and 0.6 mm in diameter and a 12” CsI/CCD image intensifier (Kalef-Ezra, et al., in press). 
The mean fluoroscopic times per AAA repair were similar (Table 3), however, the superior 
image quality of the Pulsera unit allowed its operation at lower mean power during 
fluoroscopy (120 versus 250 W on the average) leading to a mean skin dose reduction by a 
factor of about two and to a 15% reduction in the mean effective dose. In addition, most of the 
procedures carried out in obese patients with the Libra unit, had to be interrupted for few 
minutes to let the non-rotating anode to cool down, increasing thus the overall procedure time. 
The machine output depends on the mode selected by the operator. For example, Vano et al. 
(2008) simulating PA projection found in eight C-arm units that the use of the low dose 
fluoroscopy mode rather the high dose one, decreases the dose rate by a factor of about 2.5 
on the average (range of values 1.5 to 4.5), while the image registration increased the rate by 
a factor of 4 on the average (range 2 to 8). In addition, the high voltage and the X-ray tube 
current are automatically selected according to the distance between the focus and the 
image receptor, and the X-ray beam attenuation (in the patient’s body and in any supporting 
material, such as the bed).  
In general EVAR is carried out with the X- ray tube located below the bed. In this geometry, 
beam attenuation in the bed is anticipated to have a marginal influence on the patient’s 
dose, but not on the staff. Scattered radiation to staff is proportional to the X-ray machine 
output. To test the influence of bed attenuation thirty AAA repairs were carried out at IUH 
using a conventional surgical bed (Marquett Alphamaxx) and sixty with an angiographic 
table with carbon table-top and bed-suspended side shielding. The use of the latter reduced 
the mean DAP per repair by ~30% and personnel dose at chest level by about 40%. 
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4.3.2 Patient related factors  
Analyzing data on 140 patients treated at IUH over a 3 year period using a mobile unit, it 
was found that DAP values were positively correlated fluoroscopy time (r=0.78), a 
parameter that is related with the complexity of the repair. Similar correlations were 
observed by Blaszak, et al. (2009), Jones, et al. (2010), and Kuhelj, et al. (2010), but not by 
Pannucio (2011). Badger (2010) found that the radiation burden is also influenced by the 
operative strategy chosen by the surgeon, that depends on the clinical presentation. Studies 
at Belfast City Hospital on possible correlations between the DAP values of 320 elective 
AAA repairs and lesion-related morphological parameters, revealed weak positive 
correlations between DAP and proximal neck, sac and distal diameters, but no statistically 
significant correlation with neck length, and sagittal or coronal neck angles (Badger, et al.; 
2010, Jones, et al., 2010). In addition, they failed to find a statistically significant difference in 
the DAP values of urgent and those of elective repairs (Table 3). Panuccio, et al. found that 
type II or II thoracoabdominal repairs require higher mean DAP values than those of type 
IV repairs (1006 and 642 Gy cm2, respectively).  
Obese patients appear in particular to benefit from EVAR over open repair (Johnson 2010). 
However, DAP was found be positively correlated with the patient’s body mass index (BMI) 
(Kalef-Ezra, et al.; 2009, Panuccio, et al., 2011). Therefore, the risks for induction of 
radiobiological effects are increased in obese patients. In addition, higher mean DAP values 
are anticipated in male than in female patients, mainly due to differences in body built and 
body composition. 
4.3.3 Staff related factors 
Aneurysm repairs are complex and demanding procedures performed according to the 
operator’s education, training and practical skills. The number of initial repairs required to 
achieve the optimal surgical result was the subject of a number of studies (Forbes, et al., 
2007). Another factor to be considered is the potential for radiation-induced damage to 
patients and clinical staff. Therefore, medical and non-medical staff related to AAA 
management should receive appropriate theoretical and practical training in both clinical 
technique and radiation protection.  
All medical students should receive basic training on radiation physics, radiation biology, 
instrumentation, and radiation protection with emphasis on justification and optimization 
as part of the basic curriculum. Additional training on the span and impact of all factors that 
modify the radiological risks is required for those who intend to perform fluoroscopically 
guided vascular interventions (EC, 2000; Hirshfeld, et al, 2005; ICRP, 2011). For example, 
according to the European Union guidelines and the International Commission on 
Radiological Protection, medical doctors involved in interventional cardiology should get an 
accredited 20 to 30 h – long training program on radiation protection, which should include 
among other things, practical exercises and practical sessions (EC, 2000; ICRP, 2011). Specific 
additional training on the safe use of new radiation-related equipment / techniques should 
be provided at each medical facility before commissioning and during the initial stages of 
use and to all new personnel before the initiation of the clinical work (Dimitriou, et al., 
2011). Such programs of initial and continuing education and training should be established 
at national, regional or institutional level, approved by the Regulatory Authority of the 
country/state, and carried out in collaboration with academic institutions and appropriate 
professional bodies.  
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4.4 Assessment of staff radiological risk 
Staff exposure has to be assessed on a regular basis. In busy facilities trunk dosimeters may 
be combined with extremity dosimeters, such as ring and eye dosimeters. They can be of 
either passive or active type, such as solid state electronic dosimeters. Passive dosimeters, 
such as thermoluminescent badges, are typically used for one month before submitted for 
processing. On the other hand, active personal dosimeters (APDs) that often provide real-
time readings, may introduce substantial errors when used in fluoroscopy. Most of the 
currently commercially available APDs may not have appropriate characteristics for use in 
pulsed X-ray fields, such as those observed in EVAR, due to the dependence of their 
response on dose rate, X-ray pulse frequency and duration, as well as on angle of incidence 
(Clairand, et al., 2011). For example, APDs of the type used by surgeons that carried out 
EVAR (Panuccio, et al., 2011) were found to have substantial energy dependent response, 
that varies up to a factor of two in the spectral region of interest and saturates at dose rates 
above 30 mGy/min. Irrespective of the type of dosimeter used, the readings have to be 
analyzed by an experience medical (health) physicist. 
If a single personal trunk dosimeter is used, it can be located either above or below the 
protective apron, usually at the waist level, the chest or the base of the neck, depending on 
local regulations The effective dose to professionals due to fluoroscopically guided 
interventions will be numerically much lower than the dose registered by their dosimeter, if 
worn below the apron, and higher, if worn above. Therefore, in some departments, two 
dosimeters are routinely used, one above and the other below the apron. For example, the 
doses registered by personnel dosimeters worn above the protective apron at IUH 
catheterization laboratories, are 15 times higher than the doses registered by dosimeters 
worn below the apron.  
Various algorithms have been developed to correlate the readings of the trunk dosimeters 
with the worker’s effective dose. However, quite often these algorithms provide very 
different results for the same configuration.  In those countries, that a specific algorithm is 
not posed by legislation, one may estimate the effective dose simply by dividing the reading 
of a dosimeter worn above an apron of lead equivalence of at least 0.35 mm (section 4.4) by 
the factor of 12 and 8, depending on the use or no use of a protective collar. Therefore, if the 
dose registered by such dosimeters during a single year is 24 mSv, the occupational effective 
dose is 2 mSv, if the worker used a protective collar and 3 mSv, if he does not use it, 
irrespective of the exact type of the apron used. 
The probability of induction of stochastic effects to staff present in an operation room during 
AAA repair is related to the collective effective dose (staff presence is required, as far as 
robotic techniques are not used). The collective dose increases with increasing DAP and kV, 
and decreases with increasing distance between staff and the centre of the irradiation port. 
The mean collective dose registered by TLD badges worn by the IUH staff outside the apron 
at chest level per to DAP ranged between 2.1 and 2.5 μGy per Gy cm2, depending on the 
type of the C-arm unit used (Kalef-Ezra, in press). About 58% of the collective dose from 
repairs carried out using a mobile unit. Corresponded to the chief surgeon, 24% to the 
surgeon that stood at the opposite side of the bed and 18% in the remaining staff present in 
the room. The relative contribution of the chief surgeon decreased by a factor of two in 
procedures carried using a stationary unit. This difference was mainly attributed mainly to a 
ceiling-suspended radiation shield available only in the room equipped with the stationary 
unit. The replacement of the surgical bed used with an angiographic table with a table 
suspended radiation shield reduced the collective dose by about 40% (Section 4.3.1).  
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Assuming a 0.1 ratio between personnel effective dose and the dose registered by a badges 
worn at chest level outside apron for the IUH staff, that used 0.5 mm Pb equivalent wrap-
around aprons and thyroid collars, the mean collective effective dose per repair carried out 
with the mobile and the stationary units coupled with angiographic beds (Table 3) were 
about 6 and 48 μSv, respectively. These values were lower than the 170 μSv value calculated 
by Panuccio, et al. (2011), i.e., 130 and 230 μSv per type IV thoracoabdominal repairs and 
type II or III repairs, respectively.  
The mean “chest” dose to the chief surgeon at IUH that used a mobile Pulsera unit was ~35 
μGy per AAA repair using an angiographic table with table-suspended side protection. The 
registered mean dose per repair increased to 50 μGy by the use of a surgical bed and to 
almost 200 μGy by the use of a stationary unit. Liptsiz et al. (2000) and Panuccio et al. (2011) 
reported mean “chest” doses 300 and 560 μGy per repair, respectively. Ho et al. (2007) 
measured eye and left index finger doses to the first surgeon 6 and 33 μGy, respectively. 
However, Liptsiz at al. measured 165 and 380 μGy mean eye and finger doses per repair. 
Similarly, Saether, et al. (2005) analyzing data on fifteen repairs, found a mean dose at the 
middle phalanx of the middle finger of the first surgeon of 350 μGy per repair (the 
maximum value was 1.18 mGy). The main reason for such a large spread of values is 
attributed in large part to the interrelationship between staff and patient exposures.  
The number of repairs that a surgeon may perform to reach a predetermined radiation level 
is related to the mean DAP per repair and the means used to control personnel exposure. 
According to ICRP recommendations (ICRP, 1990, 2007) any of the following annual limits 
must not be exceeded in those exposed to low energy X-rays due to their occupation 
(additional limits refer to pregnant worker) 
- effective dose: 20 mSv,  
- eye lens dose: 150 mGy,  
- dose to any skin area that exceeds 1 cm2: 500 mGy. 
The 20 mSv annual effective dose could be reached at IUH by the first surgeon in case that 
he was carrying out annually repairs with a total DAP of ~160 kGy cm2 (20 mSv divided by 
the experimentally determined 0.125 μSv / Gy cm2 factor), under that assumption that he is 
not occupationally exposed to any other radiation source. This value corresponds to about 
5330 AAA repairs using the Pulsera mobile unit and the angiographic table and 830 repairs 
using the Alura stationary unit (Table 3, Section 4). However, one has to consider also the 
other two limits. The dose to the lens of the eye is closely related to the dose registered by 
the badge worn out side the apron (Lie et al., 2008). In case that no eye protection is used, 
the maximum number of AAA repairs has to be reduced by 25% (3800 and 580, respectively) 
assuming an eye lens dose equal to the one measured above apron (Kim, et al., 2008). Early 
in 2011 ICRP modified its recommendations and reduced eye lens dose limit from X-rays 
from 150 to 20 mSv, averaged over defined periods of 5 years, with no single year exceeding 
50 mSv. The application of the new limit restricts the maximum number of AAA repairs 
down to 533 and 83 respectively, if no eye protection is used. 
In the case that adequate eye protection is used and one of the surgeon’s legs is close to the 
imaged region, the maximum annual number of repairs could be dictated by skin dose. 
Simulations of repairs carried out at IUH were made to assess the absorbed dose at 35 cm 
horizontal distance from the central beam axis of the X-ray tube operated at 83 kV and 
located below the angiographic table. The dose to DAP ratio increased with increasing 
height from the floor, from 10 μGy/Gy cm2 at ~3 cm height, up to 50 μGy/Gy cm2 at ~80 
height (~15 cm below the lower surface the bed), and reduced at higher heights, (e.g., ~20 
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height (~15 cm below the lower surface the bed), and reduced at higher heights, (e.g., ~20 
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Gy cm2 at 110 cm height, i.e., at the horizontal level of the centre of the patient’s body). 
Assuming the operator’s leg is unprotected by his apron up to a 60 cm height from the floor, 
i.e. at a height where the dose to DAP ratio is ~40 μGy/ Gy cm2, an annual total DAP of only 
12.5 kGy cm2 results in 500 mGy skin dose, thus reducing the maximum annual number of 
repairs to about 415 or 65, depending on the type of fluoroscopic unit used. This example 
indicates the need to increase the distance of the operator’s leg from the X-ray source and 
the importance in the use of bed mounted drapes (Section 4.5). In case that a member of the 
operating team is a pregnant woman specific measures have to be carried not to exceed the 
limits related to the conceptus dose (section 4.6). 
4.5 Determinants of personnel radiation risks 
Those present in the room during AAA repair are irradiated from scattering radiation from 
the patient’s body and the operation table, and to a lower extent from radiation leaking from 
the X-ray head. Staff exposure can be limited by using various techniques. The most obvious 
techniques to reduce patient radiation burden are the reduction of the number of workers 
present in the room to minimum required for the procedure, shielding, and the appropriate 
positioning of the workers relative to the X-ray tube and the area of the patient’s body 
where the beam enters his body.  
The ratio of the scattered dose to the incident dose decreases with increasing distance from 
the center of the area where the beam enters the scattering material, increases with 
increasing beam area and kV and depends on the scattering angle. Therefore, one has to 
increase the staff distance from the location where the beam enters in the patient’s body and 
reduce the radiation field to the needs of the repair, i.e., “collimate tightly and view only 
what has to be seen, not more”. In addition, the higher the photon energy, the higher is the 
transmission of the primary X-ray beam. However, the increase of the mean photon energy 
by either kV increase or beam hardening (e.g. addition of a 0.2 mm Cu filter), usually 
reduces staff exposure. Forward scattering ratio is less than the backwards scattering ratio 
(the maximum value of the ratio in AAA repairs occurs usually at ~120° scattering angle). 
Therefore, if the X-ray beam has to be vertical, or near vertical it is preferable to keep the X-
ray tube under the patient. On the other hand, if the beam has to be horizontal or almost 
horizontal, staff should stand close to the detector and not close to X-ray tube.  
The interposition of a suitable barrier between the source of radiation and staff reduces the 
exposure by an amount that depends on its nature and its thickness, the photon spectrum 
and the angle of incidence of the photons to the barrier. Shielding requirements depend 
among other things on the type and location of the equipment in the room, the types of 
procedures performed, room design work habits and workload. Lead is the most widely 
used shielding material in rooms where fluoroscopically guided procedures are carried out. 
Shielding properties are often expressed by the thickness of lead that provides the same 
protection when irradiated with an X-ray beam (usually a 100 kV broad x-ray beam). The 
types and thickness of the barriers to be used are specified by the radiation protection 
adviser during the design or the re-design of the room, bearing also in mind ergonomic 
factors and the anticipated workload. The various types of shielding can be divided to 
structural stationary shields, or movable shields inside the room and personal protective 
equipment.  
Structural shielding, usually made of lead sheets of total thickness 0.25 to 2.0 mm with no 
gaps or holes, is built into the walls and doors of the room (the concrete thickness of the 
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floor and the ceiling usually provide adequate shielding). Optically clear lead glass 
windows of adequate dimensions are often used to protect those outside the room, who 
may have to observe the procedure. In rooms with heavy fluoroscopic load, it may be 
advisable to provide a separate protected area inside the room for anesthesiologists in the 
form of protective cubicles.  
As a “golden rule” mobile barriers used in the room should be placed as close to the 
radiation source as practicable, casting the biggest shadow. Free-standing mobile radiation 
shields with or without visible screens, which rest on the floor are particularly well suited 
for the protection of the nurses, the technicians and the anesthesia personnel as well as other 
medical staff possibly present in rooms with heavy work load. Protective drapes suspended 
from the operation bed and ergonomically designed optically clear shields suspended from 
the ceiling are often used to protect the lower and the upper body of the practitioners 
respectively. For example, in the framework of collaborative project sponsored by EU, it was 
found that when drapes and ceiling mounted screens were used, the dose to the eyes of the 
first operator was reduced by a factor of five  (Dommienick, et al, 2011).  
Bed-mounted shields, such as drapes made of flexible lead vinyl with attenuation 
characteristics similar to those of at least a 0.5 mm thick lead layer, measuring at least 60 cm 
by 80 cm (height), are often used. It is preferable that such drapes be attached to the 
accessory side rail of the table, with double joins to allow movement along the table side and 
swiveling away from the patient’s body forming two protective wings. Bed shields with an 
extra removable separate high top shielding section of similar equivalent thickness, were 
found to be very useful.  
Ceiling-suspended shields are usually made of clear leaded plastic with lead thickness 
equivalence of at least 0.5 mm, mounted either on a ceiling column or in a ceiling track and 
moved partially over the patient’s body. Such pull-down shields can be rotated and tilted 
until the ideal angle is obtained to protect the upper trunk, the neck and the head of the 
practitioners (the operator should only see the imaged area by looking through the shield to 
decrease lens exposure). Larger shielding area allows some degree of movement by the 
practitioner without having to reposition the shield and even protect more than one worker. 
In some cases, additional protection can be achieved by attaching a flexible lead-vinyl drape 
at the lower part of the transparent shield.  
Sterile disposable, protective surgical drapes that contain elements of high atomic number, 
Z, such as bismuth and tungsten, usually attenuate X-rays similar to that of a 0.25 mm thick 
lead layer and can be placed on the patient to be submitted to EVAR to reduce the dose from 
scattered radiation (Germano, et al., 2005). However, their use adds some cost to the 
procedure and in case that during manipulations such drapes are accidentally exposed in 
the primary beam, the output of the machine is automatically increased dramatically, thus 
increasing both patient and staff doses.  
Personal protective equipment, PPE, protect specific body regions, such as the trunk and the 
upper legs (aprons), the thyroid (collars), the eyes (protective glasses) and the hands 
(protective gloves). The typical flexible material for protective clothing is lead-impregnated 
vinyl or rubber. There is also lead-free clothing, that provides adequate shielding with the 
use of a combinations of elements with a high Z, such as tungsten (Z=74), barium (Z=56) 
antimony (Z=51) and tin (Z=50) at slightly reduced weight (Christodoulou et al. 2003; 
Finnerty & Brennan 2004; Zuguchi et al., 2008).  
Maximum protection will only be obtained by ergonomic PPE that fits well to the worker’s 
body and maintained to the standards specified by the manufacturer’s tests (IAEA, 2004). 
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procedure and in case that during manipulations such drapes are accidentally exposed in 
the primary beam, the output of the machine is automatically increased dramatically, thus 
increasing both patient and staff doses.  
Personal protective equipment, PPE, protect specific body regions, such as the trunk and the 
upper legs (aprons), the thyroid (collars), the eyes (protective glasses) and the hands 
(protective gloves). The typical flexible material for protective clothing is lead-impregnated 
vinyl or rubber. There is also lead-free clothing, that provides adequate shielding with the 
use of a combinations of elements with a high Z, such as tungsten (Z=74), barium (Z=56) 
antimony (Z=51) and tin (Z=50) at slightly reduced weight (Christodoulou et al. 2003; 
Finnerty & Brennan 2004; Zuguchi et al., 2008).  
Maximum protection will only be obtained by ergonomic PPE that fits well to the worker’s 
body and maintained to the standards specified by the manufacturer’s tests (IAEA, 2004). 
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Taking into account that PPE is expensive, it should be kept in good condition. The 
shielding material can develop cracks and holes over time. Therefore, folding and lying over 
a pointed object must be avoided. A visual inspection for obvious tears, rips, cuts, thickness 
variations, etc, should be carried out monthly and fluoroscopic inspection on initial receipt 
and at least once a year (Lambert & McKeon2001; Stam, et al., 2008). If defects are found, 
practical rejection criteria have to be applied. For example, if the sum of the areas of the 
holes or cracks in an apron exceeds about 5 cm2 (about 2.5 cm in radius, in case of a circular 
hole) it should be replaced. However replacement has to be carried out at an earlier stage, if 
the unprotected area over testes and the thyroid exceeds 0.2 and 0.1 cm2, respectively. 
Aprons with 0.5 mm nominal Pb equivalent thickness reduce staff effective dose by a factor 
of about eight, when an 87 kilovolatge is selected (von Boetticher, et al., 2009). Higher kV, 
such as those used on obese patients, sharply reduces the shielding benefit. When 
procedures are performed that require individuals to turn away from the radiation beam, 
wraparound protective aprons should be used. Taking into account that wraparound 0.5 
mm Pb aprons weigh about 7 kg, their use in lengthy procedures may result in fatigue, back 
pain and other more serious orthopedic complications (Klein, et al., 2209). Aprons made of 
two pieces (vest – skirt) as well as aprons with a belt to transfer the weight to the hips and 
off the shoulder, help to reduce the mechanical load on the cervical and lumbar spines (Fadl, 
et al.; 2007). Wraparound aprons with lead equivalent protection of 0.5 mm in the front and 
the sides of the trunk and 0.25 or 0.35 mm in the back could be also used. Lighter aprons, 
such as those of 0.25 lead equivalence, reduce the mechanical load on the neck, shoulders 
and the back of the user, as well as reducing the shielding benefit. However, in general, it is 
better practice to always use an apron with smaller lead equivalence than using no apron in 
some procedures. Those having to stand close to the beam entrance area during AAA repair 
are recommended to use 0.5 mm thick apron, while those at longer distances, such as the 
anesthesiologist, may wear a lighter PPE. Whatever apron design is selected, it is important 
to use an apron of appropriate size to body-build falling below the knees with adequate 
coverage at the armpits, balancing between radiation risk and the risk of induction of 
orthopedic complications associated to its use (Klein et al.; 2009). When aprons are not in 
use, they should be hung vertically by the shoulders, or in approved apron rounded hangers 
to prevent cracks and holes. 
Similar considerations to the use of protective aprons hold true on the use of collars or shields 
which mainly protect the upper oesophagus and the thyroid; the later organ is of high 
importance mainly in female workers younger than ~40 years, due increased radiosensitivity 
(ICRP, 2007; Kuon, et al., 2003). It was found that the use of 0.5 mm Pb thyroid collars in 
catheterization laboratories in combination with 0.35 mm Pb equivalent aprons, result in an 
effective dose per procedure lower than that using 0.5 mm Pb equivalent aprons without 
thyroid protection, despite the 20% reduction in total weight (von Boerricher, 2009).  
The protective eyeglasses must have additional side panels and fit properly for both 
protection and comfort (protective glasses can be worn over traditional prescription glasses, 
while others can be specially made and worn instead of regular ones). In addition, they have 
to provide protection equivalent to that of at least a 0.5 mm of lead. For example, the use 
eyeglasses with lead equivalence of 0.75 mm in interventional radiology suites was found to 
provide a reduction of the eye lens dose by a factor of 3 to 10 (Challa et al.; 2009; Thornton, 
et al., 2010). 
The physician’s hands must often be in close proximity to the X-ray beam during repair. 
Therefore, in case of heavy duty, radiation ring monitors must be worn, if possible, on the 
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middle phalanx of the hand likely to get the highest dose with the sensitive element facing 
the oncoming beam. Disposable protective gloves containing elements of a high Z, such as 
tungsten and bismuth, that pose less health and environmental problems than lead, could be 
used for hand protection from scattered radiation. However, the requirement of tactile 
sensitivity and dexterity restrict drastically the dose reduction (Kesley & Mettler, 1990). For 
example, 0.2 to 0.3 mm thick gloves with 30 to 40 μm Pb equivalent attenuation reduce the 
dose rate of the scattered radiation from a 80 kV beam by 35% to 50%. However, the use of 
such gloves not only increases the financial cost of the procedure, but also poses the risk of 
false feeling of radiation safety, that may even result to direct exposure of the hand in the 
primary beam, i.e. at dose rates many orders of magnitude higher than those outside the 
beam. In addition, the insertion of the “protected” hand in the direct field triggers the 
Automatic Brightness Control of the X-ray unit to increase the machine output usually by 
increasing the kV, decreasing the image quality and increasing the patient’s dose. In general, 
if fingers or a hand appear on the monitor, they should always be pulled back from the 
imaged area unless necessary for the safety of the patient. 
4.6 Radiation protection of the pregnant healthworker 
Taking into account the age and the sex distribution of patients with AAA, pregnancy is a 
matter for concern on workers but not on patients. According to ICRP (2000b, 2207), a 
pregnant worker can continue her work with unnecessary discrimination, as long as there is 
reasonable assurance that the conceptus dose can be kept below 1 mGy during the 
remaining pregnancy period after declaration of pregnancy, eirther verbally or in writing, to 
the radiation protection officer or the management (the 1 mGy dose is similar to the one that 
all persons receive annually from penetrating natural background radiation). Pregnancy 
declaration is voluntary in most countries and can be withdrawn by the employee at any 
time (Schreiner-Karaussou, 2009).  
In some countries other limits are used. For example, in USA, the conceptus dose should not 
exceed 5 mGy due occupational exposure during the 9 months of pregnancy, under condition 
of exposure uniform in time (US DOE, 1999), i.e., in practice not exceeding monthly the 0.5 
mGy limit after pregnancy declaration. In some countries additional limits are used, such as 
0.2 mGy and 0.5 mGy between 1-5 weeks and 5-7 weeks respectively, on top of the limit of 
the 1 mGy during the remaining gestation period after the pregnancy declaration.  
The various limits enforced by legislation do not mean that is necessary for pregnant worker 
to avoid work with radiation completely, or that she must be prevented from entering or 
working in designated radiation areas. It does, however imply that the employer should 
carefully review her exposure conditions (ICRP, 2007). 
There is great disparity in the polocies on the protection of the conceptus in different 
countries and even in different regions of the same country (Best, et al, 2011; Schrewiner -
Karoussou, 2009). For example, in some countries supervisors are prevented by law from 
removing an employee from work area simply on the basis of information that the worker is 
pregnant (Clark, 2003), while in an other country the pregnant worker is automatically 
placed in another department (Schrewiner-Karoussou, 2009).  
Following the confidential preganacy decalration to the licensee along with the estimated 
date of conception, preferably in writing, the radiation officer of the facility has to review 
the radiation history of the worker. In addition, it is desirable to discuss with the pregnant 
healthworker the associated radiological risks and the options proposed by the 
management, pointing out that fetal dose for most women who work in fluoroscopy guided 
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used for hand protection from scattered radiation. However, the requirement of tactile 
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dose rate of the scattered radiation from a 80 kV beam by 35% to 50%. However, the use of 
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beam. In addition, the insertion of the “protected” hand in the direct field triggers the 
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intervantional precedues are extremely low (Best, 2011) and reminding her the contribution 
of natural background radiation and the risks to the conceptus that are unrelated to her 
occupation. In other words the radiation expert has to put the radiological risk into 
prospective with the objective of having the pregnant worker’s attitude on neither extreme 
(Clark, 2003). 
In practice there are three options to be considered: 
1. change to a job that has essentially no radiation,  
2. modification of work assignments,  
3. no change in assigned working duties with an upgrade of protective means used, if 
required. 
The first option is sometimes requested by pregnant healthworkers who realize that risks 
may be small, but do not wish to accept any increased risk (ICRP, 2000b). The employer may 
arrange for this in order to avoid future difficulties in case the employee delivers a child 
with a spontaneous congenital abnormality (which occurs at a rate of about 3 in every 100 
births). This approach is not required on a radiation protection basis, and it obviously 
depends on the facility being sufficiently large and flexibility to easily fill the vacated 
position. 
Modification of job assignments and locations relative to radiological hazards is a widely 
emplpoyed option, ensuring that these recommendations are mutually satisfactory. For 
example, some intervenionists prefer to avoid to act as the first surgeon during pregnancy, 
because this assignment is related to the highest exposure in the team of surgeons that 
perform AAA repairs, as shown in section 4.4. Others prefer to modify the order of the 
topics to be trained, during their training as vascular surgeons, postponing thus their 
training on fluoroscopy guided porcedures after delively. Another example, is the change of 
the position of a radiation technician or a nurse from fluoroscopy suites to another position 
in the same department, such as the mammography suite, where exposure to ionizing 
radiations is considered unlike. An extra ethical consideration involved in choosing the most 
appropriate option for the pregnant healthworker is the fact that if the first two options are 
chosen, another radiation worker will get higher radiation exposure. 
There are situations that the anticipated doses are very small (such as the doses of the 
anesthesiologist that is present during AAA repairs, departments with low workload), 
situations in which the pregnant worker wishes to continue doing the same job, or the 
employer may depend on her to continue in the same job in order to maintain the level of 
patient care. From a radiation protection point of view, this is perfectly acceptable providing 
the conceptus dose can be reasonably accurately estimated and falls within the 
recommended limit (ICRP, 2000b). In this case, the radiation protection officer has to 
evaluate her workplace, watch closely the worker’s practices and the dose registered 
monthly by her personnal dosimeters (a supplementray dosimeter, a "baby's badge", could 
be issued to be worn at the waist height, under the protective apron - this practice is 
obligatory in some country).  
Sometimes, the conceptus dose can be substantially reduced by wise choise of the position 
of the worker in the fluoroscopic suite (such as one or two extra steps away from the 
location where the beam enters the patient), the use of movable radiation shileding and 
protective aprons of appropriate fit and lead equivalence. For this purpose maternity aprons 
are commercially available that are adequately wide and have extra lead in the area of the 
abdomen. However, the use of a heavy apron, especially an wraparound apron that is not 
divided to two pieces (vest, skirt), in combination with the susbsantial incerase in body  
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weight during the last trimester of pregnency, may result in fatigue, back pain and other 
orthopedic complications. A possible solution is the use an apron with non-uniform lead 
equivalence arround her trunk. However, in this case the wearer needs to ensure that her 
patrially or totally unshielded back is not facing the patient (if it happens, not only there is 
no adequate shileding, but her personal dosimeter is going to measure a dose tens of higher 
lower than the dose absorbed by the concetpus). Therefore, the type of apron to be used by 
the pregant healthworker has to been optimized on individual base.  
The proposed options for those working in suites where fluoroscopy guided interventional 
procedures are carried out, have to take into account that the recommended dose limits 
apply to the conceptus dose and differ from the dose assessed by the worker’s personell 
dosimeter. For example, Osei and Kotre (2001) found that during the first few months of 
pregnancy, the ratio of the conceptus dose to the dose registered by the dosimeter worn over 
a 0.33 mm Pb thick protective apron depends on the high voltage used, incerasing from 1% 
at 74 kV to 5.4% at 112 kV in the undercouch X-ray tube geometry. These values are 
increased by a factor of about two, when the lead equivalent thickness is reduced from 0.33 
to 0.25 mm. In case that the personal dosimeter is worn below the apron, the conceptus to 
dosimeter dose ratio is slighlty infleunceed by high voltage, ranging between 36% and 40%. 
In addition, Damilakis, et al. (2005) found that the conceptus dose in pregnant cadiologists 
that carry out fluoroscopically guided electrophysiological procedures, depends on the 
gestation period, ranging from 32% of the value of the air kerma during the 1st tremester to 
20% during the 3rd tremester, when a 80 kilovlotage is used. These values, as expected, also 
depend on kV, beeing at 60 kV 26% and 16%, respectively, and 40% and 27% at 110 kV. 
Factors other than radiation exposure should be also considered in choosing the optimum 
options for work assignments. For example, there are often requirements for lifting patients 
and for stooping or bending below knee level. Non-radiation related guidelines for such 
activities at various stages of pregnancy have to be applied. Supervisors have often the 
tendency to be overptotective of the pregnant worker. However, if he moves her from the 
usual work assignmenents without her permission, this action can be interpreted as 
discriminatory (Clark, 2003). Therefore, decisions about working in a radiation enviroment 
during pregnancy is preferable to be made by both the employer and the pregnant 
healthworker. 
In conclusion, a pregnant health worker can continue working in rooms were endovascular 
AAA repairs are carried out on a voluntary basis, as long as the there is reasonable 
assurance that the conceptus dose can be kept below the recommended levels and ALARA 
principles are enforced. Sex discrimination should be avoided based on radiation risks 
during pregnancy. If the pregnant woman prefers to continue her work, it has be reensured 
that she is adequately trained on radiation biology and practical methods to reduce her 
occupational dose and that she is controling her workload in fluoroscopically guided 
interventions. 
5. Conclusions 
Radiological risks associated with fluoroscopically guided vascular interventions are related 
to patient characteristics, the available infrastructure and staff. The practical actions to 
control radiological risks were given at various national and international guidelines 
(American Society for Gastrointestinal Endoscopy, 2010; Balter & Moses, 2007; Chambers et 
al.; 2011, CRPD, 2010; Hirshfeld, et al., 2005; Johnson et al. 2001; IAEA, 2010; ICRP, 2000; 
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occupational dose and that she is controling her workload in fluoroscopically guided 
interventions. 
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Society of Interventional Radiology Device Forum, 2003). These actions, as exemplified in 
AAA repairs can be divided in three groups, general, patient and staff related actions. 
5.1 General actions 
- Interventions should be carried out by appropriately trained staff taking into account 
the risks and the benefits to the individual patient.  
- Each facility should include in the local clinical protocol, a statement on the strategy to 
be followed before, during and after repair including the equipment maintenance and 
quality assurance programs. 
- A low-power C-arm angiographic unit (10 to 20 kW) equipped with a ~30 cm detector 
and rotating anode is to be preferred over high power unit units (~100 kW) designed 
for coronary interventions.  
- The fluoroscopic unit must provide a real-time display of dosimetric quantities (DAP, 
DAP rate, fluoroscopy time, mode of operation, focus to image receptor distance, etc.) 
on or near the operator’s imaging monitors (duplication of the indications in the control 
room is advisable).  
- The fluoroscopic unit has to be coupled with an angiographic bed and not with a 
surgical one. 
- Reduce fluoroscopy time and the number of registered images to the absolute minimum 
compatible with the task and take the advantages offered by the last image hold and 
road mapping capabilities, if available.  
- Image size and quality have to be adjusted as low as compatible with the task t (e.g., 3 
to 5 pulses or images per second, rather than 12 to 15 per second, avoid - image 
magnification, beam collimation closely to the area of interest, i.e., “image only the 
aorta length of interest”). 
- High exposure levels can be reached in a short time, when obese patients treated using 
short focus-skin distance or/and image magnification. 
- Advice should be available on patient and staff dosimetry, equipment selection and 
commissioning, and quality assurance by a radiation protection adviser, usually by a 
qualified medical radiation physicist. 
5.2 Patient related actions 
- Patient medical file has to be reviewed before procedure, for possible recent “heavy” 
exposure of the section of the body to be imaged.  
- The patient should be counselled on radiation risks,  
- Keep the detector (image receptor) as close to the patient as possible. 
- Use thick filters to harden the X-ray beam, provided that the power of the fluoroscopic 
unit and the anode heating allow their use. 
- In complex repairs, consider alternative imaging projections, to avoid the induction of 
deterministic effects to heavily irradiated skin areas.  
- Record the dosimetric data of each procedure and correlate the indications of the DAP 
meter to PSD and effective dose. In case of an anticipated dose to a skin region exceeding 
a predetermined level, inform the patient’s personal physician and avoid radiological 
procedures with high doses at the same skin region for up to 2 months post-exposure. If 
the anticipated dose to a skin region exceeds a higher limit, such as 3 Gy, the patient 
should be counselled and his skin followed-up to two weeks after repair. 
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- The operator should audit and review the outcomes of the repair, including the 
potential of radiation injuries with the aim of modifying the selection of patients, the 
method and the operational procedures to improve clinical outcomes and reduce 
complication rates. 
5.3 Staff-related actions 
Personnel exposure is in general proportional to DAP. Additional actions that can be made 
to control radiological risks are: 
- Carry out AAA repairs only in rooms with shielding adequate to the task. 
- Reduce the staff present in the room to the minimum required for the task and the 
needs of the individual patient. 
- Distribute the staff in an ergonomic and safe way (room dose mapping is a useful tool 
for optimization). 
- Extremities have to be kept far away from the X-ray beam.  
- Dose rate during image registration is much higher than that during fluoroscopy. 
Therefore, take more aggressive measures during image registration, such as increase 
staff distance from the area of entry of the beam to the patient’s body, if practical. 
- If the beam is vertical, or near vertical, keep the X-ray tube under the bed. 
- Avoid, if possible, horizontal and almost horizontal radiographic projections. 
However, if carried out, personnel should stand close to the detector and not close to 
X-ray tube.  
- Take into account that the increased kV automatically selected in obese patients, 
increases the ratio of scattered dose to DAP. 
- Use appropriate physical protection (protective aprons, thyroid shields, protective eye-
glasses, viewing screens, table-mounted shields, portable personal shields, etc.). 
- Monitor personnel doses with passive personnel dosimeters according to local 
regulations, assuring that staff knows the appropriate position, such as above the 
protective apron at the chest level. Additional dosimeters may be required in case of 
institutions with a heavy workload, and/or equipment not-state-of-art. 
- The effectiveness of the means applied to control patient and staff radiation burden has 
to be closely monitored in each medical facility and changes have to be carried out, if 
needed. 
In conclusion, justification and optimization of the methods used for AAA treatment must 
commensurate with the medical purpose. Radiation dose and image quality strategies are 
important for ensuring a balance between cost and benefit. The optimum strategy has to be 
studied and justified in each medical facility, based on solid clinical and radiobiological 
evidence. 
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Role of Cathepsin K, L and S in  
Blood Vessel Remodeling 
Andriy O. Samokhin and Dieter Brömme 
 University of British Columbia, Vancouver, 
Canada 
1. Introduction 
The development of cardiovascular diseases is characterized by the loss of structural 
integrity of blood vessels that requires extensive remodeling of the extra-cellular matrix 
(Michel et al., 2011; Garcia-Touchard et al., 2005). The entire aorta and some medium-sized 
arteries have elastic properties and mechanical strength allowing these vessels to withstand 
a surge of blood ejected from the heart. Such properties of blood vessels are contributed 
mostly by two major components of the extracellular matrix: elastin and collagen (Barbour 
et al., 2007; Wagenseil & Mecham, 2009; Sawabe, 2010). Elastin fibers are responsible for the 
elastic properties and collagen fibers provide mechanical strength to the arterial wall 
(Arteaga-Solis et al., 2000). These two proteins have a fibrillar structure and in their mature 
forms are very resistant to proteolysis. Thus elastin has a half-life around 50 years 
(Wagenseil & Mecham, 2009). However in some pathological conditions, excessive 
proteolytic activity results in extracellular matrix breakdown that is a key factor of arterial 
wall damage and the development of potential rupture. Sites of atherosclerotic and 
aneurysmatic lesions are characterized by increased elasto- and collagenolytic activity 
(Diehm et al., 2007; Shimizu et al., 2006; Barbour et al., 2007; Sukhova et al., 1998). The 
dominant histological feature of aneurysmatic lesions is a chronic medial and adventitial 
inflammation resulting in medial degeneration and smooth muscle cell apoptosis. One of 
the most important contributors to aneurysmatic degeneration is an excessive loss of 
extracellular matrix. Fragmentation of elastin and collagen fibers is a characteristic feature of 
aneurysm formation and their loss is the ultimate cause of aneurysmatic rupture as well as 
rupture of atherosclerotic plaques (Shimizu et al., 2006; Sakalihasan et al., 2005; Diehm et al., 
2007). Recently it has been shown that together with some matrix metalloproteinases, 
cathepsin K, L and S are the primary proteolytic culprits responsible for the breakdown of 
extracellular matrix proteins in blood vessels (Abdul-Hussien et al., 2010; Rizas et al., 2009; 
Sukhova & Shi, 2006). Cysteine proteinases cathepsin K, L and S belong to the most potent 
elasto- and/or collagenolytic proteinases with potent abilities to degrade extracellular 
matrix. These enzymes attracted attention due to their upregulation within the aortic wall 
under different pathological conditions (Lutgens et al., 2007; Lafarge et al., 2010; Liu et al., 
2004). Their expression was revealed in macrophages, smooth muscle cells and endothelial 
cells in atherosclerotic and aneurismal lesions in humans. These results instigated a series of 
studies on the involvement of cathepsin K, L and S in the development of cardiovascular 
diseases based on animal models of atherosclerosis and abdominal aortic aneurysm  
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formation (Lutgens et al., 2007; Lafarge et al., 2010; Liu et al., 2004). The lack of these 
proteases resulted in a plaque size reduction and delay of plaque progression as well as in 
reduced level of medial elastin degradation and smooth muscle cell transmigration from the 
media to the intima (Lutgens et al., 2006a; Rodgers et al., 2006; Samokhin et al., 2008; 
Sukhova et al., 2003). These results were corroborated by in vitro experiments that revealed 
the differences in collageno- and elastolytic activities of smooth muscle cells and 
macrophages from mice expressing and lacking these cathepsins. 
The availability of specific cathepsin inhibitors allowed the conduction of in vitro and in vivo 
experiments that confirmed the involvement of cathepsins in aortic extracellular matrix 
destruction and atherosclerosis progression (Samokhin et al., 2010b) Immunostaining for 
cathepsin K revealed its high level of expression in multinucleated giant cells in human 
specimens from carotid arteries and abdominal aortic aneurysm as well as in mouse 
atherosclerotic plaques (Samokhin et al., 2010c; Chapman et al., 1997). High level of 
cathepsin K expression is a marker of active osteoclasts; in these giant cells cathepsin K is a 
major enzyme responsible for bone resorption (Bromme et al., 1996). Similarly, cathepsin K-
expressing giant cells were found close to damaged elastin laminae in aorta, suggesting an 
important role for this enzyme in the development of cardiovascular diseases (Samokhin et 
al., 2010c; Chapman et al., 1997). 
2. Extracellular matrix of the aortic wall 
Elastin and fibrillar collagen are the main components of the arterial wall responsible for its 
mechanical properties (Wagenseil & Mecham, 2009; Arteaga-Solis et al., 2000; Sawabe, 2010). 
Elastin is the major protein that confers elastic properties to the arterial wall. It is produced 
by smooth muscle cells of the tunica media in form of the soluble precursor tropoelastin and 
after polymerization by lysyl oxidase, forms interconnecting concentric rings around the 
arterial lumen. A high number of cross-links (15-20 per tropoelastin unit) is responsible for 
elastin insolubility, long half-life and resistance to proteolysis (Wagenseil  & Mecham, 2009; 
Arteaga-Solis et al., 2000; Sawabe, 2010). Elastin fibers are formed by elastin and associated 
microfibrils. Microfibrils form a scaffold for elastin polymerization and they are mainly 
composed of fibrillin and a collagen type IV (Sawabe, 2010; Pasquali-Ronchetti & Baccarani-
Contri, 1997). This three-dimensional network of interconnecting elastin fibers is designed to 
transfer stress throughout the arterial walls and is responsible for their dilation and recoil 
(Wagenseil & Mecham, 2009; Shadwick, 1999). The aortic wall is characterized by the 
abundant presence of elastic fibers associated with smooth muscle cells in the medial area 
(Barbour et al., 2007, Sakalihasan et al., 2005). Elastic fibers are also interconnected with 
collagen bundles (Wagenseil  & Mecham, 2009). 
Collagen is made up of a triple helix of three polypeptide chains. Types I, II and III collagens 
belong to ''fibrillar'' collagens that are the most abundant (van der Rest  & Garrone, 1991). 
Types I and III collagens provide tensile strength and maintain the structural integrity of the 
blood vessels. In aorta these two types of collagens are mostly found in media and 
adventitia (Wagenseil  & Mecham, 2009; Barbour et al., 2007; Sakalihasan et al., 2005). Types 
IV, V, and VI are nonfibrillar collagens highly present in the basement membrane. Fibrillar 
collagens type I and III are highly resistant towards proteolysis. They can be degraded only 
by specific collagenases that are able to cleave within the triple helix of native fibrillar 
collagen (Abdul-Hussien et al., 2007).  
Medial elastin and collagens types I and II in the media and adventitia determine much of 
the structural integrity and stability of arteries (Shimizu et al., 2006; Arteaga-Solis et al., 
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2000). The increased turnover of elastin and collagen results in aortic dilation and possible 
rupture (Shimizu et al., 2006). The fragmentation and loss of collagen and elastin fibers is 
one of the most important and consistent histological features of aneurismal changes in 
aorta (Dobrin  & Mrkvicka, 1994; Barbour et al., 2007). 
Because of the long half-life of collagen fibers and the extremely long half-life of elastin, loss 
of these two extracellular matrix proteins almost certainly results from increased 
degradation rather than decreased synthesis. Indeed, the predominant role of increased 
proteolysis is well described for the pathogenesis of aneurysm formation (Barbour et al., 
2007; Sakalihasan et al., 2005; Michel et al., 2011). Traditionally, matrix metalloproteinases 
were considered the main culprits in blood vessel extracellular matrix cleavage (Kadoglou & 
Liapis, 2004; Newby, 2008), whereas some recent data point out to the important role of 
cathepsin K, L and S in this pathological process (Chapman et al., 1997; Shimizu et al., 2006; 
Abisi et al., 2007).  
3. Cathepsin K, L and S are strong extracellular matrix-degrading enzymes 
Cathepsin K, L and S are lysosomal cysteine proteases of the papain family. These enzymes 
share many common features but also have significant differences in distribution, activity 
and corresponding physiological functions. Cathepsin K has the highest level of expression 
in osteoclasts and plays a major role in collagen turnover in bones (Bromme et al., 1996). 
This protease is also expressed at lower levels in macrophages, epithelial cells, fibroblasts, 
smooth muscle cells which can be elevated under pathological conditions (Chapman et al., 
1997). Thus, high cathepsin K concentration was found in rheumatoid arthritic joints, in 
epithelioid and multinucleated giant cells in lungs, and in thyroid glands (Buhling et al., 
2004; Samokhin et al., 2010a; Tepel et al., 2000). Cathepsin K is not detectable in normal 
blood vessels, but is highly expressed in macrophages, smooth muscle cells, endothelial and 
multinucleated giant cells in atherosclerotic lesions and in giant cell aortitis (Sukhova et al., 
1998; Platt et al., 2007; Chapman et al., 1997; Samokhin et al., 2010c). Cathepsin K is the most 
efficient elastinolytic enzyme (Bromme et al., 1996) and, in contrast to other cathepsins, has 
the ability to cleave triple-helical collagens both outside and inside the helical regions 
(Lecaille et al., 2008; Garnero et al., 1998). This unique feature enables cathepsin K to 
perform complete cleavage of collagens, a process that usually requires a cooperative action 
of several extracellular matrix-degrading enzymes.  
Cathepsin S is predominantly expressed in spleen and antigen-presenting cells, including B 
cells, macrophages, dendritic and epithelial cells (Chapman et al., 1997; Gupta et al., 2008). 
In these cells, cathepsin S plays an important role in the proteolytic degradation of the 
invariant chain, thus regulating antigen presentation to CD4+ T-cells by MHC II molecules 
(Honey & Rudensky, 2003; Hsing & Rudensky, 2005). In addition to its role in the immune 
response, cathepsin S can be secreted by such cells as macrophages, smooth muscle cells, 
endothelial cells and some tumor cells (Gupta et al., 2008) and plays an important role in 
extracellular matrix remodeling. Similarly to cathepsin K, cathepsin S shows strong 
collagenolytic and elastolytic activities and in contrast to cathepsin K and L, this protease is 
more stable and retains activity at neutral pH (Chapman et al., 1997; Taleb & Clement, 2007). 
Under pathological conditions, cathepsin S is upregulated in lung and blood vessel tissues 
and its stability at neutral pH may significantly contribute to the degradation of the 
extracellular matrix (Deschamps et al., 2010; Samokhin et al., 2011; Hirakawa et al., 2007; 
Williams et al., 2009). 
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reduced level of medial elastin degradation and smooth muscle cell transmigration from the 
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atherosclerotic plaques (Samokhin et al., 2010c; Chapman et al., 1997). High level of 
cathepsin K expression is a marker of active osteoclasts; in these giant cells cathepsin K is a 
major enzyme responsible for bone resorption (Bromme et al., 1996). Similarly, cathepsin K-
expressing giant cells were found close to damaged elastin laminae in aorta, suggesting an 
important role for this enzyme in the development of cardiovascular diseases (Samokhin et 
al., 2010c; Chapman et al., 1997). 
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arterial lumen. A high number of cross-links (15-20 per tropoelastin unit) is responsible for 
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Arteaga-Solis et al., 2000; Sawabe, 2010). Elastin fibers are formed by elastin and associated 
microfibrils. Microfibrils form a scaffold for elastin polymerization and they are mainly 
composed of fibrillin and a collagen type IV (Sawabe, 2010; Pasquali-Ronchetti & Baccarani-
Contri, 1997). This three-dimensional network of interconnecting elastin fibers is designed to 
transfer stress throughout the arterial walls and is responsible for their dilation and recoil 
(Wagenseil & Mecham, 2009; Shadwick, 1999). The aortic wall is characterized by the 
abundant presence of elastic fibers associated with smooth muscle cells in the medial area 
(Barbour et al., 2007, Sakalihasan et al., 2005). Elastic fibers are also interconnected with 
collagen bundles (Wagenseil  & Mecham, 2009). 
Collagen is made up of a triple helix of three polypeptide chains. Types I, II and III collagens 
belong to ''fibrillar'' collagens that are the most abundant (van der Rest  & Garrone, 1991). 
Types I and III collagens provide tensile strength and maintain the structural integrity of the 
blood vessels. In aorta these two types of collagens are mostly found in media and 
adventitia (Wagenseil  & Mecham, 2009; Barbour et al., 2007; Sakalihasan et al., 2005). Types 
IV, V, and VI are nonfibrillar collagens highly present in the basement membrane. Fibrillar 
collagens type I and III are highly resistant towards proteolysis. They can be degraded only 
by specific collagenases that are able to cleave within the triple helix of native fibrillar 
collagen (Abdul-Hussien et al., 2007).  
Medial elastin and collagens types I and II in the media and adventitia determine much of 
the structural integrity and stability of arteries (Shimizu et al., 2006; Arteaga-Solis et al., 
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2000). The increased turnover of elastin and collagen results in aortic dilation and possible 
rupture (Shimizu et al., 2006). The fragmentation and loss of collagen and elastin fibers is 
one of the most important and consistent histological features of aneurismal changes in 
aorta (Dobrin  & Mrkvicka, 1994; Barbour et al., 2007). 
Because of the long half-life of collagen fibers and the extremely long half-life of elastin, loss 
of these two extracellular matrix proteins almost certainly results from increased 
degradation rather than decreased synthesis. Indeed, the predominant role of increased 
proteolysis is well described for the pathogenesis of aneurysm formation (Barbour et al., 
2007; Sakalihasan et al., 2005; Michel et al., 2011). Traditionally, matrix metalloproteinases 
were considered the main culprits in blood vessel extracellular matrix cleavage (Kadoglou & 
Liapis, 2004; Newby, 2008), whereas some recent data point out to the important role of 
cathepsin K, L and S in this pathological process (Chapman et al., 1997; Shimizu et al., 2006; 
Abisi et al., 2007).  
3. Cathepsin K, L and S are strong extracellular matrix-degrading enzymes 
Cathepsin K, L and S are lysosomal cysteine proteases of the papain family. These enzymes 
share many common features but also have significant differences in distribution, activity 
and corresponding physiological functions. Cathepsin K has the highest level of expression 
in osteoclasts and plays a major role in collagen turnover in bones (Bromme et al., 1996). 
This protease is also expressed at lower levels in macrophages, epithelial cells, fibroblasts, 
smooth muscle cells which can be elevated under pathological conditions (Chapman et al., 
1997). Thus, high cathepsin K concentration was found in rheumatoid arthritic joints, in 
epithelioid and multinucleated giant cells in lungs, and in thyroid glands (Buhling et al., 
2004; Samokhin et al., 2010a; Tepel et al., 2000). Cathepsin K is not detectable in normal 
blood vessels, but is highly expressed in macrophages, smooth muscle cells, endothelial and 
multinucleated giant cells in atherosclerotic lesions and in giant cell aortitis (Sukhova et al., 
1998; Platt et al., 2007; Chapman et al., 1997; Samokhin et al., 2010c). Cathepsin K is the most 
efficient elastinolytic enzyme (Bromme et al., 1996) and, in contrast to other cathepsins, has 
the ability to cleave triple-helical collagens both outside and inside the helical regions 
(Lecaille et al., 2008; Garnero et al., 1998). This unique feature enables cathepsin K to 
perform complete cleavage of collagens, a process that usually requires a cooperative action 
of several extracellular matrix-degrading enzymes.  
Cathepsin S is predominantly expressed in spleen and antigen-presenting cells, including B 
cells, macrophages, dendritic and epithelial cells (Chapman et al., 1997; Gupta et al., 2008). 
In these cells, cathepsin S plays an important role in the proteolytic degradation of the 
invariant chain, thus regulating antigen presentation to CD4+ T-cells by MHC II molecules 
(Honey & Rudensky, 2003; Hsing & Rudensky, 2005). In addition to its role in the immune 
response, cathepsin S can be secreted by such cells as macrophages, smooth muscle cells, 
endothelial cells and some tumor cells (Gupta et al., 2008) and plays an important role in 
extracellular matrix remodeling. Similarly to cathepsin K, cathepsin S shows strong 
collagenolytic and elastolytic activities and in contrast to cathepsin K and L, this protease is 
more stable and retains activity at neutral pH (Chapman et al., 1997; Taleb & Clement, 2007). 
Under pathological conditions, cathepsin S is upregulated in lung and blood vessel tissues 
and its stability at neutral pH may significantly contribute to the degradation of the 
extracellular matrix (Deschamps et al., 2010; Samokhin et al., 2011; Hirakawa et al., 2007; 
Williams et al., 2009). 
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Cathepsin L is ubiquitously expressed and similarly to cathepsin S, plays an important role 
in the immune system by degrading the invariant chain in MHC class II processing (Honey 
& Rudensky, 2003; Hsing & Rudensky, 2005). Mice lacking cathepsin L have epidermal 
hyperplasia with periodic hair loss, older animals develop dilative cardiomyopathy 
(Lankelma et al., 2010; Reinheckel et al., 2005). This enzyme is also involved in the 
development of kidney diseases in mice and humans and is upregulated in a variety of 
cancers (Reiser et al., 2010). Cathepsin L is a potent elastase (equivalent to cathepsin S) and 
collagenase (similar to cathepsin K) (Chapman et al., 1997). The physiological role of mouse 
cathepsins L is most likely replaced by cathepsin V in human tissues (Tolosa et al., 2003). 
A common feature of these cathepsins is their strong ability to degrade elastin and collagen 
fibers. Cathepsins have attracted attention as extracellular matrix-degrading enzymes only 
recently.  Previously it was assumed that they are inactive outside of cells due to their 
instability at neutral pH. However under pathological conditions, the acidification of the 
pericellular environment creates optimal conditions for lysosomal cathepsins. Thus, the 
destruction of elastin-rich arteries is associated with the accumulation of macrophages. In 
inflammatory conditions, macrophages secrete cathepsin K, L and S and at the same time 
increase expression of vacuolar-type H+-ATPase (Punturieri et al., 2000; Reddy et al., 1995). 
H+-ATPase acidifies the local environment and creates optimal conditions for cathepsin 
activities. Such increased expression of H+-ATPase has been revealed by 
immunohistochemical analysis in AAA in infiltrating monocytes and to a lesser extend in 
SMCs (Abdul-Hussien et al., 2010).  
In addition to their direct destructive role in blood vessel remodeling, cathepsins may 
promote the development of cardiovascular diseases by degrading lipoproteins and through 
their involvement in the regulation of apoptosis (Linke et al., 2006; Conus & Simon, 2008; 
Repnik & Turk, 2010). 
4. Increased expression of cathepsin K, L and S under pathological 
conditions in blood vessels 
4.1 Atherosclerosis 
Increased expression of cathepsin K and S in human atherosclerotic lesions was first described 
in 1998 (Sukhova et al., 1998). Until that time cathepsin K, L and S were already known as 
strong collagenases and elastases and researchers found a correlation between increased 
immunostaining for cathepsin K and S and increased elastase-degrading activity in 
atheromatous tissues extracts. The use of cathepsin and MMP inhibitors revealed that 
cathepsins had significantly greater contribution to elastolytic activity of atherosclerotic lesions 
extracts. Cathepsin K and S immunoreactivities were mostly localized in the fibrous cap region 
that suggested their important role in plaque destabilization (Sukhova et al., 1998; Rodgers et 
al., 2006). In addition, smooth muscle cells cultured with IFN- or interleukin-1 secreted 
active cathepsin S and showed significantly increased ability to degrade elastin. This elastolytic 
activity was abrogated by a selective cathepsin S inhibitor (Sukhova et al., 1998). In a similar 
experiment, a selective cathepsin S inhibitor or endogenous cathepsin inhibitor cystatin C 
significantly decreased SMC migration across an elastin gel (Cheng et al., 2006). In human 
atherosclerotic plaques cathepsins were localized in macrophages, SMCs and endothelial cells 
(Platt et al., 2007; Sukhova et al., 1998). The destructive role of cathepsin K in macrophage 
foam cells was confirmed by immunohistochemical analysis that revealed accumulation of 
collagen type I degradation products close to cathepsin K immunoreactivity. These results 
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were supported by an in vitro experiment where incubation of human macrophage foam cells 
on a collagen matrix resulted in the accumulation of collagen degradation products (Barascuk 
et al., 2010). Cathepsin K expression in endothelial cells in human atherosclerotic plaques also 
correlated with internal elastic lamina destruction (Platt et al., 2007). 
Similarly to cathepsin K and S, cathepsin L shows weak or no immunostaining in normal 
human arteries but its immunoreactivity increases significantly in atherosclerotic lesions 
and localizes in the fibrous cap and tunica media (Liu et al., 2006). Double immunostaining 
revealed that cathepsin L is mostly expressed in macrophages of the plaque shoulder 
regions, endothelial and smooth muscle cells. Serum cathepsin L level correlated with the 
development of atherosclerotic lesions (Liu et al., 2006). Furthermore, expression of 
cathepsin L correlated with apoptosis, formation of the necrotic core, decrease in collagen 
content and rupture of the fibrous cap (Li et al., 2009; Liu et al., 2006).  
4.2 Aortic aneurysm 
Increased expression of cathepsin K, L and S was found in abdominal aortic aneurysm and 
in popliteal artery aneurysm (Sukhova and Shi, 2006; Abdul-Hussien et al., 2010). Similarly 
to atherosclerosis, these enzymes were identified as major proteolytic culprits in abdominal 
aortic aneurysm and their expresion correlated with excessive collagen degradation (Abdul-
Hussien et al., 2007). The activities of cathepsin S and L were increased in abdominal aortic 
aneurysms and ruptured abdominal aortic aneurysms, whereas cathepsin K activity was not 
elevated despite a significant increase in the level of activated cathepsin K protein in aortic 
extracts (Abdul-Hussien et al., 2007; Abisi et al., 2007). Increased expression of cathepsin L 
in abdominal aortic aneurysm was localized in SMCs, Ecs and macrophages (Li et al., 2009). 
5. Studies of cathepsin K, L and S in mouse models of cardiovascular 
diseases 
5.1 Atherosclerosis 
The results of human studies prompted in vivo studies of the involvement of cathepsins in 
cardiovascular diseases using murine disease models. Apolipoprotein E- and low density 
lipoprotein receptor-deficient mice are widely used as animal models of atherosclerosis. These 
mice develop severe hypercholesterolemia and atherosclerosis similar to human 
atherosclerosis and atherosclerotic lesions progression can be accelerated by high fat diet. 
Firstly, the high expression of cathepsin L and S was shown in aorta of apolipoprotein E-
deficient mice. Immunohistochemical analysis showed positive staining for cathepsins L and S 
in the intima and within fibrous caps and cathepsin S was also detected in the medial area 
(Jormsjo et al., 2002). Soon after that, the effect of cathepsin S deficiency on atherosclerosis 
development was reported in experiments with low density lipoprotein receptor-deficient 
mice (Sukhova et al., 2003). Low density lipoprotein receptor-deficient mice lacking cathepsin 
S showed significant reduction of plaque size and area, preserved integrity of elastic lamina 
and reduced smooth muscle cell and collagen contents in the intima when compared to mice 
expressing cathepsin S. Absence of cathepsin S also resulted in decreased macrophage and 
leukocyte accumulation in atherosclerotic plaques (Sukhova et al., 2003). The atheroprotective 
effect of cathepsin S deficiency was also confirmed by experiments with apolipoprotein E-
deficient mice lacking this protease. (Rodgers et al., 2006). Atherosclerotic lesions in 
brachiocephalic arteries of apolipoprotein E-deficient and cathepsin S double deficient mice 
were significantly smaller and had fewer acute plaque ruptures. These mice also had a lower 
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were supported by an in vitro experiment where incubation of human macrophage foam cells 
on a collagen matrix resulted in the accumulation of collagen degradation products (Barascuk 
et al., 2010). Cathepsin K expression in endothelial cells in human atherosclerotic plaques also 
correlated with internal elastic lamina destruction (Platt et al., 2007). 
Similarly to cathepsin K and S, cathepsin L shows weak or no immunostaining in normal 
human arteries but its immunoreactivity increases significantly in atherosclerotic lesions 
and localizes in the fibrous cap and tunica media (Liu et al., 2006). Double immunostaining 
revealed that cathepsin L is mostly expressed in macrophages of the plaque shoulder 
regions, endothelial and smooth muscle cells. Serum cathepsin L level correlated with the 
development of atherosclerotic lesions (Liu et al., 2006). Furthermore, expression of 
cathepsin L correlated with apoptosis, formation of the necrotic core, decrease in collagen 
content and rupture of the fibrous cap (Li et al., 2009; Liu et al., 2006).  
4.2 Aortic aneurysm 
Increased expression of cathepsin K, L and S was found in abdominal aortic aneurysm and 
in popliteal artery aneurysm (Sukhova and Shi, 2006; Abdul-Hussien et al., 2010). Similarly 
to atherosclerosis, these enzymes were identified as major proteolytic culprits in abdominal 
aortic aneurysm and their expresion correlated with excessive collagen degradation (Abdul-
Hussien et al., 2007). The activities of cathepsin S and L were increased in abdominal aortic 
aneurysms and ruptured abdominal aortic aneurysms, whereas cathepsin K activity was not 
elevated despite a significant increase in the level of activated cathepsin K protein in aortic 
extracts (Abdul-Hussien et al., 2007; Abisi et al., 2007). Increased expression of cathepsin L 
in abdominal aortic aneurysm was localized in SMCs, Ecs and macrophages (Li et al., 2009). 
5. Studies of cathepsin K, L and S in mouse models of cardiovascular 
diseases 
5.1 Atherosclerosis 
The results of human studies prompted in vivo studies of the involvement of cathepsins in 
cardiovascular diseases using murine disease models. Apolipoprotein E- and low density 
lipoprotein receptor-deficient mice are widely used as animal models of atherosclerosis. These 
mice develop severe hypercholesterolemia and atherosclerosis similar to human 
atherosclerosis and atherosclerotic lesions progression can be accelerated by high fat diet. 
Firstly, the high expression of cathepsin L and S was shown in aorta of apolipoprotein E-
deficient mice. Immunohistochemical analysis showed positive staining for cathepsins L and S 
in the intima and within fibrous caps and cathepsin S was also detected in the medial area 
(Jormsjo et al., 2002). Soon after that, the effect of cathepsin S deficiency on atherosclerosis 
development was reported in experiments with low density lipoprotein receptor-deficient 
mice (Sukhova et al., 2003). Low density lipoprotein receptor-deficient mice lacking cathepsin 
S showed significant reduction of plaque size and area, preserved integrity of elastic lamina 
and reduced smooth muscle cell and collagen contents in the intima when compared to mice 
expressing cathepsin S. Absence of cathepsin S also resulted in decreased macrophage and 
leukocyte accumulation in atherosclerotic plaques (Sukhova et al., 2003). The atheroprotective 
effect of cathepsin S deficiency was also confirmed by experiments with apolipoprotein E-
deficient mice lacking this protease. (Rodgers et al., 2006). Atherosclerotic lesions in 
brachiocephalic arteries of apolipoprotein E-deficient and cathepsin S double deficient mice 
were significantly smaller and had fewer acute plaque ruptures. These mice also had a lower 
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number of buried fibrous caps, which are believed to be a marker of unstable atherosclerotic 
plaques. The fibrous caps in plaques of double knockout mice were also thicker compared to 
cathepsin S-expressing mice that most likely rendered higher stability to those plaques 
(Rodgers et al., 2006). Recently, the role of cathepsin S in atherosclerosis was investigated in 
chimeric low density lipoprotein receptor-deficient mice lacking this protease in leukocytes (de 
Nooijer et al., 2009). The absence of cathepsin S in leukocytes did not change the lesion size but 
reduced the necrotic core and changed plaque morphology. Chimeric mice contained more 
macrophages and less intimal smooth muscle cells and collagen. The lower number of intimal 
smooth muscle cells correlated with the marked decrease in the number of elastin lamina 
ruptures providing evidence for an important role of leukocyte-derived cathepsin S in elastin 
lamina disruption in atherosclerosis (de Nooijer et al., 2009). 
The role of cathepsin K in atherosclerotic lesions development was investigated in 
apolipoprotein E-deficient mice (Lutgens et al., 2006b; Samokhin et al., 2008; Lutgens et al., 
2006a).  Cathepsin K deficiency reduced the total plaque area in the aortic arch of mice 
receiving normal diet (Lutgens et al., 2006a) as well as the plaque size in the brachiocephalic 
artery after 16 weeks of high fat diet (Samokhin et al., 2008). In both experiments mice 
lacking cathepsin K had a smaller number of elastin lamina ruptures and increased collagen 
content compared to cathepsin K-expressing mice. Cathepsin K-deficient mice on normal 
diet had a borderline significant decrease in plaque macrophage content but the individual 
size of macrophages was increased and showed increased lipid uptake (Lutgens et al., 
2006b). Atherosclerotic plaques in the brachiocephalic artery of mice on high fat diet had a 
significant decrease in their macrophage content and an increase in collagen content after 8 
weeks of high fat diet. Smooth muscle cell loss in medial area was significantly lower in 
cathepsin K-deficient mice after 16 weeks of high fat diet that correlated well with the 
decreased number of elastin lamina breaks (Samokhin et al., 2008). Atherosclerotic plaques 
in brachiocephalic arteries had thicker fibrous caps and a smaller number of buried fibrous 
caps in cathepsin K-deficient mice. Similarly to cathepsin S, the effect of cathepsin K 
deficiency in leukocytes was studied in chimeric low density lipoprotein receptor-deficient 
mice (Guo et al., 2009). Leukocytes cathepsin K deficiency did not affect the plaque size but 
decreased elastin lamina fragmentation as well as collagen content and increased plaque 
macrophage content and the necrotic area. The effect of cathepsin L deficiency was studied 
on low density lipoprotein receptor-deficient mice (Kitamoto et al., 2007). Double knockout 
mice developed reduced atherosclerotic lesions with smaller lipid core compared to 
cathepsin L-expressing mice. They also had a lower number of elastin lamina ruptures and a 
decreased amount of plaque macrophages, CD4+ T-cells, smooth muscle cells and collagen. 
In in vitro experiments, cathepsin L-deficient smooth muscle cells showed delayed 
transmigration through an elastin layer, whereas cathepsin L-deficient monocytes and 
lymphocytes demonstrated reduced ability to migrate through collagen type I and IV coated 
transwell membranes. Based on these results, authors suggested that cathepsin L plays a 
significant role in medial smooth muscle cells and blood-borne leukocytes migration during 
development of atherosclerotic lesions (Kitamoto et al., 2007).  
5.2 Aortic aneurysm 
Increased expression of cathepsin K, L and S in blood vessels have been shown in several 
animal models of aneurysm induction. Cathepsin K and S were upregulated in a porcine 
model of abdominal aortic aneurysm (Sadek et al., 2008) and cathepsin L showed increased 
expression in a rabbit model of elastase-induced saccular aneurysm (Kadirvel et al., 2004). 
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The role of cathepsin K in aneurysm formation was investigated in a mouse model of 
aneurysm induction (Bai et al., 2010). Surprisingly, cathepsin K deficiency did not prevent 
aneurysm formation after angiotensin II infusion. Cathepsin K-lacking mice had the same 
aneurysm size and severity. The absence of cathepsin K did not prevent elastin degradation, 
whereas the collagen content was significantly increased in the aneurysm area in cathepsin 
K-lacking mice (Bai et al., 2010). 
6. Cathepsin inhibitors in the prevention of pathological aortic remodeling 
The highly destructive potential of cysteine cathepsins requires their tight regulation and one 
of such restrictive mechanisms is a presence of cathepsin inhibitors. Cystatin C is the most 
important inhibitor of cysteine cathepsins. It is a small protein expressed in virtually all organs 
and found in high concentration in biological fluids including blood (Shi et al., 1999). Cystatin 
C is present in normal blood vessels but its concentration significantly decreases in 
atherosclerotic and aneurismal lesions (Lindholt et al., 2001). Serum cystatin C level inversely 
correlated with abdominal aortic diameter in patients with abdominal aortic aneurysm (Shi et 
al., 1999). Animal experiments have shown that lack of cystatin C expression in apolipoprotein 
E-deficient mice results in more advanced atherosclerotic lesions with increased elastin lamina 
degradation and higher macrophage content (Bengtsson et al., 2005; Sukhova et al., 2005). In 
an angiotensin II-induced model of abdominal aortic aneurysm such mice showed aggravated 
destruction of elastin, increased cathepsin activity, fewer number of smooth muscle cells in 
tunica media and increased macrophage content and number of CD4+ T cells (Schulte et al., 
2010). Recently cathepsin K, L and S attracted a lot of attention as a potential therapeutic target 
in cardiovascular, bone and cartilage diseases (Turk, 2006; Bromme & Lecaille, 2009). The 
atheroprotective effect of a potent and selective cathepsin S inhibitor was tested in 
apolipoprotein E-deficient mice (Samokhin et al., 2010b). Animals receiving high fat diet 
containing the cathepsin S inhibitor developed significantly smaller plaques in brachiocephalic 
arteries, had smaller number of elastin ruptures, and lower levels of macrophages in plaques. 
Mice treated with cathepsin S inhibitor also showed a reduced number of buried fibrous caps 
providing evidence of more stable plaques. In this study, the cathepsin S inhibitor was also 
tested in peritoneal macrophages where cells showed reduced elastolytic activity (Samokhin et 
al., 2010b). This study also revealed some gender-related differences in atherosclerotic lesions 
development in response to inhibitor treatment. Female mice showed an almost 2-fold greater 
reduction in plaque sizes compared to the male group. The effectiveness of the cathepsin S 
inhibitor was verified by the build-up of intermediate invariant chain breakdown products in 
spleen. Cathepsin S plays an important role in MHC class II-associated antigen presentation by 
participating in proteolytic processing of invariant chain and its inhibition results in 
accumulation of invariant chain breakdown products (Honey & Rudensky, 2003). The 
inhibition of cathepsin S reflected most of the phenotype observed in experiments with 
cathepsin S-deficient mice  (Sukhova, 2003; Rodgers, 2006)  suggesting the high specificity of 
the inhibitor and the potential feasibility of the treatment of atherosclerosis with cathepsin 
inhibitors. 
7. Cathepsin K is highly expressed in multinucleated giant cells in aortic wall 
The presence of multinucleated giant cells within the aortic wall is described in giant cell 
arteritis and atherosclerosis. In these two diseases, multinucleated giant cells are formed by 
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number of buried fibrous caps, which are believed to be a marker of unstable atherosclerotic 
plaques. The fibrous caps in plaques of double knockout mice were also thicker compared to 
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(Rodgers et al., 2006). Recently, the role of cathepsin S in atherosclerosis was investigated in 
chimeric low density lipoprotein receptor-deficient mice lacking this protease in leukocytes (de 
Nooijer et al., 2009). The absence of cathepsin S in leukocytes did not change the lesion size but 
reduced the necrotic core and changed plaque morphology. Chimeric mice contained more 
macrophages and less intimal smooth muscle cells and collagen. The lower number of intimal 
smooth muscle cells correlated with the marked decrease in the number of elastin lamina 
ruptures providing evidence for an important role of leukocyte-derived cathepsin S in elastin 
lamina disruption in atherosclerosis (de Nooijer et al., 2009). 
The role of cathepsin K in atherosclerotic lesions development was investigated in 
apolipoprotein E-deficient mice (Lutgens et al., 2006b; Samokhin et al., 2008; Lutgens et al., 
2006a).  Cathepsin K deficiency reduced the total plaque area in the aortic arch of mice 
receiving normal diet (Lutgens et al., 2006a) as well as the plaque size in the brachiocephalic 
artery after 16 weeks of high fat diet (Samokhin et al., 2008). In both experiments mice 
lacking cathepsin K had a smaller number of elastin lamina ruptures and increased collagen 
content compared to cathepsin K-expressing mice. Cathepsin K-deficient mice on normal 
diet had a borderline significant decrease in plaque macrophage content but the individual 
size of macrophages was increased and showed increased lipid uptake (Lutgens et al., 
2006b). Atherosclerotic plaques in the brachiocephalic artery of mice on high fat diet had a 
significant decrease in their macrophage content and an increase in collagen content after 8 
weeks of high fat diet. Smooth muscle cell loss in medial area was significantly lower in 
cathepsin K-deficient mice after 16 weeks of high fat diet that correlated well with the 
decreased number of elastin lamina breaks (Samokhin et al., 2008). Atherosclerotic plaques 
in brachiocephalic arteries had thicker fibrous caps and a smaller number of buried fibrous 
caps in cathepsin K-deficient mice. Similarly to cathepsin S, the effect of cathepsin K 
deficiency in leukocytes was studied in chimeric low density lipoprotein receptor-deficient 
mice (Guo et al., 2009). Leukocytes cathepsin K deficiency did not affect the plaque size but 
decreased elastin lamina fragmentation as well as collagen content and increased plaque 
macrophage content and the necrotic area. The effect of cathepsin L deficiency was studied 
on low density lipoprotein receptor-deficient mice (Kitamoto et al., 2007). Double knockout 
mice developed reduced atherosclerotic lesions with smaller lipid core compared to 
cathepsin L-expressing mice. They also had a lower number of elastin lamina ruptures and a 
decreased amount of plaque macrophages, CD4+ T-cells, smooth muscle cells and collagen. 
In in vitro experiments, cathepsin L-deficient smooth muscle cells showed delayed 
transmigration through an elastin layer, whereas cathepsin L-deficient monocytes and 
lymphocytes demonstrated reduced ability to migrate through collagen type I and IV coated 
transwell membranes. Based on these results, authors suggested that cathepsin L plays a 
significant role in medial smooth muscle cells and blood-borne leukocytes migration during 
development of atherosclerotic lesions (Kitamoto et al., 2007).  
5.2 Aortic aneurysm 
Increased expression of cathepsin K, L and S in blood vessels have been shown in several 
animal models of aneurysm induction. Cathepsin K and S were upregulated in a porcine 
model of abdominal aortic aneurysm (Sadek et al., 2008) and cathepsin L showed increased 
expression in a rabbit model of elastase-induced saccular aneurysm (Kadirvel et al., 2004). 
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The role of cathepsin K in aneurysm formation was investigated in a mouse model of 
aneurysm induction (Bai et al., 2010). Surprisingly, cathepsin K deficiency did not prevent 
aneurysm formation after angiotensin II infusion. Cathepsin K-lacking mice had the same 
aneurysm size and severity. The absence of cathepsin K did not prevent elastin degradation, 
whereas the collagen content was significantly increased in the aneurysm area in cathepsin 
K-lacking mice (Bai et al., 2010). 
6. Cathepsin inhibitors in the prevention of pathological aortic remodeling 
The highly destructive potential of cysteine cathepsins requires their tight regulation and one 
of such restrictive mechanisms is a presence of cathepsin inhibitors. Cystatin C is the most 
important inhibitor of cysteine cathepsins. It is a small protein expressed in virtually all organs 
and found in high concentration in biological fluids including blood (Shi et al., 1999). Cystatin 
C is present in normal blood vessels but its concentration significantly decreases in 
atherosclerotic and aneurismal lesions (Lindholt et al., 2001). Serum cystatin C level inversely 
correlated with abdominal aortic diameter in patients with abdominal aortic aneurysm (Shi et 
al., 1999). Animal experiments have shown that lack of cystatin C expression in apolipoprotein 
E-deficient mice results in more advanced atherosclerotic lesions with increased elastin lamina 
degradation and higher macrophage content (Bengtsson et al., 2005; Sukhova et al., 2005). In 
an angiotensin II-induced model of abdominal aortic aneurysm such mice showed aggravated 
destruction of elastin, increased cathepsin activity, fewer number of smooth muscle cells in 
tunica media and increased macrophage content and number of CD4+ T cells (Schulte et al., 
2010). Recently cathepsin K, L and S attracted a lot of attention as a potential therapeutic target 
in cardiovascular, bone and cartilage diseases (Turk, 2006; Bromme & Lecaille, 2009). The 
atheroprotective effect of a potent and selective cathepsin S inhibitor was tested in 
apolipoprotein E-deficient mice (Samokhin et al., 2010b). Animals receiving high fat diet 
containing the cathepsin S inhibitor developed significantly smaller plaques in brachiocephalic 
arteries, had smaller number of elastin ruptures, and lower levels of macrophages in plaques. 
Mice treated with cathepsin S inhibitor also showed a reduced number of buried fibrous caps 
providing evidence of more stable plaques. In this study, the cathepsin S inhibitor was also 
tested in peritoneal macrophages where cells showed reduced elastolytic activity (Samokhin et 
al., 2010b). This study also revealed some gender-related differences in atherosclerotic lesions 
development in response to inhibitor treatment. Female mice showed an almost 2-fold greater 
reduction in plaque sizes compared to the male group. The effectiveness of the cathepsin S 
inhibitor was verified by the build-up of intermediate invariant chain breakdown products in 
spleen. Cathepsin S plays an important role in MHC class II-associated antigen presentation by 
participating in proteolytic processing of invariant chain and its inhibition results in 
accumulation of invariant chain breakdown products (Honey & Rudensky, 2003). The 
inhibition of cathepsin S reflected most of the phenotype observed in experiments with 
cathepsin S-deficient mice  (Sukhova, 2003; Rodgers, 2006)  suggesting the high specificity of 
the inhibitor and the potential feasibility of the treatment of atherosclerosis with cathepsin 
inhibitors. 
7. Cathepsin K is highly expressed in multinucleated giant cells in aortic wall 
The presence of multinucleated giant cells within the aortic wall is described in giant cell 
arteritis and atherosclerosis. In these two diseases, multinucleated giant cells are formed by 
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the fusion of macrophages in inflammatory infiltrates of the arterial wall (Weyand et al., 
2005; Eberhardt & Dhadly, 2007; Soilleux et al., 2002). It was shown by 
immunohistochemical analysis and in situ hybridization that multinucleated giant cells from 
different organs and from patients with different pathological conditions have strong 
cathepsin K expression (Buhling et al., 2001; Chapman et al., 1997).  
7.1 Multinucleated giant cells in human atherosclerotic plaques show strong staining 
for cathepsin K 
The analysis of atherosclerotic plaques from carotid arteries and lesions from patients with 
abdominal aortic aneurisms revealed the presence of multinucleated giant cells  (Fig. 1). 
Similarly to giant cells arteritis, they were mostly localized in the media-intima junction 
(Samokhin, 2010c). The lesions contained Langhans-type multinucleated giant cells 
recognizable by their circular arrangement of nuclei and foreign body-type giant cells with 
random arrangement of nuclei.  
 
 
Fig. 1. Multinucleated giant cells in atherosclerotic lesions from carotid artery (trichrome 
staining, x10, asterisks show multinucleated  giant cells). 
Immunohistochemical analysis revealed strong expression of cathepsin K in multinucleated 
giant cells (Fig. 2). These results suggest an important role of cathepsin K from 
multinucleated giant cells in aortic wall damage in atherosclerosis and abdominal aortic 
aneurisms.  
 




Fig. 2. Cathepsin K-positive multinucleated giant cells in atherosclerotic lesions from carotid 
artery (red – cathepsin K, blue - nuclei, x20, asterisks show multinucleated giant cells). 
7.2 Multinucleated giant cells in mouse atherosclerotic plaques 
Apolipoprotein E-deficient mice on cholate-containing high fat diet developed 
atherosclerotic lesions containing multinucleated giant cells (Fig. 3). These giant cells were 
observed in atherosclerotic plaques within the brachiocephalic artery and the aortic root and 
were easily detectable by intensive cathepsin K immunostaining (Samokhin et al., 2010c). 
They were mostly localized in the fibrous cap region and close to the elastin laminae. The 
presence of multinucleated giant cells correlated with the disruption of elastin fibers (Fig. 4) 
and the absence of smooth muscle cells within the tunica media. Similarly, in giant cell 
arteritis, multinucleated giant cells have been implicated in internal elastic laminae damage 
and their presence strongly correlated with smooth muscle cell migration (Kaiser et al., 1999; 
Penn & Dasgupta, 2003; Nordborg & Nordborg, 2003).  
Cathepsin K plays a major role in the destructive potential of osteoclasts and is suggested as 
a marker of macrophage differentiation (Brömme et al., 1996; Buhling et al., 2001). In 
contrast to macrophages, multinucleated giant cells in atherosclerotic lesions of 
apolipoprotein E-deficient mice do not show strong immunostaining for cathepsin L and S 
(Samokhin; 2010c). These results suggest that cathepsin K plays a crucial role in the 
destructive potential of multinucleated giant cells in the aortic wall.  
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Fig. 3. Cathepsin K immunostaining of atherosclerotic lesions in brachiocephalic artery of 
ApoE-/- mice (red- cathepsin K, green – elastin fibers autofluorescence, blue – nuclei, x20, 
asterisk shows multinucleated giant cell). 
 




Fig. 4. Cathepsin K-positive multinucleated giant cell at the site of an elastin fiber break 
(red- cathepsin K, green – elastin fibers autofluorescence, blue- nuclei, x63). 
 




Fig. 3. Cathepsin K immunostaining of atherosclerotic lesions in brachiocephalic artery of 
ApoE-/- mice (red- cathepsin K, green – elastin fibers autofluorescence, blue – nuclei, x20, 
asterisk shows multinucleated giant cell). 
 




Fig. 4. Cathepsin K-positive multinucleated giant cell at the site of an elastin fiber break 
(red- cathepsin K, green – elastin fibers autofluorescence, blue- nuclei, x63). 
 




Fig. 5. Predominant accumulation of elastin-FITC complexes on/inside of multinucleated 
giant cell (olive green – phalloidin-FITC, neon green – elastin-FITC, blue nuclei, x20). 
The involvement of cathepsin K in the increased elastolytic potential of multinucleated giant 
cells was further supported by an in vitro experiment where peritoneal macrophages were 
incubated with IL-4 to induce fusion and multinucleated giant cell formation. The fusion of 
macrophages resulted in dramatic increase in their elastolytic activity as was revealed by the 
cleavage of FITC-labeled elastin. On the third day of macrophage fusion, cells from 
cathepsin K-deficient mice showed a 30% reduction in their elastolytic activity compared to 
cells derived from cathepsin K-expressing animals (Samokhin, 2010c). Notably, most of the 
elastin fibers were attached to or engulfed by MGCs (Fig. 5) demonstrating that the 
observed increase in elastolytic activity was due to the process of giant cell formation.  
8. Conclusion 
The results of recent studies in humans and animal models provide evidences for the pivotal 
roles of cathepsin K, L and S in aortic extracellular matrix remodeling during pathological 
conditions. Their elasto- and/or collagenolytic activities render them into main culprits of 
matrix destruction observed in cardiovascular diseases and make these proteases attractive 
pharmaceutical targets for therapeutic interventions. 
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1. Introduction 
ESRV Elective Surgical Revascularization is the ultimate intervention in atherosclerotic 
aorto-iliac disease which has progressed up to the arterial insufficiency state [1]. Surgical 
solution of extreme forms of aorto-iliac atherosclerotic disease (such as aortic aneurysm) 
implies removal of the stenotic/dilated arterial segment, creation of an arterial derivation, 
and/or placement of a vascular prosthesis [2]. Surgical act entails a metabolic aggression 
whose cost might override the patient’s homeostatic mechanisms, resulting in complications 
and death [3-4]. Consequently, the medical team should care for the safe completion of the 
surgical procedure through identification and proactive modification of factors existing in 
the patient that might place him/her at risk of complication and death. 
Patient’s nutritional status can determine the result of surgical activity. An increased risk of 
surgical failures has been reported as patient’s nutritional status deteriorates [5-7]. However, 
relationship between the response to the surgical act and nutritional status might not be that 
straightforward, and could be modified by fuzzy variables such as age and presence of co-
morbidities [8-9].  
The present essay gives the opportunity for assessing the relationship between nutritional 
status of the patient and surgical activity from a different, entirely new, perspective. That is: 
it would be interesting to examine if body weight excess can also modify the results of 
surgical activity non-related to tumor-reduction, as would be the case of ESRV. This study 
model of systemic response to surgical aggression could be more appealing in view of the 
fact that abnormalities of the great abdominal vessels intended to be surgically corrected 
represent different stations in the progression of atherosclerotic disease, and this, in turn, is 
associated with Obesity. Thus, it could be anticipated that surgical failures rate to increase 
as patient’s body fat does. 
2. Atherosclerosis and nutrition 
Any discussion on the possible links between atherosclerotic aorto-iliac disease and 
nutrition should take into account the influence of subject’s food habits upon onset and 
history (in absence of intervention) of this illness, the nutritional status of the patient prior to 
ESRV, and nutritional influence upon the response to the surgical act. 
Atherosclerosis is intimately related with disorders of blood lipids homeostasis [10-11]. 
Although fat strip has been described as the originary atherosclerotic lesion in the aorta of 
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newborn babies, its conversion into an atheroma, with subsequent calcification, rupture and 
thrombosis, or weakening of the arterial wall, are all associated with chronic states of 
hypercholesterolemia [11-12]. However, it should be noticed that causes of 
hypercholesterolemia can be multiple and chaotic in their presentation and influences [13].  
Obesity, established from the disproportionate participation, and anomalous distribution, of 
body fat in the subject’s body composition, and the repercussion that specified 
topographical locations of adipose tissue have upon endocrine activity of human economy 
as well as cell and tissue metabolism, is an important factor in the progression of 
atherosclerotic damage [14-15]. Obesity results from the incapacity of the organism to 
correctly use food energy quantities incongruent with subject’s physical activity, in 
particular if present in his/her regular diet as refined sugars and energetically dense foods. 
Coincidently, elevated food fats intakes, with an important participation of saturated fats 
and trans fatty acids, have been described in obese subjects [15-18]. Hypercholesterolemia 
could also be the result of unbalanced intakes of long-chain, poly-unsaturated fatty acids, 
and poor representation of 3 fatty acids in the diet [13,19]. All these food influences 
converge to configure the so-called Metabolic syndrome, which eventually leads to 
hyperuricemia, blood lipids disorders, and disruption of the peripheral utilization of 
carbohydrates, that might evolve towards hyperglycemia and insulin resistance; molecular 
events all that accelerate the progression of atherosclerotic disease [20-21]. 
 
 
Legends: S: Saturated fats. P: Poly-unsaturated fats. ORSs: Oxygen-reactive species 
Fig. 1. Some influences in the progression of the originary atherosclerotic lesion. The figure 
intends to  call the attention upon factors involved in atherosclerosis dependant on Obesity 
as well as molecular defects in LDL-Cholesterol clearance. The presentation does not 
exhaust the events related with atherosclerosis, nor the relationships they sustain among 
them. For further details: See pertinent references at the end of the essay. 
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3. Nutritional phenotypes in atherosclerotic aorto-iliac disease 
Corresponding with what has been said previously, it should not come as a surprise to see 
that a significant proportion of aorto-sclerosis patients considered for ESRV show a body 
weight higher that the one expected regarding the height of their peers, as seen in Figure 2. 
Regarding BMI Body Mass Index, 69 patients assisted between 2000 – 2007 due to aorto-iliac 
atherosclerosis (more than half presenting with aortic aneurysm) at a Angiology and 
Vascular surgery of a referral, tertiary hospital of the city of Havana (Cuba) were distributed 
as follows: Malnourished: < 18.5 Kg.m-2: 4.3%; Non-Malnourished: Between 18.5 – 24.9 
Kg.m-2: 41.4%; and Body weight excess: > 24.9 Kg.m-2: 54.3%; respectively. Fourteen point 2 

























Legend: BMI: Body Mass Index.  
Source: Records of the Nutritional Support Group. Clinical surgical Hospital “Hermanos Ameijeiras”. 
La Habana. Cuba. 
Records closed on: Monday, October 10th, 2010. 
Fig. 2. Distribution of different nutritional phenotypes among patients awaiting elective 
surgical revascularization in a referral, tertiary, Angiology service. More than half of 
patients presented with aortic aneurysm. 
Having reached this point in the essay, a relevant question is pertinent: Can body weight 
excess (in either of its two forms: overweight or obesity) affect the response to ESRV? In 
other words: does the risk of complications after ESRV increase because of size/distribution 
of body fat? If this is to be the case, patient’s response to ESRV could be improved, and in 
the process, a higher-quality medical-surgical care offered, by means of the conduction of 
proactive measures oriented to modify the size as well as topographical distribution of body 
fat. 
The relevance of these considerations is not to be ignored. ESRV includes technically-
demanding procedures, such as aorto-femoral derivation, and placement of vascular 
prostheses. Complications that might occur after completion of such procedures can 
encompass from sepsis to derivation/prosthesis failure, with subsequent amputation of the 
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proactive measures oriented to modify the size as well as topographical distribution of body 
fat. 
The relevance of these considerations is not to be ignored. ESRV includes technically-
demanding procedures, such as aorto-femoral derivation, and placement of vascular 
prostheses. Complications that might occur after completion of such procedures can 
encompass from sepsis to derivation/prosthesis failure, with subsequent amputation of the 
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vascular compromised limb [3-4,22]. Interestingly, considerations about the association 
between surgical activity and nutritional status have been dominated by the discussion on 
how weight loss affects the result of surgical tumor-reduction [5-8]. On the contrary, 
documented evidences on the influence of body weight excess upon the response of the 
patient to surgical activity non-related with oncology practice are scarce. However, it has 
been hypothesized that the relationship between risk of complication after a surgical act and 
nutritional status of the patient might adopt a “U” or “J” shape, as shown in Figure 3 [23-
24]. The shape of this relationship is striking, because it stresses that polar nutritional 
phenotypes can be equivalent in their influences upon the response of the patient to the 
surgical activity1.  
 
 
Drawn with data taken from: References [23-24]. 
Fig. 3. Influence of nutritional phenotype upon response to the surgical act. 
4. Why polar nutritional phenotypes are equally deleterious for the response 
to ESRV? 
ENM Energy Nutrient Malnutrition is that disorder of body composition resulting from 
depletion of Potassium-rich, metabolic-active, lean tissues [26]. Reduction of body lean mass 
beyond a critical size is associated with an increased risk of complications after ESRV, not to 
                                                 
1 Unfortunately, the author has not been able to validate this hypothesis. After research completed in a 
Angiology and Vascular Surgery referral, tertiary Service, it was concluded that post-surgical 
complications were independent from nutritional phenotype, affecting two-thirds of non-malnourished 
patients, and half plus one of those with body weight excess [25]. 
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mention death2. ENM deeply affects all the orders of subject’s economy, and profoundly 
alters inner milieu homeostasis. Malnutrition usually associates with impaired liver protein 
synthesis and tissue repair and healing processes, and defective collagen deposition, thus 
difficulting the formation of an effective scar callous [24, 27]. Malnutrition also brings about 
disruption of the natural barriers for restraining invading pathogen bacteria, antigen-
presentation mechanisms, production and release of cytokines, immunoglobulins and cell 
mobilization factors, and the proliferation and differentiation of cells involved in immune 
response [28]. Far from exhausting the topic, malnutrition can affect ventilatory function, 
making the subject prone to failure in weaning from a mechanical ventilator and pneumonia 
[29]; as well as kidney function, thus altering depuration of toxins and other by-products of 
tissue metabolism [30]. 
By comparison, influence of body weight excess upon response to surgical activity has been 
little explored, above all in settings non-related with tumor-reduction. Excess of 
subcutaneous adipose tissue can result in an increased rate of surgical wound sepsis due to 
failure in obliterating the incision line, and subsequent appearance of dead spaces. Poor 
vascularity of subcutaneous adipose tissue can also contribute to an insufficient irrigation of 
surgically lacerated tissues, and thus, inflammation, bacterial colonization, and surgical 
wound sepsis. Suture dehiscence, incisional hernias and eventrations could then become the 
most visible face of the influence of body weight excess upon surgical activity. 
But body weight excess can also exert remote influences through altered states of peripheral 
utilization of carbohydrates. Indeed, hyperglycemia has been described as a post-surgical 
sepsis risk factor [31]. It is to be kept in mind that cells involved in immune response are 
important consumers of energy as glucose [32]. Hyperglycemia can result from disorders in 
the peripheral utilization of carbohydrates as well as hyper-insulinism states. Insulin action 
target-cell can express a reduced number of hormone-specific receptors, or uncouple the 
receptor from post-receptor cascade of events, inhibiting in one way or the other stimulation 
by insulin, a phenomenon recognized as “down-regulation”. Incapacity of using glucose as the 
energy substrate of choice forces the cell to turn to alternative energy fuels, which in the end, 
worsens hypertrigliceridemia resulting from improper cell utilization of metabolic energy. 
Body weight excess can be also associated with chronic states of inflammation. Depending on 
the topographical location, the adipocyte is able to produce cytokines (TNF Tissue Necrosis 
Factor among them), and other inflammation-promoting molecules [33]. These blood products 
also contribute to insulin resistance, hyperglycemia and hypertrigliceridemia. Hence, and 
given what has been said before, body weight excess can become a powerful negative 
predictor of complications after ESRV.  
5. Can age independently influence upon response to ESRV? 
Relationship between probability of complication after ESRV and nutritional phenotype has 
been documented in subjects younger than 60 years of age [23, 24]. However, such 
dependence relationship has not been established in older subjects. As a matter of fact, it has 
come to the attention of researchers that body weight excess is associated with a lesser risk 
of complications after completion of surgical acts non-related with tumor-reduction in 
                                                 
2 There is also depletion of adipose tissue in ENM, but this phenomenon is secondary to the reduction of 
the size of body lean mass. As a matter of fact, post-surgical complications can occur in a patient with a 
nearly constant adipose tissue.  
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elderly subjects [34]. In a recently concluded research at a referral, terminal Angiology 
Service, it was observed that age was an independent predictor of after-ESRV failures when 
higher complications rates concentrated among younger subjects notwithstanding 
nutritional phenotype [25]. Hence, it is only attractive to explore why age transit can cause 
such a profound transformation of the relationship discussed throughout this essay. 
Significant changes occur in subject’s body composition with aging. These changes could 
result from “turning off” molecular signals responsible for tissue accretion (explaining, at 
least in part, the phenomenon of “sarcopenia”); redistribution of body compartments, with 
preponderance of adipose tissue deposition at the scapular waist, and concomitant 
reduction of the circumference of body segments and/or substitution of body lean mass 
with adipose tissue [35]. These changes could, in turn, modify subject’s hormonal status, 
reducing insulin resistance, and thus, altered states of peripheral utilization of 
carbohydrates [36]. The morpho-functional substrate such as the one early described might 
then explain why Obesity, understood as an increase in body fat size, can act as a protecting 
factor in the third age of life. Hence, others events/circumstances aside, a subject with +60 
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6. On perioperatory nutritional intervention in ESRV 
Having discussed the aforementioned issues, it is time to dwell about interventions oriented 
to secure the success of ESRV by supplying the patient with selected nutrients incorporating 
intrinsic pharmacological actions, such as 3 fatty acids and dietetic fiber. 
Pharmacological actions of 3 fatty acids have been intensively studied in recent years. 3 
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elderly subjects [34]. In a recently concluded research at a referral, terminal Angiology 
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5-series prostanoids, with documented anti-inflammatory, anti-clotting, and smooth muscle-
relaxing properties [37]. Supply of such fatty acids, be either as foods or chemically defined 
preparations, could then become an intervention resulting in a lesser systemic inflammatory 
activity, and thus, a better utilization of cell as well as tissue energy substrates [38]. Use of 
3 fatty acids as part of nutritional intervention in ESRV might also result in stabilization of 
the atherosclerotic plaque, thus facilitating the work of angiologist surgeon [39]. Morever, it 
has been reported that use of parenteral lipids solutions incorporating fish oil as a source of 
3 fatty acids shortened hospital length of stay of patients electively subjected to abdominal 
aortic aneurysm surgery [40]. However, is should be remembered that prolonged use of 3 
fatty acids might modify shape, size, distribution and lipid composition of HDL High 
density Lipoproteins that have been linked to a reduced risk of atherosclerotic damage [41].  
Dietetic fiber could be another nutrient capable to influence upon response to ESRV. Low 
dietetic fiber intakes have been described after surveys completed in obese subjects [42-43]. 
Low dietetic fiber intakes have been associated with occurrence of blood lipid disorders and 
increased peripheral resistance to insulin action [44]. Supply of dietetic fiber might improve 
cell/tissue response to insulin’s stimulatory action, and hence, altered states of 
carbohydrates peripheral utilization [45]. Likewise, dietetic fiber might also modify features 
and distribution of plasma lipoproteins in charge of Cholesterol and triglycerides 
transportation [46]. 
Finally, being hyperglycemia the first complication associated with/derived from body 
weight excess upon which to intervene after ESRV, alternative sugars solutions to Glucose 
should be made available to the angiologist surgeon for energy supply to the patient. 
Several alternative sugars have been proposed, such as xylitol, glucitol and sorbitol [47]. 
Glycerol: the poly-alcohol supplying the carbon backbone sustaining triglycerides’s 
structure, has also been proposed as an alternative substrate to Glucose in post-surgical 
settings where insulin resistance, hyperglycemia, and hypertrygliceridemia are to be 
expected [48]. 
7. Clinical case: Ischemia-reperfusion syndrome - Influence upon nutritional 
status and response to ESRV 
Complicated atherosclerosis is associated with a reduced blood irrigation of regions distal to 
atherosclerotic lesion, and hence, chronic tissue ischemia. When blood supply is restored 
after ESRV, molecular signals generated by until-that-moment ischemic tissues enter the 
blood stream. Systemic influence of such molecular signals might simulate the shock picture 
firstly described in people trapped in collapses [49]. Ischemia-reperfusion syndrome thus 
configured might affect nutritional status of patient subjected to ESRV, and complicate the 
implementation of designed nutritional support scheme. 
Case presentation: The case is presented of a 55 years-old, white female, being admitted to a 
referral, terminal Angiology and Vascular Surgery Service for surgical correction of a 
mesenteric-aorto-iliac atheromatosis. The list with health problems identified in this patient 
is displayed in Table 2. During the surgical act, an aorto-iliac derivation was made, along 
with reopening of the superior mesenteric artery and placement of a bypass. Post-surgical 
evolution was torpid, marked by a Multiple Organs Dysfunction event, local as well as 
systematic sepsis, and a SIRS Systemic Inflammatory Response System. Health problems 
presented during post-operatory follow-up were all medically treated. Eventually the 
patient overcome these problems and was discharged from the Service. 
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Pr 1. Chronic tobacco use. 
Pr 2. Complicated mesenteric-aorto-iliac Atherosclerosis. 
Pr 3. Moderate Energy Nutrient Malnutrition of the Marasmatic type. 
sPr 3.1 Sixteen Kg weight loss during the last 6 months. 
 Volitional enteral Nutrition: Generic, fiberless, polimeric diet: 400 Kcal.24 h-1 
H1: Mesenteric insufficiency. 
 Jejunum biopsy: No villous atrophy is observed. Mild congestion of lymph and 
blood vessels. 
Pr 4. Peripheral arterial insufficiency. 
sPr 4.1 Intermittent claudication. 
 Oriented pharmacological treatment. 
 Laparotomy. 
 Aortic endarteriectomy. 
 Placement of an end-to-end aortic prosthesis. 
 Aorto-iliac bypass. 
 Superior mesenteric-aortic bypass. 
Pr 5. Complicated Endarteriectomy Post-operatory Status. 
sPr 5.1 Systemic sepsis: Bacterial bronchopneumonia. 
 ATB: Cefotaxime+Gentamicine 
sPr 5.2 Local sepsis: Moniliasic glosytis 
 Nistatine mouth washes. 
Pr 6. Multiple Organ Disfunction 
sPr 6.1 Small bowel dysfunction: Diarrheas. 
 Nils per Oris 
 Central Parenteral Nutrition: Dextrose 10%: 800 Kcal.24 h-1 + Aminoacids 10%: 
50 g.24 h-1 
sPr 6.2 Lung dysfunction: Lung congestion. 
sPr 6.3 Liver dysfunction: Prolonged coagulogram. 
 K Vitamin administration. 
sPr 6.4 Heart dysfunction: Acute heart insufficiency. 
 Treatment w/ Digitalics. 
 Heart function support w/ Amines 
sPr 6.5 Bone marrow dysfunction: Anemia 
 Blood transfusion: Two 500 mL-bags of blood. 
Pr 7. SIRS Systemic Inflammatory Response Syndrome. 
sPr 7.1 Hydroelectrolitic disorders. 
sPr 7.2 Upper digestive bleeding. 
H2: Stress ulcers 
 Nils per Oris 
 Interruption of Central Parenteral Nutrition scheme. 
Table 2. Patient’s health problems listing. 
Table 3 shows the evolution of selected nutritional as well as welfare markers collected 
during the patient’s treatment window. Weight loss accentuated during post-operatory 
evolution, as expression of existing tissue catabolism. Haemoglobin values never went 
beyond the 120 g.L-1 limit. Observed anemia might compound several causes, among them, 
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insufficient supply of nutrients. A marked lymphopenia was observed, as expression of the 
immune suppression accompanying SIRS installed during post-operatory evolution. Serum 
Cholesterol values were lower than 3.5 mmol.L-1, confirming inflammatory status present in 
the patient as response to the ischemia-reperfusion syndrome. Interestingly, depletion of 
serum Albumin values was not observed, pointing to a liver function preserved enough to 
sustain nitrogen anabolism. This circumstance might explain the patient’s favorable 
evolution, in spite of recorded events. There was also constancy of serum Creatinine values, 
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Legend: MAC: Mid-arm-circumference. Hb: Hemoglobin. TLC: Total Lympochytes Count. S-Cre: Serum 
Creatinine. S-Alb: Serum Albumin. S-Chol: Serum Cholesterol. 
Table 3. Behavior of selected nutritional as well as welfare markers of the patient discussed 
in the “Clinical case presentation” section. Shaded boxes indicate abnormal values of the 
corresponding marker. See text for further details. 
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Hemodynamic instability situation experienced by the patient during post-operatory course 
prevented the installment of coherent nutritional support schemes. This can be better 
appreciated in Figure 5. Important discontinuities in the use of the oral route for sustaining 
nutritional status were observed during the 20 days following the surgical act. Bowel 
insufficiency warned against the use of enteral nutrients during this stage as a substitute for 
oral feedings. In spite of all these events, the hospital NST Nutritional Support Team always 
stood for timely rehabilitation of the oral route, and prescribed the supply of energy as low-
density Dextrose solutions. A hyperglycemia event (serum Glucose: 22.1 mmol.L-1) was 
identified on day +13 of post-surgical evolution, forcing to momentarily interrupt the 
infusion of Dextrose solutions. Eventually, once hemodynamic stability was achieved, 
organic function recovered, and sepsis foci controlled, oral route was used for satisfying 
patient’s nutrients needs. This action, along with parenteral aminoacids supplementation, 
might have been determinant in patient’s response to ESRV. 
 
 
Fig. 5. Behavior of nutritional support during follow-up of the patient discussed in “Clinical 
case presentation” section. Discontinuities in the use of oral route are represented as falls of 
the solid blue line. Conduction of artificial nutritional schemes is symbolized as surges 
arising from the corresponding baseline. See text for further details. 
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The results of a study model of metabolic response to stress conveyed by ESRV have been 
presented in this work. Body weight excess might become a predictor of post-surgical 
complications. This hypothesis will be reformulated in future works in order to explore if 
occurrence of complications after ESRV can be traced back to the different facets of Insulin 
resistance Syndrome associated to body weight excess, such as arterial hypertension, 
hyperglycemia, blood lipid disorders, and hyperuricemia, among others. It is expected that 
complications risk to be minimal among obese patients presenting with few stigmas of 
insulin resistance, but maximal in those exhibiting a critical number of such stigmas. 
9. Final notice 
The preceding discussion has focused on the link between nutrition and aortic aneurysm as 
an extreme form of aorto-iliac atherosclerotic disease, given the involvement of the author 
with the practice of a referral, tertiary Angiology Service. However, aortic aneurysm might 
result from other, atherosclerosis-independent causes. The case is presented of a teen-ager 
suffering from an aortic aneurysm of probable mycological origin being assisted at a 
medical surgical clinic in Havana City [50]. Size of aneurysm prevented oral feeding, thus 
causing a significant nutritional derangement. Central Parenteral nutrition using premixed, 
all-in-one admixtures (NutriFlex Lipid Peri, B|BRAUN, Melsungen, Germany) was started 
in order to sustain patient’s nutritional status, and improve metabolic response to surgical 
trauma. 
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[14] Ashburn DD, Reed MJ. Endocrine system and obesity. Crit Care Clin 2010;26:633-6.  
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The results of a study model of metabolic response to stress conveyed by ESRV have been 
presented in this work. Body weight excess might become a predictor of post-surgical 
complications. This hypothesis will be reformulated in future works in order to explore if 
occurrence of complications after ESRV can be traced back to the different facets of Insulin 
resistance Syndrome associated to body weight excess, such as arterial hypertension, 
hyperglycemia, blood lipid disorders, and hyperuricemia, among others. It is expected that 
complications risk to be minimal among obese patients presenting with few stigmas of 
insulin resistance, but maximal in those exhibiting a critical number of such stigmas. 
9. Final notice 
The preceding discussion has focused on the link between nutrition and aortic aneurysm as 
an extreme form of aorto-iliac atherosclerotic disease, given the involvement of the author 
with the practice of a referral, tertiary Angiology Service. However, aortic aneurysm might 
result from other, atherosclerosis-independent causes. The case is presented of a teen-ager 
suffering from an aortic aneurysm of probable mycological origin being assisted at a 
medical surgical clinic in Havana City [50]. Size of aneurysm prevented oral feeding, thus 
causing a significant nutritional derangement. Central Parenteral nutrition using premixed, 
all-in-one admixtures (NutriFlex Lipid Peri, B|BRAUN, Melsungen, Germany) was started 
in order to sustain patient’s nutritional status, and improve metabolic response to surgical 
trauma. 
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The first successful open surgical repair of an abdominal aortic aneurysm was in 1951 
by Dubost and represented a tremendous milestone in the care of this challenging 
disease. The introduction of endovascular repair in 1991 by Parodi furthered the care of 
these patients by allowing for lower morbidity and mortality rates and also, enabling 
surgeons to extend surgical treatment to patients traditionally deemed too high of a 
surgical risk. This new book on Aortic Disease covers many interesting and vital topics 
necessary for both the practicing surgeon as well as a student of vascular disease. The 
book starts with background information on the evolution of aortic management 
from traditional open surgical repair to modern endovascular therapies. There is also 
a chapter covering the data supporting current treatment modalities and how these 
data have supported modern management. Also, the use of endovascular means for 
care of the challenging situation of ruptured aneurysms is discussed. In addition to 
management of abdominal aneurysm, there is a chapter on treatment of aneurysms 
of the ascending aorta. Along with surgical treatment, one must also understand 
the molecular basis for how blood vessels remodel and thus, the role of cathepsins in 
aortic disease is elucidated. Lastly, chapters discussing the perioperative management 
of radiation exposure and ultrasound-guided nerve blocks as well as the need for 
high-quality postoperative nutrition will lend well to a full understanding of how to 
management patients from presentation to hospital discharge. We hope you enjoy this 
book, its variety of topics, and gain a fuller knowledge of Aneurysmal Disease of the 
Thoracic and Abdominal Aorta.
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